=== Intervention Extract 1 (Intervention) ===
ANTE Nei pazienti fumatori o ex-fumatori che hanno fumato almeno 15 sigarette al giorno per più di 25 a
per più di 30 anni, oppure che hanno smesso meno di 10 anni prima, lo screening per tumore polmo
annuale dovrebbe essere preso in considerazione rispetto al non screening?
POPULATION: Lung cancer
INTERVENTION: LDCT screening
COMPARISON: No LDCT screening
MAIN OUTCOMES: Lung cancer related mortality; All-cause mortality; Early stage detection; Late stage disease; Resectability rate ; Overdia PERSPECTIVE: Popolazione CONFLICT OF INTERESTS: Nessun conflitto dichiarato
anni oppure almeno 10 sigar
onare con

=== Intervention Extract 2 (Intervention) ===
2021 without language restriction.
The database searches retrieved 137 records after duplicate were removed. Sixteen studies were judged as
potentially relevant. Two articles were excluded, because they were not randomized controlled trials; five because
did not included either population (n.3) or intervention (n.2) of interest and three comparing CTLS versus CXR (3,
23, 24, 25). Six randomized controlled trials comparing LDCT versus NS (6, 8, 10, 11, 13, 14) were excluded as they
were already included in the systematic review of Passiglia 2021 (15). This review was finally included
encompassing a total

=== Intervention Extract 3 (Intervention) ===
2021 without language restriction.
The database searches retrieved 137 records after duplicate were removed. Sixteen studies were judged as
potentially relevant. Two articles were excluded, because they were not randomized controlled trials; five because
did not included either population (n.3) or intervention (n.2) of interest and three comparing CTLS versus CXR (3,
23, 24, 25). Six randomized controlled trials comparing LDCT versus NS (6, 8, 10, 11, 13, 14) were excluded as they
were already included in the systematic review of Passiglia 2021 (15). This review was finally included
encompassing a total

=== Intervention Extract 4 (Intervention) ===
ability
● Probably no important uncertainty or
variability
○ No important uncertainty or
variability Does the balance between desirable and undesirable effects favor the interv
GIUDIZI RICERCA DELLE PROVE DI EVIDEN
○ Favors the comparison
○ Probably favors the comparison
○ Does not favor either the intervention
or the comparison
○ Probably favors the intervention
● Favors the intervention
○ Varies
○ Don't know What would be the impact on health equity?
GIUDIZI RICERCA DELLE PROVE DI EVIDEN
OPLAS
NZA
vention or
NZA
NZA
SIE DE
r the com
EL POL
mparison?
LMONE
E
CONS
CONS
CONS
SIDERAZIONI AGGIUNTIVE
SIDERAZI

=== Intervention Extract 5 (Intervention) ===
ility
○ No important uncertainty or
variability Does the balance between desirable and undesirable effects favor the interv
GIUDIZI RICERCA DELLE PROVE DI EVIDEN
○ Favors the comparison
○ Probably favors the comparison
○ Does not favor either the intervention
or the comparison
○ Probably favors the intervention
● Favors the intervention
○ Varies
○ Don't know What would be the impact on health equity?
GIUDIZI RICERCA DELLE PROVE DI EVIDEN
OPLAS
NZA
vention or
NZA
NZA
SIE DE
r the com
EL POL
mparison?
LMONE
E
CONS
CONS
CONS
SIDERAZIONI AGGIUNTIVE
SIDERAZIONI AGGIUNTIVE
SIDERAZIONI AGGIUNTIVE
○ Reduced
○ Pro

=== Intervention Extract 6 (Intervention) ===
tainty or
variability Does the balance between desirable and undesirable effects favor the interv
GIUDIZI RICERCA DELLE PROVE DI EVIDEN
○ Favors the comparison
○ Probably favors the comparison
○ Does not favor either the intervention
or the comparison
○ Probably favors the intervention
● Favors the intervention
○ Varies
○ Don't know What would be the impact on health equity?
GIUDIZI RICERCA DELLE PROVE DI EVIDEN
OPLAS
NZA
vention or
NZA
NZA
SIE DE
r the com
EL POL
mparison?
LMONE
E
CONS
CONS
CONS
SIDERAZIONI AGGIUNTIVE
SIDERAZIONI AGGIUNTIVE
SIDERAZIONI AGGIUNTIVE
○ Reduced
○ Probably reduced
● Probably n

=== Intervention Extract 7 (Intervention) ===
ZI RICERCA DELLE PROVE DI EVIDEN
OPLAS
NZA
vention or
NZA
NZA
SIE DE
r the com
EL POL
mparison?
LMONE
E
CONS
CONS
CONS
SIDERAZIONI AGGIUNTIVE
SIDERAZIONI AGGIUNTIVE
SIDERAZIONI AGGIUNTIVE
○ Reduced
○ Probably reduced
● Probably no impact
○ Probably increased
○ Increased
○ Varies
○ Don't know Is the intervention acce
GIUDIZI
○ No
○ Probably no
● Probably yes
○ Yes
○ Varies
○ Don't know Is the intervention feas
GIUDIZI
○ No
○ Probably no
● Probably yes
○ Yes
○ Varies
○ Don't know
eptable to
sible to im
No evid
o key stakeholders
RICERC
No evid
mplement?
RICERC
No evid
dence fou
s?
CA DELLE
dence fou
CA DELL

=== Intervention Extract 8 (Intervention) ===
LMONE
E
CONS
CONS
CONS
SIDERAZIONI AGGIUNTIVE
SIDERAZIONI AGGIUNTIVE
SIDERAZIONI AGGIUNTIVE
○ Reduced
○ Probably reduced
● Probably no impact
○ Probably increased
○ Increased
○ Varies
○ Don't know Is the intervention acce
GIUDIZI
○ No
○ Probably no
● Probably yes
○ Yes
○ Varies
○ Don't know Is the intervention feas
GIUDIZI
○ No
○ Probably no
● Probably yes
○ Yes
○ Varies
○ Don't know
eptable to
sible to im
No evid
o key stakeholders
RICERC
No evid
mplement?
RICERC
No evid
dence fou
s?
CA DELLE
dence fou
CA DELLE
dence fou
und
PROVE D
und
PROVE D
und
NEO
DI EVIDEN
DI EVIDEN
OPLAS
NZA
NZA
SIE DE
EL POL
LMO

=== Intervention Extract 9 (Intervention) ===
Moderate High
Possibly important Probably no important No important
VALUES
Important uncertainty
uncertainty or uncertainty or uncertainty or
or variability
variability variability variability
Does not favor either
Probably favors the Probably favors the
BALANCE OF EFFECTS Favors the comparison the intervention or the Favors the intervention Varies
comparison intervention
comparison
EQUITY Reduced Probably reduced Probably no impact Probably increased Increased Varies
ACCEPTABILITY No Probably no Probably yes Yes Varies
FEASIBILITY No Probably no Probably yes Yes Varies Strong recommendation against the C

=== Intervention Extract 10 (Intervention) ===
t Probably no important No important
VALUES
Important uncertainty
uncertainty or uncertainty or uncertainty or
or variability
variability variability variability
Does not favor either
Probably favors the Probably favors the
BALANCE OF EFFECTS Favors the comparison the intervention or the Favors the intervention Varies
comparison intervention
comparison
EQUITY Reduced Probably reduced Probably no impact Probably increased Increased Varies
ACCEPTABILITY No Probably no Probably yes Yes Varies
FEASIBILITY No Probably no Probably yes Yes Varies Strong recommendation against the Conditional recommendation again

=== Intervention Extract 11 (Intervention) ===
rtant
VALUES
Important uncertainty
uncertainty or uncertainty or uncertainty or
or variability
variability variability variability
Does not favor either
Probably favors the Probably favors the
BALANCE OF EFFECTS Favors the comparison the intervention or the Favors the intervention Varies
comparison intervention
comparison
EQUITY Reduced Probably reduced Probably no impact Probably increased Increased Varies
ACCEPTABILITY No Probably no Probably yes Yes Varies
FEASIBILITY No Probably no Probably yes Yes Varies Strong recommendation against the Conditional recommendation against the Conditional recommendati

=== Intervention Extract 12 (Intervention) ===
ed Probably no impact Probably increased Increased Varies
ACCEPTABILITY No Probably no Probably yes Yes Varies
FEASIBILITY No Probably no Probably yes Yes Varies Strong recommendation against the Conditional recommendation against the Conditional recommendation for the Strong recommendation for the
intervention intervention intervention intervention
Don't know
Don't know
Don't know
No included studies
Don't know
Don't know
Don't know
Don't know Nei pazienti fumatori o ex-fumatori che hanno fumato almeno 15 sigarette al giorno per più di 25 anni oppure almeno 10 sigarette al giorno per più di 30 anni, oppu

=== Intervention Extract 13 (Intervention) ===
o impact Probably increased Increased Varies
ACCEPTABILITY No Probably no Probably yes Yes Varies
FEASIBILITY No Probably no Probably yes Yes Varies Strong recommendation against the Conditional recommendation against the Conditional recommendation for the Strong recommendation for the
intervention intervention intervention intervention
Don't know
Don't know
Don't know
No included studies
Don't know
Don't know
Don't know
Don't know Nei pazienti fumatori o ex-fumatori che hanno fumato almeno 15 sigarette al giorno per più di 25 anni oppure almeno 10 sigarette al giorno per più di 30 anni, oppure che hanno

=== Intervention Extract 14 (Intervention) ===
ably increased Increased Varies
ACCEPTABILITY No Probably no Probably yes Yes Varies
FEASIBILITY No Probably no Probably yes Yes Varies Strong recommendation against the Conditional recommendation against the Conditional recommendation for the Strong recommendation for the
intervention intervention intervention intervention
Don't know
Don't know
Don't know
No included studies
Don't know
Don't know
Don't know
Don't know Nei pazienti fumatori o ex-fumatori che hanno fumato almeno 15 sigarette al giorno per più di 25 anni oppure almeno 10 sigarette al giorno per più di 30 anni, oppure che hanno smesso meno d

=== Intervention Extract 15 (Intervention) ===
d Increased Varies
ACCEPTABILITY No Probably no Probably yes Yes Varies
FEASIBILITY No Probably no Probably yes Yes Varies Strong recommendation against the Conditional recommendation against the Conditional recommendation for the Strong recommendation for the
intervention intervention intervention intervention
Don't know
Don't know
Don't know
No included studies
Don't know
Don't know
Don't know
Don't know Nei pazienti fumatori o ex-fumatori che hanno fumato almeno 15 sigarette al giorno per più di 25 anni oppure almeno 10 sigarette al giorno per più di 30 anni, oppure che hanno smesso meno di 10 anni pri

=== Intervention Extract 16 (Intervention) ===
ra, H.. Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial. J Thorac Cardiovasc
Surg; Sep 2019. Dovrebbe la segmentectomia vs lobectomia essere utilizzata per pazienti affetti da NSCLC in stadio iniziale
POPULATION: Pazienti affetti da NSCLC in stadio iniziale
INTERVENTION: La segmentectomia
COMPARISON: Lobectomia
MAIN OUTCOMES: Overall survival RCT; Overall Survival; Disease free survival RCT; Disease free Survival; Quality of life; Number of harvested lymphonodes; Lenght hospital stay; Local recurrence RCT; Local
recurrence; Postoperative air leaks; Postoperative a

=== Intervention Extract 17 (Intervention) ===
uncertainty
or variability
● Possibly important
uncertainty or
variability
○ Probably no
important uncertainty
or variability
○ No important
uncertainty or
variability
Balance of effec
Does the balance bet
GIUDIZI
○ Favors the
comparison
○ Probably favors the
comparison
○ Does not favor either
the intervention or the
comparison
● Probably favors the
intervention
○ Favors the
intervention
○ Varies
○ Don't know
ncertaint
RICERCA
Nessuna e
cts
tween de
RICERCA
ty about or variab
DELLE PROVE DI EVI
evidenza trovata.
esirable and und
DELLE PROVE DI EVI
bility in h
IDENZA
desirable
IDENZA
NEO
how muc
effects f

=== Intervention Extract 18 (Intervention) ===
rtainty or
variability
○ Probably no
important uncertainty
or variability
○ No important
uncertainty or
variability
Balance of effec
Does the balance bet
GIUDIZI
○ Favors the
comparison
○ Probably favors the
comparison
○ Does not favor either
the intervention or the
comparison
● Probably favors the
intervention
○ Favors the
intervention
○ Varies
○ Don't know
ncertaint
RICERCA
Nessuna e
cts
tween de
RICERCA
ty about or variab
DELLE PROVE DI EVI
evidenza trovata.
esirable and und
DELLE PROVE DI EVI
bility in h
IDENZA
desirable
IDENZA
NEO
how muc
effects f
OPLASIE
ch peopl
favor the
E DEL
le value t
e interv

=== Intervention Extract 19 (Intervention) ===
robably no
important uncertainty
or variability
○ No important
uncertainty or
variability
Balance of effec
Does the balance bet
GIUDIZI
○ Favors the
comparison
○ Probably favors the
comparison
○ Does not favor either
the intervention or the
comparison
● Probably favors the
intervention
○ Favors the
intervention
○ Varies
○ Don't know
ncertaint
RICERCA
Nessuna e
cts
tween de
RICERCA
ty about or variab
DELLE PROVE DI EVI
evidenza trovata.
esirable and und
DELLE PROVE DI EVI
bility in h
IDENZA
desirable
IDENZA
NEO
how muc
effects f
OPLASIE
ch peopl
favor the
E DEL
le value t
e interve
POLMO
the main
ention or

=== Intervention Extract 20 (Intervention) ===
Probably no Probably yes Yes
Small Moderate Large
Moderate Small Trivial
Low Moderate High
Probably no
Possibly important No important
important
uncertainty or uncertainty or
uncertainty or
variability variability
variability
Does not favor
Probably favors either the Probably favors
the comparison intervention or the the intervention
comparison
Probably reduced Probably no impact Probably increased
Probably no Probably yes Yes
Probably no Probably yes Yes
Favors th
interventio
d Increased
Varies
Varies
Varies
he
Varies
on
d Varies
Varies
Varies
Don't know
Don't know
Don't know
No included
studies
Don't k

=== Intervention Extract 21 (Intervention) ===
s Yes
Small Moderate Large
Moderate Small Trivial
Low Moderate High
Probably no
Possibly important No important
important
uncertainty or uncertainty or
uncertainty or
variability variability
variability
Does not favor
Probably favors either the Probably favors
the comparison intervention or the the intervention
comparison
Probably reduced Probably no impact Probably increased
Probably no Probably yes Yes
Probably no Probably yes Yes
Favors th
interventio
d Increased
Varies
Varies
Varies
he
Varies
on
d Varies
Varies
Varies
Don't know
Don't know
Don't know
No included
studies
Don't know
Don't know
Don't kno

=== Intervention Extract 22 (Intervention) ===
rventio
d Increased
Varies
Varies
Varies
he
Varies
on
d Varies
Varies
Varies
Don't know
Don't know
Don't know
No included
studies
Don't know
Don't know
Don't know
Don't know Strong recommendation against the Conditional recommendation against the Conditional recommendation for the Strong recommenda
intervention intervention intervention interventio Recommendation
L a segmentectomia rispetto alla lobectomia può essere presa in considerazione per pazienti affetti da NSCLC in stadio inizia
ation for the
on
ale Author(s): MC
Date: September 2019
Question: Durvalumab compared to placebo/Observation in patients

=== Intervention Extract 23 (Intervention) ===
reased
Varies
Varies
Varies
he
Varies
on
d Varies
Varies
Varies
Don't know
Don't know
Don't know
No included
studies
Don't know
Don't know
Don't know
Don't know Strong recommendation against the Conditional recommendation against the Conditional recommendation for the Strong recommenda
intervention intervention intervention interventio Recommendation
L a segmentectomia rispetto alla lobectomia può essere presa in considerazione per pazienti affetti da NSCLC in stadio inizia
ation for the
on
ale Author(s): MC
Date: September 2019
Question: Durvalumab compared to placebo/Observation in patients with PD-L1<1

=== Intervention Extract 24 (Intervention) ===
Varies
Varies
he
Varies
on
d Varies
Varies
Varies
Don't know
Don't know
Don't know
No included
studies
Don't know
Don't know
Don't know
Don't know Strong recommendation against the Conditional recommendation against the Conditional recommendation for the Strong recommenda
intervention intervention intervention interventio Recommendation
L a segmentectomia rispetto alla lobectomia può essere presa in considerazione per pazienti affetti da NSCLC in stadio inizia
ation for the
on
ale Author(s): MC
Date: September 2019
Question: Durvalumab compared to placebo/Observation in patients with PD-L1<1 expression,

=== Intervention Extract 25 (Intervention) ===
mised, controlled,
phase 2 study. Lancet Oncol; Dec 2016. Dovrebbe un trattamento locoregionale + terapia sistemica vs sola terapia sistemica essere utilizzato per pazienti affetti da NSCLC
in stadio avanzato oligometastatico
POPULATION: Pazienti affetti da NSCLC in stadio avanzato oligometastatico
INTERVENTION: Un trattamento locoregionale + terapia sistemica
COMPARISON: Sola terapia sistemica
MAIN OUTCOMES: Overall survival; Progression-free survival; Quality of life; ORR; Discontinuation of any treatment component; Loco-regional progression; Polmoniti; Tossicità grado 3-5
SETTING: Inpatients CONFLICT O

=== Intervention Extract 26 (Intervention) ===
the main outcom
nce bias e
mes?
imprecisio
one.
LINEE
E GUID
CON
CON
DA
NSIDERAZI
NSIDERAZI
IONI AGGIUNTIVE
IONI AGGIUNTIVE Does the balance between desirable and undesirable
GIUDIZI RICERCA DELLE PROVE DI EVIDENZA
○ Favors the comparison
○ Probably favors the
comparison
○ Does not favor either
the intervention or the
comparison
○ Probably favors the
intervention
● Favors the intervention
○ Varies
○ Don't know What would be the impact on health equity?
GIUDIZI RICERCA DELLE PROVE DI EVIDENZA
○ Reduced Nessuna evidenza trovata.
○ Probably reduced
● Probably no impact
○ Probably increased
○ Increased
○ Vari

=== Intervention Extract 27 (Intervention) ===
E GUID
CON
CON
DA
NSIDERAZI
NSIDERAZI
IONI AGGIUNTIVE
IONI AGGIUNTIVE Does the balance between desirable and undesirable
GIUDIZI RICERCA DELLE PROVE DI EVIDENZA
○ Favors the comparison
○ Probably favors the
comparison
○ Does not favor either
the intervention or the
comparison
○ Probably favors the
intervention
● Favors the intervention
○ Varies
○ Don't know What would be the impact on health equity?
GIUDIZI RICERCA DELLE PROVE DI EVIDENZA
○ Reduced Nessuna evidenza trovata.
○ Probably reduced
● Probably no impact
○ Probably increased
○ Increased
○ Varies
○ Don't know
NEO
e effects
OPLASI
favor the
IE DEL

=== Intervention Extract 28 (Intervention) ===
ZI
NSIDERAZI
IONI AGGIUNTIVE
IONI AGGIUNTIVE Does the balance between desirable and undesirable
GIUDIZI RICERCA DELLE PROVE DI EVIDENZA
○ Favors the comparison
○ Probably favors the
comparison
○ Does not favor either
the intervention or the
comparison
○ Probably favors the
intervention
● Favors the intervention
○ Varies
○ Don't know What would be the impact on health equity?
GIUDIZI RICERCA DELLE PROVE DI EVIDENZA
○ Reduced Nessuna evidenza trovata.
○ Probably reduced
● Probably no impact
○ Probably increased
○ Increased
○ Varies
○ Don't know
NEO
e effects
OPLASI
favor the
IE DEL
e interve
L POLM
ention o

=== Intervention Extract 29 (Intervention) ===
ced Nessuna evidenza trovata.
○ Probably reduced
● Probably no impact
○ Probably increased
○ Increased
○ Varies
○ Don't know
NEO
e effects
OPLASI
favor the
IE DEL
e interve
L POLM
ention or
MONE
r the com
mparison
n?
LINEE
E GUID
CON
CON
DA
NSIDERAZI
NSIDERAZI
IONI AGGIUNTIVE
IONI AGGIUNTIVE Is the intervention acceptable to key stakeholders? ○ No Nessuna evidenza trovata.
○ Probably no
● Probably yes
○ Yes
○ Varies
○ Don't know Is the intervention feasible to implement? ○ No Nessuna evidenza trovata.
○ Probably no
● Probably yes
○ Yes
○ Varies
○ Don't know PROBLEM No Trivial NEO
Probab
Sma
OPLASI
bly no

=== Intervention Extract 30 (Intervention) ===
PLASI
favor the
IE DEL
e interve
L POLM
ention or
MONE
r the com
mparison
n?
LINEE
E GUID
CON
CON
DA
NSIDERAZI
NSIDERAZI
IONI AGGIUNTIVE
IONI AGGIUNTIVE Is the intervention acceptable to key stakeholders? ○ No Nessuna evidenza trovata.
○ Probably no
● Probably yes
○ Yes
○ Varies
○ Don't know Is the intervention feasible to implement? ○ No Nessuna evidenza trovata.
○ Probably no
● Probably yes
○ Yes
○ Varies
○ Don't know PROBLEM No Trivial NEO
Probab
Sma
OPLASI
bly no
all
IE DEL
L POLM
Probab
Mode
MONE
bly yes
erate
GIUDIZ
ZI
Yes
Large
e
CON
CON
Varies
Varies
A
NSIDERAZIONI AGGIUNTIVE
NSIDERAZIONI AGGIUNTI

=== Intervention Extract 31 (Intervention) ===
arge Moderate Small Trivial
Very
Low Moderate High
low
Probably no No important
Possibly important
Important uncertainty important uncertainty
uncertainty or
or variability uncertainty or or
variability
variability variability
Does not favor either
Favors the Probably favors the Probably favors
the intervention or
comparison comparison interventio
the comparison
Probably
Reduced Probably reduced Probably no impact
increased
Probably Probably
No Yes
no yes
Probably Probably
No Yes
no yes
Varies
the Favors the
Varies
on intervention
Increased Varies
Varies
Varies
Don't know
No included
studies
Don't know
Do

=== Intervention Extract 32 (Intervention) ===
ty
Does not favor either
Favors the Probably favors the Probably favors
the intervention or
comparison comparison interventio
the comparison
Probably
Reduced Probably reduced Probably no impact
increased
Probably Probably
No Yes
no yes
Probably Probably
No Yes
no yes
Varies
the Favors the
Varies
on intervention
Increased Varies
Varies
Varies
Don't know
No included
studies
Don't know
Don't know
Don't know
Don't know Strong recommendation Conditional Conditional
against the intervention recommendation against recommendation for the
the intervention intervention Un trattamento loco-regionale + terapia sistem

=== Intervention Extract 33 (Intervention) ===
obably no impact
increased
Probably Probably
No Yes
no yes
Probably Probably
No Yes
no yes
Varies
the Favors the
Varies
on intervention
Increased Varies
Varies
Varies
Don't know
No included
studies
Don't know
Don't know
Don't know
Don't know Strong recommendation Conditional Conditional
against the intervention recommendation against recommendation for the
the intervention intervention Un trattamento loco-regionale + terapia sistemica vs. sola terapia sistemica in pazienti affetti da NSCL
considerazione. La forza della raccomandazione è forte nonostante la certezza nelle prove è stata giudicata complessiv

=== Intervention Extract 34 (Intervention) ===
ably Probably
No Yes
no yes
Varies
the Favors the
Varies
on intervention
Increased Varies
Varies
Varies
Don't know
No included
studies
Don't know
Don't know
Don't know
Don't know Strong recommendation Conditional Conditional
against the intervention recommendation against recommendation for the
the intervention intervention Un trattamento loco-regionale + terapia sistemica vs. sola terapia sistemica in pazienti affetti da NSCL
considerazione. La forza della raccomandazione è forte nonostante la certezza nelle prove è stata giudicata complessiv
l’intervento può rappresentare un trattamento salvavita.
Stron

=== Intervention Extract 35 (Intervention) ===
No Yes
no yes
Varies
the Favors the
Varies
on intervention
Increased Varies
Varies
Varies
Don't know
No included
studies
Don't know
Don't know
Don't know
Don't know Strong recommendation Conditional Conditional
against the intervention recommendation against recommendation for the
the intervention intervention Un trattamento loco-regionale + terapia sistemica vs. sola terapia sistemica in pazienti affetti da NSCL
considerazione. La forza della raccomandazione è forte nonostante la certezza nelle prove è stata giudicata complessiv
l’intervento può rappresentare un trattamento salvavita.
Strong recommendat

=== Intervention Extract 36 (Intervention) ===
nto loco-regionale + terapia sistemica vs. sola terapia sistemica in pazienti affetti da NSCL
considerazione. La forza della raccomandazione è forte nonostante la certezza nelle prove è stata giudicata complessiv
l’intervento può rappresentare un trattamento salvavita.
Strong recommendation
for the intervention
LC in stadio avanzato oligometastatico dovrebbe essere preso in
vamente bassa, poiché a fronte di un potenziale danno insignificante,
LINEE GUID Author(s): MC
Date: September 2019
Question: Osimertinib compared to standard EGFR-TKI in untreated EGFR-Mutated advanced non-small-cell lung cancer
Setti

=== Intervention Extract 37 (Intervention) ===
ng cancer in the ALEX study. Ann Oncol; Aug 2020. Dovrebbe alectinib vs crizotinib essere utilizzato per pazienti affetti da NSCLC in stadio localmente avanzato o meta
riarrangiamenti di ALK
POPULATION: Pazienti affetti da NSCLC in stadio localmente avanzato o metastatico con riarrangiamenti di ALK
INTERVENTION: Alectinib
COMPARISON: Crizotinib
MAIN OUTCOMES: PFS; OS; ORR; Time to CNS progression - Peters s. et al., Gadgeel 2018; Time to progression of brain metastasis or death - Hida T. et al; Alanine aminotrasferase in
Aspartate aminotrasferase increase - grade 3-4; Nausea - grade 3-4; Toxic deaths
SETT

=== Intervention Extract 38 (Intervention) ===
BAS
ue the main outcom
ZA
L POLM
SSA per ris
mes?
MONE
schio di d
E
distorsion
ne (perfor
rmance e
attrition
bias), pe
CONS
er
CONS
SIDERAZIONI AGGIUNTIVE
SIDERAZIONI AGGIUNTIVE Does the balance between desi
GIUDIZI
○ Favors the comparison
○ Probably favors the comparis
○ Does not favor either the
intervention or the comparison
● Probably favors the intervent
○ Favors the intervention
○ Varies
○ Don't know What would be the impact on h
GIUDIZI
○ Reduced
○ Probably reduced
● Probably no impact
○ Probably increased
○ Increased
○ Varies
○ Don't know Is the intervention acceptable t
GIUDIZI
○ No
○ Probably n

=== Intervention Extract 39 (Intervention) ===
ion
ne (perfor
rmance e
attrition
bias), pe
CONS
er
CONS
SIDERAZIONI AGGIUNTIVE
SIDERAZIONI AGGIUNTIVE Does the balance between desi
GIUDIZI
○ Favors the comparison
○ Probably favors the comparis
○ Does not favor either the
intervention or the comparison
● Probably favors the intervent
○ Favors the intervention
○ Varies
○ Don't know What would be the impact on h
GIUDIZI
○ Reduced
○ Probably reduced
● Probably no impact
○ Probably increased
○ Increased
○ Varies
○ Don't know Is the intervention acceptable t
GIUDIZI
○ No
○ Probably no
○ Probably yes
NEOPLASIE DEL POLM
irable and undesirable effects favor the

=== Intervention Extract 40 (Intervention) ===
e comparis
○ Does not favor either the
intervention or the comparison
● Probably favors the intervent
○ Favors the intervention
○ Varies
○ Don't know What would be the impact on h
GIUDIZI
○ Reduced
○ Probably reduced
● Probably no impact
○ Probably increased
○ Increased
○ Varies
○ Don't know Is the intervention acceptable t
GIUDIZI
○ No
○ Probably no
○ Probably yes
NEOPLASIE DEL POLM
irable and undesirable effects favor the intervention or the comparison
RICERCA DELLE PROVE DI EVIDENZA
Le evidenze sono molto incerte sull'effetto di alectinib sulla PF
son alla progressione delle metastasi cerebrali o alla

=== Intervention Extract 41 (Intervention) ===
○ Varies
○ Don't know What would be the impact on h
GIUDIZI
○ Reduced
○ Probably reduced
● Probably no impact
○ Probably increased
○ Increased
○ Varies
○ Don't know Is the intervention acceptable t
GIUDIZI
○ No
○ Probably no
○ Probably yes
NEOPLASIE DEL POLM
irable and undesirable effects favor the intervention or the comparison
RICERCA DELLE PROVE DI EVIDENZA
Le evidenze sono molto incerte sull'effetto di alectinib sulla PF
son alla progressione delle metastasi cerebrali o alla morte.
L'evidenza suggerisce che Alectinib determina un largo aumen
n Alectinib potrebbe leggermente incrementare l'ORR.
tion Le

=== Intervention Extract 42 (Intervention) ===
avors th
interventio
Moder
ate
saving
s
Probably
increased
Yes
Yes
or
he
on
L
Favors
the
interven
tion
Large
savings
Increased
Vari
e
s
Vari
e
s
Varies
Varies
Varies
A
No included
studies
Do
n't
kn
o
w
Do
n't
kn
o
w
Don't
know
Don't
know
Don't
know
NEOP Strong recommendation Conditional
against the intervention recommendation against
the intervention Nei pazienti affetti da NSCLC in stadio localmente avanzato o metast
terapeutica di prima scelta.
PLASIE DEL POLMONE
Conditional
recommendation for the
intervention
tatico con riarrangiamenti di ALK, un trattame
Strong recommendation
for the intervention
ento

=== Intervention Extract 43 (Intervention) ===
Probably
increased
Yes
Yes
or
he
on
L
Favors
the
interven
tion
Large
savings
Increased
Vari
e
s
Vari
e
s
Varies
Varies
Varies
A
No included
studies
Do
n't
kn
o
w
Do
n't
kn
o
w
Don't
know
Don't
know
Don't
know
NEOP Strong recommendation Conditional
against the intervention recommendation against
the intervention Nei pazienti affetti da NSCLC in stadio localmente avanzato o metast
terapeutica di prima scelta.
PLASIE DEL POLMONE
Conditional
recommendation for the
intervention
tatico con riarrangiamenti di ALK, un trattame
Strong recommendation
for the intervention
ento di prima linea con alectinib dovrebbe e

=== Intervention Extract 44 (Intervention) ===
n't
kn
o
w
Don't
know
Don't
know
Don't
know
NEOP Strong recommendation Conditional
against the intervention recommendation against
the intervention Nei pazienti affetti da NSCLC in stadio localmente avanzato o metast
terapeutica di prima scelta.
PLASIE DEL POLMONE
Conditional
recommendation for the
intervention
tatico con riarrangiamenti di ALK, un trattame
Strong recommendation
for the intervention
ento di prima linea con alectinib dovrebbe essere consi
iderato come opzione
NEOPLASI Autore/i: ACT
Domanda: Brigatinib rispetto a Crizotinib per pazienti con NSLC in fase avanzata non precedentemente trattati

=== Intervention Extract 45 (Intervention) ===
the intervention recommendation against
the intervention Nei pazienti affetti da NSCLC in stadio localmente avanzato o metast
terapeutica di prima scelta.
PLASIE DEL POLMONE
Conditional
recommendation for the
intervention
tatico con riarrangiamenti di ALK, un trattame
Strong recommendation
for the intervention
ento di prima linea con alectinib dovrebbe essere consi
iderato come opzione
NEOPLASI Autore/i: ACT
Domanda: Brigatinib rispetto a Crizotinib per pazienti con NSLC in fase avanzata non precedentemente trattati
Setting: Outpatients
Bibliografia: Camidge, D. R., et al. (2020). "Brigatinib Versus Criz

=== Intervention Extract 46 (Intervention) ===
ty
Probab
ly
favors
the
compa
rison
PLASIE DEL POLMO
Probably
yes
Moderat
e
Small
Moderat
e
Probably no importa
uncertainty or
variability
Does
not
favor
either
the
interve
ntion
or the
compar
ison
ONE
GIUDIZI
Yes
Large
Trivial
High
No
import
ant
ant
uncert
ainty
or
variabi
lity
Probably favors
the
intervention
Favors
the
interve
ntion
L
Varies
Varies
Varies
Varies
Don't
know
Don't
know
Don't
know
No included
studies
Don't know
EQUITA’
ACCETTAB
ILITÀ
FATTIBILITÀ
Reduce
d
No
No
NEOPLA
Probab
ly
reduce
d
Probab
ly no
Probab
ly no
ASIE DEL POLMON
Probably no
impact
Probabl
y yes
Probabl
y yes
NE
GIU
Pro
UDIZ

=== Intervention Extract 47 (Intervention) ===
GIUDIZI
Probably Probably
Yes
no yes
Small Moderate Large
Moderat Trivia
Small
e l
Moderat
Low High
e
Probably no
No important
Possibly important important
uncertain
uncertainty or uncertainty
ty or
variability or
variability
variability
Probably Does not favor
favors either the Probably favors
the intervention the
comparis or the intervention
on comparison
Probably Probably no Probably
reduced impact increased
Favors the
interventi
on
Increased
Varies
Varies
Varies
e
Vari
es
Varies
Don't know
Don't know
Don't know
No included
studies
Don't know
Don't
know ACCETTABILI
No Probably no
Probably
Yes Varies
ye

=== Intervention Extract 48 (Intervention) ===
yes
Small Moderate Large
Moderat Trivia
Small
e l
Moderat
Low High
e
Probably no
No important
Possibly important important
uncertain
uncertainty or uncertainty
ty or
variability or
variability
variability
Probably Does not favor
favors either the Probably favors
the intervention the
comparis or the intervention
on comparison
Probably Probably no Probably
reduced impact increased
Favors the
interventi
on
Increased
Varies
Varies
Varies
e
Vari
es
Varies
Don't know
Don't know
Don't know
No included
studies
Don't know
Don't
know ACCETTABILI
No Probably no
Probably
Yes Varies
yes
TÀ
FATTIBILITÀ No Probably no
P

=== Intervention Extract 49 (Intervention) ===
a mutazione
attivante l’EGFR o riarrangiamento di ALK e con buon performance status (0-1)?
POPULATION: Pazienti affetti da NSCLC a istologia non-squamosa con espressione di PD-L1 <50% in stadio metastatico senza mutazione attivante l’EGFR o riarrangiamento di ALK e con buon
performance status (0-1)
INTERVENTION: Un trattamento di prima linea a base di platino, pemetrexed e pembrolizumab, seguito da mantenimento con pemetrexed e pembrolizumab in caso di risposta o stabilità di
malattia dopo 4 cicli di trattamento
COMPARISON: Alla chemioterapia
MAIN OUTCOMES: Overall survival; Progression free survival; Obj

=== Intervention Extract 50 (Intervention) ===
ONE
verall qua
irections
E
ality of the evidenc
(favor to intervent
ce was jud
tion arm)
dged
ADDIT
ADDIT
TIONAL CONSIDERATIONS
TIONAL CONSIDERATIONS Does the balance between desirable and undesira
JUDGEMENT RESEAR
○ Favors the comparison
○ Probably favors the comparison
○ Does not favor either the intervention
or the comparison
○ Probably favors the intervention
x
Favors the intervention
○ Varies
○ Don't know What would be the impact on health equity?
JUDGEMENT RESEAR
○ Reduced No evi
○ Probably reduced
x
Probably no impact
○ Probably increased
○ Increased
○ Varies
○ Don't know Is the intervention accept

=== Intervention Extract 51 (Intervention) ===
r to intervent
ce was jud
tion arm)
dged
ADDIT
ADDIT
TIONAL CONSIDERATIONS
TIONAL CONSIDERATIONS Does the balance between desirable and undesira
JUDGEMENT RESEAR
○ Favors the comparison
○ Probably favors the comparison
○ Does not favor either the intervention
or the comparison
○ Probably favors the intervention
x
Favors the intervention
○ Varies
○ Don't know What would be the impact on health equity?
JUDGEMENT RESEAR
○ Reduced No evi
○ Probably reduced
x
Probably no impact
○ Probably increased
○ Increased
○ Varies
○ Don't know Is the intervention acceptable to key stakeholders
JUDGEMENT RESEAR
○ No No evi

=== Intervention Extract 52 (Intervention) ===
tion arm)
dged
ADDIT
ADDIT
TIONAL CONSIDERATIONS
TIONAL CONSIDERATIONS Does the balance between desirable and undesira
JUDGEMENT RESEAR
○ Favors the comparison
○ Probably favors the comparison
○ Does not favor either the intervention
or the comparison
○ Probably favors the intervention
x
Favors the intervention
○ Varies
○ Don't know What would be the impact on health equity?
JUDGEMENT RESEAR
○ Reduced No evi
○ Probably reduced
x
Probably no impact
○ Probably increased
○ Increased
○ Varies
○ Don't know Is the intervention acceptable to key stakeholders
JUDGEMENT RESEAR
○ No No evi
○ Probably no
○ Probably

=== Intervention Extract 53 (Intervention) ===
er the intervention
or the comparison
○ Probably favors the intervention
x
Favors the intervention
○ Varies
○ Don't know What would be the impact on health equity?
JUDGEMENT RESEAR
○ Reduced No evi
○ Probably reduced
x
Probably no impact
○ Probably increased
○ Increased
○ Varies
○ Don't know Is the intervention acceptable to key stakeholders
JUDGEMENT RESEAR
○ No No evi
○ Probably no
○ Probably yes
able effects favor t
RCH EVIDENCE
RCH EVIDENCE
idence found
s?
RCH EVIDENCE
idence found
NEO
the interv
OPLAS
vention or
SIE DE
r the com
EL POL
mparison?
LMONE
E
ADDIT
ADDIT
ADDIT
LINE
TIONAL C
TIONAL C
TIONAL

=== Intervention Extract 54 (Intervention) ===
le effects favor t
RCH EVIDENCE
RCH EVIDENCE
idence found
s?
RCH EVIDENCE
idence found
NEO
the interv
OPLAS
vention or
SIE DE
r the com
EL POL
mparison?
LMONE
E
ADDIT
ADDIT
ADDIT
LINE
TIONAL C
TIONAL C
TIONAL C
EE GUIDA
CONSIDERATIONS
CONSIDERATIONS
CONSIDERATIONS
x
Yes
○ Varies
○ Don't know Is the intervention feasible
JUDGEMENT
○ No
○ Probably no
○ Probably yes
x
Yes
○ Varies
○ Don't know
SUMMA
PROBLEM
DESIRABLE
EFFECTS
UNDESIRABLE
EFFECTS
e to implement?
RESEARCH EVI
No evidence fo
ARY OF JUDGEME
No
Trivial
Large
NEOP
IDENCE
ound
ENTS
Probab
ly no
Small
Moder
ate
PLASIE
E DEL POLMO
Probabl
y yes
Modera

=== Intervention Extract 55 (Intervention) ===
DG
GEMENT
High
No important
uncertainty or
variability
Probabl
y favors
the
interve
ntion
Probabl
y
increas
ed
Favor
interventi
Incre
ased
L
rs the
ion
Va
rie
s
Va
rie
s
A
No included
studies
D
o
n'
t
k
n
o
w
D
o
n'
t
k
n
o
w
ACCEPTAB
ILITY
FEASIBILIT
Y
TYPE OF REC
Strong recommendation
against the intervention
NEOPL
Probab
No
ly no
Probab
No
ly no
COMMENDATION
Conditional
recommendation against
the intervention
LASIE DEL POLMONE
JUDG
Probabl
y yes
Probabl
y yes
Conditional
recommendation for the
intervention
GEMENT
Yes
Yes
Strong recommendati
for the intervention
X
Va
rie
s
Va
rie
s
ion
n
A
D
o
n'
t
k
n

=== Intervention Extract 56 (Intervention) ===
reas
ed
Favor
interventi
Incre
ased
L
rs the
ion
Va
rie
s
Va
rie
s
A
No included
studies
D
o
n'
t
k
n
o
w
D
o
n'
t
k
n
o
w
ACCEPTAB
ILITY
FEASIBILIT
Y
TYPE OF REC
Strong recommendation
against the intervention
NEOPL
Probab
No
ly no
Probab
No
ly no
COMMENDATION
Conditional
recommendation against
the intervention
LASIE DEL POLMONE
JUDG
Probabl
y yes
Probabl
y yes
Conditional
recommendation for the
intervention
GEMENT
Yes
Yes
Strong recommendati
for the intervention
X
Va
rie
s
Va
rie
s
ion
n
A
D
o
n'
t
k
n
o
w
D
o
n'
t
k
n
o
w Nei pazienti affetti da NSCLC a istologia non-squamosa con espressione di PD-L1 <5

=== Intervention Extract 57 (Intervention) ===
n
o
w
D
o
n'
t
k
n
o
w
ACCEPTAB
ILITY
FEASIBILIT
Y
TYPE OF REC
Strong recommendation
against the intervention
NEOPL
Probab
No
ly no
Probab
No
ly no
COMMENDATION
Conditional
recommendation against
the intervention
LASIE DEL POLMONE
JUDG
Probabl
y yes
Probabl
y yes
Conditional
recommendation for the
intervention
GEMENT
Yes
Yes
Strong recommendati
for the intervention
X
Va
rie
s
Va
rie
s
ion
n
A
D
o
n'
t
k
n
o
w
D
o
n'
t
k
n
o
w Nei pazienti affetti da NSCLC a istologia non-squamosa con espressione di PD-L1 <50% in stadio metastatico senza mutazione attivante l’EGFR o riarrangiamento di ALK e con buon
perfo

=== Intervention Extract 58 (Intervention) ===
OF REC
Strong recommendation
against the intervention
NEOPL
Probab
No
ly no
Probab
No
ly no
COMMENDATION
Conditional
recommendation against
the intervention
LASIE DEL POLMONE
JUDG
Probabl
y yes
Probabl
y yes
Conditional
recommendation for the
intervention
GEMENT
Yes
Yes
Strong recommendati
for the intervention
X
Va
rie
s
Va
rie
s
ion
n
A
D
o
n'
t
k
n
o
w
D
o
n'
t
k
n
o
w Nei pazienti affetti da NSCLC a istologia non-squamosa con espressione di PD-L1 <50% in stadio metastatico senza mutazione attivante l’EGFR o riarrangiamento di ALK e con buon
performance status (0-1) un trattamento di prima linea a base

=== Intervention Extract 59 (Intervention) ===
ríguez-Cid, J., Wilson, J., Sugawara, S., Kato, T., Lee, K. H., Cheng, Y., Novello, S., Halmos, B., Li, X., Lubiniecki, G. M., Piperdi, B., Kowalski, D. M..
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med; Nov 22 2018.
DOMAN
Dovrebbe C
istologia squ
POPULATION:
INTERVENTION:
COMPARISON:
MAIN OUTCOMES:
SETTING:
PERSPECTIVE:
BACKGROUND:
CONFLICT OF INTERESTS: Is the problem a priority?
GIUDIZI
○ No
Probably no
Probably yes
Yes
Varies
Don't know
NDA 34
CBDCA + paclitaxel o nab-paclitaxel + pembrolizumab vs chemioterapia essere utilizzato per pazienti affetti da NSCLC a
u

=== Intervention Extract 60 (Intervention) ===
ncertainty or
variability
No important uncertainty or variability
SIDERAZIONI AGGIUNTIVE
SIDERAZIONI AGGIUNTIVE Does the balance between desir
GIUDIZI
○ Favors the comparison
Probably favors the comparison
Does not favor either the interv
or the comparison
Probably favors the interventio
Favors the intervention
Varies
Don't know What would be the impact on he
GIUDIZI
Reduced
Probably reduced
Probably no impact
Probably increased
Increased
Varies
Don't know
rable and undesirable effects favor the intervention or the comparison?
RICERCA DELLE PROVE DI EVIDENZA
Le evidenze suggeriscono che CBDCA + Paclitaxel

=== Intervention Extract 61 (Intervention) ===
ison
Does not favor either the interv
or the comparison
Probably favors the interventio
Favors the intervention
Varies
Don't know What would be the impact on he
GIUDIZI
Reduced
Probably reduced
Probably no impact
Probably increased
Increased
Varies
Don't know
rable and undesirable effects favor the intervention or the comparison?
RICERCA DELLE PROVE DI EVIDENZA
Le evidenze suggeriscono che CBDCA + Paclitaxel o Nab-Paclitaxel + Pembrolizumab deter
n sopravvivenza, della PFS e della risposta obiettiva.
vention CBDCA + Paclitaxel o Nab-Paclitaxel + Pembrolizumab potrebbero ridurre la probabilità di
trattamen

=== Intervention Extract 62 (Intervention) ===
relati all'immunoterapia.
ealth equity?
RICERCA DELLE PROVE DI EVIDENZA
Nessuna evidenza trovata.
rminano un aumen
i interruzione del
brolizumab nel dete
ccola a nessuna dif
rminano un largo
nto della
erminare
fferenza
CONS
CONS
LINEE
SIDERAZI
SIDERAZI
E GUIDA
IONI AGGIUNTIVE
IONI AGGIUNTIVE Is the intervention acce
GIUDIZI
○ No
○ Probably no
○ Probably yes
● Yes
○ Varies
○ Don't know Is the intervention feas
GIUDIZI
○ No
○ Probably no
○ Probably yes
● Yes
○ Varies
○ Don't know
NEOP
eptable to key stakeholders?
RICERCA DELLE PROVE DI EVIDENZ
Nessuna evidenza trovata.
sible to implement?
RICERCA DELLE PROV

=== Intervention Extract 63 (Intervention) ===
a.
rminano un aumen
i interruzione del
brolizumab nel dete
ccola a nessuna dif
rminano un largo
nto della
erminare
fferenza
CONS
CONS
LINEE
SIDERAZI
SIDERAZI
E GUIDA
IONI AGGIUNTIVE
IONI AGGIUNTIVE Is the intervention acce
GIUDIZI
○ No
○ Probably no
○ Probably yes
● Yes
○ Varies
○ Don't know Is the intervention feas
GIUDIZI
○ No
○ Probably no
○ Probably yes
● Yes
○ Varies
○ Don't know
NEOP
eptable to key stakeholders?
RICERCA DELLE PROVE DI EVIDENZ
Nessuna evidenza trovata.
sible to implement?
RICERCA DELLE PROVE DI EVIDENZ
Nessuna evidenza trovata.
PLASI
ZA
ZA
IE DEL
L POLM
MONE
E
CONS
CONS
SIDERAZIONI A

=== Intervention Extract 64 (Intervention) ===
es
no y yes
Small
Modera Larg
Varies
te e
Moderate Small
Trivi
Varies
al
Low
Modera
High
te
Probably no
No important
Possibly important important
uncertainty or
uncertainty or variability uncertainty or
variability
variability
Probably
Does not favor either the Probably favors
favors the Favors the
intervention or the the Varies
comparis intervention
comparison intervention
on
Probably
Probably Increase
Probably no impact increase Varies
reduced d
d
Probably Probabl
Yes Varies
no y yes
GUIDA
Don't know
Don't know
Don't know
No included
studies
Don't know
Don't know
Don't know Don
FEASIBILITY No
Probably P

=== Intervention Extract 65 (Intervention) ===
e
Moderate Small
Trivi
Varies
al
Low
Modera
High
te
Probably no
No important
Possibly important important
uncertainty or
uncertainty or variability uncertainty or
variability
variability
Probably
Does not favor either the Probably favors
favors the Favors the
intervention or the the Varies
comparis intervention
comparison intervention
on
Probably
Probably Increase
Probably no impact increase Varies
reduced d
d
Probably Probabl
Yes Varies
no y yes
GUIDA
Don't know
Don't know
Don't know
No included
studies
Don't know
Don't know
Don't know Don
FEASIBILITY No
Probably Probably
Yes
Vari 't
no yes es kno
w Stro

=== Intervention Extract 66 (Intervention) ===
aries
al
Low
Modera
High
te
Probably no
No important
Possibly important important
uncertainty or
uncertainty or variability uncertainty or
variability
variability
Probably
Does not favor either the Probably favors
favors the Favors the
intervention or the the Varies
comparis intervention
comparison intervention
on
Probably
Probably Increase
Probably no impact increase Varies
reduced d
d
Probably Probabl
Yes Varies
no y yes
GUIDA
Don't know
Don't know
Don't know
No included
studies
Don't know
Don't know
Don't know Don
FEASIBILITY No
Probably Probably
Yes
Vari 't
no yes es kno
w Strong recommendation Condit

=== Intervention Extract 67 (Intervention) ===
crease Varies
reduced d
d
Probably Probabl
Yes Varies
no y yes
GUIDA
Don't know
Don't know
Don't know
No included
studies
Don't know
Don't know
Don't know Don
FEASIBILITY No
Probably Probably
Yes
Vari 't
no yes es kno
w Strong recommendation Conditional Conditional Strong recommendation
against the intervention recommendation against recommendation for the for the intervention
the intervention intervention Un trattamento a base di carboplatino, paclitaxel o nabpaclitaxel, e pembrolizumab, seguito da mantenimento con pembrolizumab in caso di risposta o stabilità di malattia
dopo 4 cicli di trattamento dovr

=== Intervention Extract 68 (Intervention) ===
A
Don't know
Don't know
Don't know
No included
studies
Don't know
Don't know
Don't know Don
FEASIBILITY No
Probably Probably
Yes
Vari 't
no yes es kno
w Strong recommendation Conditional Conditional Strong recommendation
against the intervention recommendation against recommendation for the for the intervention
the intervention intervention Un trattamento a base di carboplatino, paclitaxel o nabpaclitaxel, e pembrolizumab, seguito da mantenimento con pembrolizumab in caso di risposta o stabilità di malattia
dopo 4 cicli di trattamento dovrebbe essere preso in considerazione come prima opzione rispetto all

=== Intervention Extract 69 (Intervention) ===
t know
Don't know
No included
studies
Don't know
Don't know
Don't know Don
FEASIBILITY No
Probably Probably
Yes
Vari 't
no yes es kno
w Strong recommendation Conditional Conditional Strong recommendation
against the intervention recommendation against recommendation for the for the intervention
the intervention intervention Un trattamento a base di carboplatino, paclitaxel o nabpaclitaxel, e pembrolizumab, seguito da mantenimento con pembrolizumab in caso di risposta o stabilità di malattia
dopo 4 cicli di trattamento dovrebbe essere preso in considerazione come prima opzione rispetto alla chemioterapia i

=== Intervention Extract 70 (Intervention) ===
know
No included
studies
Don't know
Don't know
Don't know Don
FEASIBILITY No
Probably Probably
Yes
Vari 't
no yes es kno
w Strong recommendation Conditional Conditional Strong recommendation
against the intervention recommendation against recommendation for the for the intervention
the intervention intervention Un trattamento a base di carboplatino, paclitaxel o nabpaclitaxel, e pembrolizumab, seguito da mantenimento con pembrolizumab in caso di risposta o stabilità di malattia
dopo 4 cicli di trattamento dovrebbe essere preso in considerazione come prima opzione rispetto alla chemioterapia in pazienti af

=== Intervention Extract 71 (Intervention) ===
erval includes no effect and the lower confidence limit crosses the minimal important difference (MID= 7 VAS)
14 Assuming a SD= 7.24 for both arm (Sds are not reported in the primary article) and a p-value > 0.05 (the authors reported "Not-Ssignificant" only)
15 we added a further event both in the intervention and in the control group to permit the calculation of relative and absolute effect
IDA
ore); both f
for benefit
and harm Dovrebbe maintenance therapy with pemetrexed vs placebo essere utiliz
POPOLAZIONE: Advanced NSCLC
INTERVENTO: Maintenance therapy with pemetrexed
CONFRONTO: Placebo
ESITI PRINCIP

=== Intervention Extract 72 (Intervention) ===
o
No
GIUDIZI
Probably no Probably yes Yes
Small Moderate Large
Moderate Small Trivial
Low Moderate High
Probably no
Possibly important No important
important
r uncertainty or uncertainty
uncertainty or
variability variability
variability
Does not favor
either the Probably favors
Probably favors the
intervention the
comparison
or the intervention
comparison
Probably reduced Probably no impact Probably increase
Probably no Probably yes Yes
Probably no Probably yes Yes
t
or
y
Favors t
interve
ed Increas
Varies
Varies
Varies
the
Varies
ention
sed Varies
Varies
Varies
Don't know
Don't know
Don't know
No includ

=== Intervention Extract 73 (Intervention) ===
es Yes
Small Moderate Large
Moderate Small Trivial
Low Moderate High
Probably no
Possibly important No important
important
r uncertainty or uncertainty
uncertainty or
variability variability
variability
Does not favor
either the Probably favors
Probably favors the
intervention the
comparison
or the intervention
comparison
Probably reduced Probably no impact Probably increase
Probably no Probably yes Yes
Probably no Probably yes Yes
t
or
y
Favors t
interve
ed Increas
Varies
Varies
Varies
the
Varies
ention
sed Varies
Varies
Varies
Don't know
Don't know
Don't know
No included
studies
Don't know
Don't know
Do

=== Intervention Extract 74 (Intervention) ===
w 2: |per più di 30 anni, oppure che hanno smesso meno di 10 anni prima, lo screening per tumore polmonare con la TC torace spirale a bassa dose|||
Row 3: |annuale dovrebbe essere preso in considerazione rispetto al non screening?|||
Row 4: ||||
Row 5: |POPULATION:||Lung cancer|
Row 6: ||||
Row 7: |INTERVENTION:||LDCT screening|
Row 8: ||||
Row 9: |COMPARISON:||No LDCT screening|
Row 10: ||||
Row 11: MAIN OUTCOMES:|||Lung cancer related mortality; All-cause mortality; Early stage detection; Late stage disease; Resectability rate ; Overdiagnosis; False positive rate|
Row 12: ||||
Row 13: |SETTING:|||
Row 1

=== Intervention Extract 75 (Intervention) ===
hanno fumato almeno 15 sigarette al giorno per più di 25 a|
Row 2: |per più di 30 anni, oppure che hanno smesso meno di 10 anni prima, lo screening per tumore polmo|
Row 3: |annuale dovrebbe essere preso in considerazione rispetto al non screening?|
Row 4: ||
Row 5: |POPULATION:|
Row 6: ||
Row 7: |INTERVENTION:|
Row 8: ||
Row 9: |COMPARISON:|
Row 10: ||
Row 11: MAIN OUTCOMES:||
Row 12: ||
Row 13: |SETTING:|
Row 14: ||
Row 15: |PERSPECTIVE:|
Row 16: ||
Row 17: |BACKGROUND:|
Row 18: ||
Row 19: CONFLICT OF INTERESTS:||
Row 20: || Row 1: anni oppure almeno 10 sigar
Row 2: onare con la TC torace spira
Row 3:

=== Intervention Extract 76 (Intervention) ===
2021 without language restriction. The database searches retrieved 137 records after duplicate were removed. Sixteen studies were judged as potentially relevant. Two articles were excluded, because they were not randomized controlled trials; five because did not included either population (n.3) or intervention (n.2) of interest and three comparing CTLS versus CXR (3, 23, 24, 25). Six randomized controlled trials comparing LDCT versus NS (6, 8, 10, 11, 13, 14) were excluded as they were already included in the systematic review of Passiglia 2021 (15). This review was finally included encompassing a total

=== Intervention Extract 77 (Intervention) ===
2021 without language restriction. The database searches retrieved 137 records after duplicate were removed. Sixteen studies were judged as potentially relevant. Two articles were excluded, because they were not randomized controlled trials; five because did not included either population (n.3) or intervention (n.2) of interest and three comparing CTLS versus CXR (3, 23, 24, 25). Six randomized controlled trials comparing LDCT versus NS (6, 8, 10, 11, 13, 14) were excluded as they were already included in the systematic review of Passiglia 2021 (15). This review was finally included encompassing a total

=== Intervention Extract 78 (Intervention) ===
2021 without language restriction. The database searches retrieved 137 records after duplicate were removed. Sixteen studies were judged as potentially relevant. Two articles were excluded, because they were not randomized controlled trials; five because did not included either population (n.3) or intervention (n.2) of interest and three comparing CTLS versus CXR (3, 23, 24, 25). Six randomized controlled trials comparing LDCT versus NS (6, 8, 10, 11, 13, 14) were excluded as they were already included in the systematic review of Passiglia 2021 (15). This review was finally included encompassing a total

=== Intervention Extract 79 (Intervention) ===
nty or variability ○ Possibly important uncertainty or variability ● Probably no important uncertainty or variability ○ No important uncertainty or variability||No evidence found||
Row 3: ||||
Row 4: |Balance of effects|||
Row 5: |Does the balance between desirable and undesirable effects favor the intervention or the comparison?|||
Row 6: ||||
Row 7: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 8: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention ● Favors the intervention ○ Vari

=== Intervention Extract 80 (Intervention) ===
fects|||
Row 5: |Does the balance between desirable and undesirable effects favor the intervention or the comparison?|||
Row 6: ||||
Row 7: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 8: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention ● Favors the intervention ○ Varies ○ Don't know||||
Row 9: ||||
Row 10: |Equity|||
Row 11: |What would be the impact on health equity?|||
Row 12: ||||
Row 13: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE| Row 1: GIUDIZI||
Ro

=== Intervention Extract 81 (Intervention) ===
nd undesirable effects favor the intervention or the comparison?|||
Row 6: ||||
Row 7: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 8: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention ● Favors the intervention ○ Varies ○ Don't know||||
Row 9: ||||
Row 10: |Equity|||
Row 11: |What would be the impact on health equity?|||
Row 12: ||||
Row 13: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE| Row 1: GIUDIZI||
Row 2: ○ Important uncertainty or variability ○ Possibl

=== Intervention Extract 82 (Intervention) ===
or the intervention or the comparison?|||
Row 6: ||||
Row 7: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 8: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention ● Favors the intervention ○ Varies ○ Don't know||||
Row 9: ||||
Row 10: |Equity|||
Row 11: |What would be the impact on health equity?|||
Row 12: ||||
Row 13: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE| Row 1: GIUDIZI||
Row 2: ○ Important uncertainty or variability ○ Possibly important uncertainty or

=== Intervention Extract 83 (Intervention) ===
r variability ○ No important uncertainty or variability||
Row 3: ||
Row 4: |Balance of effects|
Row 5: |Does the balance between desirable and undesirable effects favor the interv|
Row 6: ||
Row 7: GIUDIZI||
Row 8: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention ● Favors the intervention ○ Varies ○ Don't know||
Row 9: ||
Row 10: |Equity|
Row 11: |What would be the impact on health equity?|
Row 12: ||
Row 13: GIUDIZI|| Row 1: 
Row 2: 
Row 3: vention or
Row 4:  Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: 
Row 2

=== Intervention Extract 84 (Intervention) ===
ty||
Row 3: ||
Row 4: |Balance of effects|
Row 5: |Does the balance between desirable and undesirable effects favor the interv|
Row 6: ||
Row 7: GIUDIZI||
Row 8: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention ● Favors the intervention ○ Varies ○ Don't know||
Row 9: ||
Row 10: |Equity|
Row 11: |What would be the impact on health equity?|
Row 12: ||
Row 13: GIUDIZI|| Row 1: 
Row 2: 
Row 3: vention or
Row 4:  Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: 
Row 2: 
Row 3: r the com
Row 4:  Row 1: 
Row 2: 
Row 3: mp

=== Intervention Extract 85 (Intervention) ===
ance of effects|
Row 5: |Does the balance between desirable and undesirable effects favor the interv|
Row 6: ||
Row 7: GIUDIZI||
Row 8: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention ● Favors the intervention ○ Varies ○ Don't know||
Row 9: ||
Row 10: |Equity|
Row 11: |What would be the impact on health equity?|
Row 12: ||
Row 13: GIUDIZI|| Row 1: 
Row 2: 
Row 3: vention or
Row 4:  Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: 
Row 2: 
Row 3: r the com
Row 4:  Row 1: 
Row 2: 
Row 3: mparison?
Row 4:  Row 1: |
R

=== Intervention Extract 86 (Intervention) ===
1: 
Row 2: 
Row 3: r the com
Row 4:  Row 1: 
Row 2: 
Row 3: mparison?
Row 4:  Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: ○ Reduced ○ Probably reduced ● Probably no impact ○ Probably increased ○ Increased ○ Varies ○ Don't know||No evidence found||
Row 2: ||||
Row 3: |Acceptability|||
Row 4: |Is the intervention acceptable to key stakeholders?|||
Row 5: ||||
Row 6: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 7: ○ No ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know||No evidence found||
Row 8: ||||
Row 9: |Feasibility|||
Row 10: |Is the intervention feasible to implement?|

=== Intervention Extract 87 (Intervention) ===
ility|||
Row 4: |Is the intervention acceptable to key stakeholders?|||
Row 5: ||||
Row 6: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 7: ○ No ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know||No evidence found||
Row 8: ||||
Row 9: |Feasibility|||
Row 10: |Is the intervention feasible to implement?|||
Row 11: ||||
Row 12: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 13: ○ No ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know||No evidence found|| Row 1: |
Row 2: |Acceptability
Row 3: |Is the intervention acce
Row 4: | Row 1: |
Row 2: |Fea

=== Intervention Extract 88 (Intervention) ===
9: |Feasibility|||
Row 10: |Is the intervention feasible to implement?|||
Row 11: ||||
Row 12: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 13: ○ No ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know||No evidence found|| Row 1: |
Row 2: |Acceptability
Row 3: |Is the intervention acce
Row 4: | Row 1: |
Row 2: |Feasibility
Row 3: |Is the intervention feas
Row 4: | Row 1: 
Row 2: 
Row 3: eptable to
Row 4:  Row 1: 
Row 2: 
Row 3: sible to im
Row 4:  Row 1: |
Row 2: |
Row 3: o key stakeholders|
Row 4: | Row 1: |
Row 2: |
Row 3: mplement?|
Row 4: | Row 1: 
Row 2: 
Row 3: s?
Row

=== Intervention Extract 89 (Intervention) ===
||
Row 11: ||||
Row 12: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 13: ○ No ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know||No evidence found|| Row 1: |
Row 2: |Acceptability
Row 3: |Is the intervention acce
Row 4: | Row 1: |
Row 2: |Feasibility
Row 3: |Is the intervention feas
Row 4: | Row 1: 
Row 2: 
Row 3: eptable to
Row 4:  Row 1: 
Row 2: 
Row 3: sible to im
Row 4:  Row 1: |
Row 2: |
Row 3: o key stakeholders|
Row 4: | Row 1: |
Row 2: |
Row 3: mplement?|
Row 4: | Row 1: 
Row 2: 
Row 3: s?
Row 4:  Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: |
Row 2: |
Row 3: |
Row 4: |

=== Intervention Extract 90 (Intervention) ===
ncertainty or variability||Possibly important uncertainty or variability|Probably no important uncertainty or variability|No important uncertainty or variability||||
Row 17: VALUES||||||||||
Row 18: ||||||||||
Row 19: ||Favors the comparison||Probably favors the comparison|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|Varies|Don't know|
Row 20: BALANCE OF EFFECTS||||||||||
Row 21: ||||||||||
Row 22: ||Reduced||Probably reduced|Probably no impact|Probably increased|Increased|Varies|Don't know|
Row 23: EQUITY||||||||||
Row 24: ||||||||||
Ro

=== Intervention Extract 91 (Intervention) ===
tainty or variability|Probably no important uncertainty or variability|No important uncertainty or variability||||
Row 17: VALUES||||||||||
Row 18: ||||||||||
Row 19: ||Favors the comparison||Probably favors the comparison|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|Varies|Don't know|
Row 20: BALANCE OF EFFECTS||||||||||
Row 21: ||||||||||
Row 22: ||Reduced||Probably reduced|Probably no impact|Probably increased|Increased|Varies|Don't know|
Row 23: EQUITY||||||||||
Row 24: ||||||||||
Row 25: ||No||Probably no|Probably yes|Yes||Varies|Do

=== Intervention Extract 92 (Intervention) ===
obably no important uncertainty or variability|No important uncertainty or variability||||
Row 17: VALUES||||||||||
Row 18: ||||||||||
Row 19: ||Favors the comparison||Probably favors the comparison|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|Varies|Don't know|
Row 20: BALANCE OF EFFECTS||||||||||
Row 21: ||||||||||
Row 22: ||Reduced||Probably reduced|Probably no impact|Probably increased|Increased|Varies|Don't know|
Row 23: EQUITY||||||||||
Row 24: ||||||||||
Row 25: ||No||Probably no|Probably yes|Yes||Varies|Don't know|
Row 26: ACCEPT

=== Intervention Extract 93 (Intervention) ===
ITY||||||||||
Row 24: ||||||||||
Row 25: ||No||Probably no|Probably yes|Yes||Varies|Don't know|
Row 26: ACCEPTABILITY||||||||||
Row 27: ||||||||||
Row 28: ||No||Probably no|Probably yes|Yes||Varies|Don't know|
Row 29: FEASIBILITY||||||||||
Row 30: |||||||||| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|
Row 2: |||Strong recommendation for the
Row 3: |||intervention
Row 4: |||●
Row 5: ||| Row 1: ||||||||
Row 2: |||GIUDIZI|||||
Row 3: ||||||||
Row 4: ||No||Probably no|Probably yes|Yes||
Row 5:

=== Intervention Extract 94 (Intervention) ===
y no|Probably yes|Yes||Varies|Don't know|
Row 26: ACCEPTABILITY||||||||||
Row 27: ||||||||||
Row 28: ||No||Probably no|Probably yes|Yes||Varies|Don't know|
Row 29: FEASIBILITY||||||||||
Row 30: |||||||||| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|
Row 2: |||Strong recommendation for the
Row 3: |||intervention
Row 4: |||●
Row 5: ||| Row 1: ||||||||
Row 2: |||GIUDIZI|||||
Row 3: ||||||||
Row 4: ||No||Probably no|Probably yes|Yes||
Row 5: PROBLEM||||||||
Row 6: ||||||||
Row 7: ||Trivial||Smal

=== Intervention Extract 95 (Intervention) ===
ACCEPTABILITY||||||||||
Row 27: ||||||||||
Row 28: ||No||Probably no|Probably yes|Yes||Varies|Don't know|
Row 29: FEASIBILITY||||||||||
Row 30: |||||||||| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|
Row 2: |||Strong recommendation for the
Row 3: |||intervention
Row 4: |||●
Row 5: ||| Row 1: ||||||||
Row 2: |||GIUDIZI|||||
Row 3: ||||||||
Row 4: ||No||Probably no|Probably yes|Yes||
Row 5: PROBLEM||||||||
Row 6: ||||||||
Row 7: ||Trivial||Small|Moderate|Large||
Row 8: DESIRABLE EFFECTS|||||||

=== Intervention Extract 96 (Intervention) ===
no|Probably yes|Yes||Varies|Don't know|
Row 29: FEASIBILITY||||||||||
Row 30: |||||||||| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|
Row 2: |||Strong recommendation for the
Row 3: |||intervention
Row 4: |||●
Row 5: ||| Row 1: ||||||||
Row 2: |||GIUDIZI|||||
Row 3: ||||||||
Row 4: ||No||Probably no|Probably yes|Yes||
Row 5: PROBLEM||||||||
Row 6: ||||||||
Row 7: ||Trivial||Small|Moderate|Large||
Row 8: DESIRABLE EFFECTS||||||||
Row 9: ||||||||
Row 10: ||Large||Moderate|Small|Trivial||
Row 11

=== Intervention Extract 97 (Intervention) ===
tant uncertainty or variability||Possibly important uncertainty or variability|Probably no important uncertainty or variability|No important uncertainty or variability||
Row 17: VALUES||||||||
Row 18: ||||||||
Row 19: ||Favors the comparison||Probably favors the comparison|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|
Row 20: BALANCE OF EFFECTS||||||||
Row 21: ||||||||
Row 22: ||Reduced||Probably reduced|Probably no impact|Probably increased|Increased|
Row 23: EQUITY||||||||
Row 24: ||||||||
Row 25: ||No||Probably no|Probably yes|Yes||
R

=== Intervention Extract 98 (Intervention) ===
uncertainty or variability|Probably no important uncertainty or variability|No important uncertainty or variability||
Row 17: VALUES||||||||
Row 18: ||||||||
Row 19: ||Favors the comparison||Probably favors the comparison|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|
Row 20: BALANCE OF EFFECTS||||||||
Row 21: ||||||||
Row 22: ||Reduced||Probably reduced|Probably no impact|Probably increased|Increased|
Row 23: EQUITY||||||||
Row 24: ||||||||
Row 25: ||No||Probably no|Probably yes|Yes||
Row 26: ACCEPTABILITY||||||||
Row 27: ||||||||
Row 2

=== Intervention Extract 99 (Intervention) ===
ity|Probably no important uncertainty or variability|No important uncertainty or variability||
Row 17: VALUES||||||||
Row 18: ||||||||
Row 19: ||Favors the comparison||Probably favors the comparison|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|
Row 20: BALANCE OF EFFECTS||||||||
Row 21: ||||||||
Row 22: ||Reduced||Probably reduced|Probably no impact|Probably increased|Increased|
Row 23: EQUITY||||||||
Row 24: ||||||||
Row 25: ||No||Probably no|Probably yes|Yes||
Row 26: ACCEPTABILITY||||||||
Row 27: ||||||||
Row 28: ||No||Probably no|Pro

=== Intervention Extract 100 (Intervention) ===
◯ Molto bassa|CRITICO
Row 18: ||||||
Row 19: ||||||
Row 20: |-|-|-|-|-|IMPORTANTE Row 1: |Dovrebbe la segmentectomia vs lobectomia essere utilizzata per pazienti affetti da NSCLC in stadio iniziale|||
Row 2: ||||
Row 3: |POPULATION:||Pazienti affetti da NSCLC in stadio iniziale|
Row 4: ||||
Row 5: |INTERVENTION:||La segmentectomia|
Row 6: ||||
Row 7: |COMPARISON:||Lobectomia|
Row 8: ||||
Row 9: MAIN OUTCOMES:|||Overall survival RCT; Overall Survival; Disease free survival RCT; Disease free Survival; Quality of life; Number of harvested lymphonodes; Lenght hospital stay; Local recurrence RCT; Local recurre

=== Intervention Extract 101 (Intervention) ===
ainty or variability ○ Probably no important uncertainty or variability ○ No important uncertainty or variability||Nessuna evidenza trovata.|Esprimere le considerazioni aggiuntive|
Row 7: ||||
Row 8: |Balance of effects|||
Row 9: |Does the balance between desirable and undesirable effects favor the intervention or the comparison?|||
Row 10: ||||
Row 11: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 12: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ● Probably favors the intervention ○ Favors the intervention ○ V

=== Intervention Extract 102 (Intervention) ===
ts|||
Row 9: |Does the balance between desirable and undesirable effects favor the intervention or the comparison?|||
Row 10: ||||
Row 11: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 12: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ● Probably favors the intervention ○ Favors the intervention ○ Varies ○ Don't know|||| Row 1: |
Row 2: |Values
Row 3: |Is there important un
Row 4: |
Row 5: GIUDIZI|
Row 6: ○ Important uncertainty or variability ● Possibly important uncertainty or variability ○ Probably no importa

=== Intervention Extract 103 (Intervention) ===
undesirable effects favor the intervention or the comparison?|||
Row 10: ||||
Row 11: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 12: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ● Probably favors the intervention ○ Favors the intervention ○ Varies ○ Don't know|||| Row 1: |
Row 2: |Values
Row 3: |Is there important un
Row 4: |
Row 5: GIUDIZI|
Row 6: ○ Important uncertainty or variability ● Possibly important uncertainty or variability ○ Probably no important uncertainty or variability ○ No important uncertai

=== Intervention Extract 104 (Intervention) ===
the intervention or the comparison?|||
Row 10: ||||
Row 11: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 12: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ● Probably favors the intervention ○ Favors the intervention ○ Varies ○ Don't know|||| Row 1: |
Row 2: |Values
Row 3: |Is there important un
Row 4: |
Row 5: GIUDIZI|
Row 6: ○ Important uncertainty or variability ● Possibly important uncertainty or variability ○ Probably no important uncertainty or variability ○ No important uncertainty or variability|
Row 7:

=== Intervention Extract 105 (Intervention) ===
rtainty or variability ○ Probably no important uncertainty or variability ○ No important uncertainty or variability|
Row 7: |
Row 8: |Balance of effec
Row 9: |Does the balance bet
Row 10: |
Row 11: GIUDIZI|
Row 12: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ● Probably favors the intervention ○ Favors the intervention ○ Varies ○ Don't know| Row 1: 
Row 2: 
Row 3: ncertaint
Row 4:  Row 1: 
Row 2: cts
Row 3: tween de
Row 4:  Row 1: 
Row 2: 
Row 3: ty about or variab
Row 4:  Row 1: 
Row 2: 
Row 3: esirable and und
Row 4:  Row 1: 
Row 2:

=== Intervention Extract 106 (Intervention) ===
ainty or variability ○ No important uncertainty or variability|
Row 7: |
Row 8: |Balance of effec
Row 9: |Does the balance bet
Row 10: |
Row 11: GIUDIZI|
Row 12: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ● Probably favors the intervention ○ Favors the intervention ○ Varies ○ Don't know| Row 1: 
Row 2: 
Row 3: ncertaint
Row 4:  Row 1: 
Row 2: cts
Row 3: tween de
Row 4:  Row 1: 
Row 2: 
Row 3: ty about or variab
Row 4:  Row 1: 
Row 2: 
Row 3: esirable and und
Row 4:  Row 1: 
Row 2: 
Row 3: bility in h
Row 4:  Row 1: 
Row 2: 
Row 3: de

=== Intervention Extract 107 (Intervention) ===
important uncertainty or variability|
Row 7: |
Row 8: |Balance of effec
Row 9: |Does the balance bet
Row 10: |
Row 11: GIUDIZI|
Row 12: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ● Probably favors the intervention ○ Favors the intervention ○ Varies ○ Don't know| Row 1: 
Row 2: 
Row 3: ncertaint
Row 4:  Row 1: 
Row 2: cts
Row 3: tween de
Row 4:  Row 1: 
Row 2: 
Row 3: ty about or variab
Row 4:  Row 1: 
Row 2: 
Row 3: esirable and und
Row 4:  Row 1: 
Row 2: 
Row 3: bility in h
Row 4:  Row 1: 
Row 2: 
Row 3: desirable
Row 4:  Row 1: 
Ro

=== Intervention Extract 108 (Intervention) ===
n health equity?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ Reduced ○ Probably reduced ○ Probably no impact ● Probably increased ○ Increased ○ Varies ○ Don't know||Nessuna evidenza trovata.||
Row 7: ||||
Row 8: |Acceptability|||
Row 9: |Is the intervention acceptable to key stakeholders?|||
Row 10: ||||
Row 11: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 12: ○ No ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know||Nessuna evidenza trovata.||
Row 13: ||||
Row 14: |Feasibility|||
Row 15: |Is the intervention feasible t

=== Intervention Extract 109 (Intervention) ===
9: |Is the intervention acceptable to key stakeholders?|||
Row 10: ||||
Row 11: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 12: ○ No ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know||Nessuna evidenza trovata.||
Row 13: ||||
Row 14: |Feasibility|||
Row 15: |Is the intervention feasible to implement?|||
Row 16: ||||
Row 17: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 18: ○ No ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know||Nessuna evidenza trovata.|| Row 1: |
Row 2: |Equity
Row 3: |What would
Row 4: | Row 1: |
Row 2: |Acceptab
Row 3:

=== Intervention Extract 110 (Intervention) ===
ncertainty or variability||Possibly important uncertainty or variability|Probably no important uncertainty or variability|No important uncertainty or variability||||
Row 17: VALUES||||||||||
Row 18: ||||||||||
Row 19: ||Favors the comparison||Probably favors the comparison|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|Varies|Don't know|
Row 20: BALANCE OF EFFECTS||||||||||
Row 21: ||||||||||
Row 22: ||Reduced||Probably reduced|Probably no impact|Probably increased|Increased|Varies|Don't know|
Row 23: EQUITY||||||||||
Row 24: ||||||||||
Ro

=== Intervention Extract 111 (Intervention) ===
tainty or variability|Probably no important uncertainty or variability|No important uncertainty or variability||||
Row 17: VALUES||||||||||
Row 18: ||||||||||
Row 19: ||Favors the comparison||Probably favors the comparison|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|Varies|Don't know|
Row 20: BALANCE OF EFFECTS||||||||||
Row 21: ||||||||||
Row 22: ||Reduced||Probably reduced|Probably no impact|Probably increased|Increased|Varies|Don't know|
Row 23: EQUITY||||||||||
Row 24: ||||||||||
Row 25: ||No||Probably no|Probably yes|Yes||Varies|Do

=== Intervention Extract 112 (Intervention) ===
obably no important uncertainty or variability|No important uncertainty or variability||||
Row 17: VALUES||||||||||
Row 18: ||||||||||
Row 19: ||Favors the comparison||Probably favors the comparison|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|Varies|Don't know|
Row 20: BALANCE OF EFFECTS||||||||||
Row 21: ||||||||||
Row 22: ||Reduced||Probably reduced|Probably no impact|Probably increased|Increased|Varies|Don't know|
Row 23: EQUITY||||||||||
Row 24: ||||||||||
Row 25: ||No||Probably no|Probably yes|Yes||Varies|Don't know|
Row 26: ACCEPT

=== Intervention Extract 113 (Intervention) ===
0: ||| Row 1: 
Row 2: GIUDIZI
Row 3:  Row 1: Probably no|Probably yes
Row 2: Small|Moderate
Row 3: Moderate|Small
Row 4: Low|Moderate
Row 5: Possibly important uncertainty or variability|Probably no important uncertainty or variability
Row 6: Probably favors the comparison|Does not favor either the intervention or the comparison
Row 7: Probably reduced|Probably no impact
Row 8: Probably no|Probably yes
Row 9: Probably no|Probably yes Row 1: |
Row 2: |
Row 3: |
Row 4: |
Row 5: |
Row 6: |
Row 7: |
Row 8: |
Row 9: |
Row 10: |
Row 11: |
Row 12: |
Row 13: |
Row 14: |
Row 15: |
Row 16: |
Row 17: |
Row 18: | Row

=== Intervention Extract 114 (Intervention) ===
:  Row 1: ||
Row 2: ||
Row 3: ||
Row 4: |Don't know|
Row 5: |Don't know|
Row 6: |Don't know|
Row 7: |No included studies|
Row 8: ||
Row 9: ||
Row 10: ||
Row 11: ||
Row 12: ||
Row 13: |Don't know|
Row 14: |Don't know|
Row 15: |Don't know|
Row 16: |Don't know| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ●|Strong recommendation for the intervention ○ Row 1: ||
Row 2: |Recommendation|
Row 3: || Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervent

=== Intervention Extract 115 (Intervention) ===
ow 5: |Don't know|
Row 6: |Don't know|
Row 7: |No included studies|
Row 8: ||
Row 9: ||
Row 10: ||
Row 11: ||
Row 12: ||
Row 13: |Don't know|
Row 14: |Don't know|
Row 15: |Don't know|
Row 16: |Don't know| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ●|Strong recommendation for the intervention ○ Row 1: ||
Row 2: |Recommendation|
Row 3: || Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention

=== Intervention Extract 116 (Intervention) ===
included studies|
Row 8: ||
Row 9: ||
Row 10: ||
Row 11: ||
Row 12: ||
Row 13: |Don't know|
Row 14: |Don't know|
Row 15: |Don't know|
Row 16: |Don't know| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ●|Strong recommendation for the intervention ○ Row 1: ||
Row 2: |Recommendation|
Row 3: || Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ● Row 1: |
Row 2: |Recommendation
Row 3: | Row 1:

=== Intervention Extract 117 (Intervention) ===
||
Row 11: ||
Row 12: ||
Row 13: |Don't know|
Row 14: |Don't know|
Row 15: |Don't know|
Row 16: |Don't know| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ●|Strong recommendation for the intervention ○ Row 1: ||
Row 2: |Recommendation|
Row 3: || Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ● Row 1: |
Row 2: |Recommendation
Row 3: | Row 1: |
Row 2: |
Row 3: | Row 1: ||||||||||||
Row 2

=== Intervention Extract 118 (Intervention) ===
n't know| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ●|Strong recommendation for the intervention ○ Row 1: ||
Row 2: |Recommendation|
Row 3: || Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ● Row 1: |
Row 2: |Recommendation
Row 3: | Row 1: |
Row 2: |
Row 3: | Row 1: ||||||||||||
Row 2: Certainty assessment|||||||№ of patients||Effect||Certainty|Importance
Row 3: ||||||||||||
Row 4:

=== Intervention Extract 119 (Intervention) ===
ervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ●|Strong recommendation for the intervention ○ Row 1: ||
Row 2: |Recommendation|
Row 3: || Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ● Row 1: |
Row 2: |Recommendation
Row 3: | Row 1: |
Row 2: |
Row 3: | Row 1: ||||||||||||
Row 2: Certainty assessment|||||||№ of patients||Effect||Certainty|Importance
Row 3: ||||||||||||
Row 4: ||||||||||||
Row 5: № of studies|Study design|Risk of

=== Intervention Extract 120 (Intervention) ===
intervention ○|Conditional recommendation for the intervention ●|Strong recommendation for the intervention ○ Row 1: ||
Row 2: |Recommendation|
Row 3: || Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ● Row 1: |
Row 2: |Recommendation
Row 3: | Row 1: |
Row 2: |
Row 3: | Row 1: ||||||||||||
Row 2: Certainty assessment|||||||№ of patients||Effect||Certainty|Importance
Row 3: ||||||||||||
Row 4: ||||||||||||
Row 5: № of studies|Study design|Risk of bias|Inconsistency|Indirectness|Imprecision|Other

=== Intervention Extract 121 (Intervention) ===
|Dovrebbe un trattamento locoregionale + terapia sistemica vs sola terapia sistemica essere utilizzato per pazienti affetti da NSCLC|||
Row 2: |in stadio avanzato oligometastatico|||
Row 3: ||||
Row 4: |POPULATION:||Pazienti affetti da NSCLC in stadio avanzato oligometastatico|
Row 5: ||||
Row 6: |INTERVENTION:||Un trattamento locoregionale + terapia sistemica|
Row 7: ||||
Row 8: |||Sola terapia sistemica|
Row 9: |COMPARISON:|||
Row 10: ||||
Row 11: |MAIN OUTCOMES:||Overall survival; Progression-free survival; Quality of life; ORR; Discontinuation of any treatment component; Loco-regional progression; Po

=== Intervention Extract 122 (Intervention) ===
3: 
Row 4:  Row 1: 
Row 2: 
Row 3: uch peop
Row 4:  Row 1: 
Row 2: 
Row 3: ple value the main outcom
Row 4:  Row 1: 
Row 2: 
Row 3: mes?
Row 4:  Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: ||||
Row 2: |Balance of effects|||
Row 3: |Does the balance between desirable and undesirable effects favor the intervention or the comparison?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention ● Favors the intervention ○ Vari

=== Intervention Extract 123 (Intervention) ===
fects|||
Row 3: |Does the balance between desirable and undesirable effects favor the intervention or the comparison?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention ● Favors the intervention ○ Varies ○ Don't know||||
Row 7: ||||
Row 8: |Equity|||
Row 9: |What would be the impact on health equity?|||
Row 10: ||||
Row 11: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 12: ○ Reduced ○ P

=== Intervention Extract 124 (Intervention) ===
nd undesirable effects favor the intervention or the comparison?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention ● Favors the intervention ○ Varies ○ Don't know||||
Row 7: ||||
Row 8: |Equity|||
Row 9: |What would be the impact on health equity?|||
Row 10: ||||
Row 11: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 12: ○ Reduced ○ Probably reduced ● Probably no impact ○ Probably incre

=== Intervention Extract 125 (Intervention) ===
or the intervention or the comparison?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention ● Favors the intervention ○ Varies ○ Don't know||||
Row 7: ||||
Row 8: |Equity|||
Row 9: |What would be the impact on health equity?|||
Row 10: ||||
Row 11: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 12: ○ Reduced ○ Probably reduced ● Probably no impact ○ Probably increased ○ Increased ○ Varies

=== Intervention Extract 126 (Intervention) ===
Probably increased ○ Increased ○ Varies ○ Don't know||Nessuna evidenza trovata.|| Row 1: ||
Row 2: |Balance of effects|
Row 3: |Does the balance between desirable and undesirable|
Row 4: ||
Row 5: GIUDIZI||
Row 6: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention ● Favors the intervention ○ Varies ○ Don't know||
Row 7: ||
Row 8: |Equity|
Row 9: |What would be the impact on health equity?|
Row 10: ||
Row 11: GIUDIZI||
Row 12: ○ Reduced ○ Probably reduced ● Probably no impact ○ Probably increased ○ Increase

=== Intervention Extract 127 (Intervention) ===
||Nessuna evidenza trovata.|| Row 1: ||
Row 2: |Balance of effects|
Row 3: |Does the balance between desirable and undesirable|
Row 4: ||
Row 5: GIUDIZI||
Row 6: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention ● Favors the intervention ○ Varies ○ Don't know||
Row 7: ||
Row 8: |Equity|
Row 9: |What would be the impact on health equity?|
Row 10: ||
Row 11: GIUDIZI||
Row 12: ○ Reduced ○ Probably reduced ● Probably no impact ○ Probably increased ○ Increased ○ Varies ○ Don't know|| Row 1: 
Row 2: 
Row 3: e ef

=== Intervention Extract 128 (Intervention) ===
.|| Row 1: ||
Row 2: |Balance of effects|
Row 3: |Does the balance between desirable and undesirable|
Row 4: ||
Row 5: GIUDIZI||
Row 6: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention ● Favors the intervention ○ Varies ○ Don't know||
Row 7: ||
Row 8: |Equity|
Row 9: |What would be the impact on health equity?|
Row 10: ||
Row 11: GIUDIZI||
Row 12: ○ Reduced ○ Probably reduced ● Probably no impact ○ Probably increased ○ Increased ○ Varies ○ Don't know|| Row 1: 
Row 2: 
Row 3: e effects
Row 4:  Row 1: 
Row

=== Intervention Extract 129 (Intervention) ===
: 
Row 3: favor the
Row 4:  Row 1: 
Row 2: 
Row 3: e interve
Row 4:  Row 1: 
Row 2: 
Row 3: ention or
Row 4:  Row 1: 
Row 2: 
Row 3: r the com
Row 4:  Row 1: 
Row 2: 
Row 3: mparison
Row 4:  Row 1: 
Row 2: 
Row 3: n?
Row 4:  Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: |||
Row 2: Acceptability Is the intervention acceptable to key stakeholders?|||
Row 3: |||
Row 4: GIUDIZI|RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 5: ○ No ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know|Nessuna evidenza trovata.||
Row 6: |||
Row 7: Feasibility Is the intervention feasible to implement?|||
Row 8:

=== Intervention Extract 130 (Intervention) ===
|||
Row 2: Acceptability Is the intervention acceptable to key stakeholders?|||
Row 3: |||
Row 4: GIUDIZI|RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 5: ○ No ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know|Nessuna evidenza trovata.||
Row 6: |||
Row 7: Feasibility Is the intervention feasible to implement?|||
Row 8: |||
Row 9: GIUDIZI|RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 10: ○ No ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know|Nessuna evidenza trovata.|| Row 1: ||||||||||
Row 2: |||GIUDIZI|||||||
Row 3: ||||||||||
Row 4: ||No||Probably no|Prob

=== Intervention Extract 131 (Intervention) ===
ZI|||||||
Row 3: ||||||||||
Row 4: ||No||Probably no|Probably yes|Yes||Varies|Don't know|
Row 5: PROBLEM||||||||||
Row 6: ||||||||||
Row 7: ||Trivial||Small|Moderate|Large||Varies|Don't know|
Row 8: DESIRABLE||||||||||
Row 9: EFFECTS||||||||||
Row 10: |||||||||| Row 1: |
Row 2: Acceptability Is the intervention acceptable to key stakeholders?|
Row 3: |
Row 4: GIUDIZI|
Row 5: ○ No ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know|
Row 6: |
Row 7: Feasibility Is the intervention feasible to implement?|
Row 8: |
Row 9: GIUDIZI|
Row 10: ○ No ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know| Row

=== Intervention Extract 132 (Intervention) ===
ies|Don't know|
Row 8: DESIRABLE||||||||||
Row 9: EFFECTS||||||||||
Row 10: |||||||||| Row 1: |
Row 2: Acceptability Is the intervention acceptable to key stakeholders?|
Row 3: |
Row 4: GIUDIZI|
Row 5: ○ No ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know|
Row 6: |
Row 7: Feasibility Is the intervention feasible to implement?|
Row 8: |
Row 9: GIUDIZI|
Row 10: ○ No ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know| Row 1: |||
Row 2: |||
Row 3: |||
Row 4: ||No|
Row 5: PROBLEM|||
Row 6: |||
Row 7: ||Trivial|
Row 8: DESIRABLE|||
Row 9: EFFECTS|||
Row 10: ||| Row 1: 
Row 2: 
Row 3: 
Row 4:  Row

=== Intervention Extract 133 (Intervention) ===
ncertainty or variability||Possibly important uncertainty or variability|Probably no important uncertainty or variability|No important uncertainty or variability||||
Row 11: VALUES||||||||||
Row 12: ||||||||||
Row 13: ||Favors the comparison||Probably favors the comparison|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|Varies|Don't know|
Row 14: BALANCE OF EFFECTS||||||||||
Row 15: ||||||||||
Row 16: ||Reduced||Probably reduced|Probably no impact|Probably increased|Increased|Varies|Don't know|
Row 17: EQUITY||||||||||
Row 18: ||||||||||
Ro

=== Intervention Extract 134 (Intervention) ===
tainty or variability|Probably no important uncertainty or variability|No important uncertainty or variability||||
Row 11: VALUES||||||||||
Row 12: ||||||||||
Row 13: ||Favors the comparison||Probably favors the comparison|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|Varies|Don't know|
Row 14: BALANCE OF EFFECTS||||||||||
Row 15: ||||||||||
Row 16: ||Reduced||Probably reduced|Probably no impact|Probably increased|Increased|Varies|Don't know|
Row 17: EQUITY||||||||||
Row 18: ||||||||||
Row 19: ||No||Probably no|Probably yes|Yes||Varies|Do

=== Intervention Extract 135 (Intervention) ===
obably no important uncertainty or variability|No important uncertainty or variability||||
Row 11: VALUES||||||||||
Row 12: ||||||||||
Row 13: ||Favors the comparison||Probably favors the comparison|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|Varies|Don't know|
Row 14: BALANCE OF EFFECTS||||||||||
Row 15: ||||||||||
Row 16: ||Reduced||Probably reduced|Probably no impact|Probably increased|Increased|Varies|Don't know|
Row 17: EQUITY||||||||||
Row 18: ||||||||||
Row 19: ||No||Probably no|Probably yes|Yes||Varies|Don't know|
Row 20: ACCEPT

=== Intervention Extract 136 (Intervention) ===
w 9: |||||
Row 10: |||||
Row 11: |||||
Row 12: ||Important uncertainty or variability||Possibly important uncertainty or variability|Probably no important uncertainty or variability
Row 13: |||||
Row 14: |||||
Row 15: ||Favors the comparison||Probably favors the comparison|Does not favor either the intervention or the comparison
Row 16: |||||
Row 17: |||||
Row 18: ||Reduced||Probably reduced|Probably no impact
Row 19: |||||
Row 20: |||||
Row 21: ||No||Probably no|Probably yes
Row 22: |||||
Row 23: |||||
Row 24: ||No||Probably no|Probably yes
Row 25: |||||
Row 26: ||||| Row 1: 
Row 2:  Row 1: 
Row 2: 
Row

=== Intervention Extract 137 (Intervention) ===
w 19: |||||
Row 20: |||||
Row 21: ||No||Probably no|Probably yes
Row 22: |||||
Row 23: |||||
Row 24: ||No||Probably no|Probably yes
Row 25: |||||
Row 26: ||||| Row 1: 
Row 2:  Row 1: 
Row 2: 
Row 3:  Row 1: |
Row 2: |
Row 3: |
Row 4: |
Row 5: |
Row 6: |
Row 7: |
Row 8: |
Row 9: |
Row 10: Favors the intervention|
Row 11: Increased|
Row 12: |
Row 13: |
Row 14: |
Row 15: |
Row 16: |
Row 17: | Row 1: ||
Row 2: ||
Row 3: ||
Row 4: |Don't know|
Row 5: |No included studies|
Row 6: ||
Row 7: ||
Row 8: ||
Row 9: ||
Row 10: ||
Row 11: |Don't know|
Row 12: |Don't know|
Row 13: |Don't know|
Row 14: |Don't know| Row 1

=== Intervention Extract 138 (Intervention) ===
3: |
Row 14: |
Row 15: |
Row 16: |
Row 17: | Row 1: ||
Row 2: ||
Row 3: ||
Row 4: |Don't know|
Row 5: |No included studies|
Row 6: ||
Row 7: ||
Row 8: ||
Row 9: ||
Row 10: ||
Row 11: |Don't know|
Row 12: |Don't know|
Row 13: |Don't know|
Row 14: |Don't know| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|
Row 2: |||Strong recommendation
Row 3: |||for the intervention
Row 4: |||
Row 5: |||●
Row 6: ||| Row 1: ||
Row 2: |Recommendation|
Row 3: || Row 1: ||
Row 2: |Justification|
Row 3: || Row 1: S

=== Intervention Extract 139 (Intervention) ===
Row 2: ||
Row 3: ||
Row 4: |Don't know|
Row 5: |No included studies|
Row 6: ||
Row 7: ||
Row 8: ||
Row 9: ||
Row 10: ||
Row 11: |Don't know|
Row 12: |Don't know|
Row 13: |Don't know|
Row 14: |Don't know| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|
Row 2: |||Strong recommendation
Row 3: |||for the intervention
Row 4: |||
Row 5: |||●
Row 6: ||| Row 1: ||
Row 2: |Recommendation|
Row 3: || Row 1: ||
Row 2: |Justification|
Row 3: || Row 1: Strong recommendation against the intervention ○|Condit

=== Intervention Extract 140 (Intervention) ===
o included studies|
Row 6: ||
Row 7: ||
Row 8: ||
Row 9: ||
Row 10: ||
Row 11: |Don't know|
Row 12: |Don't know|
Row 13: |Don't know|
Row 14: |Don't know| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|
Row 2: |||Strong recommendation
Row 3: |||for the intervention
Row 4: |||
Row 5: |||●
Row 6: ||| Row 1: ||
Row 2: |Recommendation|
Row 3: || Row 1: ||
Row 2: |Justification|
Row 3: || Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○ Ro

=== Intervention Extract 141 (Intervention) ===
: ||
Row 11: |Don't know|
Row 12: |Don't know|
Row 13: |Don't know|
Row 14: |Don't know| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|
Row 2: |||Strong recommendation
Row 3: |||for the intervention
Row 4: |||
Row 5: |||●
Row 6: ||| Row 1: ||
Row 2: |Recommendation|
Row 3: || Row 1: ||
Row 2: |Justification|
Row 3: || Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○ Row 1: |
Row 2: |Recommendation
Row 3: | Row 1: |
Row 2: |Justificat

=== Intervention Extract 142 (Intervention) ===
inst the intervention ○|Conditional recommendation for the intervention ○|
Row 2: |||Strong recommendation
Row 3: |||for the intervention
Row 4: |||
Row 5: |||●
Row 6: ||| Row 1: ||
Row 2: |Recommendation|
Row 3: || Row 1: ||
Row 2: |Justification|
Row 3: || Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○ Row 1: |
Row 2: |Recommendation
Row 3: | Row 1: |
Row 2: |Justification
Row 3: | Row 1: 
Row 2: Strong recommendation
Row 3: for the intervention
Row 4: 
Row 5: ●
Row 6:  Row 1: |
Row 2: |
Row 3: | Row 1: ||||||||||||
Row 2: Certainty assessme

=== Intervention Extract 143 (Intervention) ===
the intervention ○|
Row 2: |||Strong recommendation
Row 3: |||for the intervention
Row 4: |||
Row 5: |||●
Row 6: ||| Row 1: ||
Row 2: |Recommendation|
Row 3: || Row 1: ||
Row 2: |Justification|
Row 3: || Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○ Row 1: |
Row 2: |Recommendation
Row 3: | Row 1: |
Row 2: |Justification
Row 3: | Row 1: 
Row 2: Strong recommendation
Row 3: for the intervention
Row 4: 
Row 5: ●
Row 6:  Row 1: |
Row 2: |
Row 3: | Row 1: ||||||||||||
Row 2: Certainty assessment|||||||№ of patients||Effect|||Importance
Row 3: |||

=== Intervention Extract 144 (Intervention) ===
on|
Row 3: || Row 1: ||
Row 2: |Justification|
Row 3: || Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○ Row 1: |
Row 2: |Recommendation
Row 3: | Row 1: |
Row 2: |Justification
Row 3: | Row 1: 
Row 2: Strong recommendation
Row 3: for the intervention
Row 4: 
Row 5: ●
Row 6:  Row 1: |
Row 2: |
Row 3: | Row 1: ||||||||||||
Row 2: Certainty assessment|||||||№ of patients||Effect|||Importance
Row 3: ||||||||||||
Row 4: |||||||||||Certainty|
Row 5: № of studies|Study design|Risk of bias|Inconsistency|Indirectness|Imprecision|Other considerations|Osi

=== Intervention Extract 145 (Intervention) ===
e utilizzato per pazienti affetti da NSCLC in stadio localmente avanzato o metastatico con|||
Row 2: |riarrangiamenti di ALK|||
Row 3: ||||
Row 4: |POPULATION:||Pazienti affetti da NSCLC in stadio localmente avanzato o metastatico con riarrangiamenti di ALK|
Row 5: ||||
Row 6: |||Alectinib|
Row 7: |INTERVENTION:|||
Row 8: ||||
Row 9: |COMPARISON:||Crizotinib|
Row 10: ||||
Row 11: MAIN OUTCOMES:|||PFS; OS; ORR; Time to CNS progression - Peters s. et al., Gadgeel 2018; Time to progression of brain metastasis or death - Hida T. et al; Alanine aminotrasferase increase- grade 3-4; Aspartate aminotrasferase inc

=== Intervention Extract 146 (Intervention) ===
IUNTIVE|
Row 6: ○ No ○ Probably no ○ Probably yes ● Yes ○ Varies ○ Don't know|||| Row 1: |Dovrebbe alectinib vs crizotinib essere utilizzato per pazienti affetti da NSCLC in stadio localmente avanzato o meta|
Row 2: |riarrangiamenti di ALK|
Row 3: ||
Row 4: |POPULATION:|
Row 5: ||
Row 6: ||
Row 7: |INTERVENTION:|
Row 8: ||
Row 9: |COMPARISON:|
Row 10: ||
Row 11: MAIN OUTCOMES:||
Row 12: ||
Row 13: |SETTING:|
Row 14: ||
Row 15: |PERSPECTIVE:|
Row 16: ||
Row 17: |BACKGROUND:|
Row 18: ||
Row 19: |CONFLICT OF INTERESTS:|
Row 20: || Row 1: ||
Row 2: |Problem|
Row 3: |Is the problem a priority?|
Row 4: ||
Row 5

=== Intervention Extract 147 (Intervention) ===
certainty or variability|| Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: 
Row 2: 
Row 3: ue the main outcom
Row 4:  Row 1: 
Row 2: 
Row 3: mes?
Row 4:  Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: ||||
Row 2: |Balance of effects|||
Row 3: |Does the balance between desirable and undesirable effects favor the intervention or the comparison?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ● Probably favors the intervention ○ Favors the intervention ○ Vari

=== Intervention Extract 148 (Intervention) ===
fects|||
Row 3: |Does the balance between desirable and undesirable effects favor the intervention or the comparison?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ● Probably favors the intervention ○ Favors the intervention ○ Varies ○ Don't know||Le evidenze sono molto incerte sull'effetto di alectinib sulla PFS, sul tempo alla progressione sul SNC, sul tempo alla progressione delle metastasi cerebrali o alla morte. L'evidenza suggerisce ch

=== Intervention Extract 149 (Intervention) ===
nd undesirable effects favor the intervention or the comparison?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ● Probably favors the intervention ○ Favors the intervention ○ Varies ○ Don't know||Le evidenze sono molto incerte sull'effetto di alectinib sulla PFS, sul tempo alla progressione sul SNC, sul tempo alla progressione delle metastasi cerebrali o alla morte. L'evidenza suggerisce che Alectinib determina un largo aumento della sopravvi

=== Intervention Extract 150 (Intervention) ===
or the intervention or the comparison?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ● Probably favors the intervention ○ Favors the intervention ○ Varies ○ Don't know||Le evidenze sono molto incerte sull'effetto di alectinib sulla PFS, sul tempo alla progressione sul SNC, sul tempo alla progressione delle metastasi cerebrali o alla morte. L'evidenza suggerisce che Alectinib determina un largo aumento della sopravvivenza. Alectinib potrebbe

=== Intervention Extract 151 (Intervention) ===
on health equity?|||
Row 10: ||||
Row 11: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 12: ○ Reduced ○ Probably reduced ● Probably no impact ○ Probably increased ○ Increased ○ Varies ○ Don't know||No evidence found||
Row 13: ||||
Row 14: |Acceptability|||
Row 15: |Is the intervention acceptable to key stakeholders?|||
Row 16: ||||
Row 17: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 18: ○ No ○ Probably no ○ Probably yes||no evidence found|| Row 1: |
Row 2: |Balance of effects
Row 3: |Does the balance between desi
Row 4: | Row 1: |
Row 2: |Equity
Row 3

=== Intervention Extract 152 (Intervention) ===
EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 18: ○ No ○ Probably no ○ Probably yes||no evidence found|| Row 1: |
Row 2: |Balance of effects
Row 3: |Does the balance between desi
Row 4: | Row 1: |
Row 2: |Equity
Row 3: |What would be the impact on h
Row 4: | Row 1: |
Row 2: |Acceptability
Row 3: |Is the intervention acceptable t
Row 4: | Row 1: 
Row 2: 
Row 3: irable and undesirable effects favor the intervention or the comparison
Row 4:  Row 1: |
Row 2: |
Row 3: health equity?|
Row 4: | Row 1: |
Row 2: |
Row 3: to key stakeholders?|
Row 4: | Row 1: 
Row 2: 
Row 3: n?
Row 4:  Row 1: 
Row 2: 
Row 3: 
Row 4:  Ro

=== Intervention Extract 153 (Intervention) ===
Row 1: |
Row 2: |Balance of effects
Row 3: |Does the balance between desi
Row 4: | Row 1: |
Row 2: |Equity
Row 3: |What would be the impact on h
Row 4: | Row 1: |
Row 2: |Acceptability
Row 3: |Is the intervention acceptable t
Row 4: | Row 1: 
Row 2: 
Row 3: irable and undesirable effects favor the intervention or the comparison
Row 4:  Row 1: |
Row 2: |
Row 3: health equity?|
Row 4: | Row 1: |
Row 2: |
Row 3: to key stakeholders?|
Row 4: | Row 1: 
Row 2: 
Row 3: n?
Row 4:  Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: ● Yes ○ Varies ○ Don't know||||
Row 2: ||||
Row 3: |Feasib

=== Intervention Extract 154 (Intervention) ===
:  Row 1: |
Row 2: |
Row 3: health equity?|
Row 4: | Row 1: |
Row 2: |
Row 3: to key stakeholders?|
Row 4: | Row 1: 
Row 2: 
Row 3: n?
Row 4:  Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: ● Yes ○ Varies ○ Don't know||||
Row 2: ||||
Row 3: |Feasibility|||
Row 4: |Is the intervention feasible to implement?|||
Row 5: ||||
Row 6: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 7: ○ No ○ Probably no ○ Probably yes ● Yes ○ Varies ○ Don't know||No evidence found|| Row 1: ||||||||||
Row 2: |||GIUDIZI|||||||
Row 3: ||||||||||
Row 4: ||No||Probably no|Probably y

=== Intervention Extract 155 (Intervention) ===
ainty or variability|Probably no important uncertainty or variability|No important uncertainty or variability||||
Row 8: VALUES||||||||||
Row 9: ||||||||||
Row 10: ||Favors the compari son||Probably favors the comparison|Does not favor either the interven tion or the compari son|Probably favors the intervention|Favors the interven tion|Vari e s|Do n't kn o w|
Row 11: BALANCE OF EFFECTS||||||||||
Row 12: ||||||||||
Row 13: ||Large costs||Moder ate costs|Negligibl e costs and savings|Moder ate saving s|Large savings|Vari e s|Do n't kn o w|
Row 14: RESOURCES REQUIRED||||||||||
Row 15: ||||||||||
Row 16: ||Re

=== Intervention Extract 156 (Intervention) ===
ow 5: 
Row 6: 
Row 7: 
Row 8: 
Row 9:  Row 1: ||
Row 2: ||
Row 3: ||
Row 4: |No included studies|
Row 5: ||
Row 6: ||
Row 7: ||
Row 8: ||
Row 9: ||
Row 10: |Do n't kn o w|
Row 11: |Do n't kn o w|
Row 12: |Don't know|
Row 13: |Don't know|
Row 14: |Don't know| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|
Row 2: |||Strong recommendation
Row 3: |||for the intervention
Row 4: |||
Row 5: |||●
Row 6: ||| Row 1: ||
Row 2: |Recommendation|
Row 3: || Row 1: |
Row 2: |Recommendation
Row 3: | Row 1: 
Ro

=== Intervention Extract 157 (Intervention) ===
: ||
Row 3: ||
Row 4: |No included studies|
Row 5: ||
Row 6: ||
Row 7: ||
Row 8: ||
Row 9: ||
Row 10: |Do n't kn o w|
Row 11: |Do n't kn o w|
Row 12: |Don't know|
Row 13: |Don't know|
Row 14: |Don't know| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|
Row 2: |||Strong recommendation
Row 3: |||for the intervention
Row 4: |||
Row 5: |||●
Row 6: ||| Row 1: ||
Row 2: |Recommendation|
Row 3: || Row 1: |
Row 2: |Recommendation
Row 3: | Row 1: 
Row 2: 
Row 3:  Row 1: 
Row 2: Strong recommendation
Row

=== Intervention Extract 158 (Intervention) ===
||
Row 6: ||
Row 7: ||
Row 8: ||
Row 9: ||
Row 10: |Do n't kn o w|
Row 11: |Do n't kn o w|
Row 12: |Don't know|
Row 13: |Don't know|
Row 14: |Don't know| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|
Row 2: |||Strong recommendation
Row 3: |||for the intervention
Row 4: |||
Row 5: |||●
Row 6: ||| Row 1: ||
Row 2: |Recommendation|
Row 3: || Row 1: |
Row 2: |Recommendation
Row 3: | Row 1: 
Row 2: 
Row 3:  Row 1: 
Row 2: Strong recommendation
Row 3: for the intervention
Row 4: 
Row 5: ●
Row 6:

=== Intervention Extract 159 (Intervention) ===
|
Row 11: |Do n't kn o w|
Row 12: |Don't know|
Row 13: |Don't know|
Row 14: |Don't know| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|
Row 2: |||Strong recommendation
Row 3: |||for the intervention
Row 4: |||
Row 5: |||●
Row 6: ||| Row 1: ||
Row 2: |Recommendation|
Row 3: || Row 1: |
Row 2: |Recommendation
Row 3: | Row 1: 
Row 2: 
Row 3:  Row 1: 
Row 2: Strong recommendation
Row 3: for the intervention
Row 4: 
Row 5: ●
Row 6:  Row 1: |
Row 2: |
Row 3: | Row 1: ||||||||||||
Row 2: Certainty as

=== Intervention Extract 160 (Intervention) ===
al recommendation for the intervention ○|
Row 2: |||Strong recommendation
Row 3: |||for the intervention
Row 4: |||
Row 5: |||●
Row 6: ||| Row 1: ||
Row 2: |Recommendation|
Row 3: || Row 1: |
Row 2: |Recommendation
Row 3: | Row 1: 
Row 2: 
Row 3:  Row 1: 
Row 2: Strong recommendation
Row 3: for the intervention
Row 4: 
Row 5: ●
Row 6:  Row 1: |
Row 2: |
Row 3: | Row 1: ||||||||||||
Row 2: Certainty assessment|||||||№ di pazienti||Effetto||Certo|Importanza
Row 3: ||||||||||||
Row 4: № degli studi|Disegno dello studio|Rischio di distorsione|Mancanza di riproducibilità dei risultati|Mancanza di generalizzabi

=== Intervention Extract 161 (Intervention) ===
variabil ity|Probably no important uncertainty or variability|No import ant uncert ainty or variabi lity||||
Row 17: VALORI||||||||||
Row 18: ||||||||||
Row 19: ||Favors the compa rison||Probab ly favors the compa rison|Does not favor either the interve ntion or the compar ison|Probably favors the intervention|Favors the interve ntion|Varies|Don't know|
Row 20: BILANCIO DEGLI EFFETTI||||||||||
Row 21: |||||||||| Row 1: 
Row 2: PROBLEMA
Row 3: 
Row 4: 
Row 5: EFFETTI DESIDE
Row 6: 
Row 7: 
Row 8: EFFETTI INDESI
Row 9: 
Row 10: 
Row 11: QUALITA’ DE PROVE
Row 12: 
Row 13: 
Row 14: VALORI
Row 15: 
Row 16: 
R

=== Intervention Extract 162 (Intervention) ===
rtainty or variability||Possibly important uncertainty or variability|Probably no important uncertainty or variability|No important uncertain ty or variability||||
Row 17: VALORI||||||||||
Row 18: ||||||||||
Row 19: ||Favors the comparis on||Probably favors the comparis on|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the interventi on|Vari es|Don't know|
Row 20: BILANCIO DEGLI EFFETTI||||||||||
Row 21: ||||||||||
Row 22: ||Reduced||Probably reduced|Probably no impact|Probably increased|Increased|Varies|Don't know|
Row 23: EQUITA’||||||||||
Row 24: ||||||

=== Intervention Extract 163 (Intervention) ===
nty or variability|Probably no important uncertainty or variability|No important uncertain ty or variability||||
Row 17: VALORI||||||||||
Row 18: ||||||||||
Row 19: ||Favors the comparis on||Probably favors the comparis on|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the interventi on|Vari es|Don't know|
Row 20: BILANCIO DEGLI EFFETTI||||||||||
Row 21: ||||||||||
Row 22: ||Reduced||Probably reduced|Probably no impact|Probably increased|Increased|Varies|Don't know|
Row 23: EQUITA’||||||||||
Row 24: |||||||||| Row 1: 
Row 2: PROBLEMA
Row 3: 
Row 4: 
Row 5:

=== Intervention Extract 164 (Intervention) ===
3:  Row 1: 
Row 2: GIUDIZI
Row 3:  Row 1: Probably no|Probably yes
Row 2: Small|Moderate
Row 3: Moderat e|Small
Row 4: Low|Moderat e
Row 5: Possibly important uncertainty or variability|Probably no important uncertainty or variability
Row 6: Probably favors the comparis on|Does not favor either the intervention or the comparison
Row 7: Probably reduced|Probably no impact Row 1: |
Row 2: |
Row 3: |
Row 4: |
Row 5: |
Row 6: |
Row 7: |
Row 8: |
Row 9: |
Row 10: |
Row 11: |
Row 12: |
Row 13: |
Row 14: |
Row 15: |
Row 16: |
Row 17: |
Row 18: | Row 1: ||
Row 2: ||
Row 3: ||
Row 4: |Don't know|
Row 5: |Don't kno

=== Intervention Extract 165 (Intervention) ===
Row 2: ||GIUDIZI|||||||
Row 3: |||||||||
Row 4: |or variabi lity||uncert ainty or variabi lity||ainty or variabi lity||||
Row 5: |||||||||
Row 6: |||||||||
Row 7: |Favors the compa rison||Proba bly favors the compa rison|Does not favor either the interve ntion or the compa rison|Probably favors the intervention|Favors the interve ntion|V ar ie s|Don 't kno w|
Row 8: BILANCIO DEGLI EFFETTI|||||||||
Row 9: |||||||||
Row 10: |Reduc ed||Proba bly reduce d|Probably no impact|Proba bly increa sed|Increas ed|V ar ie s|Don 't kno w|
Row 11: EQUITA’|||||||||
Row 12: |||||||||
Row 13: |No||Proba bly no|Probab ly ye

=== Intervention Extract 166 (Intervention) ===
di ALK e con buon performance status (0-1)?||
Row 2: ||
Row 3: ||Pazienti affetti da NSCLC a istologia non-squamosa con espressione di PD-L1 <50% in stadio metastatico senza mutazione attivante l’EGFR o riarrangiamento di ALK e con buon performance status (0-1)
Row 4: POPULATION:||
Row 5: ||
Row 6: INTERVENTION:||Un trattamento di prima linea a base di platino, pemetrexed e pembrolizumab, seguito da mantenimento con pemetrexed e pembrolizumab in caso di risposta o stabilità di malattia dopo 4 cicli di trattamento
Row 7: ||
Row 8: COMPARISON:||Alla chemioterapia
Row 9: ||
Row 10: MAIN OUTCOMES:||Overall su

=== Intervention Extract 167 (Intervention) ===
JUDGEMENT||RESEARCH EVIDENCE|ADDITIONAL CONSIDERATIONS|
Row 6: ○ Very low ○ Low X Moderate ○ High ○ No included studies||There were critical outcome with a very low quality but the overall quality of the evidence was judged MODERATE because all outcome results went to the same directions (favor to intervention arm)||
Row 7: ||||
Row 8: |Values|||
Row 9: |Is there important uncertainty about or variability in how much people value the main outcomes?|||
Row 10: ||||
Row 11: JUDGEMENT||RESEARCH EVIDENCE|ADDITIONAL CONSIDERATIONS|
Row 12: ○ Important uncertainty or variability ○ Possibly important uncertaint

=== Intervention Extract 168 (Intervention) ===
ty or variability ○ Probably no important uncertainty or variability x No important uncertainty or variability|| Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: ||||
Row 2: |Balance of effects|||
Row 3: |Does the balance between desirable and undesirable effects favor the intervention or the comparison?|||
Row 4: ||||
Row 5: JUDGEMENT||RESEARCH EVIDENCE|ADDITIONAL CONSIDERATIONS|
Row 6: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention x Favors the intervention ○ Varies ○ Don't k

=== Intervention Extract 169 (Intervention) ===
alance of effects|||
Row 3: |Does the balance between desirable and undesirable effects favor the intervention or the comparison?|||
Row 4: ||||
Row 5: JUDGEMENT||RESEARCH EVIDENCE|ADDITIONAL CONSIDERATIONS|
Row 6: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention x Favors the intervention ○ Varies ○ Don't know||||
Row 7: ||||
Row 8: |Equity|||
Row 9: |What would be the impact on health equity?|||
Row 10: ||||
Row 11: JUDGEMENT||RESEARCH EVIDENCE|ADDITIONAL CONSIDERATIONS|
Row 12: ○ Reduced ○ Probably redu

=== Intervention Extract 170 (Intervention) ===
desirable and undesirable effects favor the intervention or the comparison?|||
Row 4: ||||
Row 5: JUDGEMENT||RESEARCH EVIDENCE|ADDITIONAL CONSIDERATIONS|
Row 6: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention x Favors the intervention ○ Varies ○ Don't know||||
Row 7: ||||
Row 8: |Equity|||
Row 9: |What would be the impact on health equity?|||
Row 10: ||||
Row 11: JUDGEMENT||RESEARCH EVIDENCE|ADDITIONAL CONSIDERATIONS|
Row 12: ○ Reduced ○ Probably reduced x Probably no impact ○ Probably increased ○ Incre

=== Intervention Extract 171 (Intervention) ===
effects favor the intervention or the comparison?|||
Row 4: ||||
Row 5: JUDGEMENT||RESEARCH EVIDENCE|ADDITIONAL CONSIDERATIONS|
Row 6: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention x Favors the intervention ○ Varies ○ Don't know||||
Row 7: ||||
Row 8: |Equity|||
Row 9: |What would be the impact on health equity?|||
Row 10: ||||
Row 11: JUDGEMENT||RESEARCH EVIDENCE|ADDITIONAL CONSIDERATIONS|
Row 12: ○ Reduced ○ Probably reduced x Probably no impact ○ Probably increased ○ Increased ○ Varies ○ Don't know

=== Intervention Extract 172 (Intervention) ===
e the impact on health equity?|||
Row 10: ||||
Row 11: JUDGEMENT||RESEARCH EVIDENCE|ADDITIONAL CONSIDERATIONS|
Row 12: ○ Reduced ○ Probably reduced x Probably no impact ○ Probably increased ○ Increased ○ Varies ○ Don't know||No evidence found||
Row 13: ||||
Row 14: |Acceptability|||
Row 15: |Is the intervention acceptable to key stakeholders?|||
Row 16: ||||
Row 17: JUDGEMENT||RESEARCH EVIDENCE|ADDITIONAL CONSIDERATIONS|
Row 18: ○ No ○ Probably no ○ Probably yes||No evidence found|| Row 1: ||
Row 2: |Balance of effects|
Row 3: |Does the balance between desirable and undesira|
Row 4: ||
Row 5: JUDGEMENT||

=== Intervention Extract 173 (Intervention) ===
ONAL CONSIDERATIONS|
Row 18: ○ No ○ Probably no ○ Probably yes||No evidence found|| Row 1: ||
Row 2: |Balance of effects|
Row 3: |Does the balance between desirable and undesira|
Row 4: ||
Row 5: JUDGEMENT||
Row 6: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention x Favors the intervention ○ Varies ○ Don't know||
Row 7: ||
Row 8: |Equity|
Row 9: |What would be the impact on health equity?|
Row 10: ||
Row 11: JUDGEMENT||
Row 12: ○ Reduced ○ Probably reduced x Probably no impact ○ Probably increased ○ Increa

=== Intervention Extract 174 (Intervention) ===
bably yes||No evidence found|| Row 1: ||
Row 2: |Balance of effects|
Row 3: |Does the balance between desirable and undesira|
Row 4: ||
Row 5: JUDGEMENT||
Row 6: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention x Favors the intervention ○ Varies ○ Don't know||
Row 7: ||
Row 8: |Equity|
Row 9: |What would be the impact on health equity?|
Row 10: ||
Row 11: JUDGEMENT||
Row 12: ○ Reduced ○ Probably reduced x Probably no impact ○ Probably increased ○ Increased ○ Varies ○ Don't know||
Row 13: ||
Row 14: |Accep

=== Intervention Extract 175 (Intervention) ===
nd|| Row 1: ||
Row 2: |Balance of effects|
Row 3: |Does the balance between desirable and undesira|
Row 4: ||
Row 5: JUDGEMENT||
Row 6: ○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention x Favors the intervention ○ Varies ○ Don't know||
Row 7: ||
Row 8: |Equity|
Row 9: |What would be the impact on health equity?|
Row 10: ||
Row 11: JUDGEMENT||
Row 12: ○ Reduced ○ Probably reduced x Probably no impact ○ Probably increased ○ Increased ○ Varies ○ Don't know||
Row 13: ||
Row 14: |Acceptability|
Row 15: |Is the

=== Intervention Extract 176 (Intervention) ===
○ Varies ○ Don't know||
Row 7: ||
Row 8: |Equity|
Row 9: |What would be the impact on health equity?|
Row 10: ||
Row 11: JUDGEMENT||
Row 12: ○ Reduced ○ Probably reduced x Probably no impact ○ Probably increased ○ Increased ○ Varies ○ Don't know||
Row 13: ||
Row 14: |Acceptability|
Row 15: |Is the intervention acceptable to key stakeholders|
Row 16: ||
Row 17: JUDGEMENT||
Row 18: ○ No ○ Probably no ○ Probably yes|| Row 1: 
Row 2: 
Row 3: able effects favor t
Row 4:  Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: 
Row 2: 
Row 3: s?
Row 4:  Row 1: 
Row 2: 
Row 3: the interv
Row 4:  Row 1: 
Row 2: 
Row 3: vention o

=== Intervention Extract 177 (Intervention) ===
2: 
Row 3: s?
Row 4:  Row 1: 
Row 2: 
Row 3: the interv
Row 4:  Row 1: 
Row 2: 
Row 3: vention or
Row 4:  Row 1: 
Row 2: 
Row 3: r the com
Row 4:  Row 1: 
Row 2: 
Row 3: mparison?
Row 4:  Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: x Yes ○ Varies ○ Don't know|||
Row 2: |||
Row 3: Feasibility Is the intervention feasible to implement?|||
Row 4: |||
Row 5: JUDGEMENT|RESEARCH EVIDENCE|ADDITIONAL CONSIDERATIONS|
Row 6: ○ No ○ Probably no ○ Probably yes x Yes ○ Varies ○ Don't know|No evidence found|| Row 1: ||||||||||
Row 2: |||JUDGEMENT|||||||
Row 3: ||||||||||
Row 4: ||No||Probab ly no|Probabl y yes|Yes||Var

=== Intervention Extract 178 (Intervention) ===
ROBLEM||||||||||
Row 6: ||||||||||
Row 7: ||Trivial||Small|Modera te|Large||Varies|Don't know|
Row 8: DESIRABLE EFFECTS||||||||||
Row 9: ||||||||||
Row 10: ||Large||Moder ate|Small|Trivial||Varies|Don't know|
Row 11: UNDESIRABLE EFFECTS||||||||||
Row 12: |||||||||| Row 1: 
Row 2: Feasibility Is the intervention feasible
Row 3:  Row 1: 
Row 2: PROBLEM
Row 3: 
Row 4: 
Row 5: DESIRABLE EFFECTS
Row 6: 
Row 7: 
Row 8: UNDESIRABLE EFFECTS
Row 9:  Row 1: |
Row 2: |
Row 3: e to implement?|
Row 4: | Row 1: |||
Row 2: |||
Row 3: |||
Row 4: |||
Row 5: |||
Row 6: |||
Row 7: |||
Row 8: |||
Row 9: |||
Row 10: |||
Row 1

=== Intervention Extract 179 (Intervention) ===
importa nt uncerta inty or variabili ty|No important uncertainty or variability||||
Row 9: VALUES||||||||||
Row 10: ||||||||||
Row 11: ||Favors the compar ison||Probab ly favors the compar ison|Does not favor either the interve ntion or the compar ison|Probabl y favors the interve ntion|Favors the intervention|Va rie s|D o n' t k n o w|
Row 12: BALANCE OF EFFECTS||||||||||
Row 13: ||||||||||
Row 14: ||Reduce d||Probab ly reduce d|Probably no impact|Probabl y increas ed|Incre ased|Va rie s|D o n' t k n o w|
Row 15: EQUITY||||||||||
Row 16: |||||||||| Row 1: BALANCE
Row 2: OF
Row 3: EFFECTS Row 1: 
Row 2:

=== Intervention Extract 180 (Intervention) ===
|||||
Row 3: |||||||||
Row 4: |No||Probab ly no|Probabl y yes|Yes||Va rie s|D o n' t k n o w|
Row 5: ACCEPTAB ILITY|||||||||
Row 6: |||||||||
Row 7: |No||Probab ly no|Probabl y yes|Yes||Va rie s|D o n' t k n o w|
Row 8: FEASIBILIT Y|||||||||
Row 9: ||||||||| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|Strong recommendation for the intervention X Row 1: |
Row 2: |
Row 3: |
Row 4: |
Row 5: ACCEPTAB ILITY|
Row 6: |
Row 7: |
Row 8: FEASIBILIT Y|
Row 9: | Row 1: 
Row 2: 
Row 3:  Row 1: 
Row 2: JU

=== Intervention Extract 181 (Intervention) ===
l y yes|Yes||Va rie s|D o n' t k n o w|
Row 5: ACCEPTAB ILITY|||||||||
Row 6: |||||||||
Row 7: |No||Probab ly no|Probabl y yes|Yes||Va rie s|D o n' t k n o w|
Row 8: FEASIBILIT Y|||||||||
Row 9: ||||||||| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|Strong recommendation for the intervention X Row 1: |
Row 2: |
Row 3: |
Row 4: |
Row 5: ACCEPTAB ILITY|
Row 6: |
Row 7: |
Row 8: FEASIBILIT Y|
Row 9: | Row 1: 
Row 2: 
Row 3:  Row 1: 
Row 2: JUDG
Row 3:  Row 1: Probabl y yes
Row 2: Probabl y yes R

=== Intervention Extract 182 (Intervention) ===
EPTAB ILITY|||||||||
Row 6: |||||||||
Row 7: |No||Probab ly no|Probabl y yes|Yes||Va rie s|D o n' t k n o w|
Row 8: FEASIBILIT Y|||||||||
Row 9: ||||||||| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|Strong recommendation for the intervention X Row 1: |
Row 2: |
Row 3: |
Row 4: |
Row 5: ACCEPTAB ILITY|
Row 6: |
Row 7: |
Row 8: FEASIBILIT Y|
Row 9: | Row 1: 
Row 2: 
Row 3:  Row 1: 
Row 2: JUDG
Row 3:  Row 1: Probabl y yes
Row 2: Probabl y yes Row 1: |
Row 2: GEMENT|
Row 3: |
Row 4: |
Row 5: |

=== Intervention Extract 183 (Intervention) ===
|No||Probab ly no|Probabl y yes|Yes||Va rie s|D o n' t k n o w|
Row 8: FEASIBILIT Y|||||||||
Row 9: ||||||||| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|Strong recommendation for the intervention X Row 1: |
Row 2: |
Row 3: |
Row 4: |
Row 5: ACCEPTAB ILITY|
Row 6: |
Row 7: |
Row 8: FEASIBILIT Y|
Row 9: | Row 1: 
Row 2: 
Row 3:  Row 1: 
Row 2: JUDG
Row 3:  Row 1: Probabl y yes
Row 2: Probabl y yes Row 1: |
Row 2: GEMENT|
Row 3: |
Row 4: |
Row 5: |
Row 6: |
Row 7: |
Row 8: |
Row 9: | Row 1: 
R

=== Intervention Extract 184 (Intervention) ===
b vs chemioterapia essere utilizzato per pazienti affetti da NSCLC a istologia squamosa in stadio metastatico e con buon performance status (0-1)||
Row 2: ||
Row 3: POPULATION:||Pazienti affetti da NSCLC a istologia squamosa in stadio metastatico e con buon performance status (0-1)
Row 4: ||
Row 5: INTERVENTION:||CBDCA + paclitaxel o nab-paclitaxel + pembrolizumab
Row 6: ||
Row 7: COMPARISON:||Chemioterapia
Row 8: ||
Row 9: MAIN OUTCOMES:||Overall survival; Progression free survival; Response rate (formato da risposte complete + risposte parziali); Qualità della vita ; Qualità della vita ; Any discontinua

=== Intervention Extract 185 (Intervention) ===
Row 18: || Row 1: ||
Row 2: Problem Is the problem a priority?||
Row 3: ||
Row 4: GIUDIZI|RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE
Row 5: ○ No Probably no ○ Probably yes ○ Yes ● Varies ○ Don't know ○|| Row 1: Dovrebbe C
Row 2: istologia squ
Row 3: 
Row 4: POPULATION:
Row 5: 
Row 6: INTERVENTION:
Row 7: 
Row 8: COMPARISON:
Row 9: 
Row 10: MAIN OUTCOMES:
Row 11: 
Row 12: 
Row 13: SETTING:
Row 14: 
Row 15: PERSPECTIVE:
Row 16: 
Row 17: BACKGROUND:
Row 18: 
Row 19: CONFLICT OF INTERESTS:
Row 20:  Row 1: 
Row 2: Problem Is the problem a priority?
Row 3:  Row 1: CBDCA + paclitaxel o nab-paclita

=== Intervention Extract 186 (Intervention) ===
tainty or ○ variability Probably no important uncertainty or ● variability No important uncertainty or variability ○||Nessuna evidenza trovata.| Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: ||||
Row 2: |Balance of effects|||
Row 3: |Does the balance between desirable and undesirable effects favor the intervention or the comparison?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ Favors the comparison Probably favors the comparison ○ Does not favor either the intervention ○ or the comparison Probably favors the intervention ○ Favors the intervention ● Varies

=== Intervention Extract 187 (Intervention) ===
effects|||
Row 3: |Does the balance between desirable and undesirable effects favor the intervention or the comparison?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ Favors the comparison Probably favors the comparison ○ Does not favor either the intervention ○ or the comparison Probably favors the intervention ○ Favors the intervention ● Varies ○ Don't know ○||Le evidenze suggeriscono che CBDCA + Paclitaxel o Nab-Paclitaxel + Pembrolizumab determinano un aumento della sopravvivenza, della PFS e della risposta obiettiva. CBDCA + Paclitaxel o Nab-Paclita

=== Intervention Extract 188 (Intervention) ===
and undesirable effects favor the intervention or the comparison?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ Favors the comparison Probably favors the comparison ○ Does not favor either the intervention ○ or the comparison Probably favors the intervention ○ Favors the intervention ● Varies ○ Don't know ○||Le evidenze suggeriscono che CBDCA + Paclitaxel o Nab-Paclitaxel + Pembrolizumab determinano un aumento della sopravvivenza, della PFS e della risposta obiettiva. CBDCA + Paclitaxel o Nab-Paclitaxel + Pembrolizumab potrebbero ridurre la probabilità

=== Intervention Extract 189 (Intervention) ===
avor the intervention or the comparison?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ Favors the comparison Probably favors the comparison ○ Does not favor either the intervention ○ or the comparison Probably favors the intervention ○ Favors the intervention ● Varies ○ Don't know ○||Le evidenze suggeriscono che CBDCA + Paclitaxel o Nab-Paclitaxel + Pembrolizumab determinano un aumento della sopravvivenza, della PFS e della risposta obiettiva. CBDCA + Paclitaxel o Nab-Paclitaxel + Pembrolizumab potrebbero ridurre la probabilità di interruzione del tratt

=== Intervention Extract 190 (Intervention) ===
bably increased ○ Increased ○ Varies ○ Don't know ○||Nessuna evidenza trovata.|| Row 1: |
Row 2: |Balance of effects
Row 3: |Does the balance between desir
Row 4: | Row 1: |
Row 2: |Equity
Row 3: |What would be the impact on he
Row 4: | Row 1: 
Row 2: 
Row 3: rable and undesirable effects favor the intervention or the comparison?
Row 4:  Row 1: |
Row 2: |
Row 3: ealth equity?|
Row 4: | Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: ||||
Row 2: |Acceptability|||
Row 3: |Is the intervention acceptable to key stakeholders?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVID

=== Intervention Extract 191 (Intervention) ===
e the impact on he
Row 4: | Row 1: 
Row 2: 
Row 3: rable and undesirable effects favor the intervention or the comparison?
Row 4:  Row 1: |
Row 2: |
Row 3: ealth equity?|
Row 4: | Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: ||||
Row 2: |Acceptability|||
Row 3: |Is the intervention acceptable to key stakeholders?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ No ○ Probably no ○ Probably yes ● Yes ○ Varies ○ Don't know||Nessuna evidenza trovata.||
Row 7: ||||
Row 8: |Feasibility|||
Row 9: |Is the intervention feasible to impl

=== Intervention Extract 192 (Intervention) ===
|
Row 3: |Is the intervention acceptable to key stakeholders?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ No ○ Probably no ○ Probably yes ● Yes ○ Varies ○ Don't know||Nessuna evidenza trovata.||
Row 7: ||||
Row 8: |Feasibility|||
Row 9: |Is the intervention feasible to implement?|||
Row 10: ||||
Row 11: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 12: ○ No ○ Probably no ○ Probably yes ● Yes ○ Varies ○ Don't know||Nessuna evidenza trovata.|| Row 1: |
Row 2: |Acceptability
Row 3: |Is the intervention acce
Row 4: | Row 1: |
Row

=== Intervention Extract 193 (Intervention) ===
sibility|||
Row 9: |Is the intervention feasible to implement?|||
Row 10: ||||
Row 11: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 12: ○ No ○ Probably no ○ Probably yes ● Yes ○ Varies ○ Don't know||Nessuna evidenza trovata.|| Row 1: |
Row 2: |Acceptability
Row 3: |Is the intervention acce
Row 4: | Row 1: |
Row 2: |Feasibility
Row 3: |Is the intervention feas
Row 4: | Row 1: 
Row 2: 
Row 3: eptable to key stakeholders?
Row 4:  Row 1: |
Row 2: |
Row 3: sible to implement?|
Row 4: | Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: ||||||||||
Row 2: |||GIU

=== Intervention Extract 194 (Intervention) ===
0: ||||
Row 11: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 12: ○ No ○ Probably no ○ Probably yes ● Yes ○ Varies ○ Don't know||Nessuna evidenza trovata.|| Row 1: |
Row 2: |Acceptability
Row 3: |Is the intervention acce
Row 4: | Row 1: |
Row 2: |Feasibility
Row 3: |Is the intervention feas
Row 4: | Row 1: 
Row 2: 
Row 3: eptable to key stakeholders?
Row 4:  Row 1: |
Row 2: |
Row 3: sible to implement?|
Row 4: | Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: ||||||||||
Row 2: |||GIUDIZI|||||||
Row 3: ||||||||||
Row 4: ||No||Probably no|Probabl y yes|Ye

=== Intervention Extract 195 (Intervention) ===
ertainty or variability||Possibly important uncertainty or variability|Probably no important uncertainty or variability|No important uncertainty or variability||||
Row 17: VALUES||||||||||
Row 18: ||||||||||
Row 19: ||Favors the comparis on||Probably favors the comparis on|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|Varies|Don't know|
Row 20: BALANCE OF EFFECTS||||||||||
Row 21: ||||||||||
Row 22: ||Reduced||Probably reduced|Probably no impact|Probably increase d|Increase d|Varies|Don't know|
Row 23: EQUITY||||||||||
Row 24: ||||||||||

=== Intervention Extract 196 (Intervention) ===
inty or variability|Probably no important uncertainty or variability|No important uncertainty or variability||||
Row 17: VALUES||||||||||
Row 18: ||||||||||
Row 19: ||Favors the comparis on||Probably favors the comparis on|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|Varies|Don't know|
Row 20: BALANCE OF EFFECTS||||||||||
Row 21: ||||||||||
Row 22: ||Reduced||Probably reduced|Probably no impact|Probably increase d|Increase d|Varies|Don't know|
Row 23: EQUITY||||||||||
Row 24: ||||||||||
Row 25: ||No||Probably no|Probabl y yes|Yes||Varies

=== Intervention Extract 197 (Intervention) ===
ably no important uncertainty or variability|No important uncertainty or variability||||
Row 17: VALUES||||||||||
Row 18: ||||||||||
Row 19: ||Favors the comparis on||Probably favors the comparis on|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|Varies|Don't know|
Row 20: BALANCE OF EFFECTS||||||||||
Row 21: ||||||||||
Row 22: ||Reduced||Probably reduced|Probably no impact|Probably increase d|Increase d|Varies|Don't know|
Row 23: EQUITY||||||||||
Row 24: ||||||||||
Row 25: ||No||Probably no|Probabl y yes|Yes||Varies|Don't know|
Row 26: ACC

=== Intervention Extract 198 (Intervention) ===
9: ||||
Row 10: Low|Modera te|High||
Row 11: ||||
Row 12: ||||
Row 13: Possibly important uncertainty or variability|Probably no important uncertainty or variability|No important uncertainty or variability||
Row 14: ||||
Row 15: ||||
Row 16: Probably favors the comparis on|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|
Row 17: Probably reduced|Probably no impact|Probably increase d|Increase d|
Row 18: Probably no|Probabl y yes|Yes||
Row 19: ||||
Row 20: |||| Row 1: 
Row 2: 
Row 3: 
Row 4: 
Row 5: 
Row 6:  Row 1: ||
Row 2: ||
Row 3: ||
Row

=== Intervention Extract 199 (Intervention) ===
ow 12: ||||
Row 13: Possibly important uncertainty or variability|Probably no important uncertainty or variability|No important uncertainty or variability||
Row 14: ||||
Row 15: ||||
Row 16: Probably favors the comparis on|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|
Row 17: Probably reduced|Probably no impact|Probably increase d|Increase d|
Row 18: Probably no|Probabl y yes|Yes||
Row 19: ||||
Row 20: |||| Row 1: 
Row 2: 
Row 3: 
Row 4: 
Row 5: 
Row 6:  Row 1: ||
Row 2: ||
Row 3: ||
Row 4: |Don't know|
Row 5: |Don't know|
Row 6: |Don't

=== Intervention Extract 200 (Intervention) ===
ibly important uncertainty or variability|Probably no important uncertainty or variability|No important uncertainty or variability||
Row 14: ||||
Row 15: ||||
Row 16: Probably favors the comparis on|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|
Row 17: Probably reduced|Probably no impact|Probably increase d|Increase d|
Row 18: Probably no|Probabl y yes|Yes||
Row 19: ||||
Row 20: |||| Row 1: 
Row 2: 
Row 3: 
Row 4: 
Row 5: 
Row 6:  Row 1: ||
Row 2: ||
Row 3: ||
Row 4: |Don't know|
Row 5: |Don't know|
Row 6: |Don't know|
Row 7: |No include

=== Intervention Extract 201 (Intervention) ===
|
Row 10: ||
Row 11: ||
Row 12: ||
Row 13: |Don't know|
Row 14: |Don't know|
Row 15: |Don't know| Row 1: ||||||||
Row 2: ||GIUDIZI||||||
Row 3: ||||||||
Row 4: |No||Probably no|Probably yes|Yes||Vari es|Don 't kno w
Row 5: FEASIBILITY||||||||
Row 6: |||||||| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|
Row 2: |||Strong recommendation
Row 3: |||for the intervention
Row 4: |||
Row 5: |||●
Row 6: ||| Row 1: 
Row 2: Recommendation
Row 3:  Row 1: ||||||||||||
Row 2: Quality assessment|||||||No of

=== Intervention Extract 202 (Intervention) ===
|
Row 14: |Don't know|
Row 15: |Don't know| Row 1: ||||||||
Row 2: ||GIUDIZI||||||
Row 3: ||||||||
Row 4: |No||Probably no|Probably yes|Yes||Vari es|Don 't kno w
Row 5: FEASIBILITY||||||||
Row 6: |||||||| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|
Row 2: |||Strong recommendation
Row 3: |||for the intervention
Row 4: |||
Row 5: |||●
Row 6: ||| Row 1: 
Row 2: Recommendation
Row 3:  Row 1: ||||||||||||
Row 2: Quality assessment|||||||No of patients||Effect|||
Row 3: |||||||||||Quality|Importa

=== Intervention Extract 203 (Intervention) ===
||||||||
Row 2: ||GIUDIZI||||||
Row 3: ||||||||
Row 4: |No||Probably no|Probably yes|Yes||Vari es|Don 't kno w
Row 5: FEASIBILITY||||||||
Row 6: |||||||| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|
Row 2: |||Strong recommendation
Row 3: |||for the intervention
Row 4: |||
Row 5: |||●
Row 6: ||| Row 1: 
Row 2: Recommendation
Row 3:  Row 1: ||||||||||||
Row 2: Quality assessment|||||||No of patients||Effect|||
Row 3: |||||||||||Quality|Importance
Row 4: ||||||||||||
Row 5: No of||||||Other|Ma

=== Intervention Extract 204 (Intervention) ===
bly no|Probably yes|Yes||Vari es|Don 't kno w
Row 5: FEASIBILITY||||||||
Row 6: |||||||| Row 1: Strong recommendation against the intervention ○|Conditional recommendation against the intervention ○|Conditional recommendation for the intervention ○|
Row 2: |||Strong recommendation
Row 3: |||for the intervention
Row 4: |||
Row 5: |||●
Row 6: ||| Row 1: 
Row 2: Recommendation
Row 3:  Row 1: ||||||||||||
Row 2: Quality assessment|||||||No of patients||Effect|||
Row 3: |||||||||||Quality|Importance
Row 4: ||||||||||||
Row 5: No of||||||Other|Maintenance therapy||Relative|||
Row 6: |Design|Risk of bias|Inconsi

=== Intervention Extract 205 (Intervention) ===
ncertainty or variability||Possibly important uncertainty or variability|Probably no important uncertainty or variability|No important uncertainty or variability||||
Row 17: VALORI||||||||||
Row 18: ||||||||||
Row 19: ||Favors the comparison||Probably favors the comparison|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|Varies|Don't know|
Row 20: BILANCIO DEGLI EFFETTI||||||||||
Row 21: ||||||||||
Row 22: ||Reduced||Probably reduced|Probably no impact|Probably increased|Increased|Varies|Don't know|
Row 23: EQUITA’||||||||||
Row 24: ||||||||

=== Intervention Extract 206 (Intervention) ===
tainty or variability|Probably no important uncertainty or variability|No important uncertainty or variability||||
Row 17: VALORI||||||||||
Row 18: ||||||||||
Row 19: ||Favors the comparison||Probably favors the comparison|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|Varies|Don't know|
Row 20: BILANCIO DEGLI EFFETTI||||||||||
Row 21: ||||||||||
Row 22: ||Reduced||Probably reduced|Probably no impact|Probably increased|Increased|Varies|Don't know|
Row 23: EQUITA’||||||||||
Row 24: ||||||||||
Row 25: ||No||Probably no|Probably yes|Yes||Vari

=== Intervention Extract 207 (Intervention) ===
obably no important uncertainty or variability|No important uncertainty or variability||||
Row 17: VALORI||||||||||
Row 18: ||||||||||
Row 19: ||Favors the comparison||Probably favors the comparison|Does not favor either the intervention or the comparison|Probably favors the intervention|Favors the intervention|Varies|Don't know|
Row 20: BILANCIO DEGLI EFFETTI||||||||||
Row 21: ||||||||||
Row 22: ||Reduced||Probably reduced|Probably no impact|Probably increased|Increased|Varies|Don't know|
Row 23: EQUITA’||||||||||
Row 24: ||||||||||
Row 25: ||No||Probably no|Probably yes|Yes||Varies|Don't know|
Row 26: A

=== Intervention Extract 208 (Intervention) ===
ow 2:  Row 1: 
Row 2: GIUDIZI
Row 3:  Row 1: Probably no|Probably yes
Row 2: Small|Moderate
Row 3: Moderate|Small
Row 4: Low|Moderate
Row 5: Possibly important uncertainty or variability|Probably no important uncertainty or variability
Row 6: Probably favors the comparison|Does not favor either the intervention or the comparison
Row 7: Probably reduced|Probably no impact
Row 8: Probably no|Probably yes
Row 9: Probably no|Probably yes Row 1: |
Row 2: |
Row 3: |
Row 4: |
Row 5: |
Row 6: |
Row 7: |
Row 8: |
Row 9: |
Row 10: |
Row 11: |
Row 12: |
Row 13: |
Row 14: |
Row 15: |
Row 16: |
Row 17: |
Row 18: | Row

=== Intervention Extract 209 (Treatment) ===
K., Moroga, T., Miyawaki, M., Chujo, M., Yamamoto, S., Kawahara, K.. Thoracoscopic segmentectomy for T1 classification of non-small cell lung cancer: a single center experience. Eur J Cardiothorac Surg; Jul 2012.
18.Yamato, Y., Koike, T., Yoshiya, K., Shinohara, H., Toyabe, S.. Results of surgical treatment for small (2 cm or under) adenocarcinomas of the lung. Surg Today; 2008.
19.Tsubokawa, N., Tsutani, Y., Miyata, Y., Handa, Y., Misumi, K., Hanaki, H., Hida, E., Okada, M.. Segmentectomy Versus Lobectomy for Radiologically Pure Solid Clinical T1a-bN0M0 Lung Cancer. World J Surg; Aug 2018.
20.Sugi, K

=== Intervention Extract 210 (Treatment) ===
tcomes after robotic-assisted pulmonary lobectomy vs segmentectomy. Am
J Surg; Dec 2016.
29.Schuchert, M.J., Pettiford, B.L., Keeley, S., D'Amato, T.A., Kilic, A., Close, J., Pennathur, A., Santos, R., Fernando, H.C., Landreneau, J.R., Luketich, J.D., Landreneau, R.J.. Anatomic segmentectomy in the treatment of stage I non-small cell lung cancer. Ann Thorac Surg 2007.
30.Sienel, W., Stremmel, C., Kirschbaum, A., Hinterberger, L., Stoelben, E., Hasse, J., Passlick, B.. Frequency of local recurrence following segmentectomy of stage IA non-small cell lung cancer is influenced by segment localisation and w

=== Intervention Extract 211 (Treatment) ===
K., Moroga, T., Miyawaki, M., Chujo, M., Yamamoto, S., Kawahara, K..
Thoracoscopic segmentectomy for T1 classification of non-small cell lung cancer: a single center experience. Eur J
Cardiothorac Surg; Jul 2012.
18. Yamato, Y., Koike, T., Yoshiya, K., Shinohara, H., Toyabe, S.. Results of surgical treatment for small (2 cm or under)
adenocarcinomas of the lung. Surg Today; 2008.
19. Tsubokawa, N., Tsutani, Y., Miyata, Y., Handa, Y., Misumi, K., Hanaki, H., Hida, E., Okada, M.. Segmentectomy
Versus Lobectomy for Radiologically Pure Solid Clinical T1a-bN0M0 Lung Cancer. World J Surg; Aug 2018.
20. Sugi,

=== Intervention Extract 212 (Treatment) ===
ion for Peripheral Stage IA Non-Small-Cell Lung Cancer. N Engl J Med; Feb 9 2023.
3. Schuchert, M. J., Pettiford, B. L., Keeley, S., D'Amato, T. A., Kilic, A., Close, J., Pennathur, A., Santos, R., Fernando, H. C.,
Landreneau, J. R., Luketich, J. D., Landreneau, R. J.. Anatomic segmentectomy in the treatment of stage I non-small cell lung
cancer. Ann Thorac Surg; Sep 2007.
4. Sienel, W., Stremmel, C., Kirschbaum, A., Hinterberger, L., Stoelben, E., Hasse, J., Passlick, B.. Frequency of local recurrence
following segmentectomy of stage IA non-small cell lung cancer is influenced by segment localisation

=== Intervention Extract 213 (Treatment) ===
r radiation 3 per 100
pneumonitis
assessed
with: NCI-
CTCAE
follow up:
median 14.5
monthsg
Grade 3-4 Study population
anemia
assessed 3 per 100
with: NCI-
CTCAE
follow up:
median 14.5
months
Grade 3-4 Study population
adverse
events 26 per 100
assessed
with: NCI-
CTCAE
follow up:
median 14.5
months
Treatment Study population
related
death 1 per 100
OPLASIE DEL
n
3 per 100
(1 to 8)
n
3 per 100
(1 to 7)
n
31 per 100
(23 to 39)
n
1 per 100
(0 to 6)
L POLMONE
RR 1.31 709
(0.52 to (1 RCT)
RR 0.86 709
(0.37 to (1 RCT)
RR 1.17 709
(0.90 to (1 RCT)
RR 1.15 709
(0.30 to (1 RCT)
) LOWa
) LOWa
) LOWa
) LOWb
a,b,f

=== Intervention Extract 214 (Treatment) ===
a,b,f
a,b,f
Ea,b
Ea,b
L
LINE
EE GUIDA
NEO
with: NCI-
CTCAE
follow up:
median 14.5
monthsg
Grade 3-4 Study population
anemia
assessed 3 per 100
with: NCI-
CTCAE
follow up:
median 14.5
months
Grade 3-4 Study population
adverse
events 26 per 100
assessed
with: NCI-
CTCAE
follow up:
median 14.5
months
Treatment Study population
related
death 1 per 100
a. We cannot exclud
Progression free
by means of blind
high risk of perfo
OPLASIE DEL POLMONE
n RR 0.86 709
(0.37 to (1 RCT)
3 per 100 2.03)
(1 to 7)
n RR 1.17 709
(0.90 to (1 RCT)
31 per 100 1.51)
(23 to 39)
n RR 1.15 709
(0.30 to (1 RCT)
1 per 100 4.41)
(0

=== Intervention Extract 215 (Treatment) ===
nzato oligometastatico
POPULATION: Pazienti affetti da NSCLC in stadio avanzato oligometastatico
INTERVENTION: Un trattamento locoregionale + terapia sistemica
COMPARISON: Sola terapia sistemica
MAIN OUTCOMES: Overall survival; Progression-free survival; Quality of life; ORR; Discontinuation of any treatment component; Loco-regional progression; Polmoniti; Tossicità grado 3-5
SETTING: Inpatients CONFLICT OF
INTERESTS: Is the problem a priority?
GIUDIZI RICERCA DELLE PROVE DI EVIDENZA
○ No
○ Probably no
○ Probably yes
● Yes
○ Varies
○ Don't know How substantial are the desirable anticipated effects?
GIU

=== Intervention Extract 216 (Treatment) ===
ivo.
DA
NSIDERAZI
IONI AGGIUNTIVE
Esiti Effetto assoluto anticipato* (95% Effetto № dei Certezza
CI) relativo partecipanti delle prove
(95% (studi) (GRADE)
Rischio con Rischio con un CI)
sola terapia trattamento loco-
sistemica regionale
Discontinuation of Popolazione in studio RR 0.95 133 ⨁⨁◯◯
any treatment (0.06 a (1 RCT)1
Bassaa,b
component 2 per 100 1 per 100 14.97)
(0 a 23)
Loco-regional Popolazione in studio RR 0.20 133 ⨁⨁◯◯
progression (0.09 a (1 RCT)1
Bassab,c
45 per 100 9 per 100 0.44)
(4 a 20)
Polmoniti Popolazione in studio RR 1.59 130 ⨁⨁◯◯
follow up: mediana (0.96 a (1 RCT)1
Bassab,c
23.6 m

=== Intervention Extract 217 (Treatment) ===
0.8 lower -
Fatigue (QOL - quality of life (3.6 higher to
fatigue) 2.1 higher)
NE
6 to
(1 RCT)
9 to (1 RCT)
(1 RCT)
(1 RCT)
(1 RCT)
(1 RCT)
(1 RCT)
LOWa,b
LOWa,b
MODERA
MODERA
MODERA
MODERA
MODERA
ATEa
ATEa
ATEa
ATEa
ATEa
L
LINE
EE GUIDA
assessed with: QLQ- - Fatigue was
C30 0
Scale from: 0 to 100
Treatment Study population RR 0.64 556
discontinuation (0.73 to (1 RCT)
(treatment 77 per 100 49 per 100 0.56)
discontinuous) (43 to 56)
Grade 3 rash or acne Study population RR 0.16 556
assessed with: NCI- (0.05 to (1 RCT)
CTCAE 7 per 100 1 per 100 0.52)
(0 to 4)
Grade 3 alanine Study population RR 0.04 556

=== Intervention Extract 218 (Treatment) ===
igher)
NE
6 to
(1 RCT)
9 to (1 RCT)
(1 RCT)
(1 RCT)
(1 RCT)
(1 RCT)
(1 RCT)
LOWa,b
LOWa,b
MODERA
MODERA
MODERA
MODERA
MODERA
ATEa
ATEa
ATEa
ATEa
ATEa
L
LINE
EE GUIDA
assessed with: QLQ- - Fatigue was
C30 0
Scale from: 0 to 100
Treatment Study population RR 0.64 556
discontinuation (0.73 to (1 RCT)
(treatment 77 per 100 49 per 100 0.56)
discontinuous) (43 to 56)
Grade 3 rash or acne Study population RR 0.16 556
assessed with: NCI- (0.05 to (1 RCT)
CTCAE 7 per 100 1 per 100 0.52)
(0 to 4)
Grade 3 alanine Study population RR 0.04 556
aminotrasferase (0.01 to (1 RCT)
assessed with: NCI- 9 per 100 0 per 100

=== Intervention Extract 219 (Treatment) ===
y of life - The mean MD 0.8 lower -
Fatigue (QOL - quality of life - (3.6 higher to
fatigue) Fatigue was 0 2.1 higher)
assessed with: QLQ-
C30
Scale from: 0 to 100
Study population
NE
(1 RCT)
(1 RCT)
(1 RCT)
(1 RCT)
(1 RCT)
MODERA
MODERA
MODERA
MODERA
MODER
ATEa
ATEa
ATEa
ATEa
RATEa
L
LINE
EE GUIDA
Treatment 77 per 100 49 per 100
RR 0.64
discontinuation (43 to 56) 556
(0.73 to
(treatment (1 RCT)
discontinuous)
Grade 3 rash or acne Study population RR 0.16 556
assessed with: NCI- (0.05 to (1 RCT)
CTCAE 7 per 100 1 per 100 0.52)
(0 to 4)
Grade 3 alanine Study population RR 0.04 556
aminotrasferase (0.01

=== Intervention Extract 220 (Treatment) ===
to
fatigue) Fatigue was 0 2.1 higher)
assessed with: QLQ-
C30
Scale from: 0 to 100
Study population
NE
(1 RCT)
(1 RCT)
(1 RCT)
(1 RCT)
(1 RCT)
MODERA
MODERA
MODERA
MODERA
MODER
ATEa
ATEa
ATEa
ATEa
RATEa
L
LINE
EE GUIDA
Treatment 77 per 100 49 per 100
RR 0.64
discontinuation (43 to 56) 556
(0.73 to
(treatment (1 RCT)
discontinuous)
Grade 3 rash or acne Study population RR 0.16 556
assessed with: NCI- (0.05 to (1 RCT)
CTCAE 7 per 100 1 per 100 0.52)
(0 to 4)
Grade 3 alanine Study population RR 0.04 556
aminotrasferase (0.01 to (1 RCT)
assessed with: NCI- 9 per 100 0 per 100 0.29)
CTCAE (0 to 3)
Grade 3 a

=== Intervention Extract 221 (Treatment) ===
Jan 2020.
3. Mok, T., Camidge, D. R., Gadgeel, S. M., Rosell, R., Dziadziuszko, R., Kim, D. W., Pérol, M., Ou, S. I., Ahn, J. S., Shaw, A. T., Bordogna, W., Smoljanović, V., Hilton, M., Ruf, T., Noé, J., Peters, S.. Updated overall survival and final progression-free survival data for patients with
treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol; Aug 2020. Dovrebbe alectinib vs crizotinib essere utilizzato per pazienti affetti da NSCLC in stadio localmente avanzato o meta
riarrangiamenti di ALK
POPULATION: Pazienti affetti da NSCLC in stadio localmente avan

=== Intervention Extract 222 (Treatment) ===
, T., Camidge, D. R., Gadgeel, S. M., Rosell, R., Dziadziuszko, R., Kim, D. W.,
Pérol, M., Ou, S. I., Ahn, J. S., Shaw, A. T., Bordogna, W., Smoljanović, V., Hilton,
L
LINE
EE GUIDA
M., Ruf, T., Noé, J., Peters, S.. Updated overall survival and final progression-free
survival data for patients with treatment-naive advanced ALK-positive non-small-
cell lung cancer in the ALEX study. Ann Oncol; Aug 2020. independent central review. The objective responses were assessed by an
independent central review only in Hida et al trial. No information about the loss to
follow-up in Nakagawa et al. and in Zhou et a

=== Intervention Extract 223 (Treatment) ===
Jan 2020.
3. Mok, T., Camidge, D. R., Gadgeel, S. M., Rosell, R., Dziadziuszko, R., Kim, D. W., Pérol, M.,
Ou, S. I., Ahn, J. S., Shaw, A. T., Bordogna, W., Smoljanović, V., Hilton, M., Ruf, T., Noé, J.,
Peters, S.. Updated overall survival and final progression-free survival data for patients with
treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann
Oncol; Aug 2020.
a. These were three open-label studies. Only the PFS outcome was assessed by an independent
central review. The objective responses were assessed by an independent central review only
in Hida et al trial.

=== Intervention Extract 224 (Treatment) ===
MPORTANT
(0.43 to 2.16) per 100 VERY LOW
(from 3
fewer to 6
more)
GGT increased - ceritinib
1 randomised not serious b not serious not serious d very serious h none 21/115 (18.3%) 0/116 (0.0%) RR 42.37 0 fewer ⨁⨁◯◯ CRITICAL
trials (2.59 to per 100 LOW
691.67) (from 0
fewer to 0
fewer)
AE leading to treatment discontinuation
2 randomised serious a,b,g not serious not serious d serious h none 10/152 (6.6%) 11/139 (7.9%) RR 0.85 1 fewer ⨁⨁◯◯ CRITICAL
trials (0.37 to 1.94) per 100 LOW
(from 5
fewer to 7
more)
CI: Confidence interval; HR: Hazard Ratio; RR: Risk ratio
Explanations
a. In Shaw et al. study no

=== Intervention Extract 225 (Treatment) ===
RADE)
s)
MODERAT
s)
LOWb,c,d,e,f
s)
LOWb,c,d,g,h
s)
VERY LOW
of the
TEa,b,c,d
Wb,c,d,g,h,i
LI
Commen
INEE G
CON
nts
GUIDA
NSIDERAZI
IONI AGGIUNTIVE
LINE
GGT increased - 0 per 100 0 per 100 RR 42.37 231 ⨁⨁◯◯
(0 to 0) (2.59 to
ceritinib
(1 RCT) LOWb,d,g
AE leading to Study population RR 0.85 291 ⨁⨁◯◯
treatment (0.37 to (2 RCTs)
LOWb,c,d,g,h
discontinuation 8 per 100 7 per 100 1.94)
(3 to 15)
I2=31%
In Shaw et al study the proportion of asian patients was: 26% in the ceritinib arm and 33% in the
chemotherapy arm.
In Shaw et al. study no information was given about the number of patients lost to follow-up.

=== Intervention Extract 226 (Treatment) ===
Ts
RR 0.96 335
(0.43 to (2 RCTs
RR 42.37 231
(2.59 to (1 RCT)
Certainty o
pants evidence
s) (GRADE)
s)
MODERAT
s) LOWb,c,d,e,f
s) LOWb,c,d,g,h
s) VERY LOW
) LOWb,d,g
of the
TEa,b,c,d
Wb,c,d,g,h,i
LI
Commen
INEE G
CON
nts
GUIDA
NSIDERAZI
IONI AGGIUNTIVE
LINE
AE leading to 8 per 100 7 per 100 RR 0.85
treatment (3 to 15) (0.37 to
(2 RCTs) LOWb,c,d,g,h
discontinuation 1.94)
I2=31%
In Shaw et al study the proportion of asian patients was: 26% in the ceritinib arm and 33% in the
chemotherapy arm.
In Shaw et al. study no information was given about the number of patients lost to follow-up. This
was an open-la

=== Intervention Extract 227 (Treatment) ===
H
2.20) (from 5
LINEE GUID
more to 33
more)
Any grade 3-5 AEs (follow up: median 25.2 months)
1 randomised serious a,d not serious not serious not serious none 48/154 (31.2%) 80/150 (53.3%) RR 0.58 22 fewer ⨁⨁
trials (0.44 to per 100 MOD
0.77) (from 30
fewer to
12 fewer)
Discontinuation rate of any treatment component
1 randomised serious a,d not serious not serious not serious none 80/154 (51.9%) e 106/151 (70.2%) RR 0.74 18 fewer ⨁⨁
trials f (0.61 to per 100 MOD
0.89) (from 27
fewer to 8
fewer)
CI: Confidence interval; HR: Hazard Ratio; RR: Risk ratio
Explanations
a. Unclear risk of selection and att

=== Intervention Extract 228 (Treatment) ===
trials f (0.61 to per 100 MOD
0.89) (from 27
fewer to 8
fewer)
CI: Confidence interval; HR: Hazard Ratio; RR: Risk ratio
Explanations
a. Unclear risk of selection and attrition bias due to the lack of information
b. As per protocol, 82 patients randomized to CHT arm crossed over to a pembrolizumab treatment after disease progression. We reported the adjusted HR for the adjusted OS for treatment crossove
c. This was an open label trial, there was a blinded, independent, central radiologic review
d. High risk of performance and detection bias
e. discontinuation reasons: 51 disease progression, 17 AE, 6

=== Intervention Extract 229 (Treatment) ===
HR: Hazard Ratio; RR: Risk ratio
Explanations
a. Unclear risk of selection and attrition bias due to the lack of information
b. As per protocol, 82 patients randomized to CHT arm crossed over to a pembrolizumab treatment after disease progression. We reported the adjusted HR for the adjusted OS for treatment crossove
c. This was an open label trial, there was a blinded, independent, central radiologic review
d. High risk of performance and detection bias
e. discontinuation reasons: 51 disease progression, 17 AE, 6 died, 4 patient withdrawal, 1 physician decision, 1 complete response
f. Discontinuation

=== Intervention Extract 230 (Treatment) ===
00
survival (49 to 71)
follow up: median
11.2 months
Objective response Study population
rate
follow up: median 28 per 100 45 per 100
11.2 months (33 to 61)
Any grade 3-5 AEs Study population
follow up: median
25.2 months 53 per 100 31 per 100
(23 to 41)
Discontinuation rate Study population
of any treatment
component 70 per 100e 52 per 100
(43 to 62)f
Unclear risk of selection and attrition bias due t
As per protocol, 82 patients randomized to CHT
after disease progression. We reported the adju
crossover.
This was an open label trial, there was a blinde
High risk of performance and detection bias.
Dis

=== Intervention Extract 231 (Treatment) ===
ttrition bias due t
As per protocol, 82 patients randomized to CHT
after disease progression. We reported the adju
crossover.
This was an open label trial, there was a blinde
High risk of performance and detection bias.
Discontinuation reasons: 69 disease progressio
physician decision, 29 completed treatment.
Discontinuation reasons: 51 disease progressio
decision, 1 complete response.
NE
HR 0.50
(0.37 to
(1 RCT) HIGHa
RR 1.61 305 ⨁⨁⨁
(1.18 to (1 RCT) HIGHa
RR 0.58 304 ⨁⨁⨁
(0.44 to (1 RCT)
MODE
RR 0.74 305 ⨁⨁⨁
(0.61 to (1 RCT)e,f
MODE
to the lack of information.
T arm crossed over to a pembro
usted HR

=== Intervention Extract 232 (Treatment) ===
edian
25.2 months 64 per 100
Progression free Study popula
survival
follow up: median 83 per 100
11.2 months
Objective response Study popula
rate
follow up: median 28 per 100
11.2 months
Any grade 3-5 AEs Study popula
follow up: median
25.2 months 53 per 100
Discontinuation rate Study popula
of any treatment
component 70 per 100e
ASIE DEL POLMONE
absolute effects* (95% CI) Relative № of Certaint
effect participants evidence
lla Risk with un (95% (studies) (GRADE
pia trattamento di prima CI)
linea con
pembrolizumab
ation HR 0.49 305 ⨁⨁⨁⨁
(0.34 to (1 RCT) HIGHa,b
39 per 100 0.69)
(29 to 50)
ation HR 0.50

=== Intervention Extract 233 (Treatment) ===
IDERAZI
IONI AGGIUNTIVE
Qualità delle pr
Qual è la qualità comples
GIUDIZI
○ Molto bassa
○ Bassa
X Moderata
○ Alta
○ Nessuno studio incluso
Unclear risk of selection and attrition bias due to the lack of information.
As per protocol, 82 patients randomized to CHT arm crossed over to a pembrolizumab treatment
after disease progression. We reported the adjusted HR for the adjusted OS for treatment
crossover.
This was an open label trial, there was a blinded, independent, central radiologic review.
High risk of performance and detection bias.
Discontinuation reasons: 69 disease progression, 16 AEs, 9 died

=== Intervention Extract 234 (Treatment) ===
○ Bassa
X Moderata
○ Alta
○ Nessuno studio incluso
Unclear risk of selection and attrition bias due to the lack of information.
As per protocol, 82 patients randomized to CHT arm crossed over to a pembrolizumab treatment
after disease progression. We reported the adjusted HR for the adjusted OS for treatment
crossover.
This was an open label trial, there was a blinded, independent, central radiologic review.
High risk of performance and detection bias.
Discontinuation reasons: 69 disease progression, 16 AEs, 9 died, 5 patient withdrawal, 7
physician decision, 29 completed treatment.
Discontinuation rea

=== Intervention Extract 235 (Treatment) ===
the adjusted OS for treatment
crossover.
This was an open label trial, there was a blinded, independent, central radiologic review.
High risk of performance and detection bias.
Discontinuation reasons: 69 disease progression, 16 AEs, 9 died, 5 patient withdrawal, 7
physician decision, 29 completed treatment.
Discontinuation reasons: 51 disease progression, 17 AE, 6 died, 4 patient withdrawal, 1 physician
decision, 1 complete response.
rove
ssiva delle prove di efficacia e sicurezza?
RICERCA DELLE PROVE CONSIDERAZI
L a certezza nelle prove è stata giudicata MODERATA per rischio di performance e detecti

=== Intervention Extract 236 (Treatment) ===
ewer)
RR 2.16 25 more ⨁⨁⨁◯ CRITICAL
) (1.58 to per 100 MODERATE
2.95) (from 12
more to
41 more)
NEOPLASIE
Certainty assessment
№ of Study Risk of
Inconsistency Indirectness Imprecisi
studies design bias
2 randomised serious a,f serious g very serious serious
trials c,d,h
Discontinuation rate of any treatment componentj
2 randomised serious a,f not serious very serious not seriou
trials c,d,k
CI: Confidence interval; HR: Hazard Ratio; RR: Risk ratio
E DEL POLMO
Other
ion
consideratio
i none
us none
ONE
№ of patients
un trattamento
di prima linea a
base di platino,
pemetrexed e
pembrolizumab,
seguito da

=== Intervention Extract 237 (Treatment) ===
ided to downgrade the quality of the evidence by one level for the risk of bias dimension because in both study crossover to pembrolizumab monotherapy was permitted
among the patients in the chemotherapy combination group who had verified disease progression
c. In Keynote-021 trial, the maintenance treatment consisted of pembrolizumab and optional indefinite pemetrexed
d. In KEYNOTE-21 study, subgroups analysis according to tumour proportion score for PD-L1 were not designed and performed. For this reason we decided to downgrade the
quality of the evidence by one level for indirectness
e. KEYNOTE-021 t

=== Intervention Extract 238 (Treatment) ===
the overall population and not according to PD-L1 tumour proportion score
i. We decided to downgrade the quality of the evidence by one level for imprecision because the 95% CI includes both negligible effect and appreciable benefit or appreciable harm
j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician
decision, 1 use of excluded medication. 43 patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician
decision

=== Intervention Extract 239 (Treatment) ===
PD-L1 tumour proportion score
i. We decided to downgrade the quality of the evidence by one level for imprecision because the 95% CI includes both negligible effect and appreciable benefit or appreciable harm
j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician
decision, 1 use of excluded medication. 43 patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician
decision, 1 use of excluded medication. KEYNOTE 189

=== Intervention Extract 240 (Treatment) ===
ligible effect and appreciable benefit or appreciable harm
j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician
decision, 1 use of excluded medication. 43 patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician
decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 150
radiographic PD, 78 AEs, 16 patie

=== Intervention Extract 241 (Treatment) ===
6 AEs, 4 patients withdrawal, 3 physician
decision, 1 use of excluded medication. 43 patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician
decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 150
radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone
arm for the following reasons: 268 patients dis

=== Intervention Extract 242 (Treatment) ===
decision, 1 use of excluded medication. 43 patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician
decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 150
radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone
arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab co

=== Intervention Extract 243 (Treatment) ===
xcluded medication. KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 150
radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone
arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients
withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression;
k. in KEYNOTE-189

=== Intervention Extract 244 (Treatment) ===
mbrolizumab combination treatment for the following reasons: 150
radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone
arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients
withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression;
k. in KEYNOTE-189 study information for this outcome were showed in the overall population and not ac

=== Intervention Extract 245 (Treatment) ===
ollowing reasons: 150
radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone
arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients
withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression;
k. in KEYNOTE-189 study information for this outcome were showed in the overall population and not according to PD-L1 tumour proportion score Do

=== Intervention Extract 246 (Treatment) ===
olizumab, seguito da mantenimento con pemetrexed e pembrolizumab in caso di risposta o stabilità di
malattia dopo 4 cicli di trattamento
COMPARISON: Alla chemioterapia
MAIN OUTCOMES: Overall survival; Progression free survival; Objective response rate; Grade 3-5 any AEs; Discontinuation rate of any treatment component
SETTING:
PERSPECTIVE:
BACKGROUND:
CONFLICT OF INTERESTS: Assenti alla votazione: Dr. Novello, Dr. Facchinetti, Dr. Passaro, Dr. Rossi, Dr. Trisolini, Dr. Ferrara, Dr. Menis Is the problem a priority? ○ No Inhibitors of programmed death 1 (PD-1) and its ligand PD-L1 are effective therapies

=== Intervention Extract 247 (Treatment) ===
(2 RCTs)
MODERATEa,c,d,e
21 per 100 46 per 100 2.95)
(33 to 63)
UIDA
Comment
ADDITIONAL
CONSIDERATIONS
ts
Grade 3-5 any AEs Study population RR 1.06 728 ⨁◯◯◯
(0.94 to (2 RCTs)
VERY
56 per 100 60 per 100 1.19)
LOWa,c,d,f,g,h,i
(53 to 67)
Discontinuation rate Study population RR 0.80 739 ⨁◯◯◯
of any treatment (0.73 to (2 RCTs)
VERY LOWa,c,d,i,k
componentj 78 per 100 62 per 100 0.88)
(57 to 68)
a. Unclear risk of attrition bias in both studies due to the lack of information
b. We decided to downgrade the quality of the evidence by one level for the risk of bias dimension because in both
study crossover t

=== Intervention Extract 248 (Treatment) ===
ided to downgrade the quality of the evidence by one level for the risk of bias dimension because in both
study crossover to pembrolizumab monotherapy was permitted among the patients in the chemotherapy
combination group who had verified disease progression
c. In Keynote-021 trial, the maintenance treatment consisted of pembrolizumab and optional indefinite pemetrexed
d. In KEYNOTE-21 study, subgroups analysis according to tumour proportion score for PD-L1 were not designed and
performed. For this reason we decided to downgrade the quality of the evidence by one level for indirectness
dimension
e. KEY

=== Intervention Extract 249 (Treatment) ===
fit or appreciable harm
g. I2=53%
h. In KEYNOTE 189 study safety results were showed in the overall population and not according to PD-L1 tumour
proportion score
i. High risk of performance and detection bias because KEYNOTE-021 was an open-label trial
j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination treatment for the
following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43
patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients
withdrawal, 2 physician decision

=== Intervention Extract 250 (Treatment) ===
NOTE 189 study safety results were showed in the overall population and not according to PD-L1 tumour
proportion score
i. High risk of performance and detection bias because KEYNOTE-021 was an open-label trial
j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination treatment for the
following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43
patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients
withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189

=== Intervention Extract 251 (Treatment) ===
detection bias because KEYNOTE-021 was an open-label trial
j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination treatment for the
following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43
patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients
withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued
treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs,
16 patie

=== Intervention Extract 252 (Treatment) ===
6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43
patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients
withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued
treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs,
16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients
discontinued treatment in the CHT alone arm for the following reasons: 268 patients dis

=== Intervention Extract 253 (Treatment) ===
decision, 1 use of excluded medication. 43
patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients
withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued
treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs,
16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients
discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in
the Pembrolizumab co

=== Intervention Extract 254 (Treatment) ===
xcluded medication. KEYNOTE 189 study: 268 patients discontinued
treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs,
16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients
discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in
the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients
withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression;
k. in KEYNOTE-189

=== Intervention Extract 255 (Treatment) ===
mbrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs,
16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients
discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in
the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients
withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression;
k. in KEYNOTE-189 study information for this outc
PD-L1 tumour proportion score
Forest Plot
OS: Objec

=== Intervention Extract 256 (Treatment) ===
ollowing reasons: 150 radiographic PD, 78 AEs,
16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients
discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in
the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients
withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression;
k. in KEYNOTE-189 study information for this outc
PD-L1 tumour proportion score
Forest Plot
OS: Objective response rate:
E
come were showed in t

=== Intervention Extract 257 (Treatment) ===
46 per 100 2.95)
(33 to 63)
Grade 3-5 any AEs Study population RR 1.06 728 ⨁◯◯◯
(0.94 to (2 RCTs)
VERY
56 per 100 60 per 100 1.19)
LOWa,c,d,f,g,h,i
( 53 to 67)
UIDA
Comment
ADDITIONAL
CONSIDERATIONS
ts
Discontinuation Study population RR 0.80 739 ⨁◯◯◯
rate of any (0.73 to (2 RCTs) VERY LOWa,c,d,i,k
treatment 78 per 100 62 per 100 0.88)
(57 to 68)
componentj
a. Unclear risk of attrition bias in both studies due to the lack of information
b. We decided to downgrade the quality of the evidence by one level for the risk of bias dimension because in both
study crossover to pembrolizumab monotherapy was perm

=== Intervention Extract 258 (Treatment) ===
ided to downgrade the quality of the evidence by one level for the risk of bias dimension because in both
study crossover to pembrolizumab monotherapy was permitted among the patients in the chemotherapy
combination group who had verified disease progression
c. In Keynote-021 trial, the maintenance treatment consisted of pembrolizumab and optional indefinite pemetrexed
d. In KEYNOTE-21 study, subgroups analysis according to tumour proportion score for PD-L1 were not designed and
performed. For this reason we decided to downgrade the quality of the evidence by one level for indirectness
dimension
e. KEY

=== Intervention Extract 259 (Treatment) ===
fit or appreciable harm
g. I2=53%
h. In KEYNOTE 189 study safety results were showed in the overall population and not according to PD-L1 tumour
proportion score
i. High risk of performance and detection bias because KEYNOTE-021 was an open-label trial
j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination treatment for the
following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43
patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients
withdrawal, 2 physician decision

=== Intervention Extract 260 (Treatment) ===
NOTE 189 study safety results were showed in the overall population and not according to PD-L1 tumour
proportion score
i. High risk of performance and detection bias because KEYNOTE-021 was an open-label trial
j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination treatment for the
following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43
patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients
withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189

=== Intervention Extract 261 (Treatment) ===
detection bias because KEYNOTE-021 was an open-label trial
j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination treatment for the
following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43
patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients
withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued
treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs,
16 patie

=== Intervention Extract 262 (Treatment) ===
6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43
patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients
withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued
treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs,
16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients
discontinued treatment in the CHT alone arm for the following reasons: 268 patients dis

=== Intervention Extract 263 (Treatment) ===
decision, 1 use of excluded medication. 43
patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients
withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued
treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs,
16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients
discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in
the Pembrolizumab co

=== Intervention Extract 264 (Treatment) ===
xcluded medication. KEYNOTE 189 study: 268 patients discontinued
treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs,
16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients
discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in
the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients
withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression;
k. in KEYNOTE-189

=== Intervention Extract 265 (Treatment) ===
mbrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs,
16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients
discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in
the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients
withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression;
k. in KEYNOTE-189 study information for this outcome were showed in the overall population and not ac

=== Intervention Extract 266 (Treatment) ===
ollowing reasons: 150 radiographic PD, 78 AEs,
16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients
discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in
the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients
withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression;
k. in KEYNOTE-189 study information for this outcome were showed in the overall population and not according to
PD-L1 tumour proportion score
NE

=== Intervention Extract 267 (Treatment) ===
(follow-up median 12.5 months; assessed with: not rilevant )
1 randomised no serious risk no serious no serious no serious none 255/359
trials of bias inconsistency indirectness imprecision (71%)
Progression free survival (follow-up median 5 months4; assessed with: indipendent radiologist masked to treatment using RECIST 1.05
1 randomised no serious risk no serious no serious no serious none 175/359
trials of bias inconsistency indirectness imprecision (48.7%)
Objective responce rate (follow-up median 24.3 months; assessed with: overall responce rate (compleate and partial response) RECIS
1 randomised

=== Intervention Extract 268 (Treatment) ===
39 ⨁⨁⨁⨁
Survival (OS) 0.78 (1 RCT)
ALTA
valutato con: 78 per 69 per 100 (0.64 a
not rilevant 100 (62 a 76) 0.96)
follow up:
mediana 12.5
m esi
Popolazione in studio
SIDERAZIO
LINE
ONI AGG
EE GUIDA
GIUNTIVE
NE
Progression 34 per
free survival 100
(PFS)
valutato con:
indipendent
radiologist
masked to
treatment
using
RECIST 1.0
follow up:
mediana 5
mesia
Objective Popola
responce rate
(ORR) 1 per
valutato con: 100
overall
responce rate
(compleate
and partial
response)
RECIST 1.0
follow up:
mediana 24.3
mesib
Quality of life La
-EQ-5D media
(QOL) quality
valutato con: of life
EQ-5D index EQ-5D
score - Cycl

=== Intervention Extract 269 (Treatment) ===
bilità
dei risultati
Overall Survival
5 1,2,3 studi non importante non importante non importante non importante nessuno
randomizzati 5 1,2,3 studi serio a,b non importante non importante non importante nessuno
randomizzati 5 studi serio a,b serio c non importante non importante nessuno
randomizzati
Treatment-related AE (grade 3 or 4)
5 1,2,3 studi serio b non importante d non importante non importante nessuno
randomizzati 5 1,2,3 studi serio b non importante non importante non importante nessuno
randomizzati
OLMONE
ocalmente avanzato o metastatico in progressione dopo una prima linea di chemioterapia
A

=== Intervention Extract 270 (Treatment) ===
5 RCTs) HIGHa
76 per 100 64 per 100 0.77)
(61 to 67)
Progression free Study population HR 0.85 2737 ⨁⨁⨁◯
survival (0.79 to (4 RCTs)
MODERA
83 per 100 78 per 100 0.92)
(76 to 81)
Overall response Study population RR 1.93 3024 ⨁⨁◯◯
rate (1.12 to (5 RCTs)
LOWa,b,c
9 per 100 17 per 100 1.73)
(10 to 16)
Treatment-related Study population RR 0.32 3014 ⨁⨁⨁◯
AE (grade 3 or 4) (0.28 to (5 RCTs)
MODERA
47 per 100 15 per 100 0.36)
(13 to 17)
Study population
y of the
E)
ATEa,b
ATEa,b,d
LI
Commen
INEE G
CON
nts
GUIDA
NSIDERAZI
IONI AGGIUNTIVE
Discontinuation 17 per 100 8 per 100 RR 0.47 3014 ⨁⨁⨁◯
(6 to 10) (0.38 t

=== Intervention Extract 271 (Treatment) ===
and detection bias, all studies were open label Although heterogeneity across study was found (I2=82%), we decided not to downgrade for
inconsistency, because heterogeneity is related to magnitude and not to direction of effects
Overall survival
progression free survival
NEO
Objective response rate
treatment related AEs
OPLAS
SIE DEL POLMON
NE
Discontinu
NEO
uation rate
OPLAS
SIE DEL POLMON
NE
Effetti ind
Quanto conside
GIUDIZI
○ Grandi
○ Moderati
○ Piccoli
X
Irrilevanti
○ Variano
○ Non so
deside
erevoli son
erabili
no gli effet
tti indesiderabili attesi?
RICERCA DELLE PROVE
Outcomes Anticipated absolu

=== Intervention Extract 272 (Treatment) ===
5 RCTs) HIGHa
76 per 100 64 per 100 0.77)
(61 to 67)
Progression free Study population HR 0.85 2737 ⨁⨁⨁◯
survival (0.79 to (4 RCTs)
MODERA
83 per 100 78 per 100 0.92)
(76 to 81)
Overall response Study population RR 1.93 3024 ⨁⨁◯◯
rate (1.12 to (5 RCTs)
LOWa,b,c
9 per 100 17 per 100 1.73)
(10 to 16)
Treatment-related Study population RR 0.32 3014 ⨁⨁⨁◯
AE (grade 3 or 4) (0.28 to (5 RCTs)
MODERA
47 per 100 15 per 100 0.36)
(13 to 17)
Discontinuation Study population RR 0.47 3014 ⨁⨁⨁◯
rate (0.38 to (5 RCTs)
MODERA
17 per 100 8 per 100 0.59)
(6 to 10)
y of the
E)
ATEa,b
ATEa,b,d
ATEa,b
LI
Commen
INEE G
CON

=== Intervention Extract 273 (Treatment) ===
E DEL POLMONE
ment was not clear in two studies (OAK and POPLAR studies)
mance and detection bias, all studies were open label
neity across study was found (I2=82%), we decided not to downgrade for
use heterogeneity is related to magnitude and not to direction of effects
NEO
Objective response rate
Treatment related AEs
OPLAS
SIE DEL POLMON
NE
Qualità delle pr
Qual è la qualità comples
GIUDIZI
○ Molto bassa
○ Bassa
X Moderata
○ Alta
○ Nessuno studio incluso
NEOPLA
Discontinuation rate
rove
ssiva delle prove di efficacia e sicurezza?
RICERCA DELLE PROVE
La certezza nelle prove è stata giudic
o
ASIE DEL

=== Intervention Extract 274 (Treatment) ===
., Poltoratskiy, A., Ponce, S., Verderame, F., Havel, L., Bondarenko, I., Każarnowicz, A., Losonczy, G., Conev, N. V.,
Armstrong, J., Byrne, N., Thiyagarajah, P., Jiang, H., Paz-Ares, L.. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised,
controlled, open-label, phase 3 trial. Lancet Oncol; Jan 2021.
DOMAN
Dovrebbe d
per pazient
POPOLAZIONE:
INTERVENTO:
CONFRONTO:
ESITI PRINCIPALI:
SETTING:
PROSPETTIVA:
BACKGROUND:
CONFLITTI DI INTERESSE
VALUTA I

=== Intervention Extract 275 (Treatment) ===
., Poltoratskiy, A., Ponce, S., Verderame, F., Havel, L., Bondarenko, I.,
Każarnowicz, A., Losonczy, G., Conev, N. V., Armstrong, J., Byrne, N.,
Thiyagarajah, P., Jiang, H., Paz-Ares, L.. Durvalumab, with or without
tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in
first-line treatment of extensive-stage small-cell lung cancer (CASPIAN):
updated results from a randomised, controlled, open-label, phase 3 trial. Lancet
Oncol; Jan 2021.
a. Rischio di performance bias poichè lo studio non è stato condotto in cieco e di
detection bias considerato che gli outcomes venivano valutati dal

=== Intervention Extract 276 (Treatment) ===
ğlu, M., Ji, J. H., Garassin
Voitko, O., Poltoratskiy, A., Ponce, S., Verderame, F., Havel, L.,
Każarnowicz, A., Losonczy, G., Conev, N. V., Armstrong, J., Byrn
Thiyagarajah, P., Jiang, H., Paz-Ares, L.. Durvalumab, with or wi
tremelimumab, plus platinum-etoposide versus platinum-etoposi
first-line treatment of extensive-stage small-cell lung cancer (CA
qualunque
grado.
Durvalumab
TAa
chemioterapia
con platino ed
etoposide
probabilmente
non
incrementano
la probabilità
di tossicità di
grado 3-4.
Durvalumab
TAa
chemioterapia
con platino ed
etoposide
probabilmente
non
incrementano
la probabilità
di
discon

=== Intervention Extract 277 (Treatment) ===
on and outcome bias. The quality of the included RCTs was assessed according to the Cochrane Handbook 5.1. Studies had, in general, a low risk of bias
d. I2=84%
e. Patients included in the Prophylactic Cranial irradiation overview collaborative group had achieved a complete response after induction treatment. In Rule at al. all patients were 70 years or older.
Salama et al presented a secondary analysis of the CALGB 30504 study, included patients received placebo or sunitinib
f. This is not the total number of events, Ge 2018 et al. did not show the number of events but only the overall number of patie

=== Intervention Extract 278 (Treatment) ===
d 12 observational studies
b. This is not the total number of events, Ge 2018 et al. did not showed the number of events
but only the overall number of patients
c. Patients included in the Prophylactic Cranial irradiation overview collaborative group had
achieved a complete response after induction treatment. In Rule at al. all patients were 70
years or older. Salama et al presented a secondary analysis of the CALGB 30504 study,
included patients received placebo or sunitinib
d. I2=84%
e. In 13 out of 21 studies, the number of events were not showed
f. The quality of the observational included studies

=== Intervention Extract 279 (Treatment) ===
and 12 observational studies
b. This is not the total number of events, Ge 2018 et al. did not show the number of events but
only the overall number of patients
c. Patients included in the Prophylactic Cranial irradiation overview collaborative group had
achieved a complete response after induction treatment. In Rule at al. all patients were 70
years or older. Salama et al presented a secondary analysis of the CALGB 30504 study,
included patients received placebo or sunitinib
d. I2=84%
e. In 13 out of 21 studies, the number of events were not showed
EE GUIDA
f. The quality of the observational included

=== Intervention Extract 280 (Treatment) ===
best pathology practice. Int J Surg Pathol. 2013; 21:326-36.
Row 10: Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69:7-34.
Row 11: Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for
Row 12: diagnosis, treatment and follow-up. Ann Oncol. 2019; 30:863-70. Updated on 15 Sept 2020.
Row 13: Yatabe Y, Dacic S, Borczuk AC, et al. Best practices recommendations for diagnostic immunohistochemistry in
Row 14: lung cancer. J Thorac Oncol. 2019; 14:377-407.
Row 15: Lozano MD, Echeveste JI, Abengozar M, et al. Cytolog

=== Intervention Extract 281 (Treatment) ===
chial needle aspiration specimens for the diagnosis and molecular testing
Row 28: of patients with known of suspected lung cancer. Respiration. 2014; 88:500-17.
Row 29: Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer
Row 30: patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists,
Row 31: the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac
Row 32: Oncol. 2018; 13:323-58.
Row 33: Mino-Kenudson M, Le Stang N, Daigneault JB

=== Intervention Extract 282 (Treatment) ===
apy for EGFR mutation-positive lung
Row 50: adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3
Row 51: trials. Lancet Oncol. 2015; 16:141-51.
Row 52: Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European
Row 53: patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label,
Row 54: randomised phase 3 trial. Lancet Oncol. 2012; 13:239-46. Row 1: Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-smal

=== Intervention Extract 283 (Treatment) ===
C: a consensus statement from the
Row 7: International Association for the Study of Lung Cancer. J Thorac Oncol. 2021; 16(10):1647-62.
Row 8: Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO
Row 9: clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; Suppl 28:1-21.
Row 10: Lung cancer diagnosis and management. NICE guideline 2019. Available from: www.nice.org.uk/guidance/ng122
Row 11: Minjae K, Chong HS, Sang ML, et al. Diagnostic yield of staging brain MRI in patients with newly diagnosed non-
Row 12: small cell

=== Intervention Extract 284 (Treatment) ===
PE, D’Amico T, et al. European guidelines on structure and qualification of general thoracic
Row 49: surgery. Eur J Cardiothorac Surg. 2014; 45:779-86.
Row 50: Von Meyenfeldt EM, Gooiker GA, van Gijn W, et al. The relationship between volume or surgeon specialty and
Row 51: outcome in the surgical treatment of lung cancer: a systematic review and meta-analysis. J Thorac Oncol. 2012;
Row 52: 7:1170-8.
Row 53: Camposilvan I, Akhtar-Danesh N, Schneider L, et al. The effect of surgeon volume on procedure selection in non-
Row 54: small cell lung cancer surgeries. J Thorac Cardiovasc Surg. 2015; 150:507-12

=== Intervention Extract 285 (Treatment) ===
cell lung cancer. J Clin
Row 17: Oncol. 2009; 27:2553-62.
Row 18: Villamizar NR, Darrabie MD, Burfeind WR, et al. Thoracoscopic lobectomy is associated with lower morbidity
Row 19: compared with thoracotomy. J Thorac Cardiovasc Surg. 2009; 138:419-25.
Row 20: Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: diagnosis and
Row 21: management of lung cancer, 3rd ed.: American College of Chest Physicians evidence-based clinical practice
Row 22: guidelines. Chest. 2013; 143:e278S-e313S.
Row 23: Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in

=== Intervention Extract 286 (Treatment) ===
2015; 3:CD011430.
Row 45: Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation
Row 46: in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy
Row 47: Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008; 26:5043-51.
Row 48: Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with
Row 49: observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.
Row 50:

=== Intervention Extract 287 (Treatment) ===
y resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.
Row 50: J Clin Oncol. 2010; 28(1):29-34.
Row 51: Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO
Row 52: Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(Suppl 4):1-21.
Row 53: Kris MG, Gaspar LE, Chaft JE, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA
Row 54: completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario
Row 55: Clin

=== Intervention Extract 288 (Treatment) ===
Row 34: EVAN study of erlotinib versus vinorelbine plus cisplatin adjuvant therapy in stage IIIA epidermal growth
Row 35: factor receptor+ non-small-cell lung cancer. J Clin Oncol. 2022; 40(34):3912-7.
Row 36: Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-
Row 37: IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet
Row 38: Oncol. 2018; 19(1):139-48.
Row 39: Zhong WZ, Wang Q, Mao WM et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-
Row 40: IIIA (N1-N2)

=== Intervention Extract 289 (Treatment) ===
orelbine plus cisplatin as adjuvant treatment for stage II-
Row 37: IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet
Row 38: Oncol. 2018; 19(1):139-48.
Row 39: Zhong WZ, Wang Q, Mao WM et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-
Row 40: IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial. J Clin Oncol.
Row 41: 2021; 39(7):713-22 Row 1: |Randomized phase III study of gefitinib versus cisplatin plus Vinorelbine
Row 2: for patients with resected stage II-IIIA non-small-ce

=== Intervention Extract 290 (Treatment) ===
Row 14: with neoadjuvant chemoradiation therapy and surgery for stage IIIA non-small cell lung cancer: a population-based,
Row 15: comparative effectiveness analysis. Int J Radiat Oncol Biol Phys. 2015; 92(2):307-16.
Row 16: Allen AM, Shochat T, Flex D, et al. High-dose radiotherapy as neoadjuvant treatment in non-small-cell lung cancer.
Row 17: Oncology. 2018; 95(1):13-9.
Row 18: Vyfhuis MAL, Burrows WM, Bhooshan N, et al. Implications of pathologic complete response beyond mediastinal
Row 19: nodal clearance with high-dose neoadjuvant chemoradiation therapy in locally advanced, non-small cell lung c

=== Intervention Extract 291 (Treatment) ===
erative radiotherapy in non-small cell lung cancer: systematic review
Row 25: and meta-analysis of individual patient data from nine randomized controlled trials. Lancet. 1998; 352:257-63.
Row 26: Nestle U, De Ruysscher D, Ricardi U, et al. ESTRO ACROP guidelines for target volume definition in the treatment
Row 27: of locally advanced non-small cell lung cancer. Radiother Oncol. 2018; 127(1):1-5.
Row 28: Billiet C, Decaluvè H, Peeters S, et al. Modern post-operative radiotherapy for stage III non-small cell lung cancer
Row 29: may improve local control and survival: a meta-analysis. Radiother Oncol. 2

=== Intervention Extract 292 (Treatment) ===
ow 44: multidisciplinary approach at the University of Texas M.D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys.
Row 45: 2000; 48:347-54.
Row 46: Kappers I, Belderbos JS, Burgers JA, et al. Non-small cell lung carcinoma of the superior sulcus: favourable
Row 47: outcomes of combined modality treatment in carefully selected patients. Lung Cancer. 2008; 59:385-90.
Row 48: Rowell NP,O’Rourke NP. Concurrent chemo-radiotherapy in non-small cell lung cancer. Cochrane Database Syst
Row 49: Rev. 2004; (4):CD002140.
Row 50: O’Rourke N, Roqué I, Figuls M, et al. Concurrent chemo-radiotherapy in non-small

=== Intervention Extract 293 (Treatment) ===
stage III NSCLC. J Clin Oncol. 2022; 40(12):1301-11.
Row 24: Garassino MC, Mazieres J, Reck M, et al. Durvalumab after sequential chemoradiotherapy in stage III, unresectable
Row 25: NSCLC: the phase 2 PACIFIC-6 trial. J Thorac Oncol. 2022; 17(12):1415-27.
Row 26: Girard N, Bar J, Garrido P, et al. Treatment characteristics and real-world progression-free survival in patients with
Row 27: unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R
Row 28: study. J Thorac Oncol. 2023; 18(2):181-93.
Row 29: Hellman S, Weichselbaum RR. Oligometastases. J Clin

=== Intervention Extract 294 (Treatment) ===
ol. 1995; 13(1):8-10.
Row 30: Juan O, Sanjay Popat. Ablative therapy for oligometastatic non-small cell lung cancer. Clin Lung Cancer. 2017;
Row 31: 18(6):595-606.
Row 32: Ashworth AB, Senan S, Palma DA, et al. An individual patient data metaanalysis of outcomes and prognostic factors
Row 33: after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2014; 15(5):346-55.
Row 34: Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a
Row 35: European Society for Radiotherapy and Oncology and European Organisation for Research an

=== Intervention Extract 295 (Treatment) ===
f oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2014; 15(5):346-55.
Row 34: Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a
Row 35: European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer
Row 36: consensus recommendation. Lancet Oncol. 2020; 21(1):e18-28.
Row 37: Levy A, Hendriks LEL, Berghmans T, et al. EORTC Lung Cancer Group survey on the definition of NSCLC
Row 38: synchronous oligometastatic disease. Eur J Cancer. 2019; 122:109-14.
Row 39: Palma DA, Olson R, Harrow S,

=== Intervention Extract 296 (Treatment) ===
Row 37: Levy A, Hendriks LEL, Berghmans T, et al. EORTC Lung Cancer Group survey on the definition of NSCLC
Row 38: synchronous oligometastatic disease. Eur J Cancer. 2019; 122:109-14.
Row 39: Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment
Row 40: in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;
Row 41: 393(10185):2051-8.
Row 42: Xu Q, Zhou F, Liu H, et al. Consolidative local ablative therapy improves the survival of patients with synchronous
Row 43: oligometastatic NSCLC

=== Intervention Extract 297 (Treatment) ===
Row 12: phase 3 trial. Lancet Oncol. 2010; 11:121-8.
Row 13: Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated
Row 14: EGFR. N Engl J Med. 2010; 362:2380-8.
Row 15: Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced
Row 16: EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label,
Row 17: randomised, phase 3 study. Lancet Oncol. 2011; 12:735-42.
Row 18: Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-l

=== Intervention Extract 298 (Treatment) ===
patients with advanced
Row 16: EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label,
Row 17: randomised, phase 3 study. Lancet Oncol. 2011; 12:735-42.
Row 18: Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European
Row 19: patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label,
Row 20: randomised phase 3 trial. Lancet Oncol. 2012; 13:239-46.
Row 21: Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexe

=== Intervention Extract 299 (Treatment) ===
equist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with
Row 22: metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31:3327-34.
Row 23: Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients
Row 24: with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised
Row 25: phase 3 trial. Lancet Oncol. 2014; 15:213-22.
Row 26: Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positiv

=== Intervention Extract 300 (Treatment) ===
harma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nature Rev
Row 32: Cancer. 2007; 7:169-81.
Row 33: Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal:
Row 34: perspectives for individualized treatment strategy. Cancer Sci. 2016; 107:1179-86.
Row 35: Planchard D, Boyer MJ, Lee JS, et al. Postprogression outcomes for osimertinib versus standard-of-care EGFR-TKI
Row 36: in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer. Clin Cancer Res. 2019;
Row 37: 25(7):2058-

=== Intervention Extract 301 (Treatment) ===
. Clinical activity of afatinib in patients with advanced non-small-cell lung
Row 41: cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and
Row 42: LUX-Lung 6. Lancet Oncol. 2015; 16:830-8.
Row 43: Yang JC, Schuler M, Popat S, et al. Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a
Row 44: database of 693 cases. J Thorac Oncol. 2020; 15(5):803-15.
Row 45: Yang JCH, Shuler M, Popat S, et al. Afatinib for the treatment of NSCLC with uncommon EGFR mutations: an
Row 46: updated database of 1023 cases. ePoster presented at ESMO 2021 vi

=== Intervention Extract 302 (Treatment) ===
and
Row 42: LUX-Lung 6. Lancet Oncol. 2015; 16:830-8.
Row 43: Yang JC, Schuler M, Popat S, et al. Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a
Row 44: database of 693 cases. J Thorac Oncol. 2020; 15(5):803-15.
Row 45: Yang JCH, Shuler M, Popat S, et al. Afatinib for the treatment of NSCLC with uncommon EGFR mutations: an
Row 46: updated database of 1023 cases. ePoster presented at ESMO 2021 virtual meeting. Front Oncol. 2022; 12:834704.
Row 47: Miura S, Tanaka H, Misumi T, et al. Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer
Row 48: with a sens

=== Intervention Extract 303 (Treatment) ===
Yang JCH, Shuler M, Popat S, et al. Afatinib for the treatment of NSCLC with uncommon EGFR mutations: an
Row 46: updated database of 1023 cases. ePoster presented at ESMO 2021 virtual meeting. Front Oncol. 2022; 12:834704.
Row 47: Miura S, Tanaka H, Misumi T, et al. Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer
Row 48: with a sensitizing uncommon epidermal growth factor receptor mutation: a phase III study
Row 49: (ACHILLES/TORG1834). Ann Oncol. 2023; 34(suppl_2):S1254-S1335.
Row 50: Cho JH, Lim SH, An HJ, et al. Osimertinib for patients with non-small-cell lung cancer har

=== Intervention Extract 304 (Treatment) ===
w 1: Okuma Y, Kubota K, Shimokawa M, et al. First-line osimertinib for previously untreated patients with NSCLC and
Row 2: uncommon EGFR mutations: the UNICORN phase 2 nonrandomized clinical trial. JAMA Oncol. 2024; 10(1):43-
Row 3: 51.
Row 4: Van Veggel B, Madeira R, Santos JFV, et al. Osimertinib treatment for patients with EGFR exon 20 mutation
Row 5: positive non-small cell lung cancer. Lung Cancer. 2020; 141:9-13.
Row 6: Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer
Row 7: progressing on platinum chemotherapy: initial results from the

=== Intervention Extract 305 (Treatment) ===
uchi T, Tamiya A, et al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond
Row 23: progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol.
Row 24: 2012; 7(11):1722-7.
Row 25: Asami K, Okuma T, Hirashima T, et al. Continued treatment with gefitinib beyond progressive disease benefits
Row 26: patients with activating EGFR mutations. Lung Cancer. 2013; 79(3):276-82.
Row 27: Park K, Yu CJ, Kim SW, et al. First-line erlotinib therapy until and beyond response evaluation criteria in solid
Row 28: tumors progression in asian patients

=== Intervention Extract 306 (Treatment) ===
to
Row 33: osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin Cancer Res. 2018;
Row 34: 24(24):6195-203.
Row 35: Mu Y, Hao X, Yang K, et al. Clinical modality of resistance and subsequent management of patients with advanced
Row 36: non‑small cell lung cancer failing treatment with osimertinib. Target Oncol. 2019; 14(3):335-42.
Row 37: Cortellini A, Leonetti A, Catino A, et al. Osimertinib beyond disease progression in T790M EGFR‑positive NSCLC
Row 38: patients: a multicenter study of clinicians’ attitudes. Clin Transl Oncol. 2020; 22(6):844-51
Row 39: Cavanna L, Citteri

=== Intervention Extract 307 (Treatment) ===
12: crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC). J Clin|
Row 13: Oncol. 2021; 39(15_suppl):9022-9022.|
Row 14: Mok T, Camidge DR, Gadgeel SM, et al.|Updated overall survival and final progression-free survival data for
Row 15: patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol.|
Row 16: 2020; 31(8):1056-64.|
Row 17: Gadgeel S, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-|
Row 18: positive (ALK+) non-small-cell lung cancer: CNS efficac

=== Intervention Extract 308 (Treatment) ===
et al.|Updated overall survival and final progression-free survival data for
Row 15: patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol.|
Row 16: 2020; 31(8):1056-64.|
Row 17: Gadgeel S, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-|
Row 18: positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018;|
Row 19: 29(11):2214-22.|
Row 20: Zhou C, Lu Y, Kim SW, et al. LBA11 Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-|
Row 21:

=== Intervention Extract 309 (Treatment) ===
otinib in treatment-naive anaplastic lymphoma kinase-|
Row 18: positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018;|
Row 19: 29(11):2214-22.|
Row 20: Zhou C, Lu Y, Kim SW, et al. LBA11 Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-|
Row 21: naïve advanced ALK+ non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study. 2022;|
Row 22: 33(9):S1563.|
Row 23: Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N|
Row 24: Engl J Med. 2018; 379(21):2027

=== Intervention Extract 310 (Treatment) ===
et al. Progression-free and overall survival in patients with ALK|
Row 45: rearrangement-positive non-small cell lung cancer treated sequentially with crizotinib and alectinib. Clin Lung|
Row 46: Cancer. 2016; 17(6):528-34.|
Row 47: Chiari R, Metro G, Iacono D, et al. Clinical impact of sequential treatment with ALK-TKIs in patients with advanced|
Row 48: ALK-positive non-small cell lung cancer: results of a multicenter analysis. Lung Cancer. 2015; 90(2):255-60.|
Row 49: Liu J, Cui S, Pan F, et al. Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell|
Row 50: lung ca

=== Intervention Extract 311 (Treatment) ===
ll cell|
Row 50: lung cancer patients with ALK/ROS1 mutations. J Cancer. 2018; 9(10):1863-9.|
Row 51: Zhao Y, Zhang B, Wang S, et al. Management of central nervous system metastases in patients with advanced|
Row 52: anaplastic lymphoma kinase-rearranged nonesmall-cell lung cancer during crizotinib treatment. Clin Lung Cancer.|
Row 53: 2019; 20(6):e631-7.|
Row 54: Hubbeling H, Choudhury N, Flynn J, et al. Outcomes with local therapy and tyrosine kinase inhibition in patients|
Row 55: with ALK/ROS1/RET-rearranged lung cancers. JCO Precis Oncol. 2022; 6:e2200024.| Row 1: Shaw AT, Ou SH, Bang YJ, et al. C

=== Intervention Extract 312 (Treatment) ===
hou J, et al. Intracranial activity of Selpercatinib in Chinese patients with advanced RET fusion-
Row 5: positive non-small-cell lung cancer in the phase II LIBRETTO-321 trial. JCO Precis Oncol. 2023; 7:e2200708.
Row 6: Lu S, Zheng X, Sun Y, et al. Patient-reported outcomes following selpercatinib treatment in Chinese patients with
Row 7: advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET-mutant medullary thyroid
Row 8: cancer in the phase II LIBRETTO-321 trial. Ther Adv Med Oncol. 2023; 15:17588359231189429.
Row 9: Illini O, Hochmair MJ, Fabikan H, et al. Selpercatini

=== Intervention Extract 313 (Treatment) ===
; 39(15):suppl_9020.
Row 25: Wolf J, Garon EB, Groen HJM, et al. Patient-reported outcomes in capmatinib-treated patients with METex14-
Row 26: mutated advanced NSCLC: results from the GEOMETRY mono-1 study. Eur J Cancer. 2023; 183:98-108.
Row 27: Mazieres J, Paik PK, Garassino MC, et al. Tepotinib treatment in patients with MET exon 14-skipping non-small
Row 28: cell lung cancer. JAMA. 2023; 9(9):1260-6.
Row 29: Hong DS, Fakih MG, Strickler JH, et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J
Row 30: Med. 2020; 383(13):1207-17.
Row 31: Skoulidis F, Li BT, Dy GK, et al. Soto

=== Intervention Extract 314 (Treatment) ===
Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy
Row 39: for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥50. J Clin Oncol. 2021; 39(21):2339-
Row 40: 49.
Row 41: Herbst R, Giaccone G, De Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with
Row 42: NSCLC. N Engl J Med. 2020; 383(14):1328-39.
Row 43: Jassem J, de Marinis F, Giaccone G, et al. Updated overall survival analysis from IMpower110: Atezolizumab versus
Row 44: platinum-based chemotherapy in treatment-naive programmed death-ligand 1-Selected NSC

=== Intervention Extract 315 (Treatment) ===
arinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with
Row 42: NSCLC. N Engl J Med. 2020; 383(14):1328-39.
Row 43: Jassem J, de Marinis F, Giaccone G, et al. Updated overall survival analysis from IMpower110: Atezolizumab versus
Row 44: platinum-based chemotherapy in treatment-naive programmed death-ligand 1-Selected NSCLC. J Thorac Oncol.
Row 45: 2021; 16(11):1872-82.
Row 46: Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell
Row 47: lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, ph

=== Intervention Extract 316 (Treatment) ===
l. Updated overall survival analysis from IMpower110: Atezolizumab versus
Row 44: platinum-based chemotherapy in treatment-naive programmed death-ligand 1-Selected NSCLC. J Thorac Oncol.
Row 45: 2021; 16(11):1872-82.
Row 46: Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell
Row 47: lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Row 48: Lancet. 2021; 397:592-604.
Row 49: Özgüroğlu M, Kilickap S, Sezer A, et al. First-line cemiplimab monotherapy and continued cemiplimab beyond

=== Intervention Extract 317 (Treatment) ===
hase III randomized trial comparing three platinum-based doublets
Row 34: in advanced non-small-cell lung cancer. J Clin Oncol. 2002; 20:4285-91.
Row 35: Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine
Row 36: plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group
Row 37: trial. J Clin Oncol. 2001; 19:3210-8.
Row 38: Fossella F, Pereira JR, Von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum
Row 39: combinations verso vinorelbine plus cispla

=== Intervention Extract 318 (Treatment) ===
Row 40: J Clin Oncol. 2003; 21:1-9.
Row 41: Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and
Row 42: paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization
Row 43: for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. J Clin Oncol. 2003; 21:3909-17.
Row 44: Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of
Row 45: advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Ins

=== Intervention Extract 319 (Treatment) ===
dvanced non-small-cell lung cancer: a phase III trial of the European Organization
Row 43: for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. J Clin Oncol. 2003; 21:3909-17.
Row 44: Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of
Row 45: advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007; 99:847-57.
Row 46: Rossi A, Chiodini P, Sun JM, et al. Six versus fewer planned cycles of first-line platinum-based chemotherapy for
Row 47: non-small-cell lung cancer: a systematic r

=== Intervention Extract 320 (Treatment) ===
er (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol.
Row 55: 2012; 13:247-55. Row 1: Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of
Row 2: maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for
Row 3: advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013; 31:2895-902.
Row 4: Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus
Row 5: carboplatin and paclitaxel with carboplatin and paclitaxel al

=== Intervention Extract 321 (Treatment) ===
in advanced non-small cell lung
Row 16: cancer: a systematic review and meta-analysis. PLoS One. 2011; 6:e22681.
Row 17: Soria JC, Mauguen A, Reck M, et al. Systematic review and metaanalysis of randomised, phase II/III trials adding
Row 18: bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung
Row 19: cancer. Ann Oncol. 2013; 24:20-30.
Row 20: Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in
Row 21: patients with non-small-cell lung cancer previously treated with platinum-based c

=== Intervention Extract 322 (Treatment) ===
emotherapy. J Clin Oncol. 2004; 22:1589-97.
Row 28: Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N
Row 29: Engl J Med. 2005; 353:123-32.
Row 30: Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with
Row 31: advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet
Row 32: Oncol. 2013; 14:981-8.
Row 33: Zhao N, Zhang XC, Yan HH, et al. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as
Row 34: seco

=== Intervention Extract 323 (Treatment) ===
ents with
Row 31: advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet
Row 32: Oncol. 2013; 14:981-8.
Row 33: Zhao N, Zhang XC, Yan HH, et al. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as
Row 34: second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized
Row 35: controlled clinical trials. Lung Cancer. 2014; 85:66-73.
Row 36: Armoiry X, Tsertsvadze A, Connock M, et al. Comparative efficacy and safety of licensed treatments for previously
Row 37: treated non-sm

=== Intervention Extract 324 (Treatment) ===
Row 22: Lancet. 2011; 378:1079-88.
Row 23: Santos FN, de Castria TB, Cruz MR, et al. Chemotherapy for advanced non-small cell lung cancer in the elderly
Row 24: population. Cochrane Database Syst Rev. 2015; (10):CD010463.
Row 25: Gridelli C, Morabito A, Cavanna L, et al. Cisplatin-based first-line treatment of elderly patients with advanced non-
Row 26: small-cell lung cancer: joint analysis of MILES-3 and MILES-4 Phase III Trials. J Clin Oncol. 2018; 36(25):2585-
Row 27: 92.
Row 28: Langer C, Li S, Schiller J, et al. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplat

=== Intervention Extract 325 (Treatment) ===
al of paclitaxel plus carboplatin or gemcitabine plus cisplatin
Row 29: in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J
Row 30: Clin Oncol. 2007; 25:418-23.
Row 31: Bronte G, Rolfo C, Passiglia F, et al. What can platinum offer yet in the treatment of PS2 NSCLC patients? A
Row 32: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2015; 95(3):306-17.
Row 33: Marur S, Singh H, Mishra-Kalyani P, et al. FDA analyses of survival in older adults with metastatic non-small cell
Row 34: lung cancer in controlled trials of PD-1/PD-L1 blockin

=== Intervention Extract 326 (Treatment) ===
tients with
Row 24: extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin
Row 25: Oncol. 2021; 39(6):619-30.
Row 26: Paz-Ares LG, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-
Row 27: line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase 3
Row 28: trial. Lancet. 2019; 394(10212):1929-39.
Row 29: Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide
Row 30: versus platinum-etoposide alone

=== Intervention Extract 327 (Treatment) ===
tage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase 3
Row 28: trial. Lancet. 2019; 394(10212):1929-39.
Row 29: Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide
Row 30: versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN):
Row 31: updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021; 22(1):51-65.
Row 32: Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-
Row 33: stag

=== Intervention Extract 328 (Treatment) ===
al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-
Row 33: stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study. Ann Oncol. 2021;
Row 34: 32(suppl_5): S1283-S1346.
Row 35: Pujol JL, Carestia L, Daurès JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-
Row 36: analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J
Row 37: Cancer. 2000; 83(1):8-15.
Row 38: Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line

=== Intervention Extract 329 (Treatment) ===
of small-cell lung cancer? A meta-
Row 36: analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J
Row 37: Cancer. 2000; 83(1):8-15.
Row 38: Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-
Row 39: cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012; 30:1692-8.
Row 40: Amarasena IU, Chatterjee S, Walters JA, et al. Platinum versus non-platinum chemotherapy regimens for small cell
Row 41: lung cancer. Cochrane Database Syst Rev. 2015; (8):

=== Intervention Extract 330 (Treatment) ===
e effects of prophylactic cranial irradiation versus control on survival of patients with
Row 12: extensive-stage small-cell lung cancer: a meta-analysis of 14 trials. Radiat Oncol. 2018; 13(1):155.
Row 13: Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients
Row 14: with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol. 1999; 17:2092-9.
Row 15: Yee D, Butts C, Reiman A, et al. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for
Row 16: extensive-stage small cell lung cancer. Radiother Oncol.

=== Intervention Extract 331 (Treatment) ===
H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer:
Row 18: a phase 3 randomised controlled trial. Lancet. 2015; 385:36-42.
Row 19: Von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for
Row 20: the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999; 17(2):658-67.
Row 21: O’Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care
Row 22: with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006; 24(34):5441

=== Intervention Extract 332 (Treatment) ===
Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line
Row 24: therapy in small-cell lung cancer. J Clin Oncol. 2007; 25(15):2086-92.
Row 25: Von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line
Row 26: treatment for patients with small-cell lung cancer. J Clin Oncol. 2014; 32(35):4012-9.
Row 27: Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment or patients with small-cell lung cancer:
Row 28: results from a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020; 21(5):645

=== Intervention Extract 333 (Treatment) ===
5):2086-92.
Row 25: Von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line
Row 26: treatment for patients with small-cell lung cancer. J Clin Oncol. 2014; 32(35):4012-9.
Row 27: Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment or patients with small-cell lung cancer:
Row 28: results from a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020; 21(5):645-54.
Row 29: Partridge AH, Seah DS, King T, et al. Developing a service model that integrates palliative care throughout cancer
Row 30: care: the time is now. J

=== Intervention Extract 334 (Treatment) ===
K., Moroga, T., Miyawaki, M., Chujo, M., Yamamoto, S., Kawahara, K.. Thoracoscopic segmentectomy for T1 classification of non-small cell lung cancer: a single center experience. Eur J Cardiothorac Surg; Jul 2012. 18. Yamato, Y., Koike, T., Yoshiya, K., Shinohara, H., Toyabe, S.. Results of surgical treatment for small (2 cm or under) adenocarcinomas of the lung. Surg Today; 2008. 19. Tsubokawa, N., Tsutani, Y., Miyata, Y., Handa, Y., Misumi, K., Hanaki, H., Hida, E., Okada, M.. Segmentectomy Versus Lobectomy for Radiologically Pure Solid Clinical T1a-bN0M0 Lung Cancer. World J Surg; Aug 2018. 20. Sugi,

=== Intervention Extract 335 (Treatment) ===
ion for Peripheral Stage IA Non-Small-Cell Lung Cancer. N Engl J Med; Feb 9 2023. 3. Schuchert, M. J., Pettiford, B. L., Keeley, S., D'Amato, T. A., Kilic, A., Close, J., Pennathur, A., Santos, R., Fernando, H. C., Landreneau, J. R., Luketich, J. D., Landreneau, R. J.. Anatomic segmentectomy in the treatment of stage I non-small cell lung cancer. Ann Thorac Surg; Sep 2007. 4. Sienel, W., Stremmel, C., Kirschbaum, A., Hinterberger, L., Stoelben, E., Hasse, J., Passlick, B.. Frequency of local recurrence following segmentectomy of stage IA non-small cell lung cancer is influenced by segment localisation

=== Intervention Extract 336 (Treatment) ===
nts (follow up: median 14.5 months; assessed with: NCI-CTCAE 4.03)|||||||||||||
Row 3: |||||||||||||
Row 4: 1|randomised trials|not serious a|not serious|serious b|serious f|none|145/475 (30.5%)|61/234 (26.1%)|RR 1.17 (0.90 to 1.51)|4 more per 100 (from 3 fewer to 13 more)|⨁⨁◯◯ LOW|CRITICAL|
Row 5: Treatment related death|||||||||||||
Row 6: |||||||||||||
Row 7: 1|randomised trials|not serious|not serious|serious b|serious f|none|7/475 (1.5%)|3/234 (1.3%)|RR 1.15 (0.30 to 4.41)|0 fewer per 100 (from 1 fewer to 4 more)|⨁⨁◯◯ LOW|CRITICAL| Row 1: ||
Row 2: ||
Row 3: POPOLAZIONE:||Pazienti affetti da NSCLC

=== Intervention Extract 337 (Treatment) ===
o (1 RCT) LOWa,b,f assessed 3 per 100 3 per 100 2.03) with: NCI- (1 to 7) CTCAE 4.03 follow up: median 14.5 months Grade 3-4 Study population RR 1.17 709 ⨁⨁◯◯ adverse (0.90 to (1 RCT) LOWa,b,f events 26 per 100 31 per 100 1.51) assessed (23 to 39) with: NCI- CTCAE 4.03 follow up: median 14.5 months Treatment Study population RR 1.15 709 ⨁⨁◯◯ related (0.30 to (1 RCT) LOWb,f death 1 per 100 1 per 100 4.41) (0 to 6)| Row 1: Grade 3-4 pneumonitis or radiation pneumonitis assessed with: NCI- CTCAE 4.03 follow up: median 14.5 monthsg||||||RR 1.31 (0.52 to 3.31)|709 (1 RCT)|⨁⨁◯◯ LOWa,b,f|
Row 2: ||Study popul

=== Intervention Extract 338 (Treatment) ===
|||||
Row 13: Grade 3-4 adverse events assessed with: NCI- CTCAE 4.03 follow up: median 14.5 months||||||RR 1.17 (0.90 to 1.51)|709 (1 RCT)|⨁⨁◯◯ LOWa,b,f|
Row 14: ||Study population|||||||
Row 15: |||||||||
Row 16: |||||||||
Row 17: |26 per 100||31 per 100 (23 to 39)||||||
Row 18: |||||||||
Row 19: Treatment related death||||||RR 1.15 (0.30 to 4.41)|709 (1 RCT)|⨁⨁◯◯ LOWb,f|
Row 20: ||Study population|||||||
Row 21: |||||||||
Row 22: |||||||||
Row 23: |1 per 100|||1 per 100|||||
Row 24: ||||(0 to 6)|||||
Row 25: ||||||||| Row 1: 3 per 100
Row 2: (1 to 8) Row 1: 3 per 100
Row 2: (1 to 7) Row 1: 31 per 10

=== Intervention Extract 339 (Treatment) ===
ian 14.5 months||
Row 8: ||Study population
Row 9: ||
Row 10: ||
Row 11: |3 per 100|3 per 100
Row 12: ||
Row 13: Grade 3-4 adverse events assessed with: NCI- CTCAE 4.03 follow up: median 14.5 months||
Row 14: ||Study population
Row 15: ||
Row 16: ||
Row 17: |26 per 100|26 per 100
Row 18: ||
Row 19: Treatment related death||
Row 20: ||Study population
Row 21: ||
Row 22: ||
Row 23: |1 per 100|1 per 100
Row 24: || Row 1: ||
Row 2: n||
Row 3: ||
Row 4: ||
Row 5: |3 per 100 (1 to 8)|3 per 100
Row 6: ||(1 to 8)
Row 7: ||
Row 8: ||
Row 9: n||
Row 10: ||
Row 11: ||
Row 12: |3 per 100 (1 to 7)|3 per 100
Row 13:

=== Intervention Extract 340 (Treatment) ===
o (1 RCT) LOWa,b,f assessed 3 per 100 3 per 100 2.03) with: NCI- (1 to 7) CTCAE 4.03 follow up: median 14.5 months Grade 3-4 Study population RR 1.17 709 ⨁⨁◯◯ adverse (0.90 to (1 RCT) LOWa,b,f events 26 per 100 31 per 100 1.51) assessed (23 to 39) with: NCI- CTCAE 4.03 follow up: median 14.5 months Treatment Study population RR 1.15 709 ⨁⨁◯◯ related (0.30 to (1 RCT) LOWb,f death 1 per 100 1 per 100 4.41) (0 to 6) a. We cannot exclude the risk of selection bias due to the lack of information. Progression free survival/Objective response and duraion of response were assessed by means of blinded independe

=== Intervention Extract 341 (Treatment) ===
|||||
Row 10: Grade 3-4 adverse events assessed with: NCI- CTCAE 4.03 follow up: median 14.5 months||||||RR 1.17 (0.90 to 1.51)|709 (1 RCT)|⨁⨁◯◯ LOWa,b,f|
Row 11: ||Study population|||||||
Row 12: |||||||||
Row 13: |||||||||
Row 14: |26 per 100||31 per 100 (23 to 39)||||||
Row 15: |||||||||
Row 16: Treatment related death||||||RR 1.15 (0.30 to 4.41)|709 (1 RCT)|⨁⨁◯◯ LOWb,f|
Row 17: ||Study population|||||||
Row 18: |||||||||
Row 19: |||||||||
Row 20: |1 per 100|||1 per 100|||||
Row 21: ||||(0 to 6)|||||
Row 22: ||||||||| Row 1: 3 per 100
Row 2: (1 to 7) Row 1: 31 per 100
Row 2: (23 to 39) Row 1: with:

=== Intervention Extract 342 (Treatment) ===
median 14.5 months||
Row 5: ||Study population
Row 6: ||
Row 7: ||
Row 8: |3 per 100|3 per 100
Row 9: ||
Row 10: Grade 3-4 adverse events assessed with: NCI- CTCAE 4.03 follow up: median 14.5 months||
Row 11: ||Study population
Row 12: ||
Row 13: ||
Row 14: |26 per 100|26 per 100
Row 15: ||
Row 16: Treatment related death||
Row 17: ||Study population
Row 18: ||
Row 19: ||
Row 20: |1 per 100|1 per 100
Row 21: || Row 1: ||||
Row 2: ||||
Row 3: ||||
Row 4: ||||RR 0.86 (0.37 to 2.03)
Row 5: n||||
Row 6: ||||
Row 7: ||||
Row 8: |3 per 100 (1 to 7)|||
Row 9: ||||
Row 10: ||||RR 1.17 (0.90 to 1.51)
Row 11: n|

=== Intervention Extract 343 (Treatment) ===
4: -|-|-|-|-|-|-|-|-|-|-|-|CRITICO
Row 15: ORR||||||||||||
Row 16: ||||||||||||
Row 17: 12|studi randomizzati|serioc|non importante|non importante|seriob|nessuno|30/72 (41.7%)|15/76 (19.7%)|RR 2.11 (1.24 a 3.58)|22 più per 100 (da 5 più a 51 più)|⨁⨁◯◯ Bassa|IMPORTANTE
Row 18: Discontinuation of any treatment component||||||||||||
Row 19: |||||||||||| Row 1: |||||||||||
Row 2: Certainty assessment|||||||№ di pazienti||Effetto||Certo
Row 3: |||||||||||
Row 4: № degli studi|Disegno dello studio|Rischio di distorsione|Mancanza di riproducibilità dei risultati|Mancanza di generalizzabilità|Imprecisione|Ulte

=== Intervention Extract 344 (Treatment) ===
||||||
Row 13: |||||||||||
Row 14: -|-|-|-|-|-|-|-|-|-|-|
Row 15: ORR|||||||||||
Row 16: |||||||||||
Row 17: 12|studi randomizzati|serioc|non importante|non importante|seriob|nessuno|30/72 (41.7%)|15/76 (19.7%)|RR 2.11 (1.24 a 3.58)|22 più per 100 (da 5 più a 51 più)|
Row 18: Discontinuation of any treatment component|||||||||||
Row 19: ||||||||||| Row 1: |
Row 2: |Importanza
Row 3: |
Row 4: |
Row 5: |
Row 6: |CRITICO
Row 7: |
Row 8: |
Row 9: |CRITICO
Row 10: |
Row 11: |
Row 12: |CRITICO
Row 13: |
Row 14: |
Row 15: |IMPORTANTE
Row 16: |
Row 17: | Row 1: ||||||||||||
Row 2: Certainty assessment|||||||№

=== Intervention Extract 345 (Treatment) ===
oligometastatico|
Row 5: ||||
Row 6: |INTERVENTION:||Un trattamento locoregionale + terapia sistemica|
Row 7: ||||
Row 8: |||Sola terapia sistemica|
Row 9: |COMPARISON:|||
Row 10: ||||
Row 11: |MAIN OUTCOMES:||Overall survival; Progression-free survival; Quality of life; ORR; Discontinuation of any treatment component; Loco-regional progression; Polmoniti; Tossicità grado 3-5|
Row 12: ||||
Row 13: |SETTING:||Inpatients|
Row 14: ||||
Row 15: |PERSPECTIVE:|||
Row 16: ||||
Row 17: |BACKGROUND:|||
Row 18: ||||
Row 19: |CONFLICT OF|||
Row 20: |INTERESTS:|||
Row 21: |||| Row 1: ||||
Row 2: |Problem|||
Row 3:

=== Intervention Extract 346 (Treatment) ===
uto anticipato* (95% Effetto № dei Certezza Commenti CI) relativo partecipanti delle prove (95% (studi) (GRADE) Rischio con Rischio con un CI) sola terapia trattamento loco- sistemica regionale Discontinuation of Popolazione in studio RR 0.95 133 ⨁⨁◯◯ L'aggiunta di un trattamento loco-regionale any treatment (0.06 a (1 RCT)1 alla terapia sistemica potrebbe non Bassaa,b component 2 per 100 1 per 100 14.97) determinare alcuna differenza nel tasso di (0 a 23) discontinuità dal trattamento, sia sistemico, che loco-regionale. Loco-regional Popolazione in studio RR 0.20 133 ⨁⨁◯◯ L'aggiunta di un trattamento

=== Intervention Extract 347 (Treatment) ===
I)|№ dei partecipanti (studi)|Certezza delle prove (GRADE)|Commenti
Row 3: ||CI)||||||||
Row 4: ||||||||||
Row 5: ||||||||||
Row 6: ||Rischio con|||Rischio con un|||||
Row 7: ||sola terapia|||trattamento loco-|||||
Row 8: ||sistemica|||regionale|||||
Row 9: ||||||||||
Row 10: Discontinuation of any treatment component|||||||RR 0.95 (0.06 a 14.97)|133 (1 RCT)1|⨁⨁◯◯ Bassaa,b|L'aggiunta di un trattamento loco-regionale alla terapia sistemica potrebbe non determinare alcuna differenza nel tasso di discontinuità dal trattamento, sia sistemico, che loco-regionale.
Row 11: ||Popolazione in studio||||||||
Row

=== Intervention Extract 348 (Treatment) ===
nti (studi)|Certezza delle prove (GRADE)|Certezza
Row 3: ||CI)||||||||delle prove
Row 4: ||||||||||(GRADE)
Row 5: ||||||||||
Row 6: ||Rischio con|||Rischio con un|||||
Row 7: ||sola terapia|||trattamento loco-|||||
Row 8: ||sistemica|||regionale|||||
Row 9: ||||||||||
Row 10: Discontinuation of any treatment component|||||||RR 0.95 (0.06 a 14.97)|133 (1 RCT)1||
Row 11: ||Popolazione in studio||||||||
Row 12: ||||||||||
Row 13: ||||||||||
Row 14: |2 per 100|||1 per 100 (0 a 23)||||||
Row 15: ||||||||||
Row 16: Loco-regional progression|||||||RR 0.20 (0.09 a 0.44)|133 (1 RCT)1||
Row 17: ||Popolazione in

=== Intervention Extract 349 (Treatment) ===
r)|⨁⨁⨁◯ MODERATE|CRITICAL|
Row 2: Quality of life - Fatigue (assessed with: QLQ-C30; Scale from: 0 to 100)|||||||||||||
Row 3: |||||||||||||
Row 4: 1|randomised trials|not serious|not serious|serious b|not serious|none|252|247|-|MD 0.8 lower (3.6 higher to 2.1 higher)|⨁⨁⨁◯ MODERATE|CRITICAL|
Row 5: Treatment discontinuation|||||||||||||
Row 6: |||||||||||||
Row 7: 1|randomised trials|not serious|not serious|serious b|not serious d|none|138/279 (49.5%)|213/277 (76.9%)|RR 0.64 (0.73 to 0.56)|28 fewer per 100 (from 34 fewer to 21 fewer)|⨁⨁⨁◯ MODERATE|CRITICAL|
Row 8: Grade 3 rash or acne (assessed with: N

=== Intervention Extract 350 (Treatment) ===
100 (from 9 fewer to 6 fewer)|⨁⨁◯◯ LOW|CRITICAL| Row 1: 1|randomised trials|not serious|not serious|serious b|not serious
Row 2: Quality of life - Fatigue (assessed with: QLQ-C30; Scale from: 0 to 100)|||||
Row 3: |||||
Row 4: 1|randomised trials|not serious|not serious|serious b|not serious
Row 5: Treatment discontinuation|||||
Row 6: |||||
Row 7: 1|randomised trials|not serious|not serious|serious b|not serious d
Row 8: Grade 3 rash or acne (assessed with: NCI-CTCAE)|||||
Row 9: |||||
Row 10: 1|randomised trials|not serious|not serious|serious b|serious c,d
Row 11: Grade 3 alanine aminotrasferase (as

=== Intervention Extract 351 (Treatment) ===
0||MD 0.5 lower (3.7 lower to 2.7 higher)||
Row 22: |||||
Row 23: Quality of life - Fatigue (QOL - fatigue)|||||
Row 24: |The mean quality of life|||MD 0.8 lower|
Row 25: ||||(3.6 higher to|
Row 26: ||||2.1 higher)|
Row 27: ||||| Row 1: |assessed with: QLQ- - Fatigue was C30 0 Scale from: 0 to 100 Treatment Study population RR 0.64 556 ⨁⨁⨁◯ discontinuation (0.73 to (1 RCT) MODERATEa,c (treatment 77 per 100 49 per 100 0.56) discontinuous) (43 to 56) Grade 3 rash or acne Study population RR 0.16 556 ⨁⨁◯◯ assessed with: NCI- (0.05 to (1 RCT) LOWa,b,c CTCAE 7 per 100 1 per 100 0.52) (0 to 4) Grade 3 alani

=== Intervention Extract 352 (Treatment) ===
ue (QOL - fatigue)|||||
Row 24: |The mean quality of life|||MD 0.8 lower|
Row 25: ||||(3.6 higher to|
Row 26: ||||2.1 higher)|
Row 27: ||||| Row 1: |assessed with: QLQ- - Fatigue was C30 0 Scale from: 0 to 100 Treatment Study population RR 0.64 556 ⨁⨁⨁◯ discontinuation (0.73 to (1 RCT) MODERATEa,c (treatment 77 per 100 49 per 100 0.56) discontinuous) (43 to 56) Grade 3 rash or acne Study population RR 0.16 556 ⨁⨁◯◯ assessed with: NCI- (0.05 to (1 RCT) LOWa,b,c CTCAE 7 per 100 1 per 100 0.52) (0 to 4) Grade 3 alanine Study population RR 0.04 556 ⨁⨁◯◯ aminotrasferase (0.01 to (1 RCT) LOWa,b,c assessed wi

=== Intervention Extract 353 (Treatment) ===
◯ events (0.62 to (1 RCT) LOWa,b 41 per 100 32 per 100 0.97) (26 to 40) a. prevalence of Asiatic population (62%) b. low number of events (OIS <300) c. inferencial caluclation of RR| Row 1: assessed with: QLQ- C30 Scale from: 0 to 100|||||||||
Row 2: |- Fatigue was 0||||||||
Row 3: |||||||||
Row 4: Treatment discontinuation (treatment discontinuous)||||||RR 0.64 (0.73 to 0.56)|556 (1 RCT)|⨁⨁⨁◯ MODERATEa,c|
Row 5: ||Study population|||||||
Row 6: |||||||||
Row 7: |||||||||
Row 8: |77 per 100|||49 per 100|||||
Row 9: ||||(43 to 56)|||||
Row 10: |||||||||
Row 11: Grade 3 rash or acne assessed with: NCI- C

=== Intervention Extract 354 (Treatment) ===
OWa,b 41 per 100 32 per 100 0.97) (26 to 40) a. prevalence of Asiatic population (62%) b. low number of events (OIS <300) c. inferencial caluclation of RR| Row 1: assessed with: QLQ- C30 Scale from: 0 to 100|||||||||
Row 2: |- Fatigue was 0||||||||
Row 3: |||||||||
Row 4: Treatment discontinuation (treatment discontinuous)||||||RR 0.64 (0.73 to 0.56)|556 (1 RCT)|⨁⨁⨁◯ MODERATEa,c|
Row 5: ||Study population|||||||
Row 6: |||||||||
Row 7: |||||||||
Row 8: |77 per 100|||49 per 100|||||
Row 9: ||||(43 to 56)|||||
Row 10: |||||||||
Row 11: Grade 3 rash or acne assessed with: NCI- CTCAE||||||RR 0.16 (0.05 to

=== Intervention Extract 355 (Treatment) ===
n|||||||
Row 33: |||||||||
Row 34: |||||||||
Row 35: |41 per 100|||32 per 100|||||
Row 36: ||||(26 to 40)|||||
Row 37: ||||||||| Row 1: - Fatigue was
Row 2: 0 Row 1: 1 per 100
Row 2: (0 to 3) Row 1: assessed with: QLQ- C30 Scale from: 0 to 100||||||
Row 2: |- Fatigue was 0|||||
Row 3: ||||||
Row 4: Treatment discontinuation (treatment discontinuous)||||||RR 0.64 (0.73 to 0.56)
Row 5: ||Study population||||
Row 6: ||||||
Row 7: ||||||
Row 8: |77 per 100|||49 per 100||
Row 9: ||||(43 to 56)||
Row 10: ||||||
Row 11: Grade 3 rash or acne assessed with: NCI- CTCAE||||||RR 0.16 (0.05 to 0.52)
Row 12: ||Study

=== Intervention Extract 356 (Treatment) ===
Row 34: |||||||||
Row 35: |41 per 100|||32 per 100|||||
Row 36: ||||(26 to 40)|||||
Row 37: ||||||||| Row 1: - Fatigue was
Row 2: 0 Row 1: 1 per 100
Row 2: (0 to 3) Row 1: assessed with: QLQ- C30 Scale from: 0 to 100||||||
Row 2: |- Fatigue was 0|||||
Row 3: ||||||
Row 4: Treatment discontinuation (treatment discontinuous)||||||RR 0.64 (0.73 to 0.56)
Row 5: ||Study population||||
Row 6: ||||||
Row 7: ||||||
Row 8: |77 per 100|||49 per 100||
Row 9: ||||(43 to 56)||
Row 10: ||||||
Row 11: Grade 3 rash or acne assessed with: NCI- CTCAE||||||RR 0.16 (0.05 to 0.52)
Row 12: ||Study population||||
Row 13: |||

=== Intervention Extract 357 (Treatment) ===
wer to 2.7 higher)|
Row 12: ||||
Row 13: Quality of life - Fatigue (QOL - fatigue) assessed with: QLQ- C30 Scale from: 0 to 100||||
Row 14: |The mean quality of life - Fatigue was 0||MD 0.8 lower (3.6 higher to 2.1 higher)|
Row 15: ||||
Row 16: ||||
Row 17: ||Study population||
Row 18: |||| Row 1: |Treatment 77 per 100 49 per 100 RR 0.64 discontinuation (43 to 56) 556 ⨁⨁⨁◯ (0.73 to (treatment (1 RCT) MODERATEa,c 0.56) discontinuous) Grade 3 rash or acne Study population RR 0.16 556 ⨁⨁◯◯ assessed with: NCI- (0.05 to (1 RCT) LOWa,b,c CTCAE 7 per 100 1 per 100 0.52) (0 to 4) Grade 3 alanine Study populati

=== Intervention Extract 358 (Treatment) ===
essed with: QLQ- C30 Scale from: 0 to 100||||
Row 14: |The mean quality of life - Fatigue was 0||MD 0.8 lower (3.6 higher to 2.1 higher)|
Row 15: ||||
Row 16: ||||
Row 17: ||Study population||
Row 18: |||| Row 1: |Treatment 77 per 100 49 per 100 RR 0.64 discontinuation (43 to 56) 556 ⨁⨁⨁◯ (0.73 to (treatment (1 RCT) MODERATEa,c 0.56) discontinuous) Grade 3 rash or acne Study population RR 0.16 556 ⨁⨁◯◯ assessed with: NCI- (0.05 to (1 RCT) LOWa,b,c CTCAE 7 per 100 1 per 100 0.52) (0 to 4) Grade 3 alanine Study population RR 0.04 556 ⨁⨁◯◯ aminotrasferase (0.01 to (1 RCT) LOWa,b,c assessed with: NCI- 9 pe

=== Intervention Extract 359 (Treatment) ===
per 100 1 per 100 0.73) assessed with: NCI- (0 to 3) CTCAE Grade 3-5 adverse Study population RR 0.78 556 ⨁⨁◯◯ events (0.62 to (1 RCT) LOWa,b 41 per 100 32 per 100 0.97) (26 to 40) d. prevalence of Asiatic population (62%) e. low number of events (OIS <300) f. inferencial caluclation of RR| Row 1: Treatment discontinuation (treatment discontinuous)||||||RR 0.64 (0.73 to 0.56)|556 (1 RCT)|⨁⨁⨁◯ MODERATEa,c|
Row 2: |77 per 100||49 per 100 (43 to 56)||||||
Row 3: |||||||||
Row 4: Grade 3 rash or acne assessed with: NCI- CTCAE||||||RR 0.16 (0.05 to 0.52)|556 (1 RCT)|⨁⨁◯◯ LOWa,b,c|
Row 5: ||Study population

=== Intervention Extract 360 (Treatment) ===
sessed with: NCI- (0 to 3) CTCAE Grade 3-5 adverse Study population RR 0.78 556 ⨁⨁◯◯ events (0.62 to (1 RCT) LOWa,b 41 per 100 32 per 100 0.97) (26 to 40) d. prevalence of Asiatic population (62%) e. low number of events (OIS <300) f. inferencial caluclation of RR| Row 1: Treatment discontinuation (treatment discontinuous)||||||RR 0.64 (0.73 to 0.56)|556 (1 RCT)|⨁⨁⨁◯ MODERATEa,c|
Row 2: |77 per 100||49 per 100 (43 to 56)||||||
Row 3: |||||||||
Row 4: Grade 3 rash or acne assessed with: NCI- CTCAE||||||RR 0.16 (0.05 to 0.52)|556 (1 RCT)|⨁⨁◯◯ LOWa,b,c|
Row 5: ||Study population|||||||
Row 6: |||||||||
Ro

=== Intervention Extract 361 (Treatment) ===
5 adverse events||||||RR 0.78 (0.62 to 0.97)|556 (1 RCT)|⨁⨁◯◯ LOWa,b|
Row 25: ||Study population|||||||
Row 26: |||||||||
Row 27: |||||||||
Row 28: |41 per 100|||32 per 100|||||
Row 29: ||||(26 to 40)|||||
Row 30: ||||||||| Row 1: 49 per 100
Row 2: (43 to 56) Row 1: 1 per 100
Row 2: (0 to 3) Row 1: Treatment discontinuation (treatment discontinuous)||||||RR 0.64 (0.73 to 0.56)
Row 2: |77 per 100||49 per 100 (43 to 56)|||
Row 3: ||||||
Row 4: Grade 3 rash or acne assessed with: NCI- CTCAE||||||RR 0.16 (0.05 to 0.52)
Row 5: ||Study population||||
Row 6: ||||||
Row 7: ||||||
Row 8: |7 per 100|||1 per 100|

=== Intervention Extract 362 (Treatment) ===
78 (0.62 to 0.97)|556 (1 RCT)|⨁⨁◯◯ LOWa,b|
Row 25: ||Study population|||||||
Row 26: |||||||||
Row 27: |||||||||
Row 28: |41 per 100|||32 per 100|||||
Row 29: ||||(26 to 40)|||||
Row 30: ||||||||| Row 1: 49 per 100
Row 2: (43 to 56) Row 1: 1 per 100
Row 2: (0 to 3) Row 1: Treatment discontinuation (treatment discontinuous)||||||RR 0.64 (0.73 to 0.56)
Row 2: |77 per 100||49 per 100 (43 to 56)|||
Row 3: ||||||
Row 4: Grade 3 rash or acne assessed with: NCI- CTCAE||||||RR 0.16 (0.05 to 0.52)
Row 5: ||Study population||||
Row 6: ||||||
Row 7: ||||||
Row 8: |7 per 100|||1 per 100||
Row 9: ||||(0 to 4)||
Row

=== Intervention Extract 363 (Treatment) ===
. 3. Mok, T., Camidge, D. R., Gadgeel, S. M., Rosell, R., Dziadziuszko, R., Kim, D. W., Pérol, M., Ou, S. I., Ahn, J. S., Shaw, A. T., Bordogna, W., Smoljanović, V., Hilton, Row 1: |M., Ruf, T., Noé, J., Peters, S.. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small- cell lung cancer in the ALEX study. Ann Oncol; Aug 2020. a. These were three open-label studies. Only the PFS outcome was assessed by an independent central review. The objective responses were assessed by an independent central review only in Hida et al trial

=== Intervention Extract 364 (Treatment) ===
o in considerazione solo la popolazione asiatica. e. Nonostante il basso numero di eventi, non abbiamo abbassato la qualità perche l'incidenza della patologia è rara PFS OS| Row 1: |M., Ruf, T., Noé, J., Peters, S.. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small- cell lung cancer in the ALEX study. Ann Oncol; Aug 2020. a. These were three open-label studies. Only the PFS outcome was assessed by an independent central review. The objective responses were assessed by an independent central review only in Hida et al trial

=== Intervention Extract 365 (Treatment) ===
Jan 2020. 3. Mok, T., Camidge, D. R., Gadgeel, S. M., Rosell, R., Dziadziuszko, R., Kim, D. W., Pérol, M., Ou, S. I., Ahn, J. S., Shaw, A. T., Bordogna, W., Smoljanović, V., Hilton, M., Ruf, T., Noé, J., Peters, S.. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol; Aug 2020. a. These were three open-label studies. Only the PFS outcome was assessed by an independent central review. The objective responses were assessed by an independent central review only in Hida et al trial.

=== Intervention Extract 366 (Treatment) ===
Jan 2020. 3. Mok, T., Camidge, D. R., Gadgeel, S. M., Rosell, R., Dziadziuszko, R., Kim, D. W., Pérol, M., Ou, S. I., Ahn, J. S., Shaw, A. T., Bordogna, W., Smoljanović, V., Hilton, M., Ruf, T., Noé, J., Peters, S.. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol; Aug 2020. a. These were three open-label studies. Only the PFS outcome was assessed by an independent central review. The objective responses were assessed by an independent central review only in Hida et al trial.

=== Intervention Extract 367 (Treatment) ===
6 more)|⨁◯◯◯ VERY LOW|IMPORTANT Row 1: GGT increased - ceritinib||||||||||||
Row 2: 1|randomised trials|not serious b|not serious|not serious d|very serious h|none|21/115 (18.3%)|0/116 (0.0%)|RR 42.37 (2.59 to 691.67)|0 fewer per 100 (from 0 fewer to 0 fewer)|⨁⨁◯◯ LOW|CRITICAL
Row 3: AE leading to treatment discontinuation||||||||||||
Row 4: 2|randomised trials|serious a,b,g|not serious|not serious d|serious h|none|10/152 (6.6%)|11/139 (7.9%)|RR 0.85 (0.37 to 1.94)|1 fewer per 100 (from 5 fewer to 7 more)|⨁⨁◯◯ LOW|CRITICAL Row 1: ||
Row 2: POPOLAZIONE:||Pazienti affetti da NSCLC in stadio localmente a

=== Intervention Extract 368 (Treatment) ===
: s)||(GRADE) Row 1: 
Row 2: of the
Row 3: 
Row 4:  Row 1: |
Row 2: Commen|Commen Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: 
Row 2: nts Row 1: |GGT increased - 0 per 100 0 per 100 RR 42.37 231 ⨁⨁◯◯ (0 to 0) (2.59 to ceritinib (1 RCT) LOWb,d,g 691.67) AE leading to Study population RR 0.85 291 ⨁⨁◯◯ treatment (0.37 to (2 RCTs) LOWb,c,d,g,h discontinuation 8 per 100 7 per 100 1.94) (3 to 15) I2=31% In Shaw et al study the proportion of asian patients was: 26% in the ceritinib arm and 33% in the chemotherapy arm. In Shaw et al. study no information was given about the number of patients lost to follow-up.

=== Intervention Extract 369 (Treatment) ===
hemotherapy to ceritinib after disease progression Low number of events High risk of performance and/or detection bias I2=89%| Row 1: GGT increased - ceritinib||||||RR 42.37 (2.59 to 691.67)|231 (1 RCT)|⨁⨁◯◯ LOWb,d,g|
Row 2: |0 per 100||0 per 100 (0 to 0)||||||
Row 3: |||||||||
Row 4: AE leading to treatment discontinuation||||||RR 0.85 (0.37 to 1.94)|291 (2 RCTs)|⨁⨁◯◯ LOWb,c,d,g,h|
Row 5: ||Study population|||||||
Row 6: |||||||||
Row 7: |||||||||
Row 8: |8 per 100|||7 per 100|||||
Row 9: ||||(3 to 15)|||||
Row 10: ||||||||| Row 1: 0 per 100
Row 2: (0 to 0) Row 1: |GGT increased - 0 per 100 0 per 100

=== Intervention Extract 370 (Treatment) ===
|||||||
Row 7: |||||||||
Row 8: |8 per 100|||7 per 100|||||
Row 9: ||||(3 to 15)|||||
Row 10: ||||||||| Row 1: 0 per 100
Row 2: (0 to 0) Row 1: |GGT increased - 0 per 100 0 per 100 RR 42.37 231 ⨁⨁◯◯ (0 to 0) (2.59 to ceritinib (1 RCT) LOWb,d,g 691.67) AE leading to Study population RR 0.85 291 ⨁⨁◯◯ treatment (0.37 to (2 RCTs) LOWb,c,d,g,h discontinuation 8 per 100 7 per 100 1.94) (3 to 15) I2=31% In Shaw et al study the proportion of asian patients was: 26% in the ceritinib arm and 33% in the chemotherapy arm. In Shaw et al. study no information was given about the number of patients lost to follow-up.

=== Intervention Extract 371 (Treatment) ===
|||
Row 47: |||| Row 1: ||
Row 2: |Certainty o evidence (GRADE)|Certainty o
Row 3: pants||evidence
Row 4: s)||(GRADE) Row 1: 
Row 2: of the
Row 3: 
Row 4:  Row 1: |
Row 2: Commen|Commen Row 1: 
Row 2: nts Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: |AE leading to 8 per 100 7 per 100 RR 0.85 291 ⨁⨁◯◯ treatment (3 to 15) (0.37 to (2 RCTs) LOWb,c,d,g,h discontinuation 1.94) I2=31% In Shaw et al study the proportion of asian patients was: 26% in the ceritinib arm and 33% in the chemotherapy arm. In Shaw et al. study no information was given about the number of patients lost to follow-up. This was an open-la

=== Intervention Extract 372 (Treatment) ===
llo et al study 70.6% of patients crossed over from chemotherapy to alectinib after progression. In Shaw et al study 69% of patients crossed over from chemotherapy to ceritinib after disease progression Low number of events High risk of performance and/or detection bias I2=89%| Row 1: AE leading to treatment discontinuation|||RR 0.85 (0.37 to 1.94)|291 (2 RCTs)|⨁⨁◯◯ LOWb,c,d,g,h|
Row 2: |8 per 100|7 per 100 (3 to 15)||||
Row 3: |||||| Row 1: 7 per 100
Row 2: (3 to 15) Row 1: |AE leading to 8 per 100 7 per 100 RR 0.85 291 ⨁⨁◯◯ treatment (3 to 15) (0.37 to (2 RCTs) LOWb,c,d,g,h discontinuation 1.94) I2=3

=== Intervention Extract 373 (Treatment) ===
k of performance and/or detection bias I2=89%| Row 1: AE leading to treatment discontinuation|||RR 0.85 (0.37 to 1.94)|291 (2 RCTs)|⨁⨁◯◯ LOWb,c,d,g,h|
Row 2: |8 per 100|7 per 100 (3 to 15)||||
Row 3: |||||| Row 1: 7 per 100
Row 2: (3 to 15) Row 1: |AE leading to 8 per 100 7 per 100 RR 0.85 291 ⨁⨁◯◯ treatment (3 to 15) (0.37 to (2 RCTs) LOWb,c,d,g,h discontinuation 1.94) I2=31% In Shaw et al study the proportion of asian patients was: 26% in the ceritinib arm and 33% in the chemotherapy arm. In Shaw et al. study no information was given about the number of patients lost to follow-up. This was an open-la

=== Intervention Extract 374 (Treatment) ===
llow up: median 25.2 months)|||||||||||||
Row 3: |||||||||||||
Row 4: 1|randomised trials|serious a,d|not serious|not serious|not serious|none|48/154 (31.2%)|80/150 (53.3%)|RR 0.58 (0.44 to 0.77)|22 fewer per 100 (from 30 fewer to 12 fewer)|⨁⨁⨁◯ MODERATE|CRITICAL|
Row 5: Discontinuation rate of any treatment component|||||||||||||
Row 6: |||||||||||||
Row 7: 1|randomised trials|serious a,d|not serious|not serious|not serious|none|80/154 (51.9%) e|106/151 (70.2%) f|RR 0.74 (0.61 to 0.89)|18 fewer per 100 (from 27 fewer to 8 fewer)|⨁⨁⨁◯ MODERATE|CRITICAL| Row 1: ||||||||||more to 33 more)
Row 2: Any grad

=== Intervention Extract 375 (Treatment) ===
)
Row 2: Any grade 3-5 AEs (follow up: median 25.2 months)||||||||||
Row 3: ||||||||||
Row 4: 1|randomised trials|serious a,d|not serious|not serious|not serious|none|48/154 (31.2%)|80/150 (53.3%)|RR 0.58 (0.44 to 0.77)|22 fewer per 100 (from 30 fewer to 12 fewer)
Row 5: Discontinuation rate of any treatment component||||||||||
Row 6: ||||||||||
Row 7: 1|randomised trials|serious a,d|not serious|not serious|not serious|none|80/154 (51.9%) e|106/151 (70.2%) f|RR 0.74 (0.61 to 0.89)|18 fewer per 100 (from 27 fewer to 8 fewer) Row 1: 
Row 2:  Row 1: |
Row 2: |
Row 3: |
Row 4: CRITICAL|
Row 5: |
Row 6: |
R

=== Intervention Extract 376 (Treatment) ===
to (1 RCT) HIGHa,c follow up: median 28 per 100 45 per 100 2.20) 11.2 months (33 to 61) Any grade 3-5 AEs Study population RR 0.58 304 ⨁⨁⨁◯ follow up: median (0.44 to (1 RCT) MODERATEa,d 25.2 months 53 per 100 31 per 100 0.77) (23 to 41) Discontinuation rate Study population RR 0.74 305 ⨁⨁⨁◯ of any treatment (0.61 to (1 RCT)e,f MODERATEa,d component 70 per 100e 52 per 100 0.89) (43 to 62)f Unclear risk of selection and attrition bias due to the lack of information. As per protocol, 82 patients randomized to CHT arm crossed over to a pembrolizumab treatment after disease progression. We reported the adj

=== Intervention Extract 377 (Treatment) ===
rate Study population RR 0.74 305 ⨁⨁⨁◯ of any treatment (0.61 to (1 RCT)e,f MODERATEa,d component 70 per 100e 52 per 100 0.89) (43 to 62)f Unclear risk of selection and attrition bias due to the lack of information. As per protocol, 82 patients randomized to CHT arm crossed over to a pembrolizumab treatment after disease progression. We reported the adjusted HR for the adjusted OS for treatment crossover. This was an open label trial, there was a blinded, independent, central radiologic review. High risk of performance and detection bias. Discontinuation reasons: 69 disease progression, 16 AEs, 9 died

=== Intervention Extract 378 (Treatment) ===
component 70 per 100e 52 per 100 0.89) (43 to 62)f Unclear risk of selection and attrition bias due to the lack of information. As per protocol, 82 patients randomized to CHT arm crossed over to a pembrolizumab treatment after disease progression. We reported the adjusted HR for the adjusted OS for treatment crossover. This was an open label trial, there was a blinded, independent, central radiologic review. High risk of performance and detection bias. Discontinuation reasons: 69 disease progression, 16 AEs, 9 died, 5 patient withdrawal, 7 physician decision, 29 completed treatment. Discontinuation rea

=== Intervention Extract 379 (Treatment) ===
the adjusted OS for treatment crossover. This was an open label trial, there was a blinded, independent, central radiologic review. High risk of performance and detection bias. Discontinuation reasons: 69 disease progression, 16 AEs, 9 died, 5 patient withdrawal, 7 physician decision, 29 completed treatment. Discontinuation reasons: 51 disease progression, 17 AE, 6 died, 4 patient withdrawal, 1 physician decision, 1 complete response.| Row 1: Progression free survival follow up: median 11.2 months|||HR 0.50 (0.37 to 0.68)|305 (1 RCT)|⨁⨁⨁⨁ HIGHa,c|
Row 2: |83 per 100|59 per 100 (49 to 71)||||
Row 3: ||

=== Intervention Extract 380 (Treatment) ===
0 (33 to 61)||||
Row 9: ||||||
Row 10: Any grade 3-5 AEs follow up: median 25.2 months|||RR 0.58 (0.44 to 0.77)|304 (1 RCT)|⨁⨁⨁◯ MODERATEa,d|
Row 11: |Study population|||||
Row 12: ||||||
Row 13: ||||||
Row 14: |53 per 100|31 per 100 (23 to 41)||||
Row 15: ||||||
Row 16: Discontinuation rate of any treatment component|||RR 0.74 (0.61 to 0.89)|305 (1 RCT)e,f|⨁⨁⨁◯ MODERATEa,d|
Row 17: |Study population|||||
Row 18: ||||||
Row 19: ||||||
Row 20: |70 per 100e|52 per 100 (43 to 62)f||||
Row 21: |||||| Row 1: Progression free survival follow up: median 11.2 months||
Row 2: |83 per 100|59 per 100 (49 to 71)
R

=== Intervention Extract 381 (Treatment) ===
nths||
Row 5: |Study population|
Row 6: ||
Row 7: ||
Row 8: |28 per 100|45 per 100 (33 to 61)
Row 9: ||
Row 10: Any grade 3-5 AEs follow up: median 25.2 months||
Row 11: |Study population|
Row 12: ||
Row 13: ||
Row 14: |53 per 100|31 per 100 (23 to 41)
Row 15: ||
Row 16: Discontinuation rate of any treatment component||
Row 17: |Study population|
Row 18: ||
Row 19: ||
Row 20: |70 per 100e|52 per 100 (43 to 62)f
Row 21: || Row 1: |HR 0.50 (0.37 to 0.68)|305 (1 RCT)
Row 2: ||
Row 3: ||
Row 4: ||
Row 5: ||
Row 6: |RR 1.61 (1.18 to 2.20)|305 (1 RCT)
Row 7: ||
Row 8: ||
Row 9: ||
Row 10: ||
Row 11: ||
Row 1

=== Intervention Extract 382 (Treatment) ===
to (1 RCT) HIGHa,c follow up: median 28 per 100 45 per 100 2.20) 11.2 months (33 to 61) Any grade 3-5 AEs Study population RR 0.58 304 ⨁⨁⨁◯ follow up: median (0.44 to (1 RCT) MODERATEa,d 25.2 months 53 per 100 31 per 100 0.77) (23 to 41) Discontinuation rate Study population RR 0.74 305 ⨁⨁⨁◯ of any treatment (0.61 to (1 RCT)e,f MODERATEa,d component 70 per 100e 52 per 100 0.89) (43 to 62)f|| Row 1: ||||||
Row 2: Outcomes|Anticipated absolute effects* (95% CI)||Relative effect (95% CI)|№ of participants (studies)|Certainty of the evidence (GRADE)|Comments
Row 3: ||||||
Row 4: ||||||
Row 5: |Risk with al

=== Intervention Extract 383 (Treatment) ===
(33 to 61)||||
Row 24: ||||||
Row 25: Any grade 3-5 AEs follow up: median 25.2 months|||RR 0.58 (0.44 to 0.77)|304 (1 RCT)|⨁⨁⨁◯ MODERATEa,d|
Row 26: |Study population|||||
Row 27: ||||||
Row 28: ||||||
Row 29: |53 per 100|31 per 100 (23 to 41)||||
Row 30: ||||||
Row 31: Discontinuation rate of any treatment component|||RR 0.74 (0.61 to 0.89)|305 (1 RCT)e,f|⨁⨁⨁◯ MODERATEa,d|
Row 32: |Study population|||||
Row 33: ||||||
Row 34: ||||||
Row 35: |70 per 100e|52 per 100 (43 to 62)f||||
Row 36: |||||| Row 1: № of
Row 2: participants
Row 3: (studies) Row 1: |
Row 2: |Effetti ind
Row 3: |Quanto conside
Row 4:

=== Intervention Extract 384 (Treatment) ===
sponse rate follow up: median 11.2 months|
Row 24: |Study popula
Row 25: |
Row 26: |
Row 27: |28 per 100
Row 28: |
Row 29: |
Row 30: Any grade 3-5 AEs follow up: median 25.2 months|
Row 31: |Study popula
Row 32: |
Row 33: |
Row 34: |53 per 100
Row 35: |
Row 36: |
Row 37: Discontinuation rate of any treatment component|
Row 38: |Study popula
Row 39: |
Row 40: |
Row 41: |70 per 100e
Row 42: |
Row 43: | Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: |||||
Row 2: absolute effects* (95% CI)||Relative effect (95% CI)|№ of participants (studies)|Certaint evidence (GRADE|Certaint
Row 3: |||||evidence
Row 4: |||||
Row

=== Intervention Extract 385 (Treatment) ===
62)f||||
Row 36: ||||| Row 1: 
Row 2: ty of the e E) Row 1: 
Row 2: Commen Row 1: 
Row 2: nts Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: ||Unclear risk of selection and attrition bias due to the lack of information. As per protocol, 82 patients randomized to CHT arm crossed over to a pembrolizumab treatment after disease progression. We reported the adjusted HR for the adjusted OS for treatment crossover. This was an open label trial, there was a blinded, independent, central radiologic review. High risk of performance and detection bias. Discontinuation reasons: 69 disease progression, 16 AEs, 9 died

=== Intervention Extract 386 (Treatment) ===
: nts Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: ||Unclear risk of selection and attrition bias due to the lack of information. As per protocol, 82 patients randomized to CHT arm crossed over to a pembrolizumab treatment after disease progression. We reported the adjusted HR for the adjusted OS for treatment crossover. This was an open label trial, there was a blinded, independent, central radiologic review. High risk of performance and detection bias. Discontinuation reasons: 69 disease progression, 16 AEs, 9 died, 5 patient withdrawal, 7 physician decision, 29 completed treatment. Discontinuation rea

=== Intervention Extract 387 (Treatment) ===
the adjusted OS for treatment crossover. This was an open label trial, there was a blinded, independent, central radiologic review. High risk of performance and detection bias. Discontinuation reasons: 69 disease progression, 16 AEs, 9 died, 5 patient withdrawal, 7 physician decision, 29 completed treatment. Discontinuation reasons: 51 disease progression, 17 AE, 6 died, 4 patient withdrawal, 1 physician decision, 1 complete response.||
Row 2: ||||
Row 3: |Qualità delle prove|||
Row 4: |Qual è la qualità complessiva delle prove di efficacia e sicurezza?|||
Row 5: ||||
Row 6: GIUDIZI||RICERCA DELLE PRO

=== Intervention Extract 388 (Treatment) ===
MODERATA per rischio di performance e detection bias|| Row 1: |
Row 2: |Qualità delle pr
Row 3: |Qual è la qualità comples
Row 4: | Row 1: |Unclear risk of selection and attrition bias due to the lack of information. As per protocol, 82 patients randomized to CHT arm crossed over to a pembrolizumab treatment after disease progression. We reported the adjusted HR for the adjusted OS for treatment crossover. This was an open label trial, there was a blinded, independent, central radiologic review. High risk of performance and detection bias. Discontinuation reasons: 69 disease progression, 16 AEs, 9 died

=== Intervention Extract 389 (Treatment) ===
Row 3: |Qual è la qualità comples
Row 4: | Row 1: |Unclear risk of selection and attrition bias due to the lack of information. As per protocol, 82 patients randomized to CHT arm crossed over to a pembrolizumab treatment after disease progression. We reported the adjusted HR for the adjusted OS for treatment crossover. This was an open label trial, there was a blinded, independent, central radiologic review. High risk of performance and detection bias. Discontinuation reasons: 69 disease progression, 16 AEs, 9 died, 5 patient withdrawal, 7 physician decision, 29 completed treatment. Discontinuation rea

=== Intervention Extract 390 (Treatment) ===
the adjusted OS for treatment crossover. This was an open label trial, there was a blinded, independent, central radiologic review. High risk of performance and detection bias. Discontinuation reasons: 69 disease progression, 16 AEs, 9 died, 5 patient withdrawal, 7 physician decision, 29 completed treatment. Discontinuation reasons: 51 disease progression, 17 AE, 6 died, 4 patient withdrawal, 1 physician decision, 1 complete response.|
Row 2: ||
Row 3: rove||
Row 4: ssiva delle prove di efficacia e sicurezza?||
Row 5: || Row 1: RICERCA DELLE PROVE
Row 2: L a certezza nelle prove è stata giudicata MODE

=== Intervention Extract 391 (Treatment) ===
di|||||
Row 20: |||||||trattamento|||||
Row 21: ||||||||||||
Row 22: 2|randomised trials|serious a,f|serious g|very serious c,d,h|serious i|none|295/464 (63.6%)|149/264 (56.4%)|RR 1.06 (0.94 to 1.19)|3 more per 100 (from 3 fewer to 11 more)|⨁◯◯◯ VERY LOW|CRITICAL
Row 23: Discontinuation rate of any treatment componentj||||||||||||
Row 24: ||||||||||||
Row 25: 2|randomised trials|serious a,f|not serious|very serious c,d,k|not serious|none|299/470 (63.6%)|209/269 (77.7%)|RR 0.80 (0.73 to 0.88)|16 fewer per 100 (from 21 fewer to 9 fewer)|⨁◯◯◯ VERY LOW|CRITICAL Row 1: |||||
Row 2: Certainty assessment|||||

=== Intervention Extract 392 (Treatment) ===
wer)|⨁◯◯◯ VERY LOW|CRITICAL Row 1: |||||
Row 2: Certainty assessment|||||
Row 3: |||||
Row 4: |||||
Row 5: № of studies|Study design|Risk of bias|Inconsistency|Indirectness|Imprecisi
Row 6: |||||
Row 7: 2|randomised trials|serious a,f|serious g|very serious c,d,h|
Row 8: Discontinuation rate of any treatment componentj|||||
Row 9: |||||
Row 10: 2|randomised trials|serious a,f|not serious|very serious c,d,k| Row 1: |
Row 2: |
Row 3: |
Row 4: |
Row 5: ion|Other consideratio
Row 6: | Row 1: 
Row 2:  Row 1: ||
Row 2: |№ of patients|
Row 3: ||
Row 4: ||
Row 5: ons|un trattamento|alla chemiotera
Row 6: |di p

=== Intervention Extract 393 (Treatment) ===
pemetrexed e pembrolizumab in caso di risposta o stabilità di malattia dopo 4 cicli di trattamento
Row 7: ||
Row 8: COMPARISON:||Alla chemioterapia
Row 9: ||
Row 10: MAIN OUTCOMES:||Overall survival; Progression free survival; Objective response rate; Grade 3-5 any AEs; Discontinuation rate of any treatment component
Row 11: ||
Row 12: SETTING:||
Row 13: ||
Row 14: PERSPECTIVE:||
Row 15: ||
Row 16: BACKGROUND:||
Row 17: ||
Row 18: CONFLICT OF INTERESTS:||Assenti alla votazione: Dr. Novello, Dr. Facchinetti, Dr. Passaro, Dr. Rossi, Dr. Trisolini, Dr. Ferrara, Dr. Menis
Row 19: || Row 1: ||
Row 2: Probl

=== Intervention Extract 394 (Treatment) ===
1: ||
Row 2: ||
Row 3: ||
Row 4: ||
Row 5: |ADDITIONAL CONSIDERATIONS|
Row 6: || Row 1: 
Row 2: ts Row 1: |Grade 3-5 any AEs Study population RR 1.06 728 ⨁◯◯◯ (0.94 to (2 RCTs) VERY 56 per 100 60 per 100 1.19) LOWa,c,d,f,g,h,i (53 to 67) Discontinuation rate Study population RR 0.80 739 ⨁◯◯◯ of any treatment (0.73 to (2 RCTs) VERY LOWa,c,d,i,k componentj 78 per 100 62 per 100 0.88) (57 to 68) a. Unclear risk of attrition bias in both studies due to the lack of information b. We decided to downgrade the quality of the evidence by one level for the risk of bias dimension because in both study crossover t

=== Intervention Extract 395 (Treatment) ===
ided to downgrade the quality of the evidence by one level for the risk of bias dimension because in both study crossover to pembrolizumab monotherapy was permitted among the patients in the chemotherapy combination group who had verified disease progression c. In Keynote-021 trial, the maintenance treatment consisted of pembrolizumab and optional indefinite pemetrexed d. In KEYNOTE-21 study, subgroups analysis according to tumour proportion score for PD-L1 were not designed and performed. For this reason we decided to downgrade the quality of the evidence by one level for indirectness dimension e. KEY

=== Intervention Extract 396 (Treatment) ===
fit or appreciable harm g. I2=53% h. In KEYNOTE 189 study safety results were showed in the overall population and not according to PD-L1 tumour proportion score i. High risk of performance and detection bias because KEYNOTE-021 was an open-label trial j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43 patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician decision

=== Intervention Extract 397 (Treatment) ===
NOTE 189 study safety results were showed in the overall population and not according to PD-L1 tumour proportion score i. High risk of performance and detection bias because KEYNOTE-021 was an open-label trial j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43 patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189

=== Intervention Extract 398 (Treatment) ===
detection bias because KEYNOTE-021 was an open-label trial j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43 patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs, 16 patie

=== Intervention Extract 399 (Treatment) ===
6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43 patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone arm for the following reasons: 268 patients dis

=== Intervention Extract 400 (Treatment) ===
decision, 1 use of excluded medication. 43 patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab co

=== Intervention Extract 401 (Treatment) ===
xcluded medication. KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression;| Row 1: Grade 3-5

=== Intervention Extract 402 (Treatment) ===
mbrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression;| Row 1: Grade 3-5 any AEs||||||RR 1.06 (0.94 to 1.19)|728 (2 RCTs)|⨁◯◯◯ VERY LOWa,c,d,f,g,h,i|
Row 2:

=== Intervention Extract 403 (Treatment) ===
ollowing reasons: 150 radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression;| Row 1: Grade 3-5 any AEs||||||RR 1.06 (0.94 to 1.19)|728 (2 RCTs)|⨁◯◯◯ VERY LOWa,c,d,f,g,h,i|
Row 2: ||Study population|||||||
Row 3: |||||||||

=== Intervention Extract 404 (Treatment) ===
clinical progression;| Row 1: Grade 3-5 any AEs||||||RR 1.06 (0.94 to 1.19)|728 (2 RCTs)|⨁◯◯◯ VERY LOWa,c,d,f,g,h,i|
Row 2: ||Study population|||||||
Row 3: |||||||||
Row 4: |||||||||
Row 5: |56 per 100|||60 per 100|||||
Row 6: ||||(53 to 67)|||||
Row 7: |||||||||
Row 8: Discontinuation rate of any treatment componentj||||||RR 0.80 (0.73 to 0.88)|739 (2 RCTs)|⨁◯◯◯ VERY LOWa,c,d,i,k|
Row 9: ||Study population|||||||
Row 10: |||||||||
Row 11: |||||||||
Row 12: |78 per 100|||62 per 100|||||
Row 13: ||||(57 to 68)|||||
Row 14: ||||||||| Row 1: |k. in KEYNOTE-189 study information for this outcome were show

=== Intervention Extract 405 (Treatment) ===
67)|||||
Row 40: ||||||||| Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: 
Row 2: Comment
Row 3:  Row 1: ||
Row 2: ||
Row 3: ||
Row 4: ||
Row 5: |ADDITIONAL CONSIDERATIONS|
Row 6: || Row 1: 
Row 2: ts Row 1: |Discontinuation Study population RR 0.80 739 ⨁◯◯◯ rate of any (0.73 to (2 RCTs) VERY LOWa,c,d,i,k treatment 78 per 100 62 per 100 0.88) (57 to 68) componentj a. Unclear risk of attrition bias in both studies due to the lack of information b. We decided to downgrade the quality of the evidence by one level for the risk of bias dimension because in both study crossover to pembrolizumab monotherapy was perm

=== Intervention Extract 406 (Treatment) ===
ided to downgrade the quality of the evidence by one level for the risk of bias dimension because in both study crossover to pembrolizumab monotherapy was permitted among the patients in the chemotherapy combination group who had verified disease progression c. In Keynote-021 trial, the maintenance treatment consisted of pembrolizumab and optional indefinite pemetrexed d. In KEYNOTE-21 study, subgroups analysis according to tumour proportion score for PD-L1 were not designed and performed. For this reason we decided to downgrade the quality of the evidence by one level for indirectness dimension e. KEY

=== Intervention Extract 407 (Treatment) ===
fit or appreciable harm g. I2=53% h. In KEYNOTE 189 study safety results were showed in the overall population and not according to PD-L1 tumour proportion score i. High risk of performance and detection bias because KEYNOTE-021 was an open-label trial j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43 patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician decision

=== Intervention Extract 408 (Treatment) ===
NOTE 189 study safety results were showed in the overall population and not according to PD-L1 tumour proportion score i. High risk of performance and detection bias because KEYNOTE-021 was an open-label trial j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43 patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189

=== Intervention Extract 409 (Treatment) ===
detection bias because KEYNOTE-021 was an open-label trial j. KEYNOTE-021 study: 31 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 17 PD, 6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43 patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs, 16 patie

=== Intervention Extract 410 (Treatment) ===
6 AEs, 4 patients withdrawal, 3 physician decision, 1 use of excluded medication. 43 patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone arm for the following reasons: 268 patients dis

=== Intervention Extract 411 (Treatment) ===
decision, 1 use of excluded medication. 43 patients discontinued treatment in the CHT alone arm for the following reasons: 31 PD, 6 AEs, 3 patients withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab co

=== Intervention Extract 412 (Treatment) ===
xcluded medication. KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression; k. in KEYNOTE-189

=== Intervention Extract 413 (Treatment) ===
mbrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression; k. in KEYNOTE-189 study information for this outcome were showed in the overall population and not ac

=== Intervention Extract 414 (Treatment) ===
ollowing reasons: 150 radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression; k. in KEYNOTE-189 study information for this outcome were showed in the overall population and not according to PD-L1 tumour proportion score| R

=== Intervention Extract 415 (Treatment) ===
diographic PD, 21 AEs, 8 patients withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression; k. in KEYNOTE-189 study information for this outcome were showed in the overall population and not according to PD-L1 tumour proportion score| Row 1: Discontinuation rate of any treatment componentj|||||RR 0.80 (0.73 to 0.88)|739 (2 RCTs)|⨁◯◯◯ VERY LOWa,c,d,i,k|
Row 2: ||Study population||||||
Row 3: ||||||||
Row 4: ||||||||
Row 5: |78 per 100||62 per 100 (57 to 68)|||||
Row 6: |||||||| Row 1: 62 per 100
Row 2: (57 to 68) Row 1: |Forest Plot OS: PFS: Objective response rate:| Row 1:

=== Intervention Extract 416 (Treatment) ===
o serious inconsistency|no serious indirectness|no serious imprecision|none|255/359 (71%)|140/180 (77.8%)|HR 0.78 (0.64 to 0.96)2|9 fewer per 100 (from 1 fewer to 16 fewer)|HIGH|CRITICAL3
Row 11: Progression free survival (follow-up median 5 months4; assessed with: indipendent radiologist masked to treatment using RECIST 1.05)||||||||||||
Row 12: 1|randomised trials|no serious risk of bias|no serious inconsistency|no serious indirectness|no serious imprecision|none|175/359 (48.7%)|62/180 (34.4%)|HR 0.62 (0.49 to 0.79)6|11 fewer per 100 (from 6 fewer to 16 fewer)|HIGH|IMPORTANT3
Row 13: Objective respon

=== Intervention Extract 417 (Treatment) ===
p median 12.5 months; assessed with: not rilevant )|||||||
Row 9: 1|randomised trials|no serious risk of bias|no serious inconsistency|no serious indirectness|no serious imprecision|none|
Row 10: Progression free survival (follow-up median 5 months4; assessed with: indipendent radiologist masked to treatment using RECIST 1.05|||||||
Row 11: 1|randomised trials|no serious risk of bias|no serious inconsistency|no serious indirectness|no serious imprecision|none|
Row 12: Objective responce rate (follow-up median 24.3 months; assessed with: overall responce rate (compleate and partial response) RECIS||||||

=== Intervention Extract 418 (Treatment) ===
0 (0.64 a not rilevant 100 (62 a 76) 0.96) follow up: mediana 12.5 m esi Popolazione in studio Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: |Progression 34 per 23 per 100 free survival 100 (19 a 28) (PFS) valutato con: indipendent HR radiologist 0.62 539 ⨁⨁⨁⨁ masked to treatment (0.49 a (1 RCT) ALTA 0.79) using RECIST 1.0 follow up: mediana 5 mesia Objective Popolazione in studio RR 472 ⨁⨁⨁⨁ responce rate 4.44 (1 RCT) ALTAc (ORR) 1 per 3 per 100 (0.57 a valutato con: 100 (0 a 22) 34.36) overall responce rate (compleate and partial response) RECIST 1.0 follow up: mediana 24

=== Intervention Extract 419 (Treatment) ===
p: mediana 24.3 mesib Quality of life La SMD 0.04 - 134 ⨁⨁◯◯ -EQ-5D media inferiore (1 RCT) BASSAd,e (QOL) quality (0.42 inferiore valutato con: of life - a 0.34 EQ-5D index EQ-5D maggiore) score - Cycle era 0 6| Row 1: Progression free survival (PFS) valutato con: indipendent radiologist masked to treatment using RECIST 1.0 follow up: mediana 5 mesia|||||HR 0.62 (0.49 a 0.79)|539 (1 RCT)|⨁⨁⨁⨁ ALTA|
Row 2: |34 per 100||23 per 100 (19 a 28)|||||
Row 3: ||||||||
Row 4: Objective responce rate (ORR) valutato con: overall responce rate (compleate and partial response) RECIST 1.0 follow up: mediana 24.3 mes

=== Intervention Extract 420 (Treatment) ===
Row 2: 100 Row 1: 3 per 100
Row 2: (0 a 22) Row 1: La
Row 2: media
Row 3: quality
Row 4: of life -
Row 5: EQ-5D
Row 6: era 0 Row 1: SMD 0.04
Row 2: inferiore
Row 3: (0.42 inferiore
Row 4: a 0.34
Row 5: maggiore) Row 1: Progression free survival (PFS) valutato con: indipendent radiologist masked to treatment using RECIST 1.0 follow up: mediana 5 mesia||
Row 2: |34 per 100|34 per
Row 3: ||100
Row 4: ||
Row 5: Objective responce rate (ORR) valutato con: overall responce rate (compleate and partial response) RECIST 1.0 follow up: mediana 24.3 mesib||
Row 6: ||Popola
Row 7: ||
Row 8: ||
Row 9: |1 per 100|1

=== Intervention Extract 421 (Treatment) ===
3 meno)|⨁⨁⨁◯ MODERATA|IMPORTANTE
Row 13: Overall response rate||||||||||||
Row 14: ||||||||||||
Row 15: 5|studi randomizzati|serio a,b|serio c|non importante|non importante|nessuno|226/1686 (13.4%)|121/1338 (9.0%)|RR 1.39 (1.12 a 1.73)|4 più per 100 (da 1 più a 7 più)|⨁⨁◯◯ BASSA|IMPORTANTE
Row 16: Treatment-related AE (grade 3 or 4)||||||||||||
Row 17: ||||||||||||
Row 18: 5 1,2,3|studi randomizzati|serio b|non importante d|non importante|non importante|nessuno|251/1868 (13.4%)|623/1483 (42.0%)|RR 0.32 (0.28 a 0.37)|29 meno per 100 (da 30 meno a 26 meno)|⨁⨁⨁◯ MODERATA|
Row 19: Discontinuation rate||||

=== Intervention Extract 422 (Treatment) ===
|non importante|
Row 10: Progression free survival||||||
Row 11: ||||||
Row 12: 5 1,2,3|studi randomizzati|serio a,b|non importante|non importante|non importante|
Row 13: Overall response rate||||||
Row 14: ||||||
Row 15: 5|studi randomizzati|serio a,b|serio c|non importante|non importante|
Row 16: Treatment-related AE (grade 3 or 4)||||||
Row 17: ||||||
Row 18: 5 1,2,3|studi randomizzati|serio b|non importante d|non importante|non importante|
Row 19: Discontinuation rate||||||
Row 20: ||||||
Row 21: 5 1,2,3|studi randomizzati|serio b|non importante|non importante|non importante| Row 1: |||||
Row 2: |№

=== Intervention Extract 423 (Treatment) ===
s) HIGHa 76 per 100 64 per 100 0.77) (61 to 67) Progression free Study population HR 0.85 2737 ⨁⨁⨁◯ survival (0.79 to (4 RCTs) MODERATEa,b 83 per 100 78 per 100 0.92) (76 to 81) Overall response Study population RR 1.93 3024 ⨁⨁◯◯ rate (1.12 to (5 RCTs) LOWa,b,c 9 per 100 17 per 100 1.73) (10 to 16) Treatment-related Study population RR 0.32 3014 ⨁⨁⨁◯ AE (grade 3 or 4) (0.28 to (5 RCTs) MODERATEa,b,d 47 per 100 15 per 100 0.36) (13 to 17) Study population|| Row 1: |||||||||
Row 2: Outcomes||Anticipated absolute effects* (95% CI)||||Relative effect (95% CI)|№ of participants (studies)|Certainty of the ev

=== Intervention Extract 424 (Treatment) ===
|||||
Row 23: ||||(76 to 81)|||||
Row 24: |||||||||
Row 25: Overall response rate||||||RR 1.93 (1.12 to 1.73)|3024 (5 RCTs)|⨁⨁◯◯ LOWa,b,c|
Row 26: ||Study population|||||||
Row 27: |||||||||
Row 28: |||||||||
Row 29: |9 per 100|||17 per 100|||||
Row 30: ||||(10 to 16)|||||
Row 31: |||||||||
Row 32: Treatment-related AE (grade 3 or 4)||||||RR 0.32 (0.28 to 0.36)|3014 (5 RCTs)|⨁⨁⨁◯ MODERATEa,b,d|
Row 33: ||Study population|||||||
Row 34: |||||||||
Row 35: |||||||||
Row 36: |47 per 100|||15 per 100|||||
Row 37: ||||(13 to 17)|||||
Row 38: |||||||||
Row 39: |||||||||
Row 40: ||Study population|||||||
Row 4

=== Intervention Extract 425 (Treatment) ===
|||78 per 100|||||
Row 23: ||||(76 to 81)|||||
Row 24: |||||||||
Row 25: Overall response rate||||||RR 1.93 (1.12 to 1.73)|3024 (5 RCTs)||
Row 26: ||Study population|||||||
Row 27: |||||||||
Row 28: |||||||||
Row 29: |9 per 100|||17 per 100|||||
Row 30: ||||(10 to 16)|||||
Row 31: |||||||||
Row 32: Treatment-related AE (grade 3 or 4)||||||RR 0.32 (0.28 to 0.36)|3014 (5 RCTs)||
Row 33: ||Study population|||||||
Row 34: |||||||||
Row 35: |||||||||
Row 36: |47 per 100|||15 per 100|||||
Row 37: ||||(13 to 17)|||||
Row 38: |||||||||
Row 39: |||||||||
Row 40: ||Study population|||||||
Row 41: ||||||||| Row 1

=== Intervention Extract 426 (Treatment) ===
ed to magnitude and not to direction of effects Overall survival progression free survival| Row 1: Discontinuation rate|||RR 0.47 (0.38 to 0.59)|3014 (5 RCTs)|⨁⨁⨁◯ MODERATEa,b|
Row 2: |17 per 100|8 per 100 (6 to 10)||||
Row 3: |||||| Row 1: 8 per 100
Row 2: (6 to 10) Row 1: |Objective response rate treatment related AEs| Row 1: |Discontinuation rate| Row 1: ||||
Row 2: |Effetti indesiderabili|||
Row 3: |Quanto considerevoli sono gli effetti indesiderabili attesi?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ Grandi ○ Moderati ○ Piccoli X Irrilevanti ○ Variano ○

=== Intervention Extract 427 (Treatment) ===
s) HIGHa 76 per 100 64 per 100 0.77) (61 to 67) Progression free Study population HR 0.85 2737 ⨁⨁⨁◯ survival (0.79 to (4 RCTs) MODERATEa,b 83 per 100 78 per 100 0.92) (76 to 81) Overall response Study population RR 1.93 3024 ⨁⨁◯◯ rate (1.12 to (5 RCTs) LOWa,b,c 9 per 100 17 per 100 1.73) (10 to 16) Treatment-related Study population RR 0.32 3014 ⨁⨁⨁◯ AE (grade 3 or 4) (0.28 to (5 RCTs) MODERATEa,b,d 47 per 100 15 per 100 0.36) (13 to 17) Discontinuation Study population RR 0.47 3014 ⨁⨁⨁◯ rate (0.38 to (5 RCTs) MODERATEa,b 17 per 100 8 per 100 0.59) (6 to 10)|| Row 1: |||||||||
Row 2: Outcomes||Anticipa

=== Intervention Extract 428 (Treatment) ===
|||||
Row 23: ||||(76 to 81)|||||
Row 24: |||||||||
Row 25: Overall response rate||||||RR 1.93 (1.12 to 1.73)|3024 (5 RCTs)|⨁⨁◯◯ LOWa,b,c|
Row 26: ||Study population|||||||
Row 27: |||||||||
Row 28: |||||||||
Row 29: |9 per 100|||17 per 100|||||
Row 30: ||||(10 to 16)|||||
Row 31: |||||||||
Row 32: Treatment-related AE (grade 3 or 4)||||||RR 0.32 (0.28 to 0.36)|3014 (5 RCTs)|⨁⨁⨁◯ MODERATEa,b,d|
Row 33: ||Study population|||||||
Row 34: |||||||||
Row 35: |||||||||
Row 36: |47 per 100|||15 per 100|||||
Row 37: ||||(13 to 17)|||||
Row 38: |||||||||
Row 39: Discontinuation rate||||||RR 0.47 (0.38 to 0.59)|

=== Intervention Extract 429 (Treatment) ===
|||78 per 100|||||
Row 23: ||||(76 to 81)|||||
Row 24: |||||||||
Row 25: Overall response rate||||||RR 1.93 (1.12 to 1.73)|3024 (5 RCTs)||
Row 26: ||Study population|||||||
Row 27: |||||||||
Row 28: |||||||||
Row 29: |9 per 100|||17 per 100|||||
Row 30: ||||(10 to 16)|||||
Row 31: |||||||||
Row 32: Treatment-related AE (grade 3 or 4)||||||RR 0.32 (0.28 to 0.36)|3014 (5 RCTs)||
Row 33: ||Study population|||||||
Row 34: |||||||||
Row 35: |||||||||
Row 36: |47 per 100|||15 per 100|||||
Row 37: ||||(13 to 17)|||||
Row 38: |||||||||
Row 39: Discontinuation rate||||||RR 0.47 (0.38 to 0.59)|3014 (5 RCTs)||
Ro

=== Intervention Extract 430 (Treatment) ===
n bias, all studies were open label I2=61% Although heterogeneity across study was found (I2=82%), we decided not to downgrade for inconcistency, because heterogeneity is related to magnitude and not to direction of effects Overall survival Progression free survival| Row 1: |Objective response rate Treatment related AEs| Row 1: ||Discontinuation rate||
Row 2: ||||
Row 3: |Qualità delle prove|||
Row 4: |Qual è la qualità complessiva delle prove di efficacia e sicurezza?|||
Row 5: ||||
Row 6: GIUDIZI||RICERCA DELLE PROVE|CONSIDERAZIONI AGGIUNTIVE|
Row 7: ○ Molto bassa ○ Bassa X Moderata ○ Alta ○ Nessuno

=== Intervention Extract 431 (Treatment) ===
., Poltoratskiy, A., Ponce, S., Verderame, F., Havel, L., Bondarenko, I., Każarnowicz, A., Losonczy, G., Conev, N. V., Armstrong, J., Byrne, N., Thiyagarajah, P., Jiang, H., Paz-Ares, L.. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol; Jan 2021. a. Rischio di performance bias poichè lo studio non è stato condotto in cieco e di detection bias considerato che gli outcomes venivano valutati dal

=== Intervention Extract 432 (Treatment) ===
., Poltoratskiy, A., Ponce, S., Verderame, F., Havel, L., Bondarenko, I., Każarnowicz, A., Losonczy, G., Conev, N. V., Armstrong, J., Byrne, N., Thiyagarajah, P., Jiang, H., Paz-Ares, L.. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN):| Row 1: ||||||||qualunque grado.
Row 2: ||||||||
Row 3: ||||||||
Row 4: AE grade >=3 follow up: mediana 25.1 mesi|||||RR 0.99 (0.88 a 1.12)|531 (1 RCT)1|⨁⨁⨁◯ MODERATAa|Durvalumab + chemioterapia con platino ed etoposide probabilmente non incremen

=== Intervention Extract 433 (Treatment) ===
d 12 observational studies b. This is not the total number of events, Ge 2018 et al. did not showed the number of events but only the overall number of patients c. Patients included in the Prophylactic Cranial irradiation overview collaborative group had achieved a complete response after induction treatment. In Rule at al. all patients were 70 years or older. Salama et al presented a secondary analysis of the CALGB 30504 study, included patients received placebo or sunitinib d. I2=84% e. In 13 out of 21 studies, the number of events were not showed f. The quality of the observational included studies

=== Intervention Extract 434 (Treatment) ===
d 12 observational studies b. This is not the total number of events, Ge 2018 et al. did not showed the number of events but only the overall number of patients c. Patients included in the Prophylactic Cranial irradiation overview collaborative group had achieved a complete response after induction treatment. In Rule at al. all patients were 70 years or older. Salama et al presented a secondary analysis of the CALGB 30504 study, included patients received placebo or sunitinib d. I2=84% e. In 13 out of 21 studies, the number of events were not showed f. The quality of the observational included studies

=== Intervention Extract 435 (Treatment) ===
and 12 observational studies b. This is not the total number of events, Ge 2018 et al. did not show the number of events but only the overall number of patients c. Patients included in the Prophylactic Cranial irradiation overview collaborative group had achieved a complete response after induction treatment. In Rule at al. all patients were 70 years or older. Salama et al presented a secondary analysis of the CALGB 30504 study, included patients received placebo or sunitinib d. I2=84% e. In 13 out of 21 studies, the number of events were not showed| Row 1: |||||||VERY LOWc,h,i|
Row 2: ||||||||
Row 3:

=== Intervention Extract 436 (Treatment) ===
and 12 observational studies b. This is not the total number of events, Ge 2018 et al. did not show the number of events but only the overall number of patients c. Patients included in the Prophylactic Cranial irradiation overview collaborative group had achieved a complete response after induction treatment. In Rule at al. all patients were 70 years or older. Salama et al presented a secondary analysis of the CALGB 30504 study, included patients received placebo or sunitinib d. I2=84% e. In 13 out of 21 studies, the number of events were not showed Row 1: |f. The quality of the observational included

=== Intervention Extract 437 (Drug) ===
on osimertinib e inibitore specifico, nell’ambito di studi clinici o programmi off-label.
Nuovi scenari di trattamento si apriranno auspicabilmente grazie a due classi di farmaci nuovi nell’ambito
delle neoplasie polmonari EGFR-mutate: anticorpi bispecifici (anti-EGFR/MET, amivantamab) ed antibody-
drug conjugates (ADC anti-HER3, patritumab deruxtecan; ADC anti-TROP2, datopotamab deruxtecan),
attualmente in corso di sperimentazione clinica.
Prolungare il più possibile il beneficio ottenibile con un trattamento a bersaglio molecolare rappresenta un
elemento di chiaro interesse nell’ambito della ges

=== Intervention Extract 438 (Drug) ===
icated by higher values)
1 randomised serious10 no serious no serious serious13 none 98 36 - SMD 0.38 lower (0.76 CRITICAL3
trials inconsistency indirectness lower to 0.01 higher)14 LOW
Severe Toxicity (Non laboratory) (follow-up median 12.5 months; assessed with: N° Patient hospitalized because of drug related adverse events)
1 randomised no serious risk no serious no serious no serious none 30/359 6/180 RR 2.51 (1.06 to 5 more per 100 (from 0 CRITICAL3
trials of bias inconsistency indirectness imprecision (8.4%) (3.3%) 5.91)9 more to 16 more) HIGH
Fatigue grade 3-4 (follow-up median 24.3 months;

=== Intervention Extract 439 (Drug) ===
partecipanti delle prove
(95% (studi) (GRADE)
Rischio Rischio con CI)
con maintenance
placebo therapy with
pemetrexed
Severe Popolazione in studio RR 539 ⨁⨁⨁⨁
Toxicity (Non 2.51 (1 RCT) ALTA
laboratory) 3 per 8 per 100 (1.06 a
(ST) 100 (4 a 20) 5.91)
valutato con:
N° Patient
hospitalized
because of
drug related
adverse events
follow up:
mediana 12.5
mesi
Popolazione in studio
a
ti
a
i
LINE
EE GUIDA
NEOPLASIE DE
Fatigue grade 1 per 5 per 100
3-4 100 (1 a 20)
valutato con:
Grade 3-4
follow up:
mediana 24.3
m esi
transfusion Popolazione in studio
follow up:
mediana 12.5 5 per 13 per 100
mesi 100 (7 a

=== Intervention Extract 440 (Drug) ===
assisted
Thoracic Surgery (VATS) Lobectomy"[Title/Abstract] OR "Video-assisted Thoracic
Surgery"[Title/Abstract]))) OR ("VATS segmentectomy"[Title/Abstract] OR
segmentectomy[Title/Abstract])))) AND (((((((((("Randomized Controlled Trial"[Publication Type]) OR
"Clinical Trial"[Publication Type]) OR "drug therapy"[Subheading])) OR ((randomized[Title/Abstract]
OR randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] OR
trial[Title/Abstract] OR groups)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND
"Humans"[Mesh])))))
AND ("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) AND (

=== Intervention Extract 441 (Drug) ===
OR #2
#4 'adjuvant chemotherapy'/exp/mj
#5 #3 AND #4 Q6: Nei pazienti con NSCLC radicalmente operato in stadio IB-IIIA e mutazioni attivanti classiche
del gene EGFR, una terapia adiuvante con osimertinib è raccomandata?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstrac

=== Intervention Extract 442 (Drug) ===
rato in stadio IB-IIIA e mutazioni attivanti classiche
del gene EGFR, una terapia adiuvante con osimertinib è raccomandata?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abst

=== Intervention Extract 443 (Drug) ===
OR #6 Q7: Nei pazienti con NSCLC radicalmente operato in stadio II-IIIA e livelli di e
L1 ≥50% un trattamento immunoterapico di consolidamento con atez
chemioterapia adiuvante a base di platino è raccomandato?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcino
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "Non small c

=== Intervention Extract 444 (Drug) ===
lli di e
L1 ≥50% un trattamento immunoterapico di consolidamento con atez
chemioterapia adiuvante a base di platino è raccomandato?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcino
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-sm
carcinoma"[Title/Abstract] OR "Non

=== Intervention Extract 445 (Drug) ===
r*[Title/Abstract]) OR NSCLC
AND ((("grade IA"[Title/Abstract] OR "stage IA"[Title/Abstract])))))) OR ("grade I"[T
"grade II"[Title/Abstract] OR "stage I"[Title/Abstract] OR "stage II"[Title/Abstract]))))
surgery")) AND (((((((("Randomized Controlled Trial" [Publication Type]) OR "Clinic
Type]) OR "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR
randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract]
trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mes
"Humans"[Mesh]))) espressione del
zolizumab dopo
oma, Non-Small-
g
mall-cell

=== Intervention Extract 446 (Drug) ===
raccomandata (rispetto a sola chirurgia)?
(("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
"neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
"neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All
Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All
Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR "resectates"

=== Intervention Extract 447 (Drug) ===
chirurgia)?
(("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
"neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
"neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All
Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All
Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR "resectates"[All Fields] OR
"resected"[All

=== Intervention Extract 448 (Drug) ===
R ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
"neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
"neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All
Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All
Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR "resectates"[All Fields] OR
"resected"[All Fields] OR "resecting"[All Fields] OR "resection"

=== Intervention Extract 449 (Drug) ===
oadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
"neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All
Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All
Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR "resectates"[All Fields] OR
"resected"[All Fields] OR "resecting"[All Fields] OR "resection"[All Fields] OR "resectional"[All Fields]
OR "resectioned"[All

=== Intervention Extract 450 (Drug) ===
di mala
dopo trattamento chemio-radioterapico a dosi radicali e con espressione di PD-L1 sulle cel
tumorali superiore o uguale a 1%, una terapia di consolidamento con durvalumab
raccomandata rispetto all’osservazione?
MEDLINE (PubMed) (2018 ad Agosto 2023)
(((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "L
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstr
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non

=== Intervention Extract 451 (Drug) ===
le cel
tumorali superiore o uguale a 1%, una terapia di consolidamento con durvalumab
raccomandata rispetto all’osservazione?
MEDLINE (PubMed) (2018 ad Agosto 2023)
(((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "L
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstr
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell l
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR "

=== Intervention Extract 452 (Drug) ===
vanti classiche del gene EGFR (Ex19dels e L858R), il trattamento di prima linea con inibitore
tirosino-chinasico di EGFR osimertinib è raccomandato (rispetto agli inibitori tirosino-chinasici
gefitinib e/o erlotinib)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstrac

=== Intervention Extract 453 (Drug) ===
rosino-chinasico di EGFR osimertinib è raccomandato (rispetto agli inibitori tirosino-chinasici
gefitinib e/o erlotinib)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abst

=== Intervention Extract 454 (Drug) ===
NSCLC metastatico, con inserzioni dell’esone 20 del gene
EGFR, in progressione dopo precedente trattamento chemioterapico a base di platino,
un trattamento con amivantamab è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstrac

=== Intervention Extract 455 (Drug) ===
trattamento chemioterapico a base di platino,
un trattamento con amivantamab è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abst

=== Intervention Extract 456 (Drug) ===
utazione T790M identificata (mediante biopsia solida o liquida) al
momento della progressione a gefitinib, erlotinib, dacomitinib o afatinib, un trattamento con
osimertinib è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstrac

=== Intervention Extract 457 (Drug) ===
gefitinib, erlotinib, dacomitinib o afatinib, un trattamento con
osimertinib è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abst

=== Intervention Extract 458 (Drug) ===
/de) Q18 Nei pazienti affetti da NSCLC in stadio localmente avanzato o metastatico con
riarrangiamenti di ALK, un trattamento di prima linea con alectinib è raccomandato (rispetto al
crizotinib)?
MEDLINE (PubMed) (2018 ad Agosto 2023)
((((((((((((((((((((((((((((((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-
Small-Cell Lung/pathology"[Mesh])) OR ("Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh]))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract]

=== Intervention Extract 459 (Drug) ===
iamenti di ALK, un trattamento di prima linea con alectinib è raccomandato (rispetto al
crizotinib)?
MEDLINE (PubMed) (2018 ad Agosto 2023)
((((((((((((((((((((((((((((((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-
Small-Cell Lung/pathology"[Mesh])) OR ("Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh]))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstr

=== Intervention Extract 460 (Drug) ===
]/lim OR 'controlled clinical trial'/de) Q19: Nei pazienti affetti da NSCLC in stadio localmente avanzato o metastatico
riarrangiamenti di ALK, un trattamento di prima linea con brigatinib è raccomandato (rispett
crizotinib)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] OR "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] OR "lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
"lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non sma

=== Intervention Extract 461 (Drug) ===
mente avanzato o metastatico
riarrangiamenti di ALK, un trattamento di prima linea con brigatinib è raccomandato (rispett
crizotinib)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] OR "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] OR "lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
"lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR

=== Intervention Extract 462 (Drug) ===
ds: 27
Selezionati 1 record
all
ent'
con
to al
] OR
g
eta-
all
NE
EOPLASIE DEL POLMONE
Q20: Nei pazienti affetti da NSCLC metastatico, con riarrangiamenti del gene ALK, un trattam
di I linea con lorlatinib è raccomandato (rispetto al crizotinib)? (((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Sm
Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract]

=== Intervention Extract 463 (Drug) ===
ei pazienti affetti da NSCLC metastatico, con riarrangiamenti del gene ALK, un trattam
di I linea con lorlatinib è raccomandato (rispetto al crizotinib)? (((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Sm
Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-small-cell lung
carcinoma"[Title/Abst

=== Intervention Extract 464 (Drug) ===
pazienti affetti da NSCLC in stadio localmente avanzato o metastatico
riarrangiamento di ALK in progressione a una terapia con alectinib o ceritinib, un trattam
con lorlatinib è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
(((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] OR "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] OR "lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstrac
"lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small

=== Intervention Extract 465 (Drug) ===
LK in progressione a una terapia con alectinib o ceritinib, un trattam
con lorlatinib è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
(((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] OR "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] OR "lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstrac
"lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lun
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR "No

=== Intervention Extract 466 (Drug) ===
ntrolled trial]/lim) Q22 GRADE: Nei pazienti affetti da NSCLC in stadio localmente avanzato o metastatico con
riarrangiamenti di ROS1, un trattamento di prima linea con crizotinib è raccomandato?
MEDLINE (PubMed) (2018 ad Agosto 2023)
((((((((((((((((((((((((((((((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-
Small-Cell Lung/pathology"[Mesh])) OR ("Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh]))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract]

=== Intervention Extract 467 (Drug) ===
etastatico con
riarrangiamenti di ROS1, un trattamento di prima linea con crizotinib è raccomandato?
MEDLINE (PubMed) (2018 ad Agosto 2023)
((((((((((((((((((((((((((((((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-
Small-Cell Lung/pathology"[Mesh])) OR ("Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh]))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstr

=== Intervention Extract 468 (Drug) ===
]/lim) NE
EOPLASIE DEL POLMONE Q23 GRADE: Nei pazienti affetti da NSCLC in stadio localmente avanzato o metastatico con
riarrangiamenti di ROS1, un trattamento di prima linea con entrectinib è raccomandato?
MEDLINE (PubMed) (2018 ad Agosto 2023)
(((((((((((((((((((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-
Cell Lung/pathology"[Mesh])) OR ("Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh]))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract]

=== Intervention Extract 469 (Drug) ===
anzato o metastatico con
riarrangiamenti di ROS1, un trattamento di prima linea con entrectinib è raccomandato?
MEDLINE (PubMed) (2018 ad Agosto 2023)
(((((((((((((((((((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-
Cell Lung/pathology"[Mesh])) OR ("Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh]))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstr

=== Intervention Extract 470 (Drug) ===
SCLC in stadio avanzato con riarrangiamenti di RET, in progressione
dopo precedente trattamento con chemioterapia a base di platino, un trattamento con
selpercatinib è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (1976 ad Agosto 2023)
(((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstrac

=== Intervention Extract 471 (Drug) ===
con chemioterapia a base di platino, un trattamento con
selpercatinib è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (1976 ad Agosto 2023)
(((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abst

=== Intervention Extract 472 (Drug) ===
NSCLC metastatico, con mutazione p.G12C del gene KRAS, in
progressione dopo precedente trattamento chemioterapico a base di platino, un trattamento con
sotorasib è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstrac

=== Intervention Extract 473 (Drug) ===
to chemioterapico a base di platino, un trattamento con
sotorasib è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abst

=== Intervention Extract 474 (Drug) ===
)) AND (expression[Title/Abstract] OR antibody[Title/Abstract] OR
diagnostic*[Title/Abstract] OR testing[Title/Abstract]))))) AND (((("pembrolizumab" [Supplementary
Concept]) OR (Ambrolizumab[Title/Abstract] OR Keytruda[Title/Abstract] OR MK-
NE
EOPLASIE DEL POLMONE
3475[Title/Abstract]))) OR (((( "Drug Therapy/therapeutic use"[Mesh] OR "Drug
Therapy/therapy"[Mesh] ))) OR (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abs
Chemotherapies[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta
Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[

=== Intervention Extract 475 (Drug) ===
tibody[Title/Abstract] OR
diagnostic*[Title/Abstract] OR testing[Title/Abstract]))))) AND (((("pembrolizumab" [Supplementary
Concept]) OR (Ambrolizumab[Title/Abstract] OR Keytruda[Title/Abstract] OR MK-
NE
EOPLASIE DEL POLMONE
3475[Title/Abstract]))) OR (((( "Drug Therapy/therapeutic use"[Mesh] OR "Drug
Therapy/therapy"[Mesh] ))) OR (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abs
Chemotherapies[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta
Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR "meta
analy*"[Title] OR "metaa

=== Intervention Extract 476 (Drug) ===
[Title/Abstract] OR testing[Title/Abstract]))))) AND (((("pembrolizumab" [Supplementary
Concept]) OR (Ambrolizumab[Title/Abstract] OR Keytruda[Title/Abstract] OR MK-
NE
EOPLASIE DEL POLMONE
3475[Title/Abstract]))) OR (((( "Drug Therapy/therapeutic use"[Mesh] OR "Drug
Therapy/therapy"[Mesh] ))) OR (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abs
Chemotherapies[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta
Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR "meta
analy*"[Title] OR "metaanaly*"[Title] OR "Meta-Analysis"[Titl

=== Intervention Extract 477 (Drug) ===
ed OR recurrence* OR relapse*:ti,ab
#4 'recurrent disease'/exp/mj
#5 (#1 OR #2) AND (#3 OR #4)
#6 'tumor marker'/exp/mj
#7 ('pd-l1' OR 'pd l1') NEAR/5 (expression OR antibody OR diagnostic* OR testing)
#8 #6 OR #7
#9 #5 AND #8
#10 'pembrolizumab'/exp/mj
#11 ambrolizumab OR keytruda OR 'mk 3475' OR 'drug therapies' OR chemotherapy OR
chemotherapies:ti,ab
#12 #10 OR #11
#13 #9 AND #12
#14 #13 AND #14 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta analysis
[controlled clinical trial]/lim OR [randomized controlled trial]/lim) Q31: Nei pazienti affetti da NSCLC metastatico, con espressi

=== Intervention Extract 478 (Drug) ===
ressione di PDL1 ≥50%, senza
attivanti il gene di EGFR o riarrangiamenti di ALK, e con buon performance status
trattamento di prima linea con atezolizumab è raccomandato (rispetto alla chemioterap
di platino)?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-S
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "No

=== Intervention Extract 479 (Drug) ===
buon performance status
trattamento di prima linea con atezolizumab è raccomandato (rispetto alla chemioterap
di platino)?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-S
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-small-cell lun
carcinoma"[Title/Abstr

=== Intervention Extract 480 (Drug) ===
mutazioni attivanti il gene di EGFR o riarrangiamenti di ALK, e con buon performance status (0-
1), un trattamento di prima linea con cemiplimab è raccomandato (rispetto alla chemioterapia a
base di platino)?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstrac

=== Intervention Extract 481 (Drug) ===
1), un trattamento di prima linea con cemiplimab è raccomandato (rispetto alla chemioterapia a
base di platino)?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-small-cell lung
carcinoma"[Title/Abst

=== Intervention Extract 482 (Drug) ===
% e con buon performance status
NE
EOPLASIE DEL POLMONE
(0-1), un trattamento di prima linea a base di cemiplimab in associazione a chemioterapia a base
di platino è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstrac

=== Intervention Extract 483 (Drug) ===
ase di cemiplimab in associazione a chemioterapia a base
di platino è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abst

=== Intervention Extract 484 (Drug) ===
arcinoma in stadio localmente avanzato o
metastatico, in progressione di malattia dopo una prima linea di chemioterapia, l’associazione
di nintedanib e docetaxel è raccomandata rispetto al docetaxel da solo?
MEDLINE (PubMed) (1966 ad Agosto 2023)
((((((((((((((((((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh])) OR ("Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh]))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract]

=== Intervention Extract 485 (Drug) ===
ma linea di chemioterapia, l’associazione
di nintedanib e docetaxel è raccomandata rispetto al docetaxel da solo?
MEDLINE (PubMed) (1966 ad Agosto 2023)
((((((((((((((((((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh])) OR ("Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh]))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstr

=== Intervention Extract 486 (Drug) ===
act]
OR
R
ract]
NE
EOPLASIE DEL POLMONE
Bris”[Title/Abstract] OR “Paclitaxel, (4 alpha)-Isomer”[Title/Abstract] OR Paxene[Title/Abstract] OR
Praxel[Title/Abstract] OR Onxol[Title/Abstract] OR vinorelbina[Title/Abstract] OR
Navelbine[Title/Abstract] OR “Vinorelbine Tartrate”[Title/Abstract]))) OR (("Drug Therapy"[Mesh]) OR
(“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abstract] OR Chemotherapies[Title/Abstract]
OR Pharmacotherapy[Title/Abstract] OR Pharmacotherapies[Title/Abstract]))))) AND
((("Etoposide"[Mesh]) OR (Eposide[Title/Abstract] OR “Demethyl Epipodophyllotoxin Ethylidine
Glucos

=== Intervention Extract 487 (Drug) ===
E DEL POLMONE
Bris”[Title/Abstract] OR “Paclitaxel, (4 alpha)-Isomer”[Title/Abstract] OR Paxene[Title/Abstract] OR
Praxel[Title/Abstract] OR Onxol[Title/Abstract] OR vinorelbina[Title/Abstract] OR
Navelbine[Title/Abstract] OR “Vinorelbine Tartrate”[Title/Abstract]))) OR (("Drug Therapy"[Mesh]) OR
(“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abstract] OR Chemotherapies[Title/Abstract]
OR Pharmacotherapy[Title/Abstract] OR Pharmacotherapies[Title/Abstract]))))) AND
((("Etoposide"[Mesh]) OR (Eposide[Title/Abstract] OR “Demethyl Epipodophyllotoxin Ethylidine
Glucoside”[Title/Abstract] OR “E

=== Intervention Extract 488 (Drug) ===
'cis-diammine(cyclobutanedicarboxylato)platinum ii' OR cbdca OR paraplatin OR
NE
EOPLASIE DEL POLMONE
paraplatine OR platinwas OR ribocarbo OR carboplat OR neocarbo OR carbosin OR carbotec OR
ercar OR 'jm-8' OR 'jm 8' OR jm8 OR nealorin OR 'nsc-241240' OR 'nsc 241240' OR nsc241240 OR
blastocarb OR 'drug therapies' OR chemotherapy OR chemotherapies OR pharmacotherapy OR
pharmacotherapies:ti,ab
#12 #10 OR #11
#13 #3 AND #6 AND #9 AND #12 Q43: Nei pazienti affetti da tumore del polmone a piccole cellule in stadio esteso, un trattamento
di prima linea a base di platino, etoposide e durvalumab, seguito

=== Intervention Extract 489 (Drug) ===
Lung”[Title/Abstract] OR “Oat Cell Carcinoma of Lung”[Title/Abstract]))))) AND ((("etoposide"[MeSH
Terms] OR "etoposide"[All Fields]) AND (("platinum"[MeSH Terms] OR "platinum"[All Fields]))))) AND
((((((("Randomized Controlled Trial" [Publication Type]) OR "Clinical Trial" [Publication Type]) OR
"drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR randomised[Title/Abstract] OR
placebo[Title/Abstract] OR randomly[Title/Abstract] OR trial[Title/Abstract] OR groups OR)))) NOT
((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND "Humans"[Mesh])) Embase (Embase.com) (1974 ad Agosto 2023)
#1 'non

=== Intervention Extract 490 (Drug) ===
n of the literature, and a new testing algorithm. J Thorac Oncol.
Row 8: 2016; 11:487-95.
Row 9: Rossi G, Ragazzi M, Tamagnini I, et al. Does immunohistochemistry represent a robust alternative technique in
Row 10: determining drugable predictive gene alterations in non-small cell lung cancer? Curr Drug Targets. 2017; 18:13-26.
Row 11: Conde E, Hernandez S, Prieto M, et al. Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-
Row 12: cell lung carcinomas. Expert Rev Mol Diagn. 2016; 16:707-13
Row 13: Conklin CM, Craddock KJ, Have C, et al. Immunohistochemistry is a reliable scre

=== Intervention Extract 491 (Drug) ===
||||||||||
Row 4: 1|randomised trials|serious10|no serious inconsistency|no serious indirectness|serious13|none|98|36|-|SMD 0.38 lower (0.76 lower to 0.01 higher)14|LOW|CRITICAL3
Row 5: Severe Toxicity (Non laboratory) (follow-up median 12.5 months; assessed with: N° Patient hospitalized because of drug related adverse events)||||||||||||
Row 6: 1|randomised trials|no serious risk of bias|no serious inconsistency|no serious indirectness|no serious imprecision|none|30/359 (8.4%)|6/180 (3.3%)|RR 2.51 (1.06 to 5.91)9|5 more per 100 (from 0 more to 16 more)|HIGH|CRITICAL3
Row 7: ||||||||||||
Row 8: Fa

=== Intervention Extract 492 (Drug) ===
partecipanti delle prove (95% (studi) (GRADE) Rischio Rischio con CI) con maintenance placebo therapy with pemetrexed Severe Popolazione in studio RR 539 ⨁⨁⨁⨁ Toxicity (Non 2.51 (1 RCT) ALTA laboratory) 3 per 8 per 100 (1.06 a (ST) 100 (4 a 20) 5.91) valutato con: N° Patient hospitalized because of drug related adverse events follow up: mediana 12.5 mesi Popolazione in studio| Row 1: |||||||||
Row 2: Esiti||Effetto assoluto||||Effetto relativo (95% CI)|№ dei partecipanti (studi)|Certezza delle prove (GRADE)|Commenti
Row 3: ||anticipato* (95% CI)|||||||
Row 4: |||||||||
Row 5: |||||||||
Row 6: |Ris

=== Intervention Extract 493 (Drug) ===
pato* (95% CI)|||||||
Row 4: |||||||||
Row 5: |||||||||
Row 6: |Rischio con placebo|||Rischio con|||||
Row 7: ||||maintenance|||||
Row 8: ||||therapy with|||||
Row 9: ||||pemetrexed|||||
Row 10: |||||||||
Row 11: Severe Toxicity (Non laboratory) (ST) valutato con: N° Patient hospitalized because of drug related adverse events follow up: mediana 12.5 mesi||||||RR 2.51 (1.06 a 5.91)|539 (1 RCT)|⨁⨁⨁⨁ ALTA|
Row 12: ||Popolazione in studio|||||||
Row 13: |||||||||
Row 14: |||||||||
Row 15: |3 per 100||8 per 100 (4 a 20)||||||
Row 16: |||||||||
Row 17: |||||||||
Row 18: ||Popolazione in studio|||||||
Ro

=== Intervention Extract 494 (Drug) ===
5% CI)||||||||
Row 4: ||||||||||
Row 5: ||||||||||
Row 6: |Rischio con placebo|||Rischio con||||||
Row 7: ||||maintenance||||||
Row 8: ||||therapy with||||||
Row 9: ||||pemetrexed||||||
Row 10: ||||||||||
Row 11: Severe Toxicity (Non laboratory) (ST) valutato con: N° Patient hospitalized because of drug related adverse events follow up: mediana 12.5 mesi||||||RR 2.51 (1.06 a 5.91)|539 (1 RCT)|⨁⨁⨁⨁ ALTA||
Row 12: ||Popolazione in studio||||||||
Row 13: ||||||||||
Row 14: ||||||||||
Row 15: |3 per 100||8 per 100 (4 a 20)|||||||
Row 16: ||||||||||
Row 17: ||||||||||
Row 18: ||Popolazione in studio|||

=== Intervention Extract 495 (Drug) ===
ndizionata contro l’intervento ○|Raccomandazione condizionata a favore dell’intervento X|Raccomandazione forte a favore dell’intervento ○ Row 1: ||
Row 2: |Raccomandazione|
Row 3: || Row 1: |
Row 2: |Raccomandazione
Row 3: | Row 1: |
Row 2: |
Row 3: | Row 1: (((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung

=== Intervention Extract 496 (Drug) ===
e forte a favore dell’intervento ○ Row 1: ||
Row 2: |Raccomandazione|
Row 3: || Row 1: |
Row 2: |Raccomandazione
Row 3: | Row 1: |
Row 2: |
Row 3: | Row 1: (((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
Row 5: cancer"[Title/Abstract] OR "Non-small-cell lung

=== Intervention Extract 497 (Drug) ===
Controlled Trial" [Publication Type]) OR "Randomized Controlled Trials as
Row 13: Topic"[Mesh]) OR ("Clinical Trial" [Publication Type])) OR (randomized[Title/Abstract] OR
Row 14: randomised[Title/Abstract] OR randomly[Title/Abstract])))))) Row 1: (((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
Row 4: neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung

=== Intervention Extract 498 (Drug) ===
linical Trial" [Publication Type])) OR (randomized[Title/Abstract] OR
Row 14: randomised[Title/Abstract] OR randomly[Title/Abstract])))))) Row 1: (((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
Row 4: neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
Row 5: cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-small-cell lung

=== Intervention Extract 499 (Drug) ===
"[Title/Abstract])))))) OR ("grade I"[Title/Abstract] OR
Row 6: "grade II"[Title/Abstract] OR "stage I"[Title/Abstract] OR "stage II"[Title/Abstract])))))) AND "radical
Row 7: surgery")) AND (((((((("Randomized Controlled Trial" [Publication Type]) OR "Clinical Trial" [Publication
Row 8: Type]) OR "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR
Row 9: randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] OR
Row 10: trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND
Row 11: "Humans"[Mesh]))) Row 1: ((((((((((((((((((

=== Intervention Extract 500 (Drug) ===
ndomized[Title/Abstract] OR
Row 9: randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] OR
Row 10: trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND
Row 11: "Humans"[Mesh]))) Row 1: (((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcino
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
Row 4: neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
Row 5: cancer"[Tit

=== Intervention Extract 501 (Drug) ===
ct] OR randomly[Title/Abstract] OR
Row 10: trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND
Row 11: "Humans"[Mesh]))) Row 1: (((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcino
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
Row 4: neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
Row 5: cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-sm
Row 6: carcin

=== Intervention Extract 502 (Drug) ===
Row 5: AND ((("grade IA"[Title/Abstract] OR "stage IA"[Title/Abstract])))))) OR ("grade I"[T
Row 6: "grade II"[Title/Abstract] OR "stage I"[Title/Abstract] OR "stage II"[Title/Abstract]))))
Row 7: surgery")) AND (((((((("Randomized Controlled Trial" [Publication Type]) OR "Clinic
Row 8: Type]) OR "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR
Row 9: randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract]
Row 10: trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mes
Row 11: "Humans"[Mesh]))) Row 1: (((((lung
Row 2: ract]) OR lu

=== Intervention Extract 503 (Drug) ===
1: OR
Row 2: sh]) AND Row 1: (("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
Row 2: "neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
Row 3: "neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
Row 4: ("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All
Row 5: Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All
Row 6: Fields] OR "resectability"[All Fields] OR "resectable"[All Fi

=== Intervention Extract 504 (Drug) ===
uvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
Row 2: "neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
Row 3: "neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
Row 4: ("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All
Row 5: Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All
Row 6: Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR "resectates"[All Fields] OR
R

=== Intervention Extract 505 (Drug) ===
Fields] AND "therapy"[All Fields]) OR
Row 2: "neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
Row 3: "neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
Row 4: ("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All
Row 5: Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All
Row 6: Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR "resectates"[All Fields] OR
Row 7: "resected"[All Fields] OR "resecting"[All F

=== Intervention Extract 506 (Drug) ===
l Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
Row 3: "neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
Row 4: ("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All
Row 5: Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All
Row 6: Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR "resectates"[All Fields] OR
Row 7: "resected"[All Fields] OR "resecting"[All Fields] OR "resection"[All Fields] OR "resectional"[All Fields]
Row 8:

=== Intervention Extract 507 (Drug) ===
ancer*[Title/Abstract]) OR NSCLC*[Title/Abstract])))))))
Row 5: AND (((grade iii OR stage iii OR advance OR locally advanced disease)) AND (inoperable OR
Row 6: surgically unresectable)))))) AND "Antineoplastic Combined Chemotherapy Protocols"[Mesh] Row 1: (((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung

=== Intervention Extract 508 (Drug) ===
e OR locally advanced disease)) AND (inoperable OR
Row 6: surgically unresectable)))))) AND "Antineoplastic Combined Chemotherapy Protocols"[Mesh] Row 1: (((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
Row 5: cancer"[Title/Abstract] OR "Non-small-cell lung

=== Intervention Extract 509 (Drug) ===
ung cancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]))
Row 5: AND (((grade iii OR stage iii OR advance OR locally advanced disease)) AND (inoperable OR
Row 6: surgically unresectable)))))) AND "Antineoplastic Combined Chemotherapy Protocols"[Mesh] Row 1: (((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "L
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstr
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Tit

=== Intervention Extract 510 (Drug) ===
vance OR locally advanced disease)) AND (inoperable OR
Row 6: surgically unresectable)))))) AND "Antineoplastic Combined Chemotherapy Protocols"[Mesh] Row 1: (((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "L
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstr
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell l
Row 5: cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"

=== Intervention Extract 511 (Drug) ===
OR "Non-small-cell lung carcinoma"[Title/Abstract] OR "Non small cell l
Row 6: carcinoma"[Title/Abstract)) OR NSCLC[Title/Abstract])))))))))))))))) AND "durvalumab" [Supplemen Row 1: -Cell
Row 2: Lung
Row 3: ract]
Row 4: lung
Row 5: lung
Row 6: ntary Row 1: ((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung

=== Intervention Extract 512 (Drug) ===
t)) OR NSCLC[Title/Abstract])))))))))))))))) AND "durvalumab" [Supplemen Row 1: -Cell
Row 2: Lung
Row 3: ract]
Row 4: lung
Row 5: lung
Row 6: ntary Row 1: ((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
Row 5: cancer"[Title/Abstract] OR "Non-small-cell lung

=== Intervention Extract 513 (Drug) ===
zed
Row 7: Controlled Trial"[Publication Type]) OR "Randomized Controlled Trials as Topic"[Mesh]) OR ("Clinical
Row 8: Trial" [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 9: randomly[Title/Abstract])))))))) Row 1: ((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung

=== Intervention Extract 514 (Drug) ===
Clinical
Row 8: Trial" [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 9: randomly[Title/Abstract])))))))) Row 1: ((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
Row 5: cancer"[Title/Abstract] OR "Non-small-cell lung

=== Intervention Extract 515 (Drug) ===
Row 12: Controlled Trial"[Publication Type]) OR "Randomized Controlled Trials as Topic"[Mesh]) OR ("Clinical
Row 13: Trial" [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 14: randomly[Title/Abstract])))))))) Row 1: ((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung

=== Intervention Extract 516 (Drug) ===
inical
Row 13: Trial" [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 14: randomly[Title/Abstract])))))))) Row 1: ((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
Row 5: cancer"[Title/Abstract] OR "Non-small-cell lung

=== Intervention Extract 517 (Drug) ===
led
Row 4: Trial"[Publication Type]) OR "Randomized Controlled Trials as Topic"[Mesh]) OR ("Clinical Trial"
Row 5: [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 6: randomly[Title/Abstract])))))))) Row 1: (((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-
Row 2: Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
Row 4: neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung

=== Intervention Extract 518 (Drug) ===
al"
Row 5: [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 6: randomly[Title/Abstract])))))))) Row 1: (((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-
Row 2: Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
Row 4: neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
Row 5: cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-small-cell lung

=== Intervention Extract 519 (Drug) ===
ry Concept]) OR "amivantamab-vmjw" [Supplementary
Row 10: Concept]) OR "lorlatinib" [Supplementary Concept]) OR (capmatinib[Title/Abstract] OR
Row 11: tepotinib[Title/Abstract] OR amivantamab[Title/Abstract] OR lorlatinib[Title/Abstract])) Row 1: (((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Sm
Row 2: Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
Row 4: neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
Row

=== Intervention Extract 520 (Drug) ===
oncept]) OR (capmatinib[Title/Abstract] OR
Row 11: tepotinib[Title/Abstract] OR amivantamab[Title/Abstract] OR lorlatinib[Title/Abstract])) Row 1: (((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Sm
Row 2: Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
Row 4: neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
Row 5: cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-small-cell lung

=== Intervention Extract 521 (Drug) ===
t])) AND (expression[Title/Abstract] OR antibody[Title/Abstract] OR
Row 9: diagnostic*[Title/Abstract] OR testing[Title/Abstract]))))) AND (((("pembrolizumab" [Supplementary
Row 10: Concept]) OR (Ambrolizumab[Title/Abstract] OR Keytruda[Title/Abstract] OR MK- Row 1: 3475[Title/Abstract]))) OR (((( "Drug Therapy/therapeutic use"[Mesh] OR "Drug
Row 2: Therapy/therapy"[Mesh] ))) OR (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abstract] OR
Row 3: Chemotherapies[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta-
Row 4: Analysis"[Publication Type]) OR "meta-analysi

=== Intervention Extract 522 (Drug) ===
antibody[Title/Abstract] OR
Row 9: diagnostic*[Title/Abstract] OR testing[Title/Abstract]))))) AND (((("pembrolizumab" [Supplementary
Row 10: Concept]) OR (Ambrolizumab[Title/Abstract] OR Keytruda[Title/Abstract] OR MK- Row 1: 3475[Title/Abstract]))) OR (((( "Drug Therapy/therapeutic use"[Mesh] OR "Drug
Row 2: Therapy/therapy"[Mesh] ))) OR (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abstract] OR
Row 3: Chemotherapies[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta-
Row 4: Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR

=== Intervention Extract 523 (Drug) ===
c*[Title/Abstract] OR testing[Title/Abstract]))))) AND (((("pembrolizumab" [Supplementary
Row 10: Concept]) OR (Ambrolizumab[Title/Abstract] OR Keytruda[Title/Abstract] OR MK- Row 1: 3475[Title/Abstract]))) OR (((( "Drug Therapy/therapeutic use"[Mesh] OR "Drug
Row 2: Therapy/therapy"[Mesh] ))) OR (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abstract] OR
Row 3: Chemotherapies[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta-
Row 4: Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR "meta
Row 5: analy*"[Title] OR "metaanaly*"

=== Intervention Extract 524 (Drug) ===
("Randomized Controlled
Row 7: Trial"[Publication Type]) OR "Randomized Controlled Trials as Topic"[Mesh]) OR ("Clinical Trial"
Row 8: [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 9: randomly[Title/Abstract])))))))) Row 1: 3475[Title/Abstract]))) OR (((( "Drug Therapy/therapeutic use"[Mesh] OR "Drug
Row 2: Therapy/therapy"[Mesh] ))) OR (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abs
Row 3: Chemotherapies[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta
Row 4: Analysis"[Publication Type]) OR "meta-analysis[Title] O

=== Intervention Extract 525 (Drug) ===
blication Type]) OR "Randomized Controlled Trials as Topic"[Mesh]) OR ("Clinical Trial"
Row 8: [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 9: randomly[Title/Abstract])))))))) Row 1: 3475[Title/Abstract]))) OR (((( "Drug Therapy/therapeutic use"[Mesh] OR "Drug
Row 2: Therapy/therapy"[Mesh] ))) OR (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abs
Row 3: Chemotherapies[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta
Row 4: Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR "meta
Row

=== Intervention Extract 526 (Drug) ===
rials as Topic"[Mesh]) OR ("Clinical Trial"
Row 8: [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 9: randomly[Title/Abstract])))))))) Row 1: 3475[Title/Abstract]))) OR (((( "Drug Therapy/therapeutic use"[Mesh] OR "Drug
Row 2: Therapy/therapy"[Mesh] ))) OR (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abs
Row 3: Chemotherapies[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta
Row 4: Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR "meta
Row 5: analy*"[Title] OR "metaanaly*"[Title] OR

=== Intervention Extract 527 (Drug) ===
zatax[Title/Abstract] OR
Row 27: Taxol[Title/Abstract] OR “Taxol A”[Title/Abstract] OR “Bris Taxol”[Title/Abstract] OR “Taxol, Row 1: Praxel[Title/Abstract] OR Onxol[Title/Abstract] OR vinorelbina[Title/Abstract] OR
Row 2: Navelbine[Title/Abstract] OR “Vinorelbine Tartrate”[Title/Abstract]))) OR (("Drug Therapy"[Mesh]) OR
Row 3: (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abstract] OR Chemotherapies[Title/Abstrac
Row 4: OR Pharmacotherapy[Title/Abstract] OR Pharmacotherapies[Title/Abstract]))))) AND
Row 5: ((("Etoposide"[Mesh]) OR (Eposide[Title/Abstract] OR “Demethyl Epipodophyllotoxi

=== Intervention Extract 528 (Drug) ===
Taxol[Title/Abstract] OR “Taxol A”[Title/Abstract] OR “Bris Taxol”[Title/Abstract] OR “Taxol, Row 1: Praxel[Title/Abstract] OR Onxol[Title/Abstract] OR vinorelbina[Title/Abstract] OR
Row 2: Navelbine[Title/Abstract] OR “Vinorelbine Tartrate”[Title/Abstract]))) OR (("Drug Therapy"[Mesh]) OR
Row 3: (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abstract] OR Chemotherapies[Title/Abstrac
Row 4: OR Pharmacotherapy[Title/Abstract] OR Pharmacotherapies[Title/Abstract]))))) AND
Row 5: ((("Etoposide"[Mesh]) OR (Eposide[Title/Abstract] OR “Demethyl Epipodophyllotoxin Ethylidine
Row 6: Glucoside”[Ti

=== Intervention Extract 529 (Drug) ===
] OR “Oat Cell Carcinoma of Lung”[Title/Abstract]))))) AND ((("etoposide"[MeSH
Row 4: Terms] OR "etoposide"[All Fields]) AND (("platinum"[MeSH Terms] OR "platinum"[All Fields]))))) AND
Row 5: ((((((("Randomized Controlled Trial" [Publication Type]) OR "Clinical Trial" [Publication Type]) OR
Row 6: "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 7: placebo[Title/Abstract] OR randomly[Title/Abstract] OR trial[Title/Abstract] OR groups OR)))) NOT
Row 8: ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND "Humans"[Mesh])) Row 1: (((("Small Cell Lung Carcinom

=== Intervention Extract 530 (Therapy) ===
gometrici; scintigrafia polmonare di perfusione (figure 4.1 e 4.2).
Figura 4.1: Algoritmo per la valutazione cardiologica in pazienti candidati a resezione polmonare per
tumore del polmone
Modificata da: Brunelli A, Charloux A, Bolliger CT, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer
patients (surgery and chemo-radiotherapy). Eur Respir J. 2009; 34:17-41.
RCRI>2 o Anamnesi
1)Qualsiasi cardiopatia necessitante terapia Esame obiettivo
2)Nuova sospetta cardiopatia (i.e. angina, claudicatio) ECG
3)Incapacità a salire due rampe di scale Calcolare RCRI
Si
No
Visita Car

=== Intervention Extract 531 (Therapy) ===
la presenza di comorbidità clinicamente significative, controindicazioni mediche
o che rifiutano la chirurgia, e in particolare nei pazienti anziani, una valida alternativa alla chirurgia è
rappresentata dalla radioterapia. In particolare, la radioterapia stereotassica (Stereotactic Body Radiation
Therapy - SBRT o Stereotactic Ablative Radiotherapy - SABR) consente di ottenere risultati migliori rispetto
alla radioterapia convenzionale. La SBRT si caratterizza per la somministrazione di dosi biologicamente molto
elevate in una o poche frazioni, mediante tecniche ad alto gradiente di dose, ed è in gr

=== Intervention Extract 532 (Therapy) ===
alutata
nell’ambito di un gruppo multidisciplinare. Nei pazienti in cui la diagnosi del coinvolgimento neoplastico dei linfonodi mediastinici emerge in fase
postoperatoria (pN2) è necessario procedere alla valutazione del trattamento radioterapico adiuvante. La PORT
metanalisi (Post-Operative Radio-Therapy) del 1998, pur dimostrando nei pazienti radicalmente resecati in
stadio I-II un effetto negativo sulla sopravvivenza, non chiarisce l’esistenza di un beneficio clinico nei pazienti
in stadio III (217). Sebbene siano giustificate alcune critiche metodologiche che riguardano tale metanalisi
(inclusio

=== Intervention Extract 533 (Therapy) ===
Zhang, J., Blumenschein, G. R.,Jr., Hernandez, M., Lee, J. J., Ye, R., Palma, D. A., Louie, A. V., Camidge, D. R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Welsh, J. W., Gibbons, D. L., Karam, J. A., Kavanagh, B. D., Tsao, A. S., Sepesi, B., Swisher, S.
G., Heymach, J. V.. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol; Jun 20 2019.
4.Iyengar, P., Wardak, Z., Gerber, D. E., Tumati, V., Ahn, C., Hughes, R. S., Dowell, J. E., Cheede

=== Intervention Extract 534 (Therapy) ===
, G. R.,Jr., Hernandez, M., Lee, J. J., Ye, R., Palma, D. A., Louie, A. V., Camidge, D. R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Welsh, J. W., Gibbons, D. L., Karam, J. A., Kavanagh, B. D., Tsao, A. S., Sepesi, B., Swisher, S.
G., Heymach, J. V.. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol; Jun 20 2019.
4.Iyengar, P., Wardak, Z., Gerber, D. E., Tumati, V., Ahn, C., Hughes, R. S., Dowell, J. E., Cheedella, N., Nedzi, L., West

=== Intervention Extract 535 (Therapy) ===
z, M., Ye, R., Camidge, D. R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Gibbons, D. L., Karam, J. A., Kavanagh, B. D., Tang, C., Komaki, R., Louie, A. V., Palma, D. A., Tsao, A. S., Sepesi, B., William, W. N., Zhang,
J., Shi, Q., Wang, X. S., Swisher, S. G., Heymach, J. V.. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled,
phase 2 study. Lancet Oncol; Dec 2016. Dovrebbe un trattamento locoregionale + terapia sistemica vs so

=== Intervention Extract 536 (Therapy) ===
R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Gibbons, D. L., Karam, J. A., Kavanagh, B. D., Tang, C., Komaki, R., Louie, A. V., Palma, D. A., Tsao, A. S., Sepesi, B., William, W. N., Zhang,
J., Shi, Q., Wang, X. S., Swisher, S. G., Heymach, J. V.. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled,
phase 2 study. Lancet Oncol; Dec 2016. Dovrebbe un trattamento locoregionale + terapia sistemica vs sola terapia sistemica essere

=== Intervention Extract 537 (Therapy) ===
., Palma, D. A., Tsao, A. S., Sepesi, B., William, W. N., Zhang,
J., Shi, Q., Wang, X. S., Swisher, S. G., Heymach, J. V.. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled,
phase 2 study. Lancet Oncol; Dec 2016. Dovrebbe un trattamento locoregionale + terapia sistemica vs sola terapia sistemica essere utilizzato per pazienti affetti da NSCLC
in stadio avanzato oligometastatico
POPULATION: Pazienti affetti da NSCLC in stadio avan

=== Intervention Extract 538 (Therapy) ===
Zhang, J., Blumenschein, G. R.,Jr., Hernandez, M., Lee, J. J., Ye, R., Palma, D. A., Louie,
A. V., Camidge, D. R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Welsh, J. W., Gibbons, D. L., Karam, J. A.,
Kavanagh, B. D., Tsao, A. S., Sepesi, B., Swisher, S. G., Heymach, J. V.. Local Consolidative Therapy Vs.
Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term
Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol; Jun 20 2019.
4. Iyengar, P., Wardak, Z., Gerber, D. E., Tumati, V., Ahn, C., Hughes, R. S., Dowell, J. E., Cheed

=== Intervention Extract 539 (Therapy) ===
, G. R.,Jr., Hernandez, M., Lee, J. J., Ye, R., Palma, D. A., Louie,
A. V., Camidge, D. R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Welsh, J. W., Gibbons, D. L., Karam, J. A.,
Kavanagh, B. D., Tsao, A. S., Sepesi, B., Swisher, S. G., Heymach, J. V.. Local Consolidative Therapy Vs.
Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term
Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol; Jun 20 2019.
4. Iyengar, P., Wardak, Z., Gerber, D. E., Tumati, V., Ahn, C., Hughes, R. S., Dowell, J. E., Cheedella, N., Nedzi, L.,
Wes

=== Intervention Extract 540 (Therapy) ===
z, M., Ye, R., Camidge, D. R., Doebele, R. C.,
Skoulidis, F., Gaspar, L. E., Gibbons, D. L., Karam, J. A., Kavanagh, B. D., Tang, C., Komaki, R., Louie, A. V.,
Palma, D. A., Tsao, A. S., Sepesi, B., William, W. N., Zhang, J., Shi, Q., Wang, X. S., Swisher, S. G., Heymach, J.
V.. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-
small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled,
phase 2 study. Lancet Oncol; Dec 2016.
a. La certezza nelle prove è stata abbassata per rischio di se

=== Intervention Extract 541 (Therapy) ===
R., Doebele, R. C.,
Skoulidis, F., Gaspar, L. E., Gibbons, D. L., Karam, J. A., Kavanagh, B. D., Tang, C., Komaki, R., Louie, A. V.,
Palma, D. A., Tsao, A. S., Sepesi, B., William, W. N., Zhang, J., Shi, Q., Wang, X. S., Swisher, S. G., Heymach, J.
V.. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-
small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled,
phase 2 study. Lancet Oncol; Dec 2016.
a. La certezza nelle prove è stata abbassata per rischio di selection bias.
b. La certezz

=== Intervention Extract 542 (Therapy) ===
,
Palma, D. A., Tsao, A. S., Sepesi, B., William, W. N., Zhang, J., Shi, Q., Wang, X. S., Swisher, S. G., Heymach, J.
V.. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-
small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled,
phase 2 study. Lancet Oncol; Dec 2016.
a. La certezza nelle prove è stata abbassata per rischio di selection bias.
b. La certezza nelle prove è stata abbassata per imprecisione, dovuta al basso numero di eventi.
c. La certezza nelle prove è stata abbassata pe

=== Intervention Extract 543 (Therapy) ===
t serious d serious f none
trials
Objective response rate
2 randomised serious a,b,g not serious not serious d serious h none
trials
Nausea Grade 3
2 randomised serious a,b,g very serious i not serious d serious h none
trials
L POLM
K rearrange
nsideration
MONE
ement and progressed after crizotinib therapy
№ of patients Effect
ceritinib or Relative Absolute Certainty Importance
ns alectinib or chemotherapy
(95% CI) (95% CI)
brigatinib
111/187 110/151 HR 0.45 28 fewer ⨁⨁⨁◯ CRITICAL
(59.4%) (72.8%) (0.34 to 0.59) per 100 MODERATE
(from 19
fewer to 37
fewer)
64/187 (34.2%) 57/151 (37.7%) HR 0.98 1 fewer

=== Intervention Extract 544 (Therapy) ===
C in stadio avanzato con riarrangiamento di ALK in progressione a una terapia con alectinib o brigatinib il tratt
Lorlatinib può essere preso in considerazione rispetto alla chemioterapia.
Don't know
Don't
know
tamento con
NEOPLASIE DEL POL Author(s): IDS
Date: September 2019
Question: a first line therapy with crizotinib compared to chemotherapy in patients with advanced NSCLC with
Setting: inpatients
Bibliography: Shaw AT et al N Engl J Med 2014; 371:1963-71;
Mazieres J et al J Clin Oncol 2015; 33:992-9
Show A: T. et al Annals of Oncology 30: 1121–1126, 2019;
Landi L. et al. Clin Cancer Res Publish

=== Intervention Extract 545 (Therapy) ===
by the NICE checklist. Shaw et al and Landi L. et al studies obtained a score of 8/8 and Maizieres et al. a score of 7/8 because of its
retrospective nature. In both studies there was not information about the outcomes stratification
b. 76% of the METROS study population received one prior line of therapy
c. In Shaw A.T et al most of patients (89%) had received at least one previous line of standard therapy for advanced NSCLC and 42% of patients were Asian. In Mazières J et al.
most of patients (80.7%) were stage IV and only one patient did not received a previous chemotherapy line
QUESITO 22: Nei p

=== Intervention Extract 546 (Therapy) ===
l. a score of 7/8 because of its
retrospective nature. In both studies there was not information about the outcomes stratification
b. 76% of the METROS study population received one prior line of therapy
c. In Shaw A.T et al most of patients (89%) had received at least one previous line of standard therapy for advanced NSCLC and 42% of patients were Asian. In Mazières J et al.
most of patients (80.7%) were stage IV and only one patient did not received a previous chemotherapy line
QUESITO 22: Nei pazienti affetti da NSCLC in stadio localmente avanzato o metastatico con riarrangiamenti di ROS1, un
tra

=== Intervention Extract 547 (Therapy) ===
bili attesi?
RICERCA DELLE PROVE
Outcomes Anticipated
(95% CI)
Risk with
chemothera
Progression free survival - Study popul
Landi L. et al (METROS)
0 per 1.000
Progression-free survival - -
Shaw A.T. et al - not reported
EL POLMONE
d absolute effects* Relat
effect
Risk with CI)
apy (Q6)a first
li e therapy
with
crizotinib
lation not
estima
0 per 1.000
(0 to 0)
tive № of Certain
t participants the evid
% (studies) (GRAD
able (1
VERY
observational
study)
nty of
dence
DE)
LOWa,b
LI
Commen
INEE G
CON
CON
nts
GUIDA
NSIDERAZI
NSIDERAZI
IONI AGGIUNTIVE
IONI AGGIUNTIVE
NEOP
Progression-free survival -
Mazièr

=== Intervention Extract 548 (Therapy) ===
sed by the NICE checklist. Shaw et al and Landi L. et al
studies obtained a score of 8/8 and Maizieres et al. a score of 7/8 because of its retrospective
nature. In both studies there was not information about the outcomes stratification
76% of the METROS study population received one prior line of therapy
In Shaw A.T et al most of patients (89%) had received at least one previous line of standard
therapy for advanced NSCLC and 42% of patients were Asian. In Mazières J et al. most of pati
(80.7%) were stage IV and only one patient did not received a previous chemotherapy line
LINE
ients
EE GUIDA
Effe

=== Intervention Extract 549 (Therapy) ===
s et al. a score of 7/8 because of its retrospective
nature. In both studies there was not information about the outcomes stratification
76% of the METROS study population received one prior line of therapy
In Shaw A.T et al most of patients (89%) had received at least one previous line of standard
therapy for advanced NSCLC and 42% of patients were Asian. In Mazières J et al. most of pati
(80.7%) were stage IV and only one patient did not received a previous chemotherapy line
LINE
ients
EE GUIDA
Effetti in
Quanto conside
GIUDIZI
○ Grandi
○ Moderati
○ Piccoli
X
Irrilevanti
○ Variano
○ Non so
ndesid
e

=== Intervention Extract 550 (Therapy) ===
t al - not reported
Progression-free survival - Study popul
Mazières J. et al.
0 per 1.000
Overall survival - Landi L et Study popul
al (METROS)
0 per 1.000
Overall survival - Shaw A.T. Study popul
et al 2019
0 per 1.000
EL POLMONE
d absolute effects* Relat
effect
Risk with CI)
apy (Q6)a first
line therapy
with
crizotinib
lation not
estima
0 per 1.000
( 0 to 0)
lation not
estima
0 per 1.000
(0 to 0)
lation not
estima
0 per 1.000
(0 to 0)
lation not
estima
0 per 1.000
(0 to 0)
tive № of Certainty of
t participants the evidence
% (studies) (GRADE)
able (1
VERY LOWa,b
observational
study)
able (1
VERY L

=== Intervention Extract 551 (Therapy) ===
aw et al and Lan
ecause of its retr
mes stratification
Wa,b
Wa,c
Wa,b
Wa,c
Wa,c
ndi L.
rospe
L
et al
ective
LINE
EE GUIDA
Qualità delle pr
Qual è la qualità comples
GIUDIZI
X
Molto bassa
○ Bassa
○ Moderata
○ Alta
○ Nessuno studio incluso
76% of the METROS study population received one prior line of therapy
In Shaw A.T et al most of patients (89%) had received at least one previous line of standard
therapy for advanced NSCLC and 42% of patients were Asian. In Mazières J et al. most of patients
(80.7%) were stage IV and only one patient did not receive a previous chemotherapy line
rove
ssiva delle prov

=== Intervention Extract 552 (Therapy) ===
ective
LINE
EE GUIDA
Qualità delle pr
Qual è la qualità comples
GIUDIZI
X
Molto bassa
○ Bassa
○ Moderata
○ Alta
○ Nessuno studio incluso
76% of the METROS study population received one prior line of therapy
In Shaw A.T et al most of patients (89%) had received at least one previous line of standard
therapy for advanced NSCLC and 42% of patients were Asian. In Mazières J et al. most of patients
(80.7%) were stage IV and only one patient did not receive a previous chemotherapy line
rove
ssiva delle prove di efficacia e sicurezza?
RICERCA DELLE PROVE CONSIDERAZI
La certezza delle prove è stata giudicata

=== Intervention Extract 553 (Therapy) ===
6 AEs, 3 patients withdrawal, 2 physician
decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 150
radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone
arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients
withdrawal, 3 physician decision, 2 new

=== Intervention Extract 554 (Therapy) ===
nical progression; 166 patients discontinued treatment in the CHT alone
arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients
withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression;
k. in KEYNOTE-189 study information for this outcome were showed in the overall population and not according to PD-L1 tumour proportion score Dovrebbe un trattamento di prima linea a base di platino, pemetrexed e pembrolizumab, seguito da mantenimento con
pemetrexed e p

=== Intervention Extract 555 (Therapy) ===
gand PD-L1 are effective therapies for metastatic non–small-cell
○ Probably no lung cancer (NSCLC) lacking sensitizing EGFR or ALK mutations. Pembrolizumab (Keytruda, Merck), nivolumab
○ Probably yes (Opdivo, Bristol-Myers Squibb), and atezolizumab (Tecentriq, Genentech) are approved as second-line therapy. [...]
X Yes
○ Varies
○ Don't know
Desirable
How substantia
JUDGEMENT
○ Trivial
○ Small
○ Moderate
X Large
○ Varies
○ Don't know
e effec
al are the d
cts
desirable a
LINEE GU
Because patients with advanced NSCLC can undergo rapid clinical deterioration during disease progression, less
than one half

=== Intervention Extract 556 (Therapy) ===
ia
JUDGEMENT
○ Trivial
○ Small
○ Moderate
X Large
○ Varies
○ Don't know
e effec
al are the d
cts
desirable a
LINEE GU
Because patients with advanced NSCLC can undergo rapid clinical deterioration during disease progression, less
than one half of patients with advanced NSCLC ever receive second-line therapy.1,2 First-line combination
regimens that include a PD-1 or PD-L1 inhibitor may maximize the chance of response and lead to prolonged
survival. Modulation of the immune response through PD-1 inhibition may be enhanced by the potential
immunogenic effects of cytotoxic chemotherapy.
Gandhi L. et al. N

=== Intervention Extract 557 (Therapy) ===
6 AEs, 3 patients
withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued
treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs,
16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients
discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in
the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients
withdrawal, 3 physician decision, 2 new

=== Intervention Extract 558 (Therapy) ===
nical progression; 166 patients
discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in
the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients
withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression;
k. in KEYNOTE-189 study information for this outc
PD-L1 tumour proportion score
Forest Plot
OS: Objective response rate:
E
come were showed in the overall pop
pulation and not according to
NE
Any AEs grade 3-5:
Discontinuation rate:
EOPL
LASIE DEL PO
OLMONE
Undesira
How

=== Intervention Extract 559 (Therapy) ===
6 AEs, 3 patients
withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued
treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs,
16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients
discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in
the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients
withdrawal, 3 physician decision, 2 new

=== Intervention Extract 560 (Therapy) ===
nical progression; 166 patients
discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in
the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients
withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression;
k. in KEYNOTE-189 study information for this outcome were showed in the overall population and not according to
PD-L1 tumour proportion score
NE
Forest Plot Objective response rate:
EOPL
LASIE DEL PO
OLMONE
NE
Any AEs grade 3-5:
Discontinuation rate:
EOPL
LASIE DEL PO
O

=== Intervention Extract 561 (Therapy) ===
stabilità di malattia
dopo 4 cicli di trattamento dovrebbe essere preso in considerazione come prima opzione rispetto alla chemioterapia in pazienti affetti da NSCLC a istologia squamosa in stadio
metastatico e con buon performance status (0-1). Author(s): IM
Date: 2021
Question: Should maintenance therapy with pemetrexed vs placebo be used for advanced NSCLC ?1
Settings: advanced NSCLC without disease progression after first line chemotherapy with platinum and pemetrexed
Bibliography: Paz-Ares L, Lacet Oncol 2012;13:247-55 Gridelli C, J Thorac Oncol 2012;7:1713-1721 Paz-Ares L, JCO 2013;3
Quality as

=== Intervention Extract 562 (Therapy) ===
NSCLC ?1
Settings: advanced NSCLC without disease progression after first line chemotherapy with platinum and pemetrexed
Bibliography: Paz-Ares L, Lacet Oncol 2012;13:247-55 Gridelli C, J Thorac Oncol 2012;7:1713-1721 Paz-Ares L, JCO 2013;3
Quality assessment No of patients
No of Other Maintenance therapy
Design Risk of bias Inconsistency Indirectness Imprecision
studies considerations with pemetrexed
Overall Survival (follow-up median 12.5 months; assessed with: not rilevant )
1 randomised no serious risk no serious no serious no serious none 255/359
trials of bias inconsistency indirectness imprec

=== Intervention Extract 563 (Therapy) ===
not reported in the primary article) and a p-value > 0.05 (the authors reported "Not-Ssignificant" only)
15 we added a further event both in the intervention and in the control group to permit the calculation of relative and absolute effect
IDA
ore); both f
for benefit
and harm Dovrebbe maintenance therapy with pemetrexed vs placebo essere utiliz
POPOLAZIONE: Advanced NSCLC
INTERVENTO: Maintenance therapy with pemetrexed
CONFRONTO: Placebo
ESITI PRINCIPALI: Overall Survival; Progression free survival; Objective responce rate; Quality of life -EQ-5D; Qual
grade 3-4; Neutropenia grade 3-4
SETTING:
PROS

=== Intervention Extract 564 (Therapy) ===
ly)
15 we added a further event both in the intervention and in the control group to permit the calculation of relative and absolute effect
IDA
ore); both f
for benefit
and harm Dovrebbe maintenance therapy with pemetrexed vs placebo essere utiliz
POPOLAZIONE: Advanced NSCLC
INTERVENTO: Maintenance therapy with pemetrexed
CONFRONTO: Placebo
ESITI PRINCIPALI: Overall Survival; Progression free survival; Objective responce rate; Quality of life -EQ-5D; Qual
grade 3-4; Neutropenia grade 3-4
SETTING:
PROSPETTIVA:
BACKGROUND:
CONFLITTI DI
INTERESSE Il problema è una priorità?
GIUDIZI RICERCA DELLE PROVE D

=== Intervention Extract 565 (Therapy) ===
n = 539) venivano randomizzati (2:1) a ricevere pemetrexed (500 mg/mq e.v. g.1 ogni
tre settimane) + BSC o placebo + BSC
Esiti Effetto assoluto Effetto № dei Certezza Commenti
anticipato* (95% CI) relativo partecipanti delle prove
(95% (studi) (GRADE)
Rischio Rischio con CI)
con maintenance
placebo therapy with
pemetrexed
Overall Popolazione in studio HR 539 ⨁⨁⨁⨁
Survival (OS) 0.78 (1 RCT)
ALTA
valutato con: 78 per 69 per 100 (0.64 a
not rilevant 100 (62 a 76) 0.96)
follow up:
mediana 12.5
m esi
Popolazione in studio
SIDERAZIO
LINE
ONI AGG
EE GUIDA
GIUNTIVE
NE
Progression 34 per
free survival 100
(PF

=== Intervention Extract 566 (Therapy) ===
= 539) venivano randomizzati (2:1) a ricevere pemetrexed (500 mg/mq e.v. g.1 ogni
tre settimane) + BSC o placebo + BSC.
Esiti Effetto assoluto Effetto № dei Certezza Commenti
anticipato* (95% CI) relativo partecipanti delle prove
(95% (studi) (GRADE)
Rischio Rischio con CI)
con maintenance
placebo therapy with
pemetrexed
Severe Popolazione in studio RR 539 ⨁⨁⨁⨁
Toxicity (Non 2.51 (1 RCT) ALTA
laboratory) 3 per 8 per 100 (1.06 a
(ST) 100 (4 a 20) 5.91)
valutato con:
N° Patient
hospitalized
because of
drug related
adverse events
follow up:
mediana 12.5
mesi
Popolazione in studio
a
ti
a
i
LINE
EE GUIDA

=== Intervention Extract 567 (Therapy) ===
ted
Thoracic Surgery (VATS) Lobectomy"[Title/Abstract] OR "Video-assisted Thoracic
Surgery"[Title/Abstract]))) OR ("VATS segmentectomy"[Title/Abstract] OR
segmentectomy[Title/Abstract])))) AND (((((((((("Randomized Controlled Trial"[Publication Type]) OR
"Clinical Trial"[Publication Type]) OR "drug therapy"[Subheading])) OR ((randomized[Title/Abstract]
OR randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] OR
trial[Title/Abstract] OR groups)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND
"Humans"[Mesh])))))
AND ("2009/07/18"[PDAT] : "2019/07/15"[PDAT]) AND ("2009/07

=== Intervention Extract 568 (Therapy) ===
#4 'adjuvant chemotherapy'/exp/mj
#5 #3 AND #4 Q6: Nei pazienti con NSCLC radicalmente operato in stadio IB-IIIA e mutazioni attivanti classiche
del gene EGFR, una terapia adiuvante con osimertinib è raccomandata?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "N

=== Intervention Extract 569 (Therapy) ===
in stadio IB-IIIA e mutazioni attivanti classiche
del gene EGFR, una terapia adiuvante con osimertinib è raccomandata?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR

=== Intervention Extract 570 (Therapy) ===
Q7: Nei pazienti con NSCLC radicalmente operato in stadio II-IIIA e livelli di e
L1 ≥50% un trattamento immunoterapico di consolidamento con atez
chemioterapia adiuvante a base di platino è raccomandato?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcino
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "Non small cell lung

=== Intervention Extract 571 (Therapy) ===
i e
L1 ≥50% un trattamento immunoterapico di consolidamento con atez
chemioterapia adiuvante a base di platino è raccomandato?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcino
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-sm
carcinoma"[Title/Abstract] OR "Non small c

=== Intervention Extract 572 (Therapy) ===
tle/Abstract]) OR NSCLC
AND ((("grade IA"[Title/Abstract] OR "stage IA"[Title/Abstract])))))) OR ("grade I"[T
"grade II"[Title/Abstract] OR "stage I"[Title/Abstract] OR "stage II"[Title/Abstract]))))
surgery")) AND (((((((("Randomized Controlled Trial" [Publication Type]) OR "Clinic
Type]) OR "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR
randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract]
trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mes
"Humans"[Mesh]))) espressione del
zolizumab dopo
oma, Non-Small-
g
mall-cell lung
pt]

=== Intervention Extract 573 (Therapy) ===
stematic review]/lim OR [meta analysis]/lim OR
[controlled clinical trial]/lim OR [randomized controlled trial]/lim) AND [embase]/lim Q9: Nei pazienti con NSCLC in stadio II-III resecabile una chemioterapia neoadiuvante seguita
da chirurgia è raccomandata (rispetto a sola chirurgia)?
(("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
"neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
"neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
("drug"[All Fields] AND "therapy"[Al

=== Intervention Extract 574 (Therapy) ===
ed clinical trial]/lim OR [randomized controlled trial]/lim) AND [embase]/lim Q9: Nei pazienti con NSCLC in stadio II-III resecabile una chemioterapia neoadiuvante seguita
da chirurgia è raccomandata (rispetto a sola chirurgia)?
(("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
"neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
"neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherap

=== Intervention Extract 575 (Therapy) ===
controlled trial]/lim) AND [embase]/lim Q9: Nei pazienti con NSCLC in stadio II-III resecabile una chemioterapia neoadiuvante seguita
da chirurgia è raccomandata (rispetto a sola chirurgia)?
(("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
"neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
"neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All
Fields] OR "drug therapy"[MeS

=== Intervention Extract 576 (Therapy) ===
omandata (rispetto a sola chirurgia)?
(("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
"neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
"neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All
Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All
Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR "resectates"[All Fie

=== Intervention Extract 577 (Therapy) ===
ant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
"neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
"neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All
Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All
Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR "resectates"[All Fields] OR
"resected"[All Fields] OR "resecting"[All

=== Intervention Extract 578 (Therapy) ===
eoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
"neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
"neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All
Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All
Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR "resectates"[All Fields] OR
"resected"[All Fields] OR "resecting"[All Fields] OR "resection"[All Fie

=== Intervention Extract 579 (Therapy) ===
vant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
"neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All
Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All
Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR "resectates"[All Fields] OR
"resected"[All Fields] OR "resecting"[All Fields] OR "resection"[All Fields] OR "resectional"[All Fields]
OR "resectioned"[All Fields]

=== Intervention Extract 580 (Therapy) ===
la
dopo trattamento chemio-radioterapico a dosi radicali e con espressione di PD-L1 sulle cel
tumorali superiore o uguale a 1%, una terapia di consolidamento con durvalumab
raccomandata rispetto all’osservazione?
MEDLINE (PubMed) (2018 ad Agosto 2023)
(((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "L
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstr
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small ce

=== Intervention Extract 581 (Therapy) ===
l
tumorali superiore o uguale a 1%, una terapia di consolidamento con durvalumab
raccomandata rispetto all’osservazione?
MEDLINE (PubMed) (2018 ad Agosto 2023)
(((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "L
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstr
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell l
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR "Non smal

=== Intervention Extract 582 (Therapy) ===
Mesh]) OR "Lung
Neoplasms"[Mesh]) OR "lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract] OR "lung
tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR NSCLC[Title/Abstract]) AND oligometastatic[Title/Abstract])) AND
(therapy[Title/Abstract] AND (systemic[Title/Abstract] OR locoregional[Title/Abstract])) Embase (Embase.com) (2019 a marzo 2021)
#1 'lung tumor'/exp OR 'non small cell lung cancer'/exp
#2 'lung cancer' OR 'lung neoplasms' OR 'lung tumor' OR 'non-small-cell lung cancer' OR 'non small cell
lung cancer' OR nsc

=== Intervention Extract 583 (Therapy) ===
classiche del gene EGFR (Ex19dels e L858R), il trattamento di prima linea con inibitore
tirosino-chinasico di EGFR osimertinib è raccomandato (rispetto agli inibitori tirosino-chinasici
gefitinib e/o erlotinib)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "N

=== Intervention Extract 584 (Therapy) ===
o-chinasico di EGFR osimertinib è raccomandato (rispetto agli inibitori tirosino-chinasici
gefitinib e/o erlotinib)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR

=== Intervention Extract 585 (Therapy) ===
C metastatico, con inserzioni dell’esone 20 del gene
EGFR, in progressione dopo precedente trattamento chemioterapico a base di platino,
un trattamento con amivantamab è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "N

=== Intervention Extract 586 (Therapy) ===
amento chemioterapico a base di platino,
un trattamento con amivantamab è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR

=== Intervention Extract 587 (Therapy) ===
one T790M identificata (mediante biopsia solida o liquida) al
momento della progressione a gefitinib, erlotinib, dacomitinib o afatinib, un trattamento con
osimertinib è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "N

=== Intervention Extract 588 (Therapy) ===
inib, erlotinib, dacomitinib o afatinib, un trattamento con
osimertinib è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR

=== Intervention Extract 589 (Therapy) ===
Q18 Nei pazienti affetti da NSCLC in stadio localmente avanzato o metastatico con
riarrangiamenti di ALK, un trattamento di prima linea con alectinib è raccomandato (rispetto al
crizotinib)?
MEDLINE (PubMed) (2018 ad Agosto 2023)
((((((((((((((((((((((((((((((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-
Small-Cell Lung/pathology"[Mesh])) OR ("Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh]))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non

=== Intervention Extract 590 (Therapy) ===
ti di ALK, un trattamento di prima linea con alectinib è raccomandato (rispetto al
crizotinib)?
MEDLINE (PubMed) (2018 ad Agosto 2023)
((((((((((((((((((((((((((((((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-
Small-Cell Lung/pathology"[Mesh])) OR ("Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh]))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR

=== Intervention Extract 591 (Therapy) ===
OR 'controlled clinical trial'/de) Q19: Nei pazienti affetti da NSCLC in stadio localmente avanzato o metastatico
riarrangiamenti di ALK, un trattamento di prima linea con brigatinib è raccomandato (rispett
crizotinib)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] OR "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] OR "lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
"lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell

=== Intervention Extract 592 (Therapy) ===
avanzato o metastatico
riarrangiamenti di ALK, un trattamento di prima linea con brigatinib è raccomandato (rispett
crizotinib)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] OR "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] OR "lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
"lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR "Non sma

=== Intervention Extract 593 (Therapy) ===
7
Selezionati 1 record
all
ent'
con
to al
] OR
g
eta-
all
NE
EOPLASIE DEL POLMONE
Q20: Nei pazienti affetti da NSCLC metastatico, con riarrangiamenti del gene ALK, un trattam
di I linea con lorlatinib è raccomandato (rispetto al crizotinib)? (((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Sm
Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "Non

=== Intervention Extract 594 (Therapy) ===
zienti affetti da NSCLC metastatico, con riarrangiamenti del gene ALK, un trattam
di I linea con lorlatinib è raccomandato (rispetto al crizotinib)? (((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Sm
Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-small-cell lung
carcinoma"[Title/Abstract] OR

=== Intervention Extract 595 (Therapy) ===
enti affetti da NSCLC in stadio localmente avanzato o metastatico
riarrangiamento di ALK in progressione a una terapia con alectinib o ceritinib, un trattam
con lorlatinib è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
(((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] OR "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] OR "lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstrac
"lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lu

=== Intervention Extract 596 (Therapy) ===
progressione a una terapia con alectinib o ceritinib, un trattam
con lorlatinib è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (2021 ad Agosto 2023)
(((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] OR "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] OR "lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstrac
"lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lun
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR "Non small

=== Intervention Extract 597 (Therapy) ===
led trial]/lim) Q22 GRADE: Nei pazienti affetti da NSCLC in stadio localmente avanzato o metastatico con
riarrangiamenti di ROS1, un trattamento di prima linea con crizotinib è raccomandato?
MEDLINE (PubMed) (2018 ad Agosto 2023)
((((((((((((((((((((((((((((((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-
Small-Cell Lung/pathology"[Mesh])) OR ("Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh]))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non

=== Intervention Extract 598 (Therapy) ===
atico con
riarrangiamenti di ROS1, un trattamento di prima linea con crizotinib è raccomandato?
MEDLINE (PubMed) (2018 ad Agosto 2023)
((((((((((((((((((((((((((((((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-
Small-Cell Lung/pathology"[Mesh])) OR ("Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh]))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR

=== Intervention Extract 599 (Therapy) ===
) NE
EOPLASIE DEL POLMONE Q23 GRADE: Nei pazienti affetti da NSCLC in stadio localmente avanzato o metastatico con
riarrangiamenti di ROS1, un trattamento di prima linea con entrectinib è raccomandato?
MEDLINE (PubMed) (2018 ad Agosto 2023)
(((((((((((((((((((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-
Cell Lung/pathology"[Mesh])) OR ("Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh]))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non

=== Intervention Extract 600 (Therapy) ===
o o metastatico con
riarrangiamenti di ROS1, un trattamento di prima linea con entrectinib è raccomandato?
MEDLINE (PubMed) (2018 ad Agosto 2023)
(((((((((((((((((((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-
Cell Lung/pathology"[Mesh])) OR ("Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh]))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR

=== Intervention Extract 601 (Therapy) ===
in stadio avanzato con riarrangiamenti di RET, in progressione
dopo precedente trattamento con chemioterapia a base di platino, un trattamento con
selpercatinib è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (1976 ad Agosto 2023)
(((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "N

=== Intervention Extract 602 (Therapy) ===
hemioterapia a base di platino, un trattamento con
selpercatinib è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (1976 ad Agosto 2023)
(((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR

=== Intervention Extract 603 (Therapy) ===
metastatico, con mutazione p.G12C del gene KRAS, in
progressione dopo precedente trattamento chemioterapico a base di platino, un trattamento con
sotorasib è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "N

=== Intervention Extract 604 (Therapy) ===
emioterapico a base di platino, un trattamento con
sotorasib è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR

=== Intervention Extract 605 (Therapy) ===
D (expression[Title/Abstract] OR antibody[Title/Abstract] OR
diagnostic*[Title/Abstract] OR testing[Title/Abstract]))))) AND (((("pembrolizumab" [Supplementary
Concept]) OR (Ambrolizumab[Title/Abstract] OR Keytruda[Title/Abstract] OR MK-
NE
EOPLASIE DEL POLMONE
3475[Title/Abstract]))) OR (((( "Drug Therapy/therapeutic use"[Mesh] OR "Drug
Therapy/therapy"[Mesh] ))) OR (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abs
Chemotherapies[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta
Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] O

=== Intervention Extract 606 (Therapy) ===
y[Title/Abstract] OR
diagnostic*[Title/Abstract] OR testing[Title/Abstract]))))) AND (((("pembrolizumab" [Supplementary
Concept]) OR (Ambrolizumab[Title/Abstract] OR Keytruda[Title/Abstract] OR MK-
NE
EOPLASIE DEL POLMONE
3475[Title/Abstract]))) OR (((( "Drug Therapy/therapeutic use"[Mesh] OR "Drug
Therapy/therapy"[Mesh] ))) OR (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abs
Chemotherapies[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta
Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR "meta
analy*"[Title] OR "metaanaly*"[T

=== Intervention Extract 607 (Therapy) ===
Abstract] OR
diagnostic*[Title/Abstract] OR testing[Title/Abstract]))))) AND (((("pembrolizumab" [Supplementary
Concept]) OR (Ambrolizumab[Title/Abstract] OR Keytruda[Title/Abstract] OR MK-
NE
EOPLASIE DEL POLMONE
3475[Title/Abstract]))) OR (((( "Drug Therapy/therapeutic use"[Mesh] OR "Drug
Therapy/therapy"[Mesh] ))) OR (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abs
Chemotherapies[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta
Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR "meta
analy*"[Title] OR "metaanaly*"[Title] OR

=== Intervention Extract 608 (Therapy) ===
one di PDL1 ≥50%, senza
attivanti il gene di EGFR o riarrangiamenti di ALK, e con buon performance status
trattamento di prima linea con atezolizumab è raccomandato (rispetto alla chemioterap
di platino)?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-S
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "Non small

=== Intervention Extract 609 (Therapy) ===
performance status
trattamento di prima linea con atezolizumab è raccomandato (rispetto alla chemioterap
di platino)?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-S
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-small-cell lun
carcinoma"[Title/Abstract] OR

=== Intervention Extract 610 (Therapy) ===
zioni attivanti il gene di EGFR o riarrangiamenti di ALK, e con buon performance status (0-
1), un trattamento di prima linea con cemiplimab è raccomandato (rispetto alla chemioterapia a
base di platino)?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "N

=== Intervention Extract 611 (Therapy) ===
un trattamento di prima linea con cemiplimab è raccomandato (rispetto alla chemioterapia a
base di platino)?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-small-cell lung
carcinoma"[Title/Abstract] OR

=== Intervention Extract 612 (Therapy) ===
on buon performance status
NE
EOPLASIE DEL POLMONE
(0-1), un trattamento di prima linea a base di cemiplimab in associazione a chemioterapia a base
di platino è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "N

=== Intervention Extract 613 (Therapy) ===
i cemiplimab in associazione a chemioterapia a base
di platino è raccomandato (rispetto alla chemioterapia)?
MEDLINE (PubMed) (1946 ad Agosto 2023)
(((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR

=== Intervention Extract 614 (Therapy) ===
oma in stadio localmente avanzato o
metastatico, in progressione di malattia dopo una prima linea di chemioterapia, l’associazione
di nintedanib e docetaxel è raccomandata rispetto al docetaxel da solo?
MEDLINE (PubMed) (1966 ad Agosto 2023)
((((((((((((((((((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh])) OR ("Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh]))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non

=== Intervention Extract 615 (Therapy) ===
nea di chemioterapia, l’associazione
di nintedanib e docetaxel è raccomandata rispetto al docetaxel da solo?
MEDLINE (PubMed) (1966 ad Agosto 2023)
((((((((((((((((((((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Lung/pathology"[Mesh])) OR ("Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Neoplasms/pathology"[Mesh]))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/Abstract] OR

=== Intervention Extract 616 (Therapy) ===
OR
R
ract]
NE
EOPLASIE DEL POLMONE
Bris”[Title/Abstract] OR “Paclitaxel, (4 alpha)-Isomer”[Title/Abstract] OR Paxene[Title/Abstract] OR
Praxel[Title/Abstract] OR Onxol[Title/Abstract] OR vinorelbina[Title/Abstract] OR
Navelbine[Title/Abstract] OR “Vinorelbine Tartrate”[Title/Abstract]))) OR (("Drug Therapy"[Mesh]) OR
(“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abstract] OR Chemotherapies[Title/Abstract]
OR Pharmacotherapy[Title/Abstract] OR Pharmacotherapies[Title/Abstract]))))) AND
((("Etoposide"[Mesh]) OR (Eposide[Title/Abstract] OR “Demethyl Epipodophyllotoxin Ethylidine
Glucoside”[Tit

=== Intervention Extract 617 (Therapy) ===
”[Title/Abstract] OR “Oat Cell Carcinoma of Lung”[Title/Abstract]))))) AND ((("etoposide"[MeSH
Terms] OR "etoposide"[All Fields]) AND (("platinum"[MeSH Terms] OR "platinum"[All Fields]))))) AND
((((((("Randomized Controlled Trial" [Publication Type]) OR "Clinical Trial" [Publication Type]) OR
"drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR randomised[Title/Abstract] OR
placebo[Title/Abstract] OR randomly[Title/Abstract] OR trial[Title/Abstract] OR groups OR)))) NOT
((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND "Humans"[Mesh])) Embase (Embase.com) (1974 ad Agosto 2023)
#1 'non small ce

=== Intervention Extract 618 (Therapy) ===
1|
Row 24: Hartmann-Boyce J, McRobbie H, Bullen C, et al. Electronic cigarettes for smoking cessation. Cochrane Database|
Row 25: Syst Rev. 2016; 9:CD010216.27622384.|
Row 26: Hajek P, Phillips-Waller AB, Dunja Przulj B, et al. A randomized trial of e-cigarettes versus nicotine-replacement|
Row 27: therapy. N Engl J Med. 2019; 380(7):629-37.|
Row 28: Auer R, Concha-Lozano N, Jacot-Sadowski I, et al. Heat-not-burn tobacco cigarettes: smoke by any other name.|
Row 29: JAMA Intern Med. 2017; 177(7):1050-2.|
Row 30: National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-can

=== Intervention Extract 619 (Therapy) ===
endorf L, Lantuejoul S, de Langen AJ, et al. Non-small cell lung carcinoma: diagnostic difficulties in small
Row 41: biopsies and cytological specimens: Number 2 in the Series “Pathology for the clinician”. Eur Respir Rev. 2017;
Row 42: 26(144):170007.
Row 43: Hanna NH, Robinson AG, Temin S, et al. Therapy for stage IV non-small cell lung cancer with driver alterations:
Row 44: ASCO and OH (CCO) joint Guideline Update. J Clin Oncol. 2021; 39:1040-91.
Row 45: Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying
Row 46: responsiveness of non-smal

=== Intervention Extract 620 (Therapy) ===
33: Li C, Wang L, Wu Q, et al. A meta-analysis comparing stereotactic body radiotherapy vs conventional radiotherapy
Row 34: in inoperable stage I non-small cell lung cancer. Medicine (Baltimore). 2020; 99(34):e21715.
Row 35: Videtic GMM, Donington J, Giuliani M, et al. Stereotactic body radiation therapy for early- stage non-small cell
Row 36: lung cancer: executive summary of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017; 7:295-301.
Row 37: Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-
Row 38: small-cell lung cancer:

=== Intervention Extract 621 (Therapy) ===
37: Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-
Row 38: small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015; 16(6):630-7.
Row 39: Chen H, Laba JM, Boldt RG, et al. Stereotactic ablative radiation therapy versus surgery in early lung cancer: a
Row 40: meta-analysis of propensity score studies. Int J Radiat Oncol Biol Phys. 2018; 101(1):186-94.
Row 41: Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE
Row 42: Collaborative Group. J Clin Onc

=== Intervention Extract 622 (Therapy) ===
ll cell lung cancer.
Row 44: Cochrane Database Syst Rev. 2015; 3:CD011430.
Row 45: Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation
Row 46: in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy
Row 47: Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008; 26:5043-51.
Row 48: Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with
Row 49: observation in completely resected stage IB and II non-small-cell

=== Intervention Extract 623 (Therapy) ===
1):29-34.
Row 51: Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO
Row 52: Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(Suppl 4):1-21.
Row 53: Kris MG, Gaspar LE, Chaft JE, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA
Row 54: completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario
Row 55: Clinical Practice Guideline Update. J Clin Oncol. 2017; 35(25):2960-74. Row 1: Salazar MC, Rosen JE, Wang Z, et al. Associati

=== Intervention Extract 624 (Therapy) ===
err KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO
Row 52: Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(Suppl 4):1-21.
Row 53: Kris MG, Gaspar LE, Chaft JE, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA
Row 54: completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario
Row 55: Clinical Practice Guideline Update. J Clin Oncol. 2017; 35(25):2960-74. Row 1: Salazar MC, Rosen JE, Wang Z, et al. Association of delayed adjuvant chemothe

=== Intervention Extract 625 (Therapy) ===
E, Wang Z, et al. Association of delayed adjuvant chemotherapy with survival after lung cancer
Row 2: surgery. JAMA Oncol. 2017; 3:610-9.
Row 3: Pisters KMW, Evans WK, Azzoli CG, et al. Cancer Care Ontario and American Society of Clinical Oncology
Row 4: adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non-small-cell lung cancer
Row 5: guideline. J Clin Oncol. 2007; 25:5506-18.
Row 6: Früh M, Rolland E, Pignon JP, et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy
Row 7: for completely resected non-small-cell lung cancer. J Clin Oncol

=== Intervention Extract 626 (Therapy) ===
ected non-small-cell lung
Row 32: cancer: results of the NCIC CTG BR19 study. J Clin Oncol. 2013; 31(27):3320-6.
Row 33: Yue D, Xu S, Wang Q, et al. Updated overall survival and exploratory analysis from randomized, phase II
Row 34: EVAN study of erlotinib versus vinorelbine plus cisplatin adjuvant therapy in stage IIIA epidermal growth
Row 35: factor receptor+ non-small-cell lung cancer. J Clin Oncol. 2022; 40(34):3912-7.
Row 36: Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-
Row 37: IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104)

=== Intervention Extract 627 (Therapy) ===
IA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study. Ann Surg Oncol.
Row 3: 2014; 21(6):2091-6
Row 4: Feng S, Wang Y, Cai K, et al. Randomized adjuvant chemotherapy of EGFR-mutated non-small cell lung cancer
Row 5: patients with or without icotinib consolidation therapy. PLoS One. 2015; 10(10):e0140794.
Row 6: Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small cell lung cancer. N Engl J Med.
Row 7: 2020; 383(18):1711-23. Row 1: Herbst RS, Wu YL, John T, et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell
Row

=== Intervention Extract 628 (Therapy) ===
uvant atezolizumab after chemotherapy in resected stage
Row 11: II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol.
Row 12: 2023; 34(10):907-19.
Row 13: O’Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely
Row 14: resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised,
Row 15: triple-blind, phase 3 trial. Lancet Oncol. 2022; 23(10):1274-86.
Row 16: PORT meta-analysis trialists group. Postoperative radiotherapy in non-small cell lung

=== Intervention Extract 629 (Therapy) ===
st x-ray for the follow-up of completely
Row 33: resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol.
Row 34: 2022; 23:1180-8.
Row 35: Lee CB, Stinchcombe TE, Moore D, et al. Late complications of high-dose thoracic conformal radiation therapy in
Row 36: combined modality trials in unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2009; 4:74-9.
Row 37: Verstegen NE, Lagerwaard FJ, Hashemi SM, et al. Patterns of disease recurrence after SABR for early stage non-
Row 38: small-cell lung cancer: optimizing follow-up schedul

=== Intervention Extract 630 (Therapy) ===
bined modality trials in unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2009; 4:74-9.
Row 37: Verstegen NE, Lagerwaard FJ, Hashemi SM, et al. Patterns of disease recurrence after SABR for early stage non-
Row 38: small-cell lung cancer: optimizing follow-up schedules for salvage therapy. J Thorac Oncol. 2015; 10(8):1195-200.
Row 39: Colt HG, Murgu SD, Korst RG, et al. Follow-up and surveillance of the patient with lung cancer after curative-intent
Row 40: therapy diagnosis and management of lung cancer, 3rd Ed: American College of Chest Physicians evidence-based
Row 41: clinical p

=== Intervention Extract 631 (Therapy) ===
e recurrence after SABR for early stage non-
Row 38: small-cell lung cancer: optimizing follow-up schedules for salvage therapy. J Thorac Oncol. 2015; 10(8):1195-200.
Row 39: Colt HG, Murgu SD, Korst RG, et al. Follow-up and surveillance of the patient with lung cancer after curative-intent
Row 40: therapy diagnosis and management of lung cancer, 3rd Ed: American College of Chest Physicians evidence-based
Row 41: clinical practice guidelines. Chest. 2013; 143(Suppl):e437-54.
Row 42: Van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy
Row 43:

=== Intervention Extract 632 (Therapy) ===
2 non-small-cell lung cancer. Ann Oncol. 2014;
Row 3: 25(Suppl 4):1v417.
Row 4: Cerfolio RJ, Bryant AS, Spencer SA, et al. Pulmonary resection after high-dose and low-dose chest irradiation. Ann
Row 5: Thorac Surg. 2005; 80(4):1224-30.
Row 6: Suntharalingam M, Paulus R, Edelman MJ, et al. Radiation therapy oncology group protocol 02-29: a phase II trial
Row 7: of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection
Row 8: and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys.
Row 9:

=== Intervention Extract 633 (Therapy) ===
: Cerfolio RJ, Bryant AS, Spencer SA, et al. Pulmonary resection after high-dose and low-dose chest irradiation. Ann
Row 5: Thorac Surg. 2005; 80(4):1224-30.
Row 6: Suntharalingam M, Paulus R, Edelman MJ, et al. Radiation therapy oncology group protocol 02-29: a phase II trial
Row 7: of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection
Row 8: and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys.
Row 9: 2012; 84(2):456-63
Row 10: Pöttgen C, Eberhardt W, Graupner B, et al. Accelera

=== Intervention Extract 634 (Therapy) ===
ion after high-dose and low-dose chest irradiation. Ann
Row 5: Thorac Surg. 2005; 80(4):1224-30.
Row 6: Suntharalingam M, Paulus R, Edelman MJ, et al. Radiation therapy oncology group protocol 02-29: a phase II trial
Row 7: of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection
Row 8: and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys.
Row 9: 2012; 84(2):456-63
Row 10: Pöttgen C, Eberhardt W, Graupner B, et al. Accelerated hyperfractionated radiotherapy within trimodality therapy

=== Intervention Extract 635 (Therapy) ===
horac Surg. 2005; 80(4):1224-30.
Row 6: Suntharalingam M, Paulus R, Edelman MJ, et al. Radiation therapy oncology group protocol 02-29: a phase II trial
Row 7: of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection
Row 8: and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys.
Row 9: 2012; 84(2):456-63
Row 10: Pöttgen C, Eberhardt W, Graupner B, et al. Accelerated hyperfractionated radiotherapy within trimodality therapy
Row 11: concepts for stage IIIA/B non-small cell lung cancer: m

=== Intervention Extract 636 (Therapy) ===
therapy followed by surgical resection
Row 8: and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys.
Row 9: 2012; 84(2):456-63
Row 10: Pöttgen C, Eberhardt W, Graupner B, et al. Accelerated hyperfractionated radiotherapy within trimodality therapy
Row 11: concepts for stage IIIA/B non-small cell lung cancer: markedly higher rate of pathologic complete remissions than
Row 12: with conventional fractionation. Eur J Cancer. 2013; 49(9):2107-15.
Row 13: Sher DJ, Fidler MJ, Seder CW, et al. Relationship between radiation therapy dose and outcome

=== Intervention Extract 637 (Therapy) ===
ithin trimodality therapy
Row 11: concepts for stage IIIA/B non-small cell lung cancer: markedly higher rate of pathologic complete remissions than
Row 12: with conventional fractionation. Eur J Cancer. 2013; 49(9):2107-15.
Row 13: Sher DJ, Fidler MJ, Seder CW, et al. Relationship between radiation therapy dose and outcome in patients treated
Row 14: with neoadjuvant chemoradiation therapy and surgery for stage IIIA non-small cell lung cancer: a population-based,
Row 15: comparative effectiveness analysis. Int J Radiat Oncol Biol Phys. 2015; 92(2):307-16.
Row 16: Allen AM, Shochat T, Flex D, et al. H

=== Intervention Extract 638 (Therapy) ===
r: markedly higher rate of pathologic complete remissions than
Row 12: with conventional fractionation. Eur J Cancer. 2013; 49(9):2107-15.
Row 13: Sher DJ, Fidler MJ, Seder CW, et al. Relationship between radiation therapy dose and outcome in patients treated
Row 14: with neoadjuvant chemoradiation therapy and surgery for stage IIIA non-small cell lung cancer: a population-based,
Row 15: comparative effectiveness analysis. Int J Radiat Oncol Biol Phys. 2015; 92(2):307-16.
Row 16: Allen AM, Shochat T, Flex D, et al. High-dose radiotherapy as neoadjuvant treatment in non-small-cell lung cancer.
Row 17:

=== Intervention Extract 639 (Therapy) ===
l. High-dose radiotherapy as neoadjuvant treatment in non-small-cell lung cancer.
Row 17: Oncology. 2018; 95(1):13-9.
Row 18: Vyfhuis MAL, Burrows WM, Bhooshan N, et al. Implications of pathologic complete response beyond mediastinal
Row 19: nodal clearance with high-dose neoadjuvant chemoradiation therapy in locally advanced, non-small cell lung cancer.
Row 20: Int J Radiat Oncol Biol Phys. 2018; 101(2):445-52.
Row 21: Hellmann MD, Chaft JE, William WN J, et al. Pathological response after neoadjuvant chemotherapy in resectable
Row 22: non-small-cell lung cancers: proposal for the use of major patho

=== Intervention Extract 640 (Therapy) ===
erapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann
Row 12: Oncol. 2017; 28(4):777-83.
Row 13: Senan S, Brade A, Wang LH, et al. Proclaim: randomized phase III trial of pemetrexed-cisplatin or etoposide-
Row 14: cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous
Row 15: non-small-cell lung cancer. J Clin Oncol. 2016; 34(9):953-62.
Row 16: Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer.
Row 17: N Engl J Med. 2017; 377:1

=== Intervention Extract 641 (Therapy) ===
ients with
Row 27: unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R
Row 28: study. J Thorac Oncol. 2023; 18(2):181-93.
Row 29: Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995; 13(1):8-10.
Row 30: Juan O, Sanjay Popat. Ablative therapy for oligometastatic non-small cell lung cancer. Clin Lung Cancer. 2017;
Row 31: 18(6):595-606.
Row 32: Ashworth AB, Senan S, Palma DA, et al. An individual patient data metaanalysis of outcomes and prognostic factors
Row 33: after treatment of oligometastatic non-small-cell lung cancer. Clin Lung C

=== Intervention Extract 642 (Therapy) ===
S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment
Row 40: in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;
Row 41: 393(10185):2051-8.
Row 42: Xu Q, Zhou F, Liu H, et al. Consolidative local ablative therapy improves the survival of patients with synchronous
Row 43: oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs. J Thorac Oncol.
Row 44: 2018; 13(9):1383-92.
Row 45: Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with w

=== Intervention Extract 643 (Therapy) ===
t Oncol. 2017; 18(8):1049-60.
Row 48: Robin TP, Camidge DR, Stuhr K, et al. Excellent outcomes with radiosurgery for multiple brain metastases in ALK
Row 49: and EGFR driven non-small cell lung cancer. J Thorac Oncol. 2018; 13(5):715-20.
Row 50: Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients
Row 51: with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized
Row 52: study. J Clin Oncol. 2019; 37(18):1558-65.
Row 53: Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy

=== Intervention Extract 644 (Therapy) ===
9-60.
Row 48: Robin TP, Camidge DR, Stuhr K, et al. Excellent outcomes with radiosurgery for multiple brain metastases in ALK
Row 49: and EGFR driven non-small cell lung cancer. J Thorac Oncol. 2018; 13(5):715-20.
Row 50: Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients
Row 51: with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized
Row 52: study. J Clin Oncol. 2019; 37(18):1558-65.
Row 53: Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic n

=== Intervention Extract 645 (Therapy) ===
Thorac Oncol.
Row 24: 2012; 7(11):1722-7.
Row 25: Asami K, Okuma T, Hirashima T, et al. Continued treatment with gefitinib beyond progressive disease benefits
Row 26: patients with activating EGFR mutations. Lung Cancer. 2013; 79(3):276-82.
Row 27: Park K, Yu CJ, Kim SW, et al. First-line erlotinib therapy until and beyond response evaluation criteria in solid
Row 28: tumors progression in asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung
Row 29: cancer: The ASPIRATION Study. JAMA Oncol. 2016; 2(3):305-12.
Row 30: Lim SW, Park S, Kim Y, et al. Continuation of

=== Intervention Extract 646 (Therapy) ===
beyond progression in patients with EGFR mutation-positive
Row 31: non-small-cell lung cancer: a phase II single-arm trial. Lung Cancer. 2018; 124:293-7.
Row 32: Le X, Puri S, Negrao MV, et al. Landscape of EGFR-dependent and independent resistance mechanisms to
Row 33: osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin Cancer Res. 2018;
Row 34: 24(24):6195-203.
Row 35: Mu Y, Hao X, Yang K, et al. Clinical modality of resistance and subsequent management of patients with advanced
Row 36: non‑small cell lung cancer failing treatment with osimertinib. Target Oncol. 2019;

=== Intervention Extract 647 (Therapy) ===
, Metro G, Iacono D, et al. Clinical impact of sequential treatment with ALK-TKIs in patients with advanced|
Row 48: ALK-positive non-small cell lung cancer: results of a multicenter analysis. Lung Cancer. 2015; 90(2):255-60.|
Row 49: Liu J, Cui S, Pan F, et al. Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell|
Row 50: lung cancer patients with ALK/ROS1 mutations. J Cancer. 2018; 9(10):1863-9.|
Row 51: Zhao Y, Zhang B, Wang S, et al. Management of central nervous system metastases in patients with advanced|
Row 52: anaplastic lymphoma kinase-rearranged nonesmall

=== Intervention Extract 648 (Therapy) ===
al. Management of central nervous system metastases in patients with advanced|
Row 52: anaplastic lymphoma kinase-rearranged nonesmall-cell lung cancer during crizotinib treatment. Clin Lung Cancer.|
Row 53: 2019; 20(6):e631-7.|
Row 54: Hubbeling H, Choudhury N, Flynn J, et al. Outcomes with local therapy and tyrosine kinase inhibition in patients|
Row 55: with ALK/ROS1/RET-rearranged lung cancers. JCO Precis Oncol. 2022; 6:e2200024.| Row 1: Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;
Row 2: 371(21):1963-71.
Row 3: Shaw AT, Riely GJ,

=== Intervention Extract 649 (Therapy) ===
Row 2: 371(21):1963-71.
Row 3: Shaw AT, Riely GJ, Bang JL, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC):
Row 4: updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019; 30(7):1121-6.
Row 5: Mazieres J, Zalcman G, Crinò L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1
Row 6: rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015; 33(9):992-9.
Row 7: Michels S, Massuti B, Schildhaus HS, et al. Safety and efficacy of crizotinib in patients with advanced or metastatic
Row 8: ROS1-rearranged lung cancer (EUCROSS

=== Intervention Extract 650 (Therapy) ===
itive non-small-cell lung cancer (ARROW):
Row 13: a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021; 22(7):959-69.
Row 14: Griesinger F, Curigliano G, Thomas M, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-
Row 15: cell lung cancer including as first-line therapy: update from the ARROW trial. Ann Oncol. 2022; 33(11):1168-78.
Row 16: Besse B, Griesinger F, Curigliano G, et al. 1170P - Updated efficacy and safety data from the phase I/II ARROW
Row 17: study of pralsetinib in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). Ann Onco

=== Intervention Extract 651 (Therapy) ===
g cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-
Row 55: 021 study. Lancet Oncol. 2016; 17(11):1497-508. Row 1: Awad MM, Gadgel SM, Borghaei H, et al. Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed
Row 2: and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC. J Thoracic
Row 3: Oncol. 2021; 16(1):162-8.
Row 4: Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell
Row 5: lung cancer. N Engl J Med. 2018; 378(22):2078-92.
Row 6: Gadgeel S, Rodríguez-Abreu D, Speranza G, et

=== Intervention Extract 652 (Therapy) ===
ikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus
Row 50: pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;
Row 51: 26:3543-51.
Row 52: Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus
Row 53: placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous
Row 54: non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol.
Row 55: 201

=== Intervention Extract 653 (Therapy) ===
xed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;
Row 51: 26:3543-51.
Row 52: Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus
Row 53: placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous
Row 54: non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol.
Row 55: 2012; 13:247-55. Row 1: Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the ph

=== Intervention Extract 654 (Therapy) ===
A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Row 8: N Engl J Med. 2006; 355:2542-50.
Row 9: Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or
Row 10: bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009; 27:1227-
Row 11: 34.
Row 12: Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo
Row 13: as first-line therapy for nonsquamous non-small-cell lung cancer: results from

=== Intervention Extract 655 (Therapy) ===
with either placebo or
Row 10: bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009; 27:1227-
Row 11: 34.
Row 12: Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo
Row 13: as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).
Row 14: Ann Oncol. 2010; 21:1804-9.
Row 15: Lima AB, Macedo LT, Sasse AD. Addition of bevacizumab to chemotherapy in advanced non-small cell lung
Row 16: cancer: a systematic review and meta-analysis. PLo

=== Intervention Extract 656 (Therapy) ===
11: Ge W, Xu H, Yan Y, et al. The effects of prophylactic cranial irradiation versus control on survival of patients with
Row 12: extensive-stage small-cell lung cancer: a meta-analysis of 14 trials. Radiat Oncol. 2018; 13(1):155.
Row 13: Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients
Row 14: with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol. 1999; 17:2092-9.
Row 15: Yee D, Butts C, Reiman A, et al. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for
Row 16: extensive-stage small

=== Intervention Extract 657 (Therapy) ===
comparing supportive care alone with supportive care
Row 22: with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006; 24(34):5441-7.
Row 23: Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line
Row 24: therapy in small-cell lung cancer. J Clin Oncol. 2007; 25(15):2086-92.
Row 25: Von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line
Row 26: treatment for patients with small-cell lung cancer. J Clin Oncol. 2014; 32(35):4012-9.
Row 27: Trigo J, Subb

=== Intervention Extract 658 (Therapy) ===
Zhang, J., Blumenschein, G. R.,Jr., Hernandez, M., Lee, J. J., Ye, R., Palma, D. A., Louie, A. V., Camidge, D. R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Welsh, J. W., Gibbons, D. L., Karam, J. A., Kavanagh, B. D., Tsao, A. S., Sepesi, B., Swisher, S. G., Heymach, J. V.. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol; Jun 20 2019. 4. Iyengar, P., Wardak, Z., Gerber, D. E., Tumati, V., Ahn, C., Hughes, R. S., Dowell, J. E., Cheed

=== Intervention Extract 659 (Therapy) ===
, G. R.,Jr., Hernandez, M., Lee, J. J., Ye, R., Palma, D. A., Louie, A. V., Camidge, D. R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Welsh, J. W., Gibbons, D. L., Karam, J. A., Kavanagh, B. D., Tsao, A. S., Sepesi, B., Swisher, S. G., Heymach, J. V.. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol; Jun 20 2019. 4. Iyengar, P., Wardak, Z., Gerber, D. E., Tumati, V., Ahn, C., Hughes, R. S., Dowell, J. E., Cheedella, N., Nedzi, L., Wes

=== Intervention Extract 660 (Therapy) ===
z, M., Ye, R., Camidge, D. R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Gibbons, D. L., Karam, J. A., Kavanagh, B. D., Tang, C., Komaki, R., Louie, A. V., Palma, D. A., Tsao, A. S., Sepesi, B., William, W. N., Zhang, J., Shi, Q., Wang, X. S., Swisher, S. G., Heymach, J. V.. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non- small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol; Dec 2016. a. La certezza nelle prove è stata abbassata per rischio di se

=== Intervention Extract 661 (Therapy) ===
R., Doebele, R. C., Skoulidis, F., Gaspar, L. E., Gibbons, D. L., Karam, J. A., Kavanagh, B. D., Tang, C., Komaki, R., Louie, A. V., Palma, D. A., Tsao, A. S., Sepesi, B., William, W. N., Zhang, J., Shi, Q., Wang, X. S., Swisher, S. G., Heymach, J. V.. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non- small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol; Dec 2016. a. La certezza nelle prove è stata abbassata per rischio di selection bias. b. La certezz

=== Intervention Extract 662 (Therapy) ===
, Palma, D. A., Tsao, A. S., Sepesi, B., William, W. N., Zhang, J., Shi, Q., Wang, X. S., Swisher, S. G., Heymach, J. V.. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non- small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol; Dec 2016. a. La certezza nelle prove è stata abbassata per rischio di selection bias. b. La certezza nelle prove è stata abbassata per imprecisione, dovuta al basso numero di eventi. c. La certezza nelle prove è stata abbassata pe

=== Intervention Extract 663 (Therapy) ===
TIBILITÀ|||||||
Row 9: ||||||| Row 1: |
Row 2: |
Row 3: |
Row 4: |on't know
Row 5: |Don't know Row 1: 
Row 2: 
Row 3:  Row 1: Certainty assessment|||||||№ of patients||Effect|||
Row 2: |||||||(Q6)a first|chemotherapy||||
Row 3: |||||||||||Certainty|Importance
Row 4: № of|Study|Risk of||||Other|line therapy||Relative|Absolute||
Row 5: |||Inconsistency|Indirectness|Imprecision|||||||
Row 6: studies|design|bias||||considerations|with||(95% CI)|(95% CI)||
Row 7: ||||||||||||
Row 8: |||||||crizotinib|||||
Row 9: Progression free survival - Landi L. et al (METROS)||||||||||||
Row 10: ||||||||||||
Row 11: 1

=== Intervention Extract 664 (Therapy) ===
PROVE|CONSIDERAZIONI AGGIUNTIVE|
Row 12: ○ Irrilevanti ○ Piccoli ○ Moderati X Grandi ○ Variano ○ Non so||Outcomes Anticipated absolute effects* Relative № of Certainty of Comments (95% CI) effect participants the evidence (95% (studies) (GRADE) Risk with Risk with CI) chemotherapy (Q6)a first li e therapy with crizotinib Progression free survival - Study population not 26 ⨁◯◯◯ Landi L. et al (METROS) estimable (1 VERY LOWa,b 0 per 1.000 0 per 1.000 observational (0 to 0) study) Progression-free survival - - - - - - Shaw A.T. et al - not reported|| Row 1: |||||||||
Row 2: Outcomes||Anticipated absolu

=== Intervention Extract 665 (Therapy) ===
||
Row 2: Outcomes||Anticipated absolute effects*||||Relative effect (95% CI)|№ of participants (studies)|Certainty of the evidence (GRADE)|Comments
Row 3: ||(95% CI)|||||||
Row 4: |||||||||
Row 5: |||||||||
Row 6: |Risk with chemotherapy|||Risk with|||||
Row 7: ||||(Q6)a first|||||
Row 8: ||||li e therapy|||||
Row 9: ||||with|||||
Row 10: ||||crizotinib|||||
Row 11: |||||||||
Row 12: Progression free survival - Landi L. et al (METROS)||||||not estimable|26 (1 observational study)|⨁◯◯◯ VERY LOWa,b|
Row 13: ||Study population|||||||
Row 14: |||||||||
Row 15: |||||||||
Row 16: |0 per 1.000|||0 per 1.00

=== Intervention Extract 666 (Therapy) ===
per 1.000
Row 14: ||
Row 15: Progression-free survival - Shaw A.T. et al - not reported||
Row 16: |-|-
Row 17: || Row 1: |||||
Row 2: d absolute effects*||||Relat effect (95% CI)|Relat
Row 3: |||||effect
Row 4: |||||(95%
Row 5: |||||
Row 6: ||Risk with|||CI)
Row 7: apy||(Q6)a first|||
Row 8: ||li e therapy|||
Row 9: ||with|||
Row 10: ||crizotinib|||
Row 11: |||||
Row 12: |||||
Row 13: lation|||||
Row 14: |||||
Row 15: |||||
Row 16: ||0 per 1.000|||
Row 17: ||(0 to 0)|||
Row 18: |||||
Row 19: |||||
Row 20: |-||||
Row 21: ||||| Row 1: |||
Row 2: tive|№ of participants (studies)|Certain the evid (GRAD|C

=== Intervention Extract 667 (Therapy) ===
sed by the NICE checklist. Shaw et al and Landi L. et al studies obtained a score of 8/8 and Maizieres et al. a score of 7/8 because of its retrospective nature. In both studies there was not information about the outcomes stratification 76% of the METROS study population received one prior line of therapy In Shaw A.T et al most of patients (89%) had received at least one previous line of standard therapy for advanced NSCLC and 42% of patients were Asian. In Mazières J et al. most of patients (80.7%) were stage IV and only one patient did not received a previous chemotherapy line| Row 1: Toxicity gra

=== Intervention Extract 668 (Therapy) ===
s et al. a score of 7/8 because of its retrospective nature. In both studies there was not information about the outcomes stratification 76% of the METROS study population received one prior line of therapy In Shaw A.T et al most of patients (89%) had received at least one previous line of standard therapy for advanced NSCLC and 42% of patients were Asian. In Mazières J et al. most of patients (80.7%) were stage IV and only one patient did not received a previous chemotherapy line| Row 1: Toxicity grade >=3 - Mazières J. et al||||-|(1 observational study)|⨁◯◯◯ VERY LOWa,c|
Row 2: ||Authors stated tha

=== Intervention Extract 669 (Therapy) ===
E PROVE|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ Grandi ○ Moderati ○ Piccoli X Irrilevanti ○ Variano ○ Non so||Outcomes Anticipated absolute effects* Relative № of Certainty of Comments (95% CI) effect participants the evidence (95% (studies) (GRADE) Risk with Risk with CI) chemotherapy (Q6)a first line therapy with crizotinib Progression free survival - tudy population not 26 ⨁◯◯◯ Landi L. et al (METROS) estimable (1 VERY LOWa,b 0 per 1.000 0 per 1.000 observational ( 0 to 0) study) Progression-free survival - - - - - - Shaw A.T. et al - not reported Progression-free survival - Study population not 30 ⨁◯

=== Intervention Extract 670 (Therapy) ===
||
Row 2: Outcomes||Anticipated absolute effects*||||Relative effect (95% CI)|№ of participants (studies)|Certainty of the evidence (GRADE)|Comments
Row 3: ||(95% CI)|||||||
Row 4: |||||||||
Row 5: |||||||||
Row 6: |Risk with chemotherapy|||Risk with|||||
Row 7: ||||(Q6)a first|||||
Row 8: ||||line therapy|||||
Row 9: ||||with|||||
Row 10: ||||crizotinib|||||
Row 11: |||||||||
Row 12: Progression free survival - Landi L. et al (METROS)||||||not estimable|26 (1 observational study)|⨁◯◯◯ VERY LOWa,b|
Row 13: ||tudy population|||||||
Row 14: |||||||||
Row 15: |||||||||
Row 16: |0 per 1.000|||0 per 1.000

=== Intervention Extract 671 (Therapy) ===
: ||Study popul
Row 32: ||
Row 33: ||
Row 34: |0 per 1.000|0 per 1.000
Row 35: || Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: |||||
Row 2: d absolute effects*||||Relat effect (95% CI)|Relat
Row 3: |||||effect
Row 4: |||||(95%
Row 5: |||||
Row 6: ||Risk with|||CI)
Row 7: apy||(Q6)a first|||
Row 8: ||line therapy|||
Row 9: ||with|||
Row 10: ||crizotinib|||
Row 11: |||||
Row 12: |||||
Row 13: lation|||||
Row 14: |||||
Row 15: |||||
Row 16: ||0 per 1.000|||
Row 17: ||( 0 to 0)|||
Row 18: |||||
Row 19: |||||
Row 20: |-||||
Row 21: |||||
Row 22: |||||
Row 23: lation|||||
Row 24: |||||
Row 25: |||||
Row 26: ||0

=== Intervention Extract 672 (Therapy) ===
grade 4 or|||
Row 32: ||5 adverse effect. One patient|||
Row 33: ||experienced a grade 3 liver|||
Row 34: ||toxicity, leading to temporary|||
Row 35: ||withdrawal of crizotinib and dose|||
Row 36: ||reduction."|||
Row 37: ||||| Row 1: ||76% of the METROS study population received one prior line of therapy In Shaw A.T et al most of patients (89%) had received at least one previous line of standard therapy for advanced NSCLC and 42% of patients were Asian. In Mazières J et al. most of patients (80.7%) were stage IV and only one patient did not receive a previous chemotherapy line||
Row 2: ||||
Row 3:

=== Intervention Extract 673 (Therapy) ===
w 34: ||toxicity, leading to temporary|||
Row 35: ||withdrawal of crizotinib and dose|||
Row 36: ||reduction."|||
Row 37: ||||| Row 1: ||76% of the METROS study population received one prior line of therapy In Shaw A.T et al most of patients (89%) had received at least one previous line of standard therapy for advanced NSCLC and 42% of patients were Asian. In Mazières J et al. most of patients (80.7%) were stage IV and only one patient did not receive a previous chemotherapy line||
Row 2: ||||
Row 3: |Qualità delle prove|||
Row 4: |Qual è la qualità complessiva delle prove di efficacia e sicurezza?||

=== Intervention Extract 674 (Therapy) ===
lto bassa ○ Bassa ○ Moderata ○ Alta ○ Nessuno studio incluso||La certezza delle prove è stata giudicata MOLTO BASSA per rischio di bias e indirectness|| Row 1: |
Row 2: |Qualità delle pr
Row 3: |Qual è la qualità comples
Row 4: | Row 1: |76% of the METROS study population received one prior line of therapy In Shaw A.T et al most of patients (89%) had received at least one previous line of standard therapy for advanced NSCLC and 42% of patients were Asian. In Mazières J et al. most of patients (80.7%) were stage IV and only one patient did not receive a previous chemotherapy line|
Row 2: ||
Row 3: rov

=== Intervention Extract 675 (Therapy) ===
ta MOLTO BASSA per rischio di bias e indirectness|| Row 1: |
Row 2: |Qualità delle pr
Row 3: |Qual è la qualità comples
Row 4: | Row 1: |76% of the METROS study population received one prior line of therapy In Shaw A.T et al most of patients (89%) had received at least one previous line of standard therapy for advanced NSCLC and 42% of patients were Asian. In Mazières J et al. most of patients (80.7%) were stage IV and only one patient did not receive a previous chemotherapy line|
Row 2: ||
Row 3: rove||
Row 4: ssiva delle prove di efficacia e sicurezza?||
Row 5: || Row 1: RICERCA DELLE PROVE
Row 2:

=== Intervention Extract 676 (Therapy) ===
med death 1 (PD-1) and its ligand PD-L1 are effective therapies for metastatic non–small-cell lung cancer (NSCLC) lacking sensitizing EGFR or ALK mutations. Pembrolizumab (Keytruda, Merck), nivolumab (Opdivo, Bristol-Myers Squibb), and atezolizumab (Tecentriq, Genentech) are approved as second-line therapy. [...]| Row 1: X Yes ○ Varies ○ Don't know||Because patients with advanced NSCLC can undergo rapid clinical deterioration during disease progression, less than one half of patients with advanced NSCLC ever receive second-line therapy.1,2 First-line combination regimens that include a PD-1 or PD-L1

=== Intervention Extract 677 (Therapy) ===
d atezolizumab (Tecentriq, Genentech) are approved as second-line therapy. [...]| Row 1: X Yes ○ Varies ○ Don't know||Because patients with advanced NSCLC can undergo rapid clinical deterioration during disease progression, less than one half of patients with advanced NSCLC ever receive second-line therapy.1,2 First-line combination regimens that include a PD-1 or PD-L1 inhibitor may maximize the chance of response and lead to prolonged survival. Modulation of the immune response through PD-1 inhibition may be enhanced by the potential immunogenic effects of cytotoxic chemotherapy. Gandhi L. et al. N

=== Intervention Extract 678 (Therapy) ===
tia
Row 4: | Row 1: 
Row 2: e effec
Row 3: al are the d
Row 4:  Row 1: 
Row 2: cts
Row 3: desirable a
Row 4:  Row 1: |Because patients with advanced NSCLC can undergo rapid clinical deterioration during disease progression, less than one half of patients with advanced NSCLC ever receive second-line therapy.1,2 First-line combination regimens that include a PD-1 or PD-L1 inhibitor may maximize the chance of response and lead to prolonged survival. Modulation of the immune response through PD-1 inhibition may be enhanced by the potential immunogenic effects of cytotoxic chemotherapy. Gandhi L. et al. N

=== Intervention Extract 679 (Therapy) ===
6 AEs, 3 patients withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients withdrawal, 3 physician decision, 2 new

=== Intervention Extract 680 (Therapy) ===
nical progression; 166 patients discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression;| Row 1: Grade 3-5 any AEs||||||RR 1.06 (0.94 to 1.19)|728 (2 RCTs)|⨁◯◯◯ VERY LOWa,c,d,f,g,h,i|
Row 2: ||Study population|||||||
Row 3: |||||||||
Row 4: |||||||||
Row 5: |56 per 100|||60 per 100|||||
Row 6: ||||(53 to 67)|||||
Row 7: |||||||||
Row 8: Discontinuation rate

=== Intervention Extract 681 (Therapy) ===
6 AEs, 3 patients withdrawal, 2 physician decision, 1 use of excluded medication. KEYNOTE 189 study: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 150 radiographic PD, 78 AEs, 16 patients withdrawal, 9 physician decision, 4 new anticancer therapy and 11 clinical progression; 166 patients discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients withdrawal, 3 physician decision, 2 new

=== Intervention Extract 682 (Therapy) ===
nical progression; 166 patients discontinued treatment in the CHT alone arm for the following reasons: 268 patients discontinued treatment in the Pembrolizumab combination treatment for the following reasons: 119 radiographic PD, 21 AEs, 8 patients withdrawal, 3 physician decision, 2 new anticancer therapy and 13 clinical progression; k. in KEYNOTE-189 study information for this outcome were showed in the overall population and not according to PD-L1 tumour proportion score| Row 1: Discontinuation rate of any treatment componentj|||||RR 0.80 (0.73 to 0.88)|739 (2 RCTs)|⨁◯◯◯ VERY LOWa,c,d,i,k|
Row 2:

=== Intervention Extract 683 (Therapy) ===
|||Strong recommendation
Row 3: |||for the intervention
Row 4: |||
Row 5: |||●
Row 6: ||| Row 1: 
Row 2: Recommendation
Row 3:  Row 1: ||||||||||||
Row 2: Quality assessment|||||||No of patients||Effect|||
Row 3: |||||||||||Quality|Importance
Row 4: ||||||||||||
Row 5: No of||||||Other|Maintenance therapy||Relative|||
Row 6: |Design|Risk of bias|Inconsistency|Indirectness|Imprecision|||Placebo||Absolute||
Row 7: studies||||||considerations|with pemetrexed||(95% CI)|||
Row 8: ||||||||||||
Row 9: Overall Survival (follow-up median 12.5 months; assessed with: not rilevant )||||||||||||
Row 10: 1|random

=== Intervention Extract 684 (Therapy) ===
lues)||||||||||||
Row 16: 1|randomised trials|serious10|no serious inconsistency|no serious indirectness|serious11|none|98|36|-|SMD 0.04 lower (0.42 lower to 0.34 higher)12|LOW|CRITICAL3 Row 1: |||||||
Row 2: Quality assessment|||||||No of patients
Row 3: |||||||
Row 4: No of||||||Other|Maintenance therapy
Row 5: |Design|Risk of bias|Inconsistency|Indirectness|Imprecision||
Row 6: studies||||||considerations|with pemetrexed
Row 7: |||||||
Row 8: Overall Survival (follow-up median 12.5 months; assessed with: not rilevant )|||||||
Row 9: 1|randomised trials|no serious risk of bias|no serious inconsiste

=== Intervention Extract 685 (Therapy) ===
boratory measure)||||||||||||
Row 18: 1|randomised trials|no serious risk of bias|no serious inconsistency|no serious indirectness|no serious imprecision8|none|22/359 (6.1%)15|1/180 (0.56%)15|RR 11.03 (1.5 to 81.18)9|6 more per 100 (from 0 more to 45 more)|HIGH|IMPORTANT Row 1: Dovrebbe maintenance therapy with pemetrexed vs placebo essere utilizzato per advanced NSCLC||
Row 2: ||
Row 3: POPOLAZIONE:||Advanced NSCLC
Row 4: ||
Row 5: INTERVENTO:||Maintenance therapy with pemetrexed
Row 6: ||
Row 7: CONFRONTO:||Placebo
Row 8: ||
Row 9: ESITI PRINCIPALI:||Overall Survival; Progression free survival; Obj

=== Intervention Extract 686 (Therapy) ===
/359 (6.1%)15|1/180 (0.56%)15|RR 11.03 (1.5 to 81.18)9|6 more per 100 (from 0 more to 45 more)|HIGH|IMPORTANT Row 1: Dovrebbe maintenance therapy with pemetrexed vs placebo essere utilizzato per advanced NSCLC||
Row 2: ||
Row 3: POPOLAZIONE:||Advanced NSCLC
Row 4: ||
Row 5: INTERVENTO:||Maintenance therapy with pemetrexed
Row 6: ||
Row 7: CONFRONTO:||Placebo
Row 8: ||
Row 9: ESITI PRINCIPALI:||Overall Survival; Progression free survival; Objective responce rate; Quality of life -EQ-5D; Quality of life -VAS; Severe Toxicity (Non laboratory); Fatigue grade 3-4; transfusion; G-CSF ; Anemia grade 3-4; Ne

=== Intervention Extract 687 (Therapy) ===
: ||
Row 17: CONFLITTI DI||
Row 18: INTERESSE||
Row 19: || Row 1: ||
Row 2: Problema Il problema è una priorità?||
Row 3: ||
Row 4: GIUDIZI|RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE
Row 5: ○ No ○ Probabilmente no ○ Probabilmente si ● Si ○ Varia ○ Non so|| Row 1: Dovrebbe maintenance therapy with pemetrexed vs placebo essere utiliz|
Row 2: |
Row 3: POPOLAZIONE:|
Row 4: |
Row 5: INTERVENTO:|
Row 6: |
Row 7: CONFRONTO:|
Row 8: |
Row 9: ESITI PRINCIPALI:| Row 1: |
Row 2: SETTING:|
Row 3: |
Row 4: PROSPETTIVA:|
Row 5: |
Row 6: BACKGROUND:|
Row 7: |
Row 8: CONFLITTI DI|
Row 9: INTERESSE|
Ro

=== Intervention Extract 688 (Therapy) ===
n = 539) venivano randomizzati (2:1) a ricevere pemetrexed (500 mg/mq e.v. g.1 ogni tre settimane) + BSC o placebo + BSC Esiti Effetto assoluto Effetto № dei Certezza Commenti anticipato* (95% CI) relativo partecipanti delle prove (95% (studi) (GRADE) Rischio Rischio con CI) con maintenance placebo therapy with pemetrexed Overall Popolazione in studio HR 539 ⨁⨁⨁⨁ Survival (OS) 0.78 (1 RCT) ALTA valutato con: 78 per 69 per 100 (0.64 a not rilevant 100 (62 a 76) 0.96) follow up: mediana 12.5 m esi Popolazione in studio|| Row 1: |||||||||
Row 2: Esiti||Effetto assoluto||||Effetto relativo (95% CI)|№ dei

=== Intervention Extract 689 (Therapy) ===
Row 1: |||||||||
Row 2: Esiti||Effetto assoluto||||Effetto relativo (95% CI)|№ dei partecipanti (studi)|Certezza delle prove (GRADE)|Commenti
Row 3: ||anticipato* (95% CI)|||||||
Row 4: |||||||||
Row 5: |||||||||
Row 6: |Rischio con placebo|||Rischio con|||||
Row 7: ||||maintenance|||||
Row 8: ||||therapy with|||||
Row 9: ||||pemetrexed|||||
Row 10: |||||||||
Row 11: Overall Survival (OS) valutato con: not rilevant follow up: mediana 12.5 m esi||||||HR 0.78 (0.64 a 0.96)|539 (1 RCT)|⨁⨁⨁⨁ ALTA|
Row 12: ||Popolazione in studio|||||||
Row 13: |||||||||
Row 14: |||||||||
Row 15: |78 per 100||69 per 100

=== Intervention Extract 690 (Therapy) ===
n = 539) venivano randomizzati (2:1) a ricevere pemetrexed (500 mg/mq e.v. g.1 ogni tre settimane) + BSC o placebo + BSC Esiti Effetto assoluto Effetto № dei Certezza Commenti anticipato* (95% CI) relativo partecipanti delle prove (95% (studi) (GRADE) Rischio Rischio con CI) con maintenance placebo therapy with pemetrexed Overall Popolazione in studio HR 539 ⨁⨁⨁⨁ Survival (OS) 0.78 (1 RCT) ALTA valutato con: 78 per 69 per 100 (0.64 a not rilevant 100 (62 a 76) 0.96) follow up: mediana 12.5 m esi Popolazione in studio Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: |Progress

=== Intervention Extract 691 (Therapy) ===
= 539) venivano randomizzati (2:1) a ricevere pemetrexed (500 mg/mq e.v. g.1 ogni tre settimane) + BSC o placebo + BSC. Esiti Effetto assoluto Effetto № dei Certezza Commenti anticipato* (95% CI) relativo partecipanti delle prove (95% (studi) (GRADE) Rischio Rischio con CI) con maintenance placebo therapy with pemetrexed Severe Popolazione in studio RR 539 ⨁⨁⨁⨁ Toxicity (Non 2.51 (1 RCT) ALTA laboratory) 3 per 8 per 100 (1.06 a (ST) 100 (4 a 20) 5.91) valutato con: N° Patient hospitalized because of drug related adverse events follow up: mediana 12.5 mesi Popolazione in studio| Row 1: |||||||||
Row

=== Intervention Extract 692 (Therapy) ===
Row 1: |||||||||
Row 2: Esiti||Effetto assoluto||||Effetto relativo (95% CI)|№ dei partecipanti (studi)|Certezza delle prove (GRADE)|Commenti
Row 3: ||anticipato* (95% CI)|||||||
Row 4: |||||||||
Row 5: |||||||||
Row 6: |Rischio con placebo|||Rischio con|||||
Row 7: ||||maintenance|||||
Row 8: ||||therapy with|||||
Row 9: ||||pemetrexed|||||
Row 10: |||||||||
Row 11: Severe Toxicity (Non laboratory) (ST) valutato con: N° Patient hospitalized because of drug related adverse events follow up: mediana 12.5 mesi||||||RR 2.51 (1.06 a 5.91)|539 (1 RCT)|⨁⨁⨁⨁ ALTA|
Row 12: ||Popolazione in studio|||||||
Row

=== Intervention Extract 693 (Therapy) ===
|||
Row 2: Esiti||Effetto assoluto||||Effetto relativo (95% CI)|№ dei partecipanti (studi)|Certezza delle prove (GRADE)|Commenti|Commenti
Row 3: ||anticipato* (95% CI)||||||||
Row 4: ||||||||||
Row 5: ||||||||||
Row 6: |Rischio con placebo|||Rischio con||||||
Row 7: ||||maintenance||||||
Row 8: ||||therapy with||||||
Row 9: ||||pemetrexed||||||
Row 10: ||||||||||
Row 11: Severe Toxicity (Non laboratory) (ST) valutato con: N° Patient hospitalized because of drug related adverse events follow up: mediana 12.5 mesi||||||RR 2.51 (1.06 a 5.91)|539 (1 RCT)|⨁⨁⨁⨁ ALTA||
Row 12: ||Popolazione in studio|||||||

=== Intervention Extract 694 (Therapy) ===
onata contro l’intervento ○|Raccomandazione condizionata a favore dell’intervento X|Raccomandazione forte a favore dell’intervento ○ Row 1: ||
Row 2: |Raccomandazione|
Row 3: || Row 1: |
Row 2: |Raccomandazione
Row 3: | Row 1: |
Row 2: |
Row 3: | Row 1: (((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[

=== Intervention Extract 695 (Therapy) ===
te a favore dell’intervento ○ Row 1: ||
Row 2: |Raccomandazione|
Row 3: || Row 1: |
Row 2: |Raccomandazione
Row 3: | Row 1: |
Row 2: |
Row 3: | Row 1: (((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
Row 5: cancer"[Title/Abstract] OR "Non-small-cell lung carcinom

=== Intervention Extract 696 (Therapy) ===
rolled Trial" [Publication Type]) OR "Randomized Controlled Trials as
Row 13: Topic"[Mesh]) OR ("Clinical Trial" [Publication Type])) OR (randomized[Title/Abstract] OR
Row 14: randomised[Title/Abstract] OR randomly[Title/Abstract])))))) Row 1: (((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
Row 4: neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
Row 5: c

=== Intervention Extract 697 (Therapy) ===
al Trial" [Publication Type])) OR (randomized[Title/Abstract] OR
Row 14: randomised[Title/Abstract] OR randomly[Title/Abstract])))))) Row 1: (((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
Row 4: neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
Row 5: cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-small-cell lung
Row 6: c

=== Intervention Extract 698 (Therapy) ===
le/Abstract])))))) OR ("grade I"[Title/Abstract] OR
Row 6: "grade II"[Title/Abstract] OR "stage I"[Title/Abstract] OR "stage II"[Title/Abstract])))))) AND "radical
Row 7: surgery")) AND (((((((("Randomized Controlled Trial" [Publication Type]) OR "Clinical Trial" [Publication
Row 8: Type]) OR "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR
Row 9: randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] OR
Row 10: trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND
Row 11: "Humans"[Mesh]))) Row 1: (((((((((((((((((( "Carcino

=== Intervention Extract 699 (Therapy) ===
zed[Title/Abstract] OR
Row 9: randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract] OR
Row 10: trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND
Row 11: "Humans"[Mesh]))) Row 1: (((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcino
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
Row 4: neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
Row 5: cancer"[Title/Abstr

=== Intervention Extract 700 (Therapy) ===
R randomly[Title/Abstract] OR
Row 10: trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND
Row 11: "Humans"[Mesh]))) Row 1: (((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcino
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
Row 4: neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
Row 5: cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-sm
Row 6: carcinoma"[Tit

=== Intervention Extract 701 (Therapy) ===
5: AND ((("grade IA"[Title/Abstract] OR "stage IA"[Title/Abstract])))))) OR ("grade I"[T
Row 6: "grade II"[Title/Abstract] OR "stage I"[Title/Abstract] OR "stage II"[Title/Abstract]))))
Row 7: surgery")) AND (((((((("Randomized Controlled Trial" [Publication Type]) OR "Clinic
Row 8: Type]) OR "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR
Row 9: randomised[Title/Abstract] OR placebo[Title/Abstract] OR randomly[Title/Abstract]
Row 10: trial[Title/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mes
Row 11: "Humans"[Mesh]))) Row 1: (((((lung
Row 2: ract]) OR lung
Row 3

=== Intervention Extract 702 (Therapy) ===
tle/Abstract] OR groups OR)))) NOT ((("Animals"[Mesh]) NOT "Animals"[Mes
Row 11: "Humans"[Mesh]))) Row 1: (((((lung
Row 2: ract]) OR lung
Row 3: ung
Row 4: C*[Title/Abstract])
Row 5: itle/Abstract] OR
Row 6: ))) AND "radical
Row 7: cal Trial" [Publica Row 1: OR
Row 2: sh]) AND Row 1: (("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
Row 2: "neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
Row 3: "neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
Row 4: ("drug"[All Fie

=== Intervention Extract 703 (Therapy) ===
OT "Animals"[Mes
Row 11: "Humans"[Mesh]))) Row 1: (((((lung
Row 2: ract]) OR lung
Row 3: ung
Row 4: C*[Title/Abstract])
Row 5: itle/Abstract] OR
Row 6: ))) AND "radical
Row 7: cal Trial" [Publica Row 1: OR
Row 2: sh]) AND Row 1: (("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
Row 2: "neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
Row 3: "neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
Row 4: ("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fi

=== Intervention Extract 704 (Therapy) ===
w 1: (((((lung
Row 2: ract]) OR lung
Row 3: ung
Row 4: C*[Title/Abstract])
Row 5: itle/Abstract] OR
Row 6: ))) AND "radical
Row 7: cal Trial" [Publica Row 1: OR
Row 2: sh]) AND Row 1: (("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
Row 2: "neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
Row 3: "neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
Row 4: ("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All
Row 5: Fields]

=== Intervention Extract 705 (Therapy) ===
Row 2: sh]) AND Row 1: (("neoadjuvant therapy"[MeSH Terms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
Row 2: "neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
Row 3: "neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
Row 4: ("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All
Row 5: Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All
Row 6: Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR

=== Intervention Extract 706 (Therapy) ===
ms] OR ("neoadjuvant"[All Fields] AND "therapy"[All Fields]) OR
Row 2: "neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
Row 3: "neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
Row 4: ("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All
Row 5: Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All
Row 6: Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR "resectates"[All Fields] OR
Row 7: "resected"[All Field

=== Intervention Extract 707 (Therapy) ===
s] AND "therapy"[All Fields]) OR
Row 2: "neoadjuvant therapy"[All Fields] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
Row 3: "neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
Row 4: ("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All
Row 5: Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All
Row 6: Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR "resectates"[All Fields] OR
Row 7: "resected"[All Fields] OR "resecting"[All Fields] O

=== Intervention Extract 708 (Therapy) ===
lds] OR "neoadjuvant"[All Fields] OR "neoadjuvants"[All Fields] OR
Row 3: "neoadjuvent"[All Fields]) AND ("chemotherapy s"[All Fields] OR "drug therapy"[MeSH Terms] OR
Row 4: ("drug"[All Fields] AND "therapy"[All Fields]) OR "drug therapy"[All Fields] OR "chemotherapies"[All
Row 5: Fields] OR "drug therapy"[MeSH Subheading] OR "chemotherapy"[All Fields]) AND ("resect"[All
Row 6: Fields] OR "resectability"[All Fields] OR "resectable"[All Fields] OR "resectates"[All Fields] OR
Row 7: "resected"[All Fields] OR "resecting"[All Fields] OR "resection"[All Fields] OR "resectional"[All Fields]
Row 8: OR "res

=== Intervention Extract 709 (Therapy) ===
*[Title/Abstract]) OR NSCLC*[Title/Abstract])))))))
Row 5: AND (((grade iii OR stage iii OR advance OR locally advanced disease)) AND (inoperable OR
Row 6: surgically unresectable)))))) AND "Antineoplastic Combined Chemotherapy Protocols"[Mesh] Row 1: (((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[

=== Intervention Extract 710 (Therapy) ===
locally advanced disease)) AND (inoperable OR
Row 6: surgically unresectable)))))) AND "Antineoplastic Combined Chemotherapy Protocols"[Mesh] Row 1: (((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
Row 5: cancer"[Title/Abstract] OR "Non-small-cell lung carcinom

=== Intervention Extract 711 (Therapy) ===
ancer*[Title/Abstract]) OR NSCLC*[Title/Abstract]))
Row 5: AND (((grade iii OR stage iii OR advance OR locally advanced disease)) AND (inoperable OR
Row 6: surgically unresectable)))))) AND "Antineoplastic Combined Chemotherapy Protocols"[Mesh] Row 1: (((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "L
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstr
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstr

=== Intervention Extract 712 (Therapy) ===
OR locally advanced disease)) AND (inoperable OR
Row 6: surgically unresectable)))))) AND "Antineoplastic Combined Chemotherapy Protocols"[Mesh] Row 1: (((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "L
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstr
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell l
Row 5: cancer"[Title/Abstract] OR "Non-small-cell lung carcinoma"[Title/A

=== Intervention Extract 713 (Therapy) ===
on-small-cell lung carcinoma"[Title/Abstract] OR "Non small cell l
Row 6: carcinoma"[Title/Abstract)) OR NSCLC[Title/Abstract])))))))))))))))) AND "durvalumab" [Supplemen Row 1: -Cell
Row 2: Lung
Row 3: ract]
Row 4: lung
Row 5: lung
Row 6: ntary Row 1: ((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[

=== Intervention Extract 714 (Therapy) ===
R NSCLC[Title/Abstract])))))))))))))))) AND "durvalumab" [Supplemen Row 1: -Cell
Row 2: Lung
Row 3: ract]
Row 4: lung
Row 5: lung
Row 6: ntary Row 1: ((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
Row 5: cancer"[Title/Abstract] OR "Non-small-cell lung carcinom

=== Intervention Extract 715 (Therapy) ===
ow 7: Controlled Trial"[Publication Type]) OR "Randomized Controlled Trials as Topic"[Mesh]) OR ("Clinical
Row 8: Trial" [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 9: randomly[Title/Abstract])))))))) Row 1: ((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[

=== Intervention Extract 716 (Therapy) ===
cal
Row 8: Trial" [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 9: randomly[Title/Abstract])))))))) Row 1: ((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
Row 5: cancer"[Title/Abstract] OR "Non-small-cell lung carcinom

=== Intervention Extract 717 (Therapy) ===
12: Controlled Trial"[Publication Type]) OR "Randomized Controlled Trials as Topic"[Mesh]) OR ("Clinical
Row 13: Trial" [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 14: randomly[Title/Abstract])))))))) Row 1: ((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[

=== Intervention Extract 718 (Therapy) ===
l
Row 13: Trial" [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 14: randomly[Title/Abstract])))))))) Row 1: ((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-Cell
Row 2: Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung neoplasms"[Title/Abstract]
Row 4: OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung cancer"[Title/Abstract] OR "Non small cell lung
Row 5: cancer"[Title/Abstract] OR "Non-small-cell lung carcinom

=== Intervention Extract 719 (Therapy) ===
ow 4: Trial"[Publication Type]) OR "Randomized Controlled Trials as Topic"[Mesh]) OR ("Clinical Trial"
Row 5: [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 6: randomly[Title/Abstract])))))))) Row 1: (((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-
Row 2: Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
Row 4: neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
Row 5:

=== Intervention Extract 720 (Therapy) ===
ow 5: [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 6: randomly[Title/Abstract])))))))) Row 1: (((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Small-
Row 2: Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
Row 4: neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
Row 5: cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-small-cell lung
Row 6: c

=== Intervention Extract 721 (Therapy) ===
ncept]) OR "amivantamab-vmjw" [Supplementary
Row 10: Concept]) OR "lorlatinib" [Supplementary Concept]) OR (capmatinib[Title/Abstract] OR
Row 11: tepotinib[Title/Abstract] OR amivantamab[Title/Abstract] OR lorlatinib[Title/Abstract])) Row 1: (((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Sm
Row 2: Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
Row 4: neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
Row 5: canc

=== Intervention Extract 722 (Therapy) ===
t]) OR (capmatinib[Title/Abstract] OR
Row 11: tepotinib[Title/Abstract] OR amivantamab[Title/Abstract] OR lorlatinib[Title/Abstract])) Row 1: (((((((((((((((((((( "Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-Sm
Row 2: Cell Lung/pathology"[Mesh] )) OR ( "Lung Neoplasms/drug therapy"[Mesh] OR "Lung
Row 3: Neoplasms/pathology"[Mesh] ))) OR (("lung cancer"[Title/Abstract] OR "lung
Row 4: neoplasms"[Title/Abstract] OR "lung tumor"[Title/Abstract] OR "Non-small-cell lung
Row 5: cancer"[Title/Abstract] OR "Non small cell lung cancer"[Title/Abstract] OR "Non-small-cell lung
Row 6: c

=== Intervention Extract 723 (Therapy) ===
AND (expression[Title/Abstract] OR antibody[Title/Abstract] OR
Row 9: diagnostic*[Title/Abstract] OR testing[Title/Abstract]))))) AND (((("pembrolizumab" [Supplementary
Row 10: Concept]) OR (Ambrolizumab[Title/Abstract] OR Keytruda[Title/Abstract] OR MK- Row 1: 3475[Title/Abstract]))) OR (((( "Drug Therapy/therapeutic use"[Mesh] OR "Drug
Row 2: Therapy/therapy"[Mesh] ))) OR (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abstract] OR
Row 3: Chemotherapies[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta-
Row 4: Analysis"[Publication Type]) OR "meta-analysis[Title]

=== Intervention Extract 724 (Therapy) ===
le/Abstract] OR
Row 9: diagnostic*[Title/Abstract] OR testing[Title/Abstract]))))) AND (((("pembrolizumab" [Supplementary
Row 10: Concept]) OR (Ambrolizumab[Title/Abstract] OR Keytruda[Title/Abstract] OR MK- Row 1: 3475[Title/Abstract]))) OR (((( "Drug Therapy/therapeutic use"[Mesh] OR "Drug
Row 2: Therapy/therapy"[Mesh] ))) OR (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abstract] OR
Row 3: Chemotherapies[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta-
Row 4: Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR "meta
Row 5: a

=== Intervention Extract 725 (Therapy) ===
act] OR
Row 9: diagnostic*[Title/Abstract] OR testing[Title/Abstract]))))) AND (((("pembrolizumab" [Supplementary
Row 10: Concept]) OR (Ambrolizumab[Title/Abstract] OR Keytruda[Title/Abstract] OR MK- Row 1: 3475[Title/Abstract]))) OR (((( "Drug Therapy/therapeutic use"[Mesh] OR "Drug
Row 2: Therapy/therapy"[Mesh] ))) OR (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abstract] OR
Row 3: Chemotherapies[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta-
Row 4: Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR "meta
Row 5: analy*"[T

=== Intervention Extract 726 (Therapy) ===
domized Controlled
Row 7: Trial"[Publication Type]) OR "Randomized Controlled Trials as Topic"[Mesh]) OR ("Clinical Trial"
Row 8: [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 9: randomly[Title/Abstract])))))))) Row 1: 3475[Title/Abstract]))) OR (((( "Drug Therapy/therapeutic use"[Mesh] OR "Drug
Row 2: Therapy/therapy"[Mesh] ))) OR (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abs
Row 3: Chemotherapies[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta
Row 4: Analysis"[Publication Type]) OR "meta-analysis[Title] OR system

=== Intervention Extract 727 (Therapy) ===
pe]) OR "Randomized Controlled Trials as Topic"[Mesh]) OR ("Clinical Trial"
Row 8: [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 9: randomly[Title/Abstract])))))))) Row 1: 3475[Title/Abstract]))) OR (((( "Drug Therapy/therapeutic use"[Mesh] OR "Drug
Row 2: Therapy/therapy"[Mesh] ))) OR (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abs
Row 3: Chemotherapies[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta
Row 4: Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR "meta
Row 5: analy*"[Tit

=== Intervention Extract 728 (Therapy) ===
"Randomized Controlled Trials as Topic"[Mesh]) OR ("Clinical Trial"
Row 8: [Publication Type])) OR (randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 9: randomly[Title/Abstract])))))))) Row 1: 3475[Title/Abstract]))) OR (((( "Drug Therapy/therapeutic use"[Mesh] OR "Drug
Row 2: Therapy/therapy"[Mesh] ))) OR (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abs
Row 3: Chemotherapies[Title/Abstract]))))) AND (((((((((((("Meta-Analysis as Topic"[Mesh]) OR "Meta
Row 4: Analysis"[Publication Type]) OR "meta-analysis[Title] OR systematic review"[Title] OR "meta
Row 5: analy*"[Title] OR "

=== Intervention Extract 729 (Therapy) ===
[Title/Abstract] OR
Row 27: Taxol[Title/Abstract] OR “Taxol A”[Title/Abstract] OR “Bris Taxol”[Title/Abstract] OR “Taxol, Row 1: Praxel[Title/Abstract] OR Onxol[Title/Abstract] OR vinorelbina[Title/Abstract] OR
Row 2: Navelbine[Title/Abstract] OR “Vinorelbine Tartrate”[Title/Abstract]))) OR (("Drug Therapy"[Mesh]) OR
Row 3: (“Drug Therapies”[Title/Abstract] OR Chemotherapy[Title/Abstract] OR Chemotherapies[Title/Abstrac
Row 4: OR Pharmacotherapy[Title/Abstract] OR Pharmacotherapies[Title/Abstract]))))) AND
Row 5: ((("Etoposide"[Mesh]) OR (Eposide[Title/Abstract] OR “Demethyl Epipodophyllotoxin Ethyli

=== Intervention Extract 730 (Therapy) ===
“Oat Cell Carcinoma of Lung”[Title/Abstract]))))) AND ((("etoposide"[MeSH
Row 4: Terms] OR "etoposide"[All Fields]) AND (("platinum"[MeSH Terms] OR "platinum"[All Fields]))))) AND
Row 5: ((((((("Randomized Controlled Trial" [Publication Type]) OR "Clinical Trial" [Publication Type]) OR
Row 6: "drug therapy" [Subheading])) OR ((randomized[Title/Abstract] OR randomised[Title/Abstract] OR
Row 7: placebo[Title/Abstract] OR randomly[Title/Abstract] OR trial[Title/Abstract] OR groups OR)))) NOT
Row 8: ((("Animals"[Mesh]) NOT "Animals"[Mesh]) AND "Humans"[Mesh])) Row 1: (((("Small Cell Lung Carcinoma"[Mesh]

=== Intervention Extract 731 (Dose) ===
ncidenza e della mortalità
associate al tumore polmonare, confermando il ruolo predominante della prevenzione primaria nella lotta
contro questa neoplasia. Il National Lung Screening Trial (NLST) è stato il primo studio a dimostrare come la diagnosi precoce di
tumore polmonare con TC torace a bassa dose (LDCT) annuale in soggetti ad alto rischio (55-74 anni, fumatori
o ex-fumatori entro 15 anni dall’arruolamento) determini una riduzione del 20% della mortalità associata a tale
neoplasia, rispetto alla radiografia standard del torace (15). Una recente sottoanalisi di questo studio ha inoltre
dimost

=== Intervention Extract 732 (Dose) ===
adiation
Therapy - SBRT o Stereotactic Ablative Radiotherapy - SABR) consente di ottenere risultati migliori rispetto
alla radioterapia convenzionale. La SBRT si caratterizza per la somministrazione di dosi biologicamente molto
elevate in una o poche frazioni, mediante tecniche ad alto gradiente di dose, ed è in grado di ottenere percentuali
di controllo di malattia elevate, in assenza di tossicità importanti.
È stata eseguita una ricerca bibliografica della letteratura sulle banche dati Medline ed Embase. Dopo la
rimozione dei duplicati e l’acquisizione dei full-text 2 studi sono stati inclusi (v

=== Intervention Extract 733 (Dose) ===
l profilo di tollerabilità, eventi avversi di grado 3 o 4 si sono registrati nel
23% dei pazienti trattati con osimertinib (prevalentemente diarrea, paronichia e secchezza cutanea) e nel 14%
dei pazienti trattati con placebo. Nel braccio osimertinib i tassi di interruzione del farmaco, riduzione di dose
e discontinuazione definitiva sono stati rispettivamente del 27%, 12% e 13% (186). I dati di sopravvivenza
globale dello studio ADAURA sono stati pubblicati sul New England Journal of Medicine nel 2023. Tra i
pazienti con stadio II-IIIA, la percentuale di pazienti vivi a 5 anni è risultata dell’85%

=== Intervention Extract 734 (Dose) ===
gata alle
radiazioni e procedure diagnostiche per falsi positivi). Si ritiene quindi opportuno suggerire l’interruzione del
follow-up radiologico al 5° anno. Qualora, nel singolo centro o per pazienti a rischio si decida di proseguire il
follow-up con la TC, si consiglia l’utilizzo della TC a bassa dose senza mdc. La durata del periodo di follow-up specialistico può essere variabile a seconda delle condizioni del paziente e
di specifici accordi tra specialisti e medici di assistenza primaria. Nella maggior parte delle situazioni si ritiene
che possa essere limitato ai primi 5 anni successivi al tr

=== Intervention Extract 735 (Dose) ===
elle condizioni cliniche generali, dell’estensione della
malattia (IIIA vs IIIB o IIIC), della presenza di alterazioni molecolari target (stadio IIIB, N3 o IIIC), della
funzionalità respiratoria, dei parametri dosimetrici radioterapici in termini di predizione di tossicità polmonare
(V20, mean lung dose) ed esofagea. Va inoltre fornita al paziente un’esauriente informazione in merito ai
benefici e al profilo di tollerabilità delle diverse opzioni terapeutiche. Le possibilità della terapia chirurgica nella malattia localmente avanzata dipendono dall’entità di estensione
del tumore primario, dal liv

=== Intervention Extract 736 (Dose) ===
iature tecnicamente non idonee all’irradiazione
toracica, volumi di trattamento e planning radioterapico non congrui), ad oggi non esiste evidenza scientifica
randomizzata a favore di un trattamento radioterapico adiuvante. In ogni caso, il trattamento deve oggi
prevedere la somministrazione di una dose totale tra i 50 Gy e i 54 Gy, con frazionamento convenzionale (1,8-
2 Gy/die), a un volume bersaglio rappresentato dalle stazioni linfonodali ilo-mediastiniche coinvolte dalla
malattia, dalla trancia di sezione considerando sempre l’ilo e la stazione sottocarenale (218). L’impiego di
tecniche radio

=== Intervention Extract 737 (Dose) ===
status 0-1, affetti da NSCLC localmente avanzato (stadio III non resecabile secondo TNM VII edizione),
in risposta o stabilità di malattia dopo un trattamento di chemio-radioterapia concomitante (almeno 2 cicli di
chemioterapia a base di platino concomitanti alla radioterapia) ad intento radicale (dose totale di radioterapia compresa
tra 54 Gy e 66 Gy). I pazienti venivano randomizzati, in un intervallo temporale compreso tra 1 e 42 giorni dall’ultima
dose di radioterapia, a ricevere un trattamento immunoterapico con durvalumab o placebo (2:1) 10 mg/kg e.v. ogni 2
settimane sino a un massimo di 1

=== Intervention Extract 738 (Dose) ===
to di chemio-radioterapia concomitante (almeno 2 cicli di
chemioterapia a base di platino concomitanti alla radioterapia) ad intento radicale (dose totale di radioterapia compresa
tra 54 Gy e 66 Gy). I pazienti venivano randomizzati, in un intervallo temporale compreso tra 1 e 42 giorni dall’ultima
dose di radioterapia, a ricevere un trattamento immunoterapico con durvalumab o placebo (2:1) 10 mg/kg e.v. ogni 2
settimane sino a un massimo di 12 mesi di trattamento. I due endpoint primari erano PFS e OS. Il tempo alla progressione
è stato valutato da un comitato di revisione centrale indipendente i

=== Intervention Extract 739 (Dose) ===
o (nel 55% dei casi di malattia OM), l’impiego
della RT stereotassica (SBRT) è in incremento negli ultimi anni. La SBRT è una tecnica moderna che, rispetto
alla RT convenzionale, consente di erogare dosi più elevate di radiazioni a bersagli tumorali più piccoli con
alta conformazione e gradiente di dose. È un trattamento non invasivo, che può essere effettuato in tutte le
principali sedi metastatiche di NSCLC come polmoni, encefalo, ghiandole surrenali, fegato e ossa. Ad oggi
non vi sono ancora studi di confronto tra chirurgia e SBRT nella malattia OM e la maggior parte degli studi
condotti in que

=== Intervention Extract 740 (Dose) ===
osti alla sola terapia medica.
In una pooled analisys (252) di 2 studi randomizzati di fase II (PEMBRO-RT e MDACC) sono stati confrontati i risultati
ottenuti in 148 pazienti sottoposti a pembrolizumab (200 mg ogni 3 settimane) con o senza l’aggiunta di radioterapia.
Nello studio PEMBRO-RT la prima dose di pembrolizumab era stata somministrata entro 1 settimana dall’ultima seduta
di radioterapia (24 Gy in 3 frazioni), mentre nello studio MDACC l’immunoterapia iniziava in concomitanza del 1°
giorno di trattamento radiante (50 Gy in 4 frazioni o 45 Gy in 15 frazioni). Le sedi irradiate erano prevale

=== Intervention Extract 741 (Dose) ===
mioterapia)?
È stata eseguita una ricerca bibliografica della letteratura sulle banche dati Medline ed Embase. Dopo la
rimozione dei duplicati e l’acquisizione dei full-text, lo studio di fase I CHRYSALIS è stato incluso
nell’analisi.
Lo studio CHRYSALIS è uno studio non randomizzato, in aperto, di dose escalation e dose expansion, che ha
valutato il profilo di attività e di tollerabilità di amivantamab in pazienti affetti da NSCLC avanzato o
metastatico con inserzioni dell’esone 20 di EGFR, in progressione ad una I linea di chemioterapia a base di
platino (276).
Gli endpoint dello studio includev

=== Intervention Extract 742 (Dose) ===
ta eseguita una ricerca bibliografica della letteratura sulle banche dati Medline ed Embase. Dopo la
rimozione dei duplicati e l’acquisizione dei full-text, lo studio di fase I CHRYSALIS è stato incluso
nell’analisi.
Lo studio CHRYSALIS è uno studio non randomizzato, in aperto, di dose escalation e dose expansion, che ha
valutato il profilo di attività e di tollerabilità di amivantamab in pazienti affetti da NSCLC avanzato o
metastatico con inserzioni dell’esone 20 di EGFR, in progressione ad una I linea di chemioterapia a base di
platino (276).
Gli endpoint dello studio includevano la ORR e la to

=== Intervention Extract 743 (Dose) ===
on, che ha
valutato il profilo di attività e di tollerabilità di amivantamab in pazienti affetti da NSCLC avanzato o
metastatico con inserzioni dell’esone 20 di EGFR, in progressione ad una I linea di chemioterapia a base di
platino (276).
Gli endpoint dello studio includevano la ORR e la tossicità dose-limitante. Gli endpoint secondari includevano
la DoR, il tasso di beneficio clinico (clinical benefit rate, CBR), la PFS e l’OS.
Sui primi 81 pazienti valutabili per l’analisi di efficacia, amivantamab ha dimostrato un ORR del 40%, con un
tasso di risposta completa del 4% e un tasso di risposta par

=== Intervention Extract 744 (Dose) ===
e a 2 anni del 13,7% (276). Tra i 114 pazienti valutati, il 13% (n=15)
ha proseguito il trattamento per 2,6 anni (277). Nella coorte di 114 pazienti valutata per l’analisi delle tossicità,
gli eventi avversi più frequenti erano rash, reazioni avverse all’infusione e paronichia, con una riduzione di
dose correlata al trattamento e discontinuazione per tossicità rispettivamente riportate nel 13% e 4% dei
pazienti (276).
Limiti: Performance e detection bias, mancanza di generalizzabilità dei risultati.
Bilancio beneficio/danno: A favore nei pazienti con NSCLC in stadio avanzato con inserzioni dell’es

=== Intervention Extract 745 (Dose) ===
nausea e vomito.
Lo studio di fase I ASCEND-8 ha dimostrato un profilo di tollerabilità migliore quando la posologia di ceritinib
era 450 mg/die e l’assunzione del farmaco veniva associata al cibo (297). Nella coorte di 73 pazienti trattati in
I linea, valutati per attività ed efficacia con questa dose di farmaco, la RR valutata da un comitato di revisione
indipendente era pari al 78%, con una PFS mediana non stimabile dopo 19,6 mesi di follow-up mediano. Nella
maggior parte dei casi gli eventi gastrointestinali erano di grado 1, solo 3% di grado 3. Nello stesso trial erano
state valutate anche l

=== Intervention Extract 746 (Dose) ===
erano di grado 1, solo 3% di grado 3. Nello stesso trial erano
state valutate anche le posologie di 600 mg/die con cibo e 750 mg/die a digiuno; pur trattandosi di uno studio
di fase I, in cui nessuna comparazione può essere effettuata, il rapporto beneficio/tossicità era risultato
superiore per la dose di 450 mg/die con cibo. Con tale posologia, in Italia ceritinib è approvato e rimborsato,
come terapia di I linea, nella malattia metastatica ALK-riarrangiata.
Quesito 18 GRADE. Nei pazienti affetti da NSCLC in stadio localmente avanzato o metastatico con
riarrangiamenti di ALK, un trattamento di I

=== Intervention Extract 747 (Dose) ===
può essere preso in considerazione come opzione
terapeutica di prima scelta.
Forza della raccomandazione: CONDIZIONATA A FAVORE
Motivazioni/commenti al bilancio beneficio/danno:
Lo studio NCT01970865, pubblicato inizialmente nel 2017 da Shaw et al., è uno studio di fase I/II volto a determinare la
dose di lorlatinib per il successivo sviluppo del farmaco, e di valutarne l’attività e lo spettro di tossicità in vari scenari di
malattia ALK-positiva (311). Recentemente, Felip et al. hanno riportato un aggiornamento della fase II dello studio, in cui
la dose di lorlatinib era 100 mg/die (312). Nella

=== Intervention Extract 748 (Dose) ===
studio di fase I/II volto a determinare la
dose di lorlatinib per il successivo sviluppo del farmaco, e di valutarne l’attività e lo spettro di tossicità in vari scenari di
malattia ALK-positiva (311). Recentemente, Felip et al. hanno riportato un aggiornamento della fase II dello studio, in cui
la dose di lorlatinib era 100 mg/die (312). Nella coorte denominata “EXP3B-5” i pazienti avevano ricevuto almeno un
inibitore di ALK di seconda generazione, ed erano stati eventualmente già esposti alla chemioterapia. I pazienti inclusi in
questa coorte erano 139; ORR, PFS (follow-up mediano 30,6 mesi) e O

=== Intervention Extract 749 (Dose) ===
ETTO-001 nella coorte di pazienti con NSCLC sono stati inizialmente riportati da
Drilon et al. nel 2020 ed aggiornati nel 2023 (338-339). Lo studio in sé includeva malati con ogni tipo di
tumore solido con attivazioni molecolari di RET (fusioni o mutazioni). La fase I dello studio aveva definito la
dose di selpercatinib da adottare pari a 160 mg b.i.d. In totale sono stati trattati 356 malati con tumore
polmonare con fusione di RET, e i dati di efficacia hanno riguardato 69 e 247 malati, rispettivamente, non pre-
trattati per malattia avanzata e che avevano ricevuto un trattamento chemioterapico a

=== Intervention Extract 750 (Dose) ===
usi per i seguenti motivi: combinazione con gefitinib (1), fase I (2), studio di
farmacocinetica (2) e studio di sottogruppo (1). È stato pertanto incluso 1 studio.
Lo studio prospettico, internazionale, in aperto e multi-coorte, GEOMETRY mono-1 valutava l’attività e la
sicurezza di capmatinib alla dose di 400 mg 2 volte al giorno lontano dai pasti, in 364 pazienti con NSCLC
avanzato (sia in I linea che in pazienti pre-trattati) e mutazione di MET con skipping dell’esone 14 oppure
amplificazione di MET determinata dal laboratorio centralizzato (350).
Nei 69 pazienti della coorte 4 (con mutazione d

=== Intervention Extract 751 (Dose) ===
erca in full-text, 4 sono stati esclusi per i seguenti motivi:
combinazione con gefitinib (2), osimertinib (1) e studio di sottogruppo (1). È stato pertanto incluso 1 studio.
La coorte A dello studio prospettico VISION, internazionale, in aperto, valutava l’attività e la sicurezza di
tepotinib alla dose di 500 mg 1 volta al giorno lontano dai pasti, in 152 pazienti sia pre-trattati che in I linea
con NSCLC avanzato e mutazione di MET exon 14 skipping alla biopsia tissutale e/o liquida analizzate dal
laboratorio centralizzato. Il tasso di risposte obiettive era 46%, la durata mediana della risposta

=== Intervention Extract 752 (Dose) ===
on trattate ha rappresentato un criterio di esclusione dallo studio. In questo sottogruppo di
pazienti il tempo di follow-up mediano è stato di 11,7 mesi. Il 32,2% dei pazienti ha avuto una risposta
confermata e l’88,1% un controllo di malattia. Le risposte sono state osservate a tutti i livelli di dose e la durata
media della risposta è stata di 10,9 mesi, mentre la PFS mediana è stata 6,3 mesi (355).
Nella fase II dello studio CodeBreaK100 sono stati arruolati 126 pazienti affetti da NSCLC con mutazione
KRAS p.G12C, tutti pre-trattati con terapie standard, a ricevere sotorasib alla dose di 960 m

=== Intervention Extract 753 (Dose) ===
velli di dose e la durata
media della risposta è stata di 10,9 mesi, mentre la PFS mediana è stata 6,3 mesi (355).
Nella fase II dello studio CodeBreaK100 sono stati arruolati 126 pazienti affetti da NSCLC con mutazione
KRAS p.G12C, tutti pre-trattati con terapie standard, a ricevere sotorasib alla dose di 960 mg/die (356).
L’endpoint primario dello studio era l’ORR valutata mediante revisione centrale indipendente, risultata essere
del 37,1%, con DoR mediana di 11,1 mesi, PFS mediana di 6,8 mesi e OS mediana di 12,5 mesi. Un totale di
88 pazienti ha presentato eventi avversi correlati al trattame

=== Intervention Extract 754 (Dose) ===
ha presentato eventi avversi correlati al trattamento, di cui 19,8% di grado 3 e 0,8% di grado 4. I
più comuni sono stati diarrea (31,7%), nausea (19%), aumento del livello di ALT (15,1%) e AST (15,1%) e
fatigue (11,1%). Gli eventi avversi correlati al trattamento hanno reso necessarie modifiche di dose e la
sospensione del sotorasib rispettivamente in 28 e 9 pazienti (356).
Più recentemente, lo studio globale di fase III CodeBreak 200 (357) primo trial clinico controllato randomizzato
di un inibitore di KRAS G12C, in cui sono stati arruolati 345 pazienti, ha dimostrato un beneficio significativo

=== Intervention Extract 755 (Dose) ===
siasi grado, <1% di grado 3), epatite (<1%) e colite (<1%). Potenziali rischi di
bias dello studio sono rappresentati da: disegno in aperto e coinvolgimento dello sponsor nell’analisi e nell’interpretazione
dei dati e nella stesura dell’articolo.
Sulla base di questi dati, in Italia nivolumab (alla dose flat di 240 mg e.v. ogni 2 settimane) è approvato per il trattamento
del NSCLC avanzato dopo una precedente chemioterapia, indipendentemente dall’espressione di PD-L1; pembrolizumab
(alla dose di 2 mg/kg e.v. ogni 3 settimane) è approvato per il trattamento del NSCLC avanzato con espressione di PD-

=== Intervention Extract 756 (Dose) ===
terpretazione
dei dati e nella stesura dell’articolo.
Sulla base di questi dati, in Italia nivolumab (alla dose flat di 240 mg e.v. ogni 2 settimane) è approvato per il trattamento
del NSCLC avanzato dopo una precedente chemioterapia, indipendentemente dall’espressione di PD-L1; pembrolizumab
(alla dose di 2 mg/kg e.v. ogni 3 settimane) è approvato per il trattamento del NSCLC avanzato con espressione di PD-L1
≥1% dopo almeno una precedente chemioterapia (i pazienti positivi per EGFR o ALK devono aver ricevuto anche una
terapia a bersaglio molecolare prima di ricevere pembrolizumab); atezolizumab

=== Intervention Extract 757 (Dose) ===
mg/kg e.v. ogni 3 settimane) è approvato per il trattamento del NSCLC avanzato con espressione di PD-L1
≥1% dopo almeno una precedente chemioterapia (i pazienti positivi per EGFR o ALK devono aver ricevuto anche una
terapia a bersaglio molecolare prima di ricevere pembrolizumab); atezolizumab (alla dose flat di 1200 mg e.v. ogni 3
settimane) è approvato per il trattamento del NSCLC avanzato dopo una precedente chemioterapia, indipendentemente
dall’espressione di PD-L1 (i pazienti positivi per EGFR o ALK devono aver ricevuto anche una terapia a bersaglio
molecolare prima di ricevere atezolizumab).

=== Intervention Extract 758 (Dose) ===
, poiché circa il 90% dei pazienti inclusi nei vari trial erano deceduti.
La metanalisi di Pignon et al. rappresenta la prima evidenza dell’efficacia del trattamento radio-chemioterapico
in pazienti affetti da SCLC in stadio limitato. Tuttavia, è importante segnalare come i trial differiscano nella
dose e nel timing della radioterapia e della chemioterapia, nello schema di terapia antiblastica utilizzata, nella
scelta del subset di pazienti trattati con radioterapia (tutti i pazienti in alcuni trial, quelli che presentavano
risposte complete o parziali o i pazienti con malattia stabile in altri) e

=== Intervention Extract 759 (Dose) ===
one, in uno studio clinico randomizzato, in cui sono stati arruolati
417 pazienti affetti da SCLC in stadio limitato, la radioterapia iperfrazionata accelerata ha prodotto un
miglioramento statisticamente significativo della sopravvivenza a 5 anni (26% vs 16%; p=0,04) (425). In
entrambi i gruppi la dose totale di radioterapia toracica era 45 Gy: 1,8 Gy/die in 25 frazioni (5 settimane) nei
pazienti con frazionamento standard, 1,5 Gy in 30 frazioni BID (3 settimane) nella modalità iperfrazionata
accelerata.
La radioterapia toracica è stata iniziata contemporaneamente al primo ciclo di chemioterapia

=== Intervention Extract 760 (Dose) ===
5 in quello standard).
Lo studio, disegnato alla fine degli anni ’80, presenta di certo un importante limite nell’applicabilità dei risultati
riportati a favore del trattamento radiante iperfrazionato accelerato, in considerazione dell’evoluzione delle
tecniche radioterapiche, ma soprattutto per la dose di radioterapia nel braccio standard, inferiore a quelle oggi
comunemente utilizzate, che determina un limitato controllo locale di malattia. Tuttavia, nello studio sono stati
ottenuti globalmente tassi rilevanti di sopravvivenza a 2 e 5 anni del 44% e 23% rispettivamente, confermando
così l’effica

=== Intervention Extract 761 (Dose) ===
ono stati
ottenuti globalmente tassi rilevanti di sopravvivenza a 2 e 5 anni del 44% e 23% rispettivamente, confermando
così l’efficacia del trattamento concomitante in questo setting.
Lo studio multicentrico di fase III CONVERT ha recentemente confrontato schemi di iperfrazionamento
accelerato con dose totale di 45 Gy (1,5 Gy in 30 frazioni BID) con uno schema di frazionamento
convenzionale, ma con dosi totali più elevate (66 Gy), 2 Gy die in 33 frazioni, in entrambi i casi in associazione
alla chemioterapia con cisplatino ed etoposide, somministrata per 4-6 cicli (426). Il trattamento antiblasti

=== Intervention Extract 762 (Dose) ===
diologico cerebrale
(HR 0,70; IC95% 0,57-0,85) (429). Uno studio prospettico randomizzato di confronto tra 25 Gy e 36 Gy ha
dimostrato che il dosaggio ottimale di PCI consiste in un totale 25 Gy somministrati in 10 frazioni, non
evidenziandosi alcun beneficio terapeutico dall’intensificazione della dose radioterapica (430).
Successivamente sono stati riportati i dati di valutazione delle tossicità neurologiche e di qualità di vita a medio
e lungo termine dello stesso studio (431). I risultati a 3 anni non evidenziano differenze significative tra i due
gruppi di pazienti trattati con dosi diverse d

=== Intervention Extract 763 (Dose) ===
zano strumenti diversi per valutare le
capacità neurocognitive e il protocollo di imaging con RM e le visite di follow-up non sono sovrapponibili (3
e 12 mesi per la valutazione precoce e tardiva rispettivamente nel trial olandese e 4 e 24 mesi nel trial
spagnolo). Differenze nelle distribuzioni di dose e anche obiettivi troppo ambiziosi potrebbero essere aspetti
da sottolineare per giustificare i risultati contrastanti e si attendono per una miglior definizione del ruolo del
risparmio dell’ippocampo i dati dello studio attualmente in corso NRG CC003 (ClinicalTrials.gov:
NCT02635009) disegnato con

=== Intervention Extract 764 (Dose) ===
icare i risultati contrastanti e si attendono per una miglior definizione del ruolo del
risparmio dell’ippocampo i dati dello studio attualmente in corso NRG CC003 (ClinicalTrials.gov:
NCT02635009) disegnato con una revisione centralizzata della contornazione dell’ippocampo e della
distribuzione di dose, al fine di ottimizzare l’uniformità e la qualità dei piani di trattamento.
Limiti: Rischi di bias e inconsistenza tra le stime degli studi inclusi.
Bilancio beneficio/danno: A favore dell’irradiazione profilattica dell’encefalo.
Qualità globale Forza della
Raccomandazione clinica
delle prove racco

=== Intervention Extract 765 (Dose) ===
in pazienti affetti da SCLC recidivati dopo una chemioterapia di I linea.
Lo studio pubblicato da von Pawel et al. (457), condotto su 211 pazienti con SCLC in progressione dopo
un’iniziale risposta alla chemioterapia di I linea, ha confrontato il trattamento con topotecano (i.v.,
somministrato alla dose di 1,5 mg/mq/die per 5 giorni, ogni 3 settimane) con la combinazione ciclofosfamide,
adriamicina e vincristina (CAV). Venivano arruolati i pazienti progrediti alla I linea da almeno 60 giorni.
Sebbene il dato non sia risultato statisticamente significativo, lo studio ha determinato una percentuale

=== Intervention Extract 766 (Dose) ===
lated mortality; All-cause mortality; Early stage detection; Late stage disease; Resectability rate ; Overdia PERSPECTIVE: Popolazione CONFLICT OF INTERESTS: Nessun conflitto dichiarato
anni oppure almeno 10 sigar
onare con la TC torace spira
agnosis; False positive rate
rette al giorno
ale a bassa dose
VALUTAZION Is the problem a prior
GIUDIZI
○ No
○ Probably no
○ Probably yes
● Yes
○ Varies
○ Don't know
Desirable effe
How substantial are th
GIUDIZI
○ Trivial
○ Small
● Moderate
○ Large
○ Varies
○ Don't know
NE
rity?
ects
he desira
RICERCA DELLE PROVE DI EVIDENZA CONS
Lung cancer (LC) screening by

=== Intervention Extract 767 (Dose) ===
TAZION Is the problem a prior
GIUDIZI
○ No
○ Probably no
○ Probably yes
● Yes
○ Varies
○ Don't know
Desirable effe
How substantial are th
GIUDIZI
○ Trivial
○ Small
● Moderate
○ Large
○ Varies
○ Don't know
NE
rity?
ects
he desira
RICERCA DELLE PROVE DI EVIDENZA CONS
Lung cancer (LC) screening by low-dose computed tomography (LDCT) achieved a 20% decrease in LC mortality in
the National Lung Screening Trial (NLST), when compared with chest radiography [1], while European randomized
clinical trials (RCT) testing LDCT versus observation showed no benefit at 5-year, possibly due to small number of
part

=== Intervention Extract 768 (Dose) ===
know
Don't know
Don't know Nei pazienti fumatori o ex-fumatori che hanno fumato almeno 15 sigarette al giorno per più di 25 anni oppure almeno 10 sigarette al giorno per più di 30 anni, oppure che hanno smesso meno di 10 anni prima, lo
screening per tumore polmonare con la TC torace spirale a bassa dose annuale dovrebbe essere preso in considerazione come prima opzione come esame di screening Autore/i: ACT
Domanda: La segmentectomia rispetto a lobectomia in pazienti affetti da NSCLC in stadio iniziale
Setting: inpatients
Bibliografia:
Certainty assessment
Mancanza di
Disegno dello Rischio di Manca

=== Intervention Extract 769 (Dose) ===
braio 2021. Dopo la rimozione dei duplicati e l'acquisizione dei full text, sono stati inclusi 2 studi.
Lo studio di Shaw et al. è un open-label single arm che ha arruolato 54 pazienti affetti da NSCLC
avanzato con riarrangiamento di ALK e ROS-1, a cui è stato somministrato Lrolatinib a un range di
dose tra i 10-200mg die o 35-100mg BID.
Lo studio di Felip et al. è un open-label single arm che ha arruolato 139 pazienti affetti da NSCLC
avanzato con riarrangiamento di ALK e precedentemente trattati con almeno 1 linea di inibitore
tirosinchinasico, a cui è stato somministrato Lorlatinib 100mg die q2

=== Intervention Extract 770 (Dose) ===
braio 2021. Dopo la rimozione dei duplicati e l'acquisizione dei full text, sono stati inclusi 2 studi.
Lo studio di Shaw et al. è un open-label single arm che ha arruolato 54 pazienti affetti da NSCLC
avanzato con riarrangiamento di ALK e ROS-1, a cui è stato somministrato Lrolatinib a un range di
dose tra i 10-200mg die o 35-100mg BID.
Lo studio di Felip et al. è un open-label single arm che ha arruolato 139 pazienti affetti da NSCLC
avanzato con riarrangiamento di ALK e precedentemente trattati con almeno 1 linea di inibitore
tirosinchinasico, a cui è stato somministrato Lorlatinib 100mg die q2

=== Intervention Extract 771 (Dose) ===
◯◯◯ CRITICAL
studies serious a nature of our study, we were only able to collect VERY LOW
information on grade 4 or 5 toxicities. In our series, no
patients experienced a grade 4 or 5 adverse effect. One
patient experienced a grade 3 liver toxicity, leading to
temporary withdrawal of crizotinib and dose reduction." a. The quality of these studies was assessed by the NICE checklist. Shaw et al and Landi L. et al studies obtained a score of 8/8 and Maizieres et al. a score of 7/8 because of its
retrospective nature. In both studies there was not information about the outcomes stratification
b. 76% o

=== Intervention Extract 772 (Dose) ===
ective nature of our observational
VERY LOWa,c
study, we were only able to study)
collect information on grade 4 or
5 toxicities. In our series, no
patients experienced a grade 4 or
5 adverse effect. One patient
experienced a grade 3 liver
toxicity, leading to temporary
withdrawal of crizotinib and dose
reduction."
The quality of these studies was assessed by the NICE checklist. Shaw et al and Landi L. et al
studies obtained a score of 8/8 and Maizieres et al. a score of 7/8 because of its retrospective
nature. In both studies there was not information about the outcomes stratification
76% of the

=== Intervention Extract 773 (Dose) ===
Because of -
J. et al the retrospective nature of our
study, we were only able to
collect information on grade 4 or
5 toxicities. In our series, no
patients experienced a grade 4 or
5 adverse effect. One patient
experienced a grade 3 liver
toxicity, leading to temporary
withdrawal of crizotinib and dose
reduction."
The quality of these studies was assessed by the NICE ch
studies obtained a score of 8/8 and Maizieres et al. a scor
nature. In both studies there was not information about t
ble observat
study)
ble (1
observat
study)
ble (1
observat
study)
ble (1
observat
study)
observat
study)
hecklis

=== Intervention Extract 774 (Dose) ===
tainty assessment
Mancanza di Impatto Certainty Importanza
№ degli Disegno dello Rischio di Mancanza di
riproducibilità Imprecisione Ulteriori considerazioni
studi studio distorsione generalizzabilità
dei risultati
Overall Survival (follow up: mediana 15.9 mesi; valutato con: dalla data della prima dose di trattamenti alla morte per ogni causa)
1 1 studi molto serio a non importante serio b molto serio c nessuno 17 pazienti su 36 (47%) sono deceduti ⨁◯◯◯ CRITICO
osservazionali
MOLTO BASSA
Progression free survival (follow up: mediana 15.9 mesi; valutato con: dalla data della prima dose di trattame

=== Intervention Extract 775 (Dose) ===
della prima dose di trattamenti alla morte per ogni causa)
1 1 studi molto serio a non importante serio b molto serio c nessuno 17 pazienti su 36 (47%) sono deceduti ⨁◯◯◯ CRITICO
osservazionali
MOLTO BASSA
Progression free survival (follow up: mediana 15.9 mesi; valutato con: dalla data della prima dose di trattamento alla progressione di malattia o morte)
1 1 studi molto serio a non importante serio b molto serio c nessuno 24 su 36 (67%) pazienti sono andati incontro a progressione di malattia o morte al tempo delle ⨁◯◯◯ CRITICO
osservazionali analisi. La mediana di PFS, valutata dagli investigat

=== Intervention Extract 776 (Dose) ===
in cicli continui di 21 giorni fino a progressione di malattia, eventi avversi
seri, ritiro del consenso o morte del paziente.
SIDERAZIO
LINE
ONI AGG
EE GUIDA
GIUNTIVE
NEOPLASIE DEL POLMON
Esiti Impatto
Overall Survival 17 pazienti su 36 (47%) sono deceduti
(OS)
valutato con: dalla
data della prima
dose di trattamenti
alla morte per ogni
causa
follow up: mediana
15.9 mesi
Progression free 24 su 36 (67%) pazienti sono andati
survival (PFS) incontro a progressione di malattia o
valutato con: dalla morte al tempo delle analisi. La mediana
data della prima di PFS, valutata dagli investigatori, è
dose

=== Intervention Extract 777 (Dose) ===
dose di trattamenti
alla morte per ogni
causa
follow up: mediana
15.9 mesi
Progression free 24 su 36 (67%) pazienti sono andati
survival (PFS) incontro a progressione di malattia o
valutato con: dalla morte al tempo delle analisi. La mediana
data della prima di PFS, valutata dagli investigatori, è
dose di trattamento risultata essere di 10.9 mesi (95% CI
alla progressione di 7·0–16·6), e la PFS a 6 mesi è risultata
malattia o morte essere del 72%
follow up: mediana
15.9 mesi
Response rate Ad un follow-up mediano di 15,9 mesi
follow up: mediana (IQR 7,8–22,0), 23 pazienti hanno
15.9 mesi ottenuto

=== Intervention Extract 778 (Dose) ===
in cicli continui di 21 giorni fino a progressione di malattia, eventi avversi
seri, ritiro del consenso o morte del paziente.
SIDERAZIO
LINE
ONI AGG
EE GUIDA
GIUNTIVE
NEOPLASIE DEL POLMON
Esiti Impatto
Overall Survival 17 pazienti su 36 (47%) sono deceduti
(OS)
valutato con: dalla
data della prima
dose di trattamenti
alla morte per ogni
causa
follow up: mediana
15.9 mesi
Progression free 24 su 36 (67%) pazienti sono andati
survival (PFS) incontro a progressione di malattia o
valutato con: dalla morte al tempo delle analisi. La mediana
data della prima di PFS, valutata dagli investigatori, è
dose

=== Intervention Extract 779 (Dose) ===
dose di trattamenti
alla morte per ogni
causa
follow up: mediana
15.9 mesi
Progression free 24 su 36 (67%) pazienti sono andati
survival (PFS) incontro a progressione di malattia o
valutato con: dalla morte al tempo delle analisi. La mediana
data della prima di PFS, valutata dagli investigatori, è
dose di trattamento risultata essere di 10.9 mesi (95% CI
alla progressione di 7·0–16·6), e la PFS a 6 mesi è risultata
malattia o morte essere del 72%
follow up: mediana
15.9 mesi
Response rate Ad un follow-up mediano di 15,9 mesi
follow up: mediana (IQR 7,8–22,0), 23 pazienti hanno
15.9 mesi ottenuto

=== Intervention Extract 780 (Dose) ===
OR "CTs Spiral"[Title/Abstract] OR "Spiral
CTs"[Title/Abstract] OR "Tomography, Helical Computed"[Title/Abstract] OR "CAT Scan*,
Spiral"[Title/Abstract] OR "Spiral CAT Scan*"[Title/Abstract] OR "Helical Computed
Tomography"[Title/Abstract] OR "Helical Computed Tomography CT"[Title/Abstract] OR "low-dose
helical computed tomography (CT)"[Title/Abstract]))))))) Q2: Nei pazienti con NSCLC in stadio clinico I la lobectomia dovrebbe essere eseguita con
approccio mini-invasivo (VATS o robotico) o toracotomico?
MEDLINE (PubMed) (2019 ad Agosto 2023)
(((((((("Carcinoma, Non-Small-Cell Lung/surgery"[Mesh])

=== Intervention Extract 781 (Dose) ===
te vicino/sovrapponibile o distante rispetto al PICO del quesito di interesse.
Una raccomandazione può essere integrata da commenti e può essere suddivisa in sotto-raccomandazioni
dove è possibile specificare meglio altre caratteristiche salienti del paziente, setting, modalità di
somministrazione, dose, tempi, monitoraggio effetti collaterali specifici, ecc. Ovvero tutto quello che può
aiutare il clinico a proporre l’intervento (farmacologico, chirurgico, etc.).
Uno degli obiettivi più importanti delle LG /raccomandazioni è il trasferimento “locale”, ossia a livello
nazionale o regionale delle ev

=== Intervention Extract 782 (Dose) ===
status 0-1, affetti da NSCLC localmente avanzato (stadio III non resecabile secondo TNM VII edizione), in risposta o stabilità di malattia dopo un trattamento di chemio-radioterapia concomitante (almeno 2 cicli di chemioterapia a base di platino concomitanti alla radioterapia) ad intento radicale (dose totale di radioterapia compresa tra 54 Gy e 66 Gy). I pazienti venivano randomizzati, in un intervallo temporale compreso tra 1 e 42 giorni dall’ultima dose di radioterapia, a ricevere un trattamento immunoterapico con durvalumab o placebo (2:1) 10 mg/kg e.v. ogni 2 settimane sino a un massimo di 1

=== Intervention Extract 783 (Dose) ===
to di chemio-radioterapia concomitante (almeno 2 cicli di chemioterapia a base di platino concomitanti alla radioterapia) ad intento radicale (dose totale di radioterapia compresa tra 54 Gy e 66 Gy). I pazienti venivano randomizzati, in un intervallo temporale compreso tra 1 e 42 giorni dall’ultima dose di radioterapia, a ricevere un trattamento immunoterapico con durvalumab o placebo (2:1) 10 mg/kg e.v. ogni 2 settimane sino a un massimo di 12 mesi di trattamento. I due endpoint primari erano PFS e OS. Il tempo alla progressione è stato valutato da un comitato di revisione centrale indipendente i

=== Intervention Extract 784 (Dose) ===
osti alla sola terapia medica. In una pooled analisys (252) di 2 studi randomizzati di fase II (PEMBRO-RT e MDACC) sono stati confrontati i risultati ottenuti in 148 pazienti sottoposti a pembrolizumab (200 mg ogni 3 settimane) con o senza l’aggiunta di radioterapia. Nello studio PEMBRO-RT la prima dose di pembrolizumab era stata somministrata entro 1 settimana dall’ultima seduta di radioterapia (24 Gy in 3 frazioni), mentre nello studio MDACC l’immunoterapia iniziava in concomitanza del 1° giorno di trattamento radiante (50 Gy in 4 frazioni o 45 Gy in 15 frazioni). Le sedi irradiate erano prevale

=== Intervention Extract 785 (Dose) ===
eso in considerazione come opzione terapeutica di prima scelta.
Row 5: Forza della raccomandazione: CONDIZIONATA A FAVORE
Row 6: Motivazioni/commenti al bilancio beneficio/danno: Lo studio NCT01970865, pubblicato inizialmente nel 2017 da Shaw et al., è uno studio di fase I/II volto a determinare la dose di lorlatinib per il successivo sviluppo del farmaco, e di valutarne l’attività e lo spettro di tossicità in vari scenari di malattia ALK-positiva (311). Recentemente, Felip et al. hanno riportato un aggiornamento della fase II dello studio, in cui la dose di lorlatinib era 100 mg/die (312). Nella

=== Intervention Extract 786 (Dose) ===
studio di fase I/II volto a determinare la dose di lorlatinib per il successivo sviluppo del farmaco, e di valutarne l’attività e lo spettro di tossicità in vari scenari di malattia ALK-positiva (311). Recentemente, Felip et al. hanno riportato un aggiornamento della fase II dello studio, in cui la dose di lorlatinib era 100 mg/die (312). Nella coorte denominata “EXP3B-5” i pazienti avevano ricevuto almeno un inibitore di ALK di seconda generazione, ed erano stati eventualmente già esposti alla chemioterapia. I pazienti inclusi in questa coorte erano 139; ORR, PFS (follow-up mediano 30,6 mesi) e O

=== Intervention Extract 787 (Dose) ===
-37.|
Row 28: Auer R, Concha-Lozano N, Jacot-Sadowski I, et al. Heat-not-burn tobacco cigarettes: smoke by any other name.|
Row 29: JAMA Intern Med. 2017; 177(7):1050-2.|
Row 30: National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with|
Row 31: low-dose computed tomographic screening. N Engl J Med. 2011; 365:395-409.|
Row 32: De Torres JP, Wisnivesky JP, Bastarrika G, et al. Exploring the impact of lung cancer screening on lung cancer|
Row 33: mortality of smokers with obstructive lung disease: analysis of the NLST-ACRIN cohort. Arch Bronconeumol.

=== Intervention Extract 788 (Dose) ===
hest CT scan plus x-ray versus chest x-ray for the follow-up of completely
Row 33: resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol.
Row 34: 2022; 23:1180-8.
Row 35: Lee CB, Stinchcombe TE, Moore D, et al. Late complications of high-dose thoracic conformal radiation therapy in
Row 36: combined modality trials in unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2009; 4:74-9.
Row 37: Verstegen NE, Lagerwaard FJ, Hashemi SM, et al. Patterns of disease recurrence after SABR for early stage non-
Row 38: small-cell lung

=== Intervention Extract 789 (Dose) ===
al results of the SAKK 16/00 Trial: a randomized phase III trial comparing
Row 2: neoadjuvant chemoradiation to chemotherapy alone in stage IIIA/N2 non-small-cell lung cancer. Ann Oncol. 2014;
Row 3: 25(Suppl 4):1v417.
Row 4: Cerfolio RJ, Bryant AS, Spencer SA, et al. Pulmonary resection after high-dose and low-dose chest irradiation. Ann
Row 5: Thorac Surg. 2005; 80(4):1224-30.
Row 6: Suntharalingam M, Paulus R, Edelman MJ, et al. Radiation therapy oncology group protocol 02-29: a phase II trial
Row 7: of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by

=== Intervention Extract 790 (Dose) ===
the SAKK 16/00 Trial: a randomized phase III trial comparing
Row 2: neoadjuvant chemoradiation to chemotherapy alone in stage IIIA/N2 non-small-cell lung cancer. Ann Oncol. 2014;
Row 3: 25(Suppl 4):1v417.
Row 4: Cerfolio RJ, Bryant AS, Spencer SA, et al. Pulmonary resection after high-dose and low-dose chest irradiation. Ann
Row 5: Thorac Surg. 2005; 80(4):1224-30.
Row 6: Suntharalingam M, Paulus R, Edelman MJ, et al. Radiation therapy oncology group protocol 02-29: a phase II trial
Row 7: of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical res

=== Intervention Extract 791 (Dose) ===
ulmonary resection after high-dose and low-dose chest irradiation. Ann
Row 5: Thorac Surg. 2005; 80(4):1224-30.
Row 6: Suntharalingam M, Paulus R, Edelman MJ, et al. Radiation therapy oncology group protocol 02-29: a phase II trial
Row 7: of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection
Row 8: and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys.
Row 9: 2012; 84(2):456-63
Row 10: Pöttgen C, Eberhardt W, Graupner B, et al. Accelerated hyperfractionated radiotherapy within t

=== Intervention Extract 792 (Dose) ===
imodality therapy
Row 11: concepts for stage IIIA/B non-small cell lung cancer: markedly higher rate of pathologic complete remissions than
Row 12: with conventional fractionation. Eur J Cancer. 2013; 49(9):2107-15.
Row 13: Sher DJ, Fidler MJ, Seder CW, et al. Relationship between radiation therapy dose and outcome in patients treated
Row 14: with neoadjuvant chemoradiation therapy and surgery for stage IIIA non-small cell lung cancer: a population-based,
Row 15: comparative effectiveness analysis. Int J Radiat Oncol Biol Phys. 2015; 92(2):307-16.
Row 16: Allen AM, Shochat T, Flex D, et al. High-d

=== Intervention Extract 793 (Dose) ===
e and outcome in patients treated
Row 14: with neoadjuvant chemoradiation therapy and surgery for stage IIIA non-small cell lung cancer: a population-based,
Row 15: comparative effectiveness analysis. Int J Radiat Oncol Biol Phys. 2015; 92(2):307-16.
Row 16: Allen AM, Shochat T, Flex D, et al. High-dose radiotherapy as neoadjuvant treatment in non-small-cell lung cancer.
Row 17: Oncology. 2018; 95(1):13-9.
Row 18: Vyfhuis MAL, Burrows WM, Bhooshan N, et al. Implications of pathologic complete response beyond mediastinal
Row 19: nodal clearance with high-dose neoadjuvant chemoradiation therapy in l

=== Intervention Extract 794 (Dose) ===
llen AM, Shochat T, Flex D, et al. High-dose radiotherapy as neoadjuvant treatment in non-small-cell lung cancer.
Row 17: Oncology. 2018; 95(1):13-9.
Row 18: Vyfhuis MAL, Burrows WM, Bhooshan N, et al. Implications of pathologic complete response beyond mediastinal
Row 19: nodal clearance with high-dose neoadjuvant chemoradiation therapy in locally advanced, non-small cell lung cancer.
Row 20: Int J Radiat Oncol Biol Phys. 2018; 101(2):445-52.
Row 21: Hellmann MD, Chaft JE, William WN J, et al. Pathological response after neoadjuvant chemotherapy in resectable
Row 22: non-small-cell lung cancers:

=== Intervention Extract 795 (Dose) ===
limited disease small cell lung cancer. Acta Oncol. 2016; 55(11):1349-54.
Row 3: Yin X, Yan D, Qiu M, et al. Prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-
Row 4: analysis. BMC Cancer. 2019; 19(1):95.
Row 5: Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in
Row 6: patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic
Row 7: radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet
Row 8: Onco

=== Intervention Extract 796 (Dose) ===
ll cell lung cancer. Acta Oncol. 2016; 55(11):1349-54.
Row 3: Yin X, Yan D, Qiu M, et al. Prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-
Row 4: analysis. BMC Cancer. 2019; 19(1):95.
Row 5: Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in
Row 6: patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic
Row 7: radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet
Row 8: Oncol. 2009; 10(5):467-

=== Intervention Extract 797 (Dose) ===
ORTANTE Row 1: |Nei pazienti fumatori o ex-fumatori che hanno fumato almeno 15 sigarette al giorno per più di 25 anni oppure almeno 10 sigarette al giorno|||
Row 2: |per più di 30 anni, oppure che hanno smesso meno di 10 anni prima, lo screening per tumore polmonare con la TC torace spirale a bassa dose|||
Row 3: |annuale dovrebbe essere preso in considerazione rispetto al non screening?|||
Row 4: ||||
Row 5: |POPULATION:||Lung cancer|
Row 6: ||||
Row 7: |INTERVENTION:||LDCT screening|
Row 8: ||||
Row 9: |COMPARISON:||No LDCT screening|
Row 10: ||||
Row 11: MAIN OUTCOMES:|||Lung cancer related mor

=== Intervention Extract 798 (Dose) ===
MAIN OUTCOMES:||
Row 12: ||
Row 13: |SETTING:|
Row 14: ||
Row 15: |PERSPECTIVE:|
Row 16: ||
Row 17: |BACKGROUND:|
Row 18: ||
Row 19: CONFLICT OF INTERESTS:||
Row 20: || Row 1: anni oppure almeno 10 sigar
Row 2: onare con la TC torace spira
Row 3: 
Row 4:  Row 1: rette al giorno|
Row 2: ale a bassa dose|
Row 3: |
Row 4: | Row 1: ||||
Row 2: |Problem|||
Row 3: |Is the problem a priority?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ No ○ Probably no ○ Probably yes ● Yes ○ Varies ○ Don't know||Lung cancer (LC) screening by low-dose computed tomogr

=== Intervention Extract 799 (Dose) ===
2: ale a bassa dose|
Row 3: |
Row 4: | Row 1: ||||
Row 2: |Problem|||
Row 3: |Is the problem a priority?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE DI EVIDENZA|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ No ○ Probably no ○ Probably yes ● Yes ○ Varies ○ Don't know||Lung cancer (LC) screening by low-dose computed tomography (LDCT) achieved a 20% decrease in LC mortality in the National Lung Screening Trial (NLST), when compared with chest radiography [1], while European randomized clinical trials (RCT) testing LDCT versus observation showed no benefit at 5-year, possibly due to small number of part

=== Intervention Extract 800 (Dose) ===
s the problem a prior
Row 4: | Row 1: |
Row 2: |Desirable effe
Row 3: |How substantial are th
Row 4: | Row 1: 
Row 2: 
Row 3: rity?
Row 4:  Row 1: 
Row 2: ects
Row 3: he desira
Row 4:  Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: |RICERCA DELLE PROVE DI EVIDENZA|
Row 2: |Lung cancer (LC) screening by low-dose computed tomography (LDCT) achieved a 20% decrease in LC mortality in the National Lung Screening Trial (NLST), when compared with chest radiography [1], while European randomized clinical trials (RCT) testing LDCT versus observation showed no benefit at 5-year, possibly due to small number of part

=== Intervention Extract 801 (Dose) ===
braio 2021. Dopo la rimozione dei duplicati e l'acquisizione dei full text, sono stati inclusi 2 studi. Lo studio di Shaw et al. è un open-label single arm che ha arruolato 54 pazienti affetti da NSCLC avanzato con riarrangiamento di ALK e ROS-1, a cui è stato somministrato Lrolatinib a un range di dose tra i 10-200mg die o 35-100mg BID. Lo studio di Felip et al. è un open-label single arm che ha arruolato 139 pazienti affetti da NSCLC avanzato con riarrangiamento di ALK e precedentemente trattati con almeno 1 linea di inibitore tirosinchinasico, a cui è stato somministrato Lorlatinib 100mg die q2

=== Intervention Extract 802 (Dose) ===
braio 2021. Dopo la rimozione dei duplicati e l'acquisizione dei full text, sono stati inclusi 2 studi. Lo studio di Shaw et al. è un open-label single arm che ha arruolato 54 pazienti affetti da NSCLC avanzato con riarrangiamento di ALK e ROS-1, a cui è stato somministrato Lrolatinib a un range di dose tra i 10-200mg die o 35-100mg BID. Lo studio di Felip et al. è un open-label single arm che ha arruolato 139 pazienti affetti da NSCLC avanzato con riarrangiamento di ALK e precedentemente trattati con almeno 1 linea di inibitore tirosinchinasico, a cui è stato somministrato Lorlatinib 100mg die q2

=== Intervention Extract 803 (Dose) ===
braio 2021. Dopo la rimozione dei duplicati e l'acquisizione dei full text, sono stati inclusi 2 studi. Lo studio di Shaw et al. è un open-label single arm che ha arruolato 54 pazienti affetti da NSCLC avanzato con riarrangiamento di ALK e ROS-1, a cui è stato somministrato Lrolatinib a un range di dose tra i 10-200mg die o 35-100mg BID. Lo studio di Felip et al. è un open-label single arm che ha arruolato 139 pazienti affetti da NSCLC avanzato con riarrangiamento di ALK e precedentemente trattati con almeno 1 linea di inibitore tirosinchinasico, a cui è stato somministrato Lorlatinib 100mg die q2

=== Intervention Extract 804 (Dose) ===
braio 2021. Dopo la rimozione dei duplicati e l'acquisizione dei full text, sono stati inclusi 2 studi. Lo studio di Shaw et al. è un open-label single arm che ha arruolato 54 pazienti affetti da NSCLC avanzato con riarrangiamento di ALK e ROS-1, a cui è stato somministrato Lrolatinib a un range di dose tra i 10-200mg die o 35-100mg BID. Lo studio di Felip et al. è un open-label single arm che ha arruolato 139 pazienti affetti da NSCLC avanzato con riarrangiamento di ALK e precedentemente trattati con almeno 1 linea di inibitore tirosinchinasico, a cui è stato somministrato Lorlatinib 100mg die q2

=== Intervention Extract 805 (Dose) ===
ated that 2Because of the retrospective nature of our study, we were only able to collect information on grade 4 or 5 toxicities. In our series, no patients experienced a grade 4 or 5 adverse effect. One patient experienced a grade 3 liver toxicity, leading to temporary withdrawal of crizotinib and dose reduction."||||⨁◯◯◯ VERY LOW|CRITICAL| Row 1: |||
Row 2: |POPOLAZIONE:||Pazienti affetti da NSCLC in stadio localmente avanzato o metastatico con riarrangiamenti di ROS1
Row 3: |||
Row 4: |INTERVENTO:||Inibitore tirosino-chinasico di ROS1 crizotinib
Row 5: |||
Row 6: |CONFRONTO:||Chemioterapia
Row

=== Intervention Extract 806 (Dose) ===
ective nature of our observational VERY LOWa,c study, we were only able to study) collect information on grade 4 or 5 toxicities. In our series, no patients experienced a grade 4 or 5 adverse effect. One patient experienced a grade 3 liver toxicity, leading to temporary withdrawal of crizotinib and dose reduction." The quality of these studies was assessed by the NICE checklist. Shaw et al and Landi L. et al studies obtained a score of 8/8 and Maizieres et al. a score of 7/8 because of its retrospective nature. In both studies there was not information about the outcomes stratification 76% of the

=== Intervention Extract 807 (Dose) ===
ect information on grade 4 or|||||
Row 6: ||5 toxicities. In our series, no|||||
Row 7: ||patients experienced a grade 4 or|||||
Row 8: ||5 adverse effect. One patient|||||
Row 9: ||experienced a grade 3 liver|||||
Row 10: ||toxicity, leading to temporary|||||
Row 11: ||withdrawal of crizotinib and dose|||||
Row 12: ||reduction."|||||
Row 13: ||||||| Row 1: Toxicity grade >=3 - Mazières J. et al||||-|(1 observational study)|⨁◯◯◯ VERY LOWa,c
Row 2: ||Authors stated that 2Because of||||
Row 3: ||the retrospective nature of our||||
Row 4: ||study, we were only able to||||
Row 5: ||collect information

=== Intervention Extract 808 (Dose) ===
||collect information on grade 4 or||||
Row 6: ||5 toxicities. In our series, no||||
Row 7: ||patients experienced a grade 4 or||||
Row 8: ||5 adverse effect. One patient||||
Row 9: ||experienced a grade 3 liver||||
Row 10: ||toxicity, leading to temporary||||
Row 11: ||withdrawal of crizotinib and dose||||
Row 12: ||reduction."||||
Row 13: |||||| Row 1: ||||
Row 2: |Effetti indesiderabili|||
Row 3: |Quanto considerevoli sono gli effetti indesiderabili attesi?|||
Row 4: ||||
Row 5: GIUDIZI||RICERCA DELLE PROVE|CONSIDERAZIONI AGGIUNTIVE|
Row 6: ○ Grandi ○ Moderati ○ Piccoli X Irrilevanti ○ Variano

=== Intervention Extract 809 (Dose) ===
ective nature of our observational VERY LOWa,c study, we were only able to study) collect information on grade 4 or 5 toxicities. In our series, no patients experienced a grade 4 or 5 adverse effect. One patient experienced a grade 3 liver toxicity, leading to temporary withdrawal of crizotinib and dose reduction." The quality of these studies was assessed by the NICE checklist. Shaw et al and Landi L. et al studies obtained a score of 8/8 and Maizieres et al. a score of 7/8 because of its retrospective nature. In both studies there was not information about the outcomes stratification| Row 1: Neu

=== Intervention Extract 810 (Dose) ===
on grade 4 or|||||||
Row 30: ||5 toxicities. In our series, no|||||||
Row 31: ||patients experienced a grade 4 or|||||||
Row 32: ||5 adverse effect. One patient|||||||
Row 33: ||experienced a grade 3 liver|||||||
Row 34: ||toxicity, leading to temporary|||||||
Row 35: ||withdrawal of crizotinib and dose|||||||
Row 36: ||reduction."|||||||
Row 37: ||||||||| Row 1: 0 per 1.000
Row 2: (0 to 0) Row 1: Neutropenia grade >=3 - Landi L. et al. (METROS)|||||
Row 2: |0 per 1.000||0 per 1.000 (0 to 0)||
Row 3: |||||
Row 4: Neutropenia grade >=3 - Shaw A.T. et al 2019|||||
Row 5: ||Study population|||
Row 6:

=== Intervention Extract 811 (Dose) ===
: ||collect information on grade 4 or|||
Row 30: ||5 toxicities. In our series, no|||
Row 31: ||patients experienced a grade 4 or|||
Row 32: ||5 adverse effect. One patient|||
Row 33: ||experienced a grade 3 liver|||
Row 34: ||toxicity, leading to temporary|||
Row 35: ||withdrawal of crizotinib and dose|||
Row 36: ||reduction."|||
Row 37: ||||| Row 1: ||76% of the METROS study population received one prior line of therapy In Shaw A.T et al most of patients (89%) had received at least one previous line of standard therapy for advanced NSCLC and 42% of patients were Asian. In Mazières J et al. most

=== Intervention Extract 812 (Dose) ===
3: |||||||||
Row 4: № degli studi|Disegno dello studio|Rischio di distorsione|Mancanza di riproducibilità dei risultati|Mancanza di generalizzabilità|Imprecisione|Ulteriori considerazioni|||
Row 5: |||||||||
Row 6: Overall Survival (follow up: mediana 15.9 mesi; valutato con: dalla data della prima dose di trattamenti alla morte per ogni causa)|||||||||
Row 7: 1 1|studi osservazionali|molto serio a|non importante|serio b|molto serio c|nessuno|17 pazienti su 36 (47%) sono deceduti|⨁◯◯◯ MOLTO BASSA|CRITICO
Row 8: Progression free survival (follow up: mediana 15.9 mesi; valutato con: dalla data della

=== Intervention Extract 813 (Dose) ===
ttamenti alla morte per ogni causa)|||||||||
Row 7: 1 1|studi osservazionali|molto serio a|non importante|serio b|molto serio c|nessuno|17 pazienti su 36 (47%) sono deceduti|⨁◯◯◯ MOLTO BASSA|CRITICO
Row 8: Progression free survival (follow up: mediana 15.9 mesi; valutato con: dalla data della prima dose di trattamento alla progressione di malattia o morte)|||||||||
Row 9: 1 1|studi osservazionali|molto serio a|non importante|serio b|molto serio c|nessuno|24 su 36 (67%) pazienti sono andati incontro a progressione di malattia o morte al tempo delle analisi. La mediana di PFS, valutata dagli investi

=== Intervention Extract 814 (Dose) ===
e. Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: |Esiti Impatto № dei Certainty of partecipanti the evidence (studi) (GRADE) Overall Survival 17 pazienti su 36 (47%) sono deceduti (1 studio ⨁◯◯◯ (OS) osservazionale)1 MOLTO valutato con: dalla BASSAa,b,c data della prima dose di trattamenti alla morte per ogni causa follow up: mediana 15.9 mesi Progression free 24 su 36 (67%) pazienti sono andati (1 studio ⨁◯◯◯ survival (PFS) incontro a progressione di malattia o osservazionale)1 MOLTO valutato con: dalla morte al tempo delle analisi. La mediana BASSAa,b,c data della pr

=== Intervention Extract 815 (Dose) ===
llow up: mediana 15.9 mesi Progression free 24 su 36 (67%) pazienti sono andati (1 studio ⨁◯◯◯ survival (PFS) incontro a progressione di malattia o osservazionale)1 MOLTO valutato con: dalla morte al tempo delle analisi. La mediana BASSAa,b,c data della prima di PFS, valutata dagli investigatori, è dose di trattamento risultata essere di 10.9 mesi (95% CI alla progressione di 7·0–16·6), e la PFS a 6 mesi è risultata malattia o morte essere del 72% follow up: mediana 15.9 mesi Response rate Ad un follow-up mediano di 15,9 mesi (1 studio ⨁◯◯◯ follow up: mediana (IQR 7,8–22,0), 23 pazienti hanno osse

=== Intervention Extract 816 (Dose) ===
nno raggiunto un controllo della malattia. Qualità della vita - - - non misurato| Row 1: |||||||||
Row 2: Esiti|Impatto||||№ dei|||Certainty of|
Row 3: |||||partecipanti|||the evidence|
Row 4: |||||(studi)|||(GRADE)|
Row 5: |||||||||
Row 6: Overall Survival (OS) valutato con: dalla data della prima dose di trattamenti alla morte per ogni causa follow up: mediana 15.9 mesi||||(1 studio osservazionale)1|||⨁◯◯◯ MOLTO BASSAa,b,c||
Row 7: |17 pazienti su 36 (47%) sono deceduti||||||||
Row 8: |||||||||
Row 9: Progression free survival (PFS) valutato con: dalla data della prima dose di trattamento alla p

=== Intervention Extract 817 (Dose) ===
alla data della prima dose di trattamenti alla morte per ogni causa follow up: mediana 15.9 mesi||||(1 studio osservazionale)1|||⨁◯◯◯ MOLTO BASSAa,b,c||
Row 7: |17 pazienti su 36 (47%) sono deceduti||||||||
Row 8: |||||||||
Row 9: Progression free survival (PFS) valutato con: dalla data della prima dose di trattamento alla progressione di malattia o morte follow up: mediana 15.9 mesi||||(1 studio osservazionale)1|||⨁◯◯◯ MOLTO BASSAa,b,c||
Row 10: |24 su 36 (67%) pazienti sono andati incontro a progressione di malattia o morte al tempo delle analisi. La mediana di PFS, valutata dagli investigatori,

=== Intervention Extract 818 (Dose) ===
le analisi. La mediana
Row 4: di PFS, valutata dagli investigatori, è
Row 5: risultata essere di 10.9 mesi (95% CI
Row 6: 7·0–16·6), e la PFS a 6 mesi è risultata
Row 7: essere del 72% Row 1: ||
Row 2: Esiti|Impatto|Impatto
Row 3: ||
Row 4: Overall Survival (OS) valutato con: dalla data della prima dose di trattamenti alla morte per ogni causa follow up: mediana 15.9 mesi||
Row 5: |17 pazienti su 36 (47%) sono deceduti|17 pazienti su 36 (47%) sono deceduti
Row 6: ||
Row 7: Progression free survival (PFS) valutato con: dalla data della prima dose di trattamento alla progressione di malattia o morte

=== Intervention Extract 819 (Dose) ===
l Survival (OS) valutato con: dalla data della prima dose di trattamenti alla morte per ogni causa follow up: mediana 15.9 mesi||
Row 5: |17 pazienti su 36 (47%) sono deceduti|17 pazienti su 36 (47%) sono deceduti
Row 6: ||
Row 7: Progression free survival (PFS) valutato con: dalla data della prima dose di trattamento alla progressione di malattia o morte follow up: mediana 15.9 mesi||
Row 8: |24 su 36 (67%) pazienti sono andati incontro a progressione di malattia o morte al tempo delle analisi. La mediana di PFS, valutata dagli investigatori, è risultata essere di 10.9 mesi (95% CI 7·0–16·6), e l

=== Intervention Extract 820 (Dose) ===
e. Row 1: 
Row 2: 
Row 3: 
Row 4:  Row 1: |
Row 2: |
Row 3: |
Row 4: | Row 1: |Esiti Impatto № dei Certainty of partecipanti the evidence (studi) (GRADE) Overall Survival 17 pazienti su 36 (47%) sono deceduti (1 studio ⨁◯◯◯ (OS) osservazionale)1 MOLTO valutato con: dalla BASSAa,b,c data della prima dose di trattamenti alla morte per ogni causa follow up: mediana 15.9 mesi Progression free 24 su 36 (67%) pazienti sono andati (1 studio ⨁◯◯◯ survival (PFS) incontro a progressione di malattia o osservazionale)1 MOLTO valutato con: dalla morte al tempo delle analisi. La mediana BASSAa,b,c data della pr

=== Intervention Extract 821 (Dose) ===
llow up: mediana 15.9 mesi Progression free 24 su 36 (67%) pazienti sono andati (1 studio ⨁◯◯◯ survival (PFS) incontro a progressione di malattia o osservazionale)1 MOLTO valutato con: dalla morte al tempo delle analisi. La mediana BASSAa,b,c data della prima di PFS, valutata dagli investigatori, è dose di trattamento risultata essere di 10.9 mesi (95% CI alla progressione di 7·0–16·6), e la PFS a 6 mesi è risultata malattia o morte essere del 72% follow up: mediana 15.9 mesi Response rate Ad un follow-up mediano di 15,9 mesi (1 studio ⨁◯◯◯ follow up: mediana (IQR 7,8–22,0), 23 pazienti hanno osse

=== Intervention Extract 822 (Dose) ===
nno raggiunto un controllo della malattia. Qualità della vita - - - non misurato| Row 1: |||||||||
Row 2: Esiti|Impatto||||№ dei|||Certainty of|
Row 3: |||||partecipanti|||the evidence|
Row 4: |||||(studi)|||(GRADE)|
Row 5: |||||||||
Row 6: Overall Survival (OS) valutato con: dalla data della prima dose di trattamenti alla morte per ogni causa follow up: mediana 15.9 mesi||||(1 studio osservazionale)1|||⨁◯◯◯ MOLTO BASSAa,b,c||
Row 7: |17 pazienti su 36 (47%) sono deceduti||||||||
Row 8: |||||||||
Row 9: Progression free survival (PFS) valutato con: dalla data della prima dose di trattamento alla p

=== Intervention Extract 823 (Dose) ===
alla data della prima dose di trattamenti alla morte per ogni causa follow up: mediana 15.9 mesi||||(1 studio osservazionale)1|||⨁◯◯◯ MOLTO BASSAa,b,c||
Row 7: |17 pazienti su 36 (47%) sono deceduti||||||||
Row 8: |||||||||
Row 9: Progression free survival (PFS) valutato con: dalla data della prima dose di trattamento alla progressione di malattia o morte follow up: mediana 15.9 mesi||||(1 studio osservazionale)1|||⨁◯◯◯ MOLTO BASSAa,b,c||
Row 10: |24 su 36 (67%) pazienti sono andati incontro a progressione di malattia o morte al tempo delle analisi. La mediana di PFS, valutata dagli investigatori,

=== Intervention Extract 824 (Dose) ===
le analisi. La mediana
Row 4: di PFS, valutata dagli investigatori, è
Row 5: risultata essere di 10.9 mesi (95% CI
Row 6: 7·0–16·6), e la PFS a 6 mesi è risultata
Row 7: essere del 72% Row 1: ||
Row 2: Esiti|Impatto|Impatto
Row 3: ||
Row 4: Overall Survival (OS) valutato con: dalla data della prima dose di trattamenti alla morte per ogni causa follow up: mediana 15.9 mesi||
Row 5: |17 pazienti su 36 (47%) sono deceduti|17 pazienti su 36 (47%) sono deceduti
Row 6: ||
Row 7: Progression free survival (PFS) valutato con: dalla data della prima dose di trattamento alla progressione di malattia o morte

=== Intervention Extract 825 (Dose) ===
l Survival (OS) valutato con: dalla data della prima dose di trattamenti alla morte per ogni causa follow up: mediana 15.9 mesi||
Row 5: |17 pazienti su 36 (47%) sono deceduti|17 pazienti su 36 (47%) sono deceduti
Row 6: ||
Row 7: Progression free survival (PFS) valutato con: dalla data della prima dose di trattamento alla progressione di malattia o morte follow up: mediana 15.9 mesi||
Row 8: |24 su 36 (67%) pazienti sono andati incontro a progressione di malattia o morte al tempo delle analisi. La mediana di PFS, valutata dagli investigatori, è risultata essere di 10.9 mesi (95% CI 7·0–16·6), e l

